utmb Health
Galveston National Laboratory

Introduction

The Galveston National Laboratory held its grand opening in November 2008, shortly after Hurricane Ike; fortunately, the laboratory withstood the storm with no damage. The cost of construction was approximately $175 million, with about two-thirds provided by the National Institutes of Health, National Institute of Allergy and Infectious Diseases and the remainder from the State of Texas, augmented with philanthropic donations. We have been fully operational at all levels of biocontainment (Biological Safety Level-2, BSL3 and BSL4) since 2010 and our faculty are involved in basic and translational research on emerging and re-emerging infectious diseases that require purpose-built containment facilities and specially trained staff to handle these high consequence pathogens. Some of our past accomplishments include contributing significantly to the development of the now licensed vaccine for Ebola virus and early discoveries on Zika virus. We have been heavily involved in research and diagnostic testing on the new coronavirus since it was first recognized and we have successful research programs for both SARS and MERS coronaviruses led by several members of our faculty.

The GNL Training Mission

We benefited greatly in building the GNL workforce through the visionary support provided by Senator Kay Bailey Hutchinson who was able to establish two projects funded through the Department of Defense (W81XWH-09-2-0053 and W81XWH-11-2-0148) that allowed us to establish the National Biocontainment Training Center at UTMB. This center provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations initially to our own staff, and later to international partners from around the world who had built or were building new biocontainment laboratories. Parenthetically, during a WHO sponsored meeting in December 2017, representatives from more than 50 BSL4 laboratories were present. Each of these laboratories was presumably being built to conduct research on especially dangerous pathogens such as Ebola virus and the need for high quality training from experienced instructors was obvious.

Recognizing the global need for training and to share best practices for both the conduct of research within biocontainment and the operations of these highly complex buildings, we began providing training for staff and leaders from many of these laboratories. The DoD funding for the National Biocontainment Training Center ended in 2016, and by that time we had provided training through more than 10,000 encounters for participants from more about 70 different countries, as well as from universities, government agencies and industry personnel throughout the U.S. Training was provided in the training center and laboratories at UTMB as well as on-site at international locations where we could reach a greater number of personnel and provide a customized learning experience for trainees within their own familiar laboratory setting.

FOIA Confidential Treatment Requested by Univ of Texas System

Training Support for China

We specifically sought to engage with the BSL4 laboratories under construction in China, which included the Wuhan Institute of Virology (WIV) laboratory located in the outskirts of Wuhan and affiliated with the Chinese Academy of Sciences. As second BSL4 laboratory remains under construction in Kunming and is associated with the Chinese Academy of Medical Sciences, and the third BSL4 laboratory is now fully operational in Harbin where it serves the Chinese Academy of Agricultural Sciences. I have personally visited all three facilities, I know each director well, and all the directors have visited the GNL. Staff members from the Kunming and Wuhan labs have participated in training here at the GNL, and we sent a team to Kunming to provide on-site training to their staff in 2013 or 2014.

In addition to providing short-term training experiences to staff from the Wuhan Institute of Virology, we also hosted two Chinese post-doctoral scientists at the GNL where they completed the full nearly year-long training needed to gain independent access to our BSL4 facilities. (This includes mentored work at BSL3 and at least 100 hours of mentored training at BSL4.) Both of these young scientists worked on cutting edge scientific projects in partnership with our faculty members and their results were published in high-impact international scientific journals. Both have since returned to WIV where they were instrumental in establishing their biosafety and biosecurity training program for the new BSL4 laboratory and continue their independent research in the new facility. We maintain contact with them and continue to collaborate scientifically. One is now heading the WIV BSL4 laboratory research program into countermeasure development for the new coronavirus.

These training efforts had two primary goals: To ensure that all scientists working in biocontainment are exposed to proven best practices in biosafety and biosecurity as well as in the safe and secure operations of these complex facilities; and second, to not only engage in scientific collaborations, but to also offer a window of transparency into each other's programs. This second goal has significant security implications. Through our collaborations we have built both professional relationships and solid friendships that allow us to talk frankly and honestly with each other, something that is especially important when there are political differences between countries.

A second area of engagement has been an ongoing scientific dialogue that is facilitated by our U.S. National Academy of Sciences, Engineering and Medicine and the Chinese Academy of Sciences. Through this partnership we have held joint meetings on emerging infectious diseases, biocontainment laboratory safety and security, and more recently gene editing. Meetings alternate between the US and China and have occurred about annually, with the first being held in Beijing in September 2015. We hosted one of the meetings here at the GNL in January of 2017.

Specific Coronavirus Discussions

Importantly, during each of these NASEM/CAS meetings we have held a session on the coronaviruses with presentations by the foremost American leaders in this field, and at each session, Dr Zhengli Shi has presented her most recent work. During the September 2015 meeting she described her studies of bat-associated coronaviruses and concluded that there was significant potential risk of transmission of some of these viruses to humans—more than four years before the start of the current pandemic! By way of background, Dr Shi is a superbly trained scientists, fluent in English, French and of course her native Chinese, and she is the one

who discovered the link between bats and the original SARS virus that caused disease world-wide in 2003. She has participated in each of our dialogues and in every session she has been fully engaged, very open and transparent about her work, and eager to collaborate. It is my understanding that she a co-investigator on a coronavirus project with an American scientist, but I do not have details and it is not someone from UTMB.

There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature given its high similarity to other know bat-associated coronaviruses. Bat-associated coronaviruses are difficult to grow in the laboratory in general, although the current pandemic SARS-2 virus does grow well in cell culture. I do not know how much of Dr Shi's work involved handling live virus or work in experimental animals.

I have been told by Dr Shi that she is confident that the virus did not escape from her laboratory.

Dr Shi was among the first to identify the new virus, to determine its genetic sequence, and to share it publicly. She was also among the first to publish about the new virus in the international scientific literature.

The Wuhan Institute of Virology Lab

I have visited the new BSL4 laboratory in Wuhan and toured it fully prior to it starting operations in 2017. The facility was built in partnership with the French and is modeled after their BSL4 laboratory in Lyon, France. It is of comparable quality and safety measures as any currently in operation in the US or Europe.

I do not know where Dr Shi has conducted her research on bat-associated coronaviruses; however, it clearly was not in the new BSL4 facility since it only began operations in 2017 and she had been working on these viruses well prior to our first official dialogue meeting in 2015 when she reported her findings.

A recent article in the South China Morning Post indicates that the first cases of the COVID-19 were identified in Hubei Province in mid-November, 2019.

([HYPERLINK "https://nam03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.scmp.com%2Fnews%2Fchina%2Fsociety%2Farticle%2F3074991%2Fcoronavirus-chinas-first-confirmed-covid-19-case-traced-back&data=02%7C01%7Cjwleduc%40UTMB.EDU%7C5ae1e3b684e245e9a2a108d7e15e4551%7C7bef256d85db4526a72d31aea2546852%7C0%7C0%7C637225667327335966&sdata=rbZ8YBDlSnQ%2Bc%2BAqa2U2TI8gpRjNy9x3%2FpsYUxRSNcU%3D&reserved=0"]

To: pkrussell@aol.com
Subject: RE: Very scary. You must watch this
Attachments: Origin of SARS-CoV-2 Mar2020.pdf; COVID-19 and Zhengli Shi's presentations at the NASEM U.S. China dialogues.docx

Yes, I just received the link this morning from Doug Watts. I don't believe that the virus originated from the lab in Wuhan and I think the attached paper makes a strong argument that it came from nature, a conclusion with which I concur. We have been working with Zhengli Shi through a dialogue established between the US National Academy of Sciences and the Chinese Academy of Sciences. Dr Shi has presented at each of these meetings starting with the first in Beijing in 2015, and her message has consistently been that these bat coronaviruses hold the ability to infect humans through the hACE2 receptor. She's a very talented scientist and a charming person. Our meetings have included Ralph Baric and Linda Saif, two of the premier coronavirologist in the US and the discussions have always been open and frank.

I can't argue with the comments against the Chinese communist party. It's too bad that the global pandemic is being conflated with the challenges the world faces from the Chinese communist party. They are both important issues, but I'm not convinced that they are linked.

Hope you (b)(6) are staying well through all this,

Jim

From: pkrussell@aol.com <pkrussell@aol.com>
Sent: Thursday, April 09, 2020 4:33 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Fwd: Very scary. You must watch this

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim,

This is gaining credibity. What do you think?

Phil

-----Original Message-----
From: Scott Halstead <halsteads@erols.com>
To: Russell, Phil <pkrussell@aol.com>; Brandt, Walter (b)(6) .net>
Sent: Thu, Apr 9, 2020 10:44 am
Subject: Very scary. You must watch this

https://www.youtube.com/watch?v=3bXWGxhd7ic

The NASEM U.S. - China Dialogue on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security

The ongoing outbreak of COVID-19 and Dr. Zhengli Shi's presentations on coronaviruses

Over the past five years representatives of the National Academies of Sciences, Engineering, and Medicine (NASEM) have worked with the Chinese Academy of Sciences (CAS), Chinese Center for Disease Control and Prevention (CCDC) and other Chinese life science and public health organizations to organize a series of dialogue meetings on infectious-disease research, combating emerging infections, life-science collaboration and data sharing, and high containment biological laboratory management. The dialogue meetings, hosted by institutes in China and the United States, have been well attended by leading scientists from NASEM, CAS, CCDC, the Chinese Academy of Agricultural Sciences (CAAS), and the Chinese Academy of Medical Sciences.[1] The meetings have enabled scientists from China and the United States to exchange research findings on diseases of mutual concern to China and the United States, to share best practices and lessons learned for managing and operating high containment biological laboratories, and to establish new collaborative research and institutional partnerships.

Each meeting included sessions on coronaviruses, with experts from China and the U.S.[2] presenting research findings. One of the Chinese participants **Dr. Zhengli Shi**,[3] is a well know virologist and coronavirus expert. Her research focuses on Swine Acute Diarrhea Syndrome Coronavirus (SADS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) , and SARS-associated Coronavirus (SARS-CoV) and the study of interspecies as well as animal-to-human transmission originating in camels, bats, mice, swine, and other animals. Dr. Shi has also built one of the world's largest databases of bat-related viruses. In 2005, she and Dr. Cui Jie found that the SARS virus likely originated in bats, a finding that has implications for the emergence of SARS-like coronaviruses or related viruses (Li et al., 2005). Recently Dr. Shi led a study with several other scientists on antiviral agents to combat COVID-19 and found that remdesivir and chloroquine are highly effective in the control of the virus in vitro. They recommended that the compounds be assessed in human patients suffering from COVID-19. Clinical trials of remdesivir have started, led by the American pharmaceutical company Gilead (Grady, 2020).

During the NASEM U.S. - China dialogue meetings Dr. Shi made some extraordinary predictions related to the ongoing COVID-19 epidemic. The following memo summarizes the presentations she gave at each dialogue meetings from 2015 to 2019 and highlights key statements.

First China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security (September 2015, Beijing, China)

Presentation Title: **Bat coronaviruses associated with human diseases**

---

[1] Key NASEM participants: Dr. Diane Griffin (Vice President NAS, Johns Hopkins University), Dr. Margaret Hamburg (NAM Foreign Secretary), Dr. James Le Duc (Director, Galveston National Laboratory), Dr. David Franz (former commander USAMRIID), Dr. Pei-Yong Shi (Galveston National Laboratory). Key Chinese participants: Dr. Fu Gao (Director-General, Chinese Center for Disease Control and Prevention), Dr. Chunli Bai (President, Academician, Chinese Academy of Sciences, CAS), Dr. Zhiming Yuan (director of the Wuhan National Biosafety Laboratory of the CAS), and Dr. Zhigao Bu (Director of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences).

[2] Dr. Linda Saif (Professor, The Ohio State University) and Dr. Ralph Baric (Professor Department of Epidemiology, University of North Carolina, Chapel Hill).

[3] Dr. Shi is director of the Center for Emerging Infectious Diseases at the Wuhan Institute of Virology (WIV) of the CAS. She holds a PhD from Montepellier II University, Masters degrees from the WIV, and a bachelors from Wuhan University.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009271

Dr. Shi presented research on a bat-transmissible coronavirus and spoke about the evolution and pathogenesis of diverse SARS-like coronaviruses (SL CoVs) in bats found by her research team in China. She explained that rhinolophid bats carry genetically diverse SL-CoVs, some of which are direct ancestors of SARS-CoV and have the potential to cause direct interspecies transmission to humans, and bats are likely natural reservoirs of MERS-CoV or an ancestral MERS-like CoV. **She warned that disease outbreaks resulting from spillover of bat coronaviruses will continue to occur in the future due to human activity increasingly overlapping the habitats of bats.** Therefore, she said, it is necessary to maintain a long-term coronavirus surveillance in bats, as well as in other wildlife and livestock animals, and that laboratory-based studies (receptor specificity, pathogenesis and animal infection) will help to conduct better risk assessment and to reveal the potential intermediate hosts.

Second China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (May 2017, Wuhan, China)

Presentation Title: **Pathogenicity analysis of bat SARS-like coronaviruses**

Dr. Shi spoke about her continuing research on the evolution and pathogenesis of bat SARS-like coronavirus (SL CoV) and **said that bat SL CoV could be the next pandemic**. Her current research focus is on the pathogenesis of SL CoV in transgenic mice, noting that the virus replicates very well in mice and in human tissue. The virus can easily enter human cells but she said that in the animal model the virus has less pathogenesis. **Her research shows that some bat SL CoVs have potential interspecies transmission to other animals and humans.** She added that continued surveillance of bat SL CoV, as well as the examination of human behavior risk for infection and serological survey are needed.

Third U.S. China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security (January 2018, Galveston, Texas, USA)

Presentation Title: **Coronaviruses associated with human and animal diseases in China - From SARS to SADS**

Dr. Shi discussed SARS and swine acute diarrhea syndrome (SADS) coronaviruses and their different hosts, the animal origin of SARS, the natural host, the possible intermediate host (likely the civet cat) and the end host. Chimeric viruses expressing the S protein of the bat SARS-like coronavirus SHC014 strain can effectively replicate in human airway epithelial cells and infected mouse lungs, achieving replication levels comparable to SARS-CoV. She said at that time there were 6 humans who had tested positive for the coronavirus, based on the study of individuals who live around bat caves. She **discussed what to do if SARS spills over to humans again, a key concern for China, including taking measures such as the generation and use of antibodies to neutralize infections.** She discussed SADS noting that bats are the natural reservoirs of a diverse set of coronaviruses, some bat coronaviruses have potential for spilling to humans, and this would be a problem because many coronaviruses have a high fatality rate in humans. She once again recommended surveillance and pathogenesis studies of bat coronaviruses. **She added that early diagnosis methods, treatment, and prevention should be prepared in advance for future emerging infectious diseases caused by bat coronaviruses.**

Fourth U.S.-China Dialogue and Workshop on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security and meeting on ***Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research*** (2019, Harbin, China)

Presentation Title: **Risks of MERS-cluster coronaviruses in China**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009272

Dr. Shi provided information on MERS-related coronavirus and cases in China. MERS shares a number of genomic similarities with SARS virus, including the importance of the viral spike protein that binds to cellular receptors as part of viral entry. For MERS, the human cellular receptor to which the spike binds is DPP4. There are multiple MERS-related coronaviruses, including strains in clades A and B that cause human infection, camel MERS-related coronaviruses, including strains in clades A and B that cause human infection, camel MERS viruses, and bat MERS-related coronaviruses including the related bat coronavirus HKU4. Dr. Shi's laboratory explored diversity in the MERS spike binding domain for its roles in interspecies infection ability. A recombinant MERS containing the spike binding domain from HKU4 could replicate in human cells. **She noted that many strains of MERS-related coronaviruses are prevalent in multiple bat host species in China and said that the potential for interspecies transmission highlights the need for long-term surveillance of this group of viruses.**

***

CDC on COVID-19 Origin

"The SARS-CoV-2 virus is a betacoronavirus, like MERS-CoV and SARS-CoV, both of which have their origins in bats. The sequences from U.S. patients are similar to the one that China initially posted, suggesting a likely single, recent emergence of this virus from an animal reservoir. Early on, many of the patients in the COVID-19 outbreak in Wuhan, China had some link to a large seafood and live animal market, suggesting animal-to-person spread. Later, a growing number of patients reportedly did not have exposure to animal markets, indicating person-to-person spread. Person-to-person spread has been reported outside China, including in the United States and other countries. Chinese officials report that sustained person-to-person spread in the community is occurring in China. In addition, other destinations have apparent community spread, meaning some people have been infected who are not sure how or where they became infected. (CDC, 2020)."

References (Zhengli Shi in bold)

Azhar, E. I., S. A. El-Kafrawy, S. A. Farraj, A. M. Hassan, M. S. Al-Saeed, A. M. Hashem, and T. A. Madani. 2014. Evidence for camel-to-human transmission of mers coronavirus. *New England Journal of Medicine* 370(26):2499-2505.

Briese, T., N. Mishra, K. Jain, I. S. Zalmout, O. J. Jabado, W. B. Karesh, P. Daszak, O. B. Mohammed, A. N. Alagaili, and W. I. Lipkin. 2014. Middle east respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in saudi arabia. *mBio* 5(3):e01146-01114.

CDC. 2020. *Coronavirus disease 2019 (covid-19) situation summary*. https://www.cdc.gov/coronavirus/2019-ncov/summary.html (accessed.

Drexler, J. F., F. Gloza-Rausch, J. Glende, V. M. Corman, D. Muth, M. Goettsche, A. Seebens, M. Niedrig, S. Pfefferle, S. Yordanov, L. Zhelyazkov, U. Hermanns, P. Vallo, A. Lukashev, M. A. Muller, H. Deng, G. Herrler, and C. Drosten. 2010. Genomic characterization of severe acute respiratory syndrome-related coronavirus in european bats and classification of coronaviruses based on partial rna-dependent rna polymerase gene sequences. *J Virol* 84(21):11336-11349.

Ge, X.-Y., J.-L. Li, X.-L. Yang, A. A. Chmura, G. Zhu, J. H. Epstein, J. K. Mazet, B. Hu, W. Zhang, C. Peng, Y.-J. Zhang, C.-M. Luo, B. Tan, N. Wang, Y. Zhu, G. Crameri, S.-Y. Zhang, L.-F. Wang, P. Daszak, and **Z.-L. Shi.** 2013. Isolation and characterization of a bat sars-like coronavirus that uses the ace2 receptor. *Nature* 503(7477):535-538.

Grady, D. 2020. China begins testing an antiviral drug in coronavirus patients. *The New York Times*, February 6, 2020.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009273

Guan, Y., B. Zheng, Y. He, X. Liu, Z. Zhuang, C. Cheung, S. Luo, P. Li, L. Zhang, and Y. Guan. 2003. Isolation and characterization of viruses related to the sars coronavirus from animals in southern china. *Science* 302(5643):276-278.

Hu, B., L.-P. Zeng, X.-L. Yang, X.-Y. Ge, W. Zhang, B. Li, J.-Z. Xie, X.-R. Shen, Y.-Z. Zhang, N. Wang, D.-S. Luo, X.-S. Zheng, M.-N. Wang, P. Daszak, L.-F. Wang, J. Cui, and **Z.-L. Shi.** 2017. Discovery of a rich gene pool of bat sars-related coronaviruses provides new insights into the origin of sars coronavirus. *PLoS pathogens* 13(11):e1006698-e1006698.

Lau, S. K. P., P. C. Y. Woo, K. S. M. Li, Y. Huang, H.-W. Tsoi, B. H. L. Wong, S. S. Y. Wong, S.-Y. Leung, K.-H. Chan, and K.-Y. Yuen. 2005. Severe acute respiratory syndrome coronavirus-like virus in chinese horseshoe bats. *Proceedings of the National Academy of Sciences of the United States of America* 102(39):14040-14045.

Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, J. Zhang, J. McEachern, H. Field, P. Daszak, B. T. Eaton, S. Zhang, and L. F. Wang. 2005. Bats are natural reservoirs of sars-like coronaviruses. *Science* 310(5748):676-679.

Li, H., E. Mendelsohn, C. Zong, W. Zhang, E. Hagan, N. Wang, S. Li, H. Yan, H. Huang, G. Zhu, N. Ross, A. Chmura, P. Terry, M. Fielder, M. Miller, **Z. Shi**, and P. Daszak. 2019. Human-animal interactions and bat coronavirus spillover potential among rural residents in southern china. *Biosafety and Health* 1.

Loo, Y.-M., D. M. Owen, K. Li, A. K. Erickson, C. L. Johnson, P. M. Fish, D. S. Carney, T. Wang, H. Ishida, M. Yoneyama, T. Fujita, T. Saito, W. M. Lee, C. H. Hagedorn, D. T.-Y. Lau, S. A. Weinman, S. M. Lemon, and M. Gale. 2006. Viral and therapeutic control of ifn-β promoter stimulator 1 during hepatitis c virus infection. *Proceedings of the National Academy of Sciences* 103(15):6001-6006.

Menachery, V. D., B. L. Yount Jr, K. Debbink, S. Agnihothram, L. E. Gralinski, J. A. Plante, R. L. Graham, T. Scobey, X.-Y. Ge, and E. F. Donaldson. 2015. A sars-like cluster of circulating bat coronaviruses shows potential for human emergence. *Nature medicine* 21(12):1508.

Ren, W., X. Qu, W. Li, Z. Han, M. Yu, P. Zhou, S. Y. Zhang, L. F. Wang, H. Deng, and **Z. Shi.** 2008. Difference in receptor usage between severe acute respiratory syndrome (sars) coronavirus and sars-like coronavirus of bat origin. *J Virol* 82(4):1899-1907.

Tong, S., C. Conrardy, S. Ruone, I. V. Kuzmin, X. Guo, Y. Tao, M. Niezgoda, L. Haynes, B. Agwanda, R. F. Breiman, L. J. Anderson, and C. E. Rupprecht. 2009. Detection of novel sars-like and other coronaviruses in bats from kenya. *Emerging infectious diseases* 15(3):482-485.

Wang, Q., J. Qi, Y. Yuan, Y. Xuan, P. Han, Y. Wan, W. Ji, Y. Li, Y. Wu, J. Wang, A. Iwamoto, P. C. Woo, K. Y. Yuen, J. Yan, G. Lu, and G. F. Gao. 2014. Bat origins of mers-cov supported by bat coronavirus hku4 usage of human receptor cd26. *Cell Host Microbe* 16(3):328-337.

WHO. 2017. *Middle east respiratory syndrome coronavirus mers-cov*. https://www.who.int/csr/don/archive/disease/mers-cov/en/ (accessed.

Wu, Z., L. Yang, X. Ren, J. Zhang, F. Yang, S. Zhang, and Q. Jin. 2015. Orf8-related genetic evidence for chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus. *The Journal of Infectious Diseases* 213(4):579-583.

Yang, X.-L., B. Hu, B. Wang, M.-N. Wang, Q. Zhang, W. Zhang, L.-J. Wu, X.-Y. Ge, Y.-Z. Zhang, P. Daszak, L.-F. Wang, and **Z.-L. Shi.** 2016. Isolation and characterization of a novel bat coronavirus closely related to the direct progenitor of severe acute respiratory syndrome coronavirus. *Journal of Virology* 90(6):3253-3256.

Yuan, J., C.-C. Hon, Y. Li, D. Wang, G. Xu, H. Zhang, P. Zhou, L. L. M. Poon, T. T.-Y. Lam, F. C.-C. Leung, and **Z. Shi.** 2010. Intraspecies diversity of sars-like coronaviruses in rhinolophus sinicus and its implications for the origin of sars coronaviruses in humans. *Journal of General Virology* 91(4):1058-1062.

Zaki, A. M., S. van Boheemen, T. M. Bestebroer, A. D. M. E. Osterhaus, and R. A. M. Fouchier. 2012. Isolation of a novel coronavirus from a man with pneumonia in saudi arabia. *New England Journal of Medicine* 367(19):1814-1820.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009274

Zeng, L.-P., X.-Y. Ge, C. Peng, W. Tai, S. Jiang, L. Du, and **Z.-L. Shi**. 2017. Cross-neutralization of sars coronavirus-specific antibodies against bat sars-like coronaviruses. *Science China Life Sciences* 60(12):1399-1402.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_009275

Date: Wednesday, April 22 2020 03:44 PM
Subject: Re: NASEM China Bio discussion
From: Howard, Anne B.
To: Holubar, Connie J. <cjholuba@UTMB.EDU>;

We don't have a current subscription, it was too expensive! I am going to see if I can get it from another library. Let me know if you find it through another avenue.
Anne

From: Howard, Anne B. <anhoward@UTMB.EDU>
Sent: Wednesday, April 22, 2020 10:21 AM
To: Holubar, Connie J. <cjholuba@UTMB.EDU>
Subject: Re: NASEM China Bio discussion

We are supposed to have a subscription but it's not working. I will continue to work on getting the articles for you.
Anne

From: Holubar, Connie J. <cjholuba@UTMB.EDU>
Sent: Wednesday, April 22, 2020 9:03 AM
To: Howard, Anne B. <anhoward@UTMB.EDU>
Subject: FW: NASEM China Bio discussion

Hi, Anne,

Does the library have a subscription to the WSJ?

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Wednesday, April 22, 2020 8:55 AM
To: Ksiazek, Thomas G. <tgksiaze@UTMB.EDU>; Holubar, Connie J. <cjholuba@UTMB.EDU>
Subject: FW: NASEM China Bio discussion

Do either of you have a subscription to the WSJ? See below re links to recent articles. If you can, please print so I can read.

Thanks

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 9:18 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: Raymond JEANLOZ <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: Re: NASEM China Bio discussion

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

WSJ also published this:
https://www.wsj.com/articles/coronavirus-and-the-laboratories-in-wuhan-11587486996
Can't even get link to WIV lab location right, it's not hard, coordinates are on Wikipedia.

Ben

On Apr 21, 2020, at 9:53 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

On Apr 21, 2020, at 9:53 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Balanced article on Zhengli Shi by the WSJ reporter who contacted Jim
https://www.wsj.com/articles/chinas-bats-expert-says-her-wuhan-lab-wasnt-source-of-new-coronavirus-11587463204

On Apr 21, 2020, at 8:42 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

Thanks Jim, sounds like your session with the House subcommittee went well and I am glad to that they are generally supportive of engagement. (I assume that the subcommittee has access to the two cables cited by the wapo.) I like the utmb statement as well.

Thanks for the edits. I have attached what I think is the final version of the China dialogue blurb for the NASEM website. Can still use the bulleted list we created last week when/if we talk about the dialogue with gov folks.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. <jwleduc@UTMB.EDU>
Sent: Tuesday, April 21, 2020 6:10 PM
To: Rusek, Benjamin <BRusek@nas.edu>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion

Attached has some suggestions. Looks fine to me.

I had an hour plus telecon with the House Foreign Affairs subcommittee on Oversight & Investigations to discuss the Washington Post article about the possible leak from WIV and the State Department inspection and cable. 5-6 participants from their side and all engaged. I provided them with the attached summary before the meeting and we had a good discussion about our relationship. The NASEM-CAS ties were of interest to them and they seemed to appreciate our efforts at engagement. As much detail as you can provide on the posting will be useful I suspect.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 3:04 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim and Dave,

Here is the latest draft of the website text for your review.

Kind regards,
Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Raymond JEANLOZ <jeanloz@berkeley.edu>
Sent: Monday, April 20, 2020 4:38 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; David Franz <davidrfranz@gmail.com>
Subject: Re: NASEM China Bio discussion

I made a new copy of the transcript of the NPR interview -- attached.

Raymond

On Mon, Apr 20, 2020 at 8:46 AM Lowenthal, Micah <mlowenth@nas.edu> wrote:

> Hi there,
> Micah Lowenthal is inviting you to a scheduled Zoom meeting.
> Join from PC, Mac, Linux, iOS or Android:
> https://nasem.zoom.us/j/95438044518?pwd=Nm9Ha2V3dXpJeS9oREpMenY0WFJEZz09
> Password: 042020
> Would you like to test your Zoom connection? Please click on the link below.
> https://nasem.zoom.us/test
> NOTICE: The Zoom service allows audio and any materials exchanged or viewed during the session to be recorded and shared. Please be aware that by participating in this activity, you consent to your voice, likeness, and any materials you provide, being recorded for use and dissemination, without payment of any compensation for such use, in any language, format, or media now known or later devised, and you release the National Academies of Sciences, Engineering, and Medicine from any and all claims, liability, or damages arising from any such use. The Academies will proceed in reliance upon such consent and release. If you do not consent to the foregoing, please do not join the session.

<U.S. China dialogue meetings v6.docx>

FOIA Confidential Treatment Requested by Univ of Texas System

To: Rusek, Benjamin [BRusek@nas.edu]; David Franz [davidrfranz@gmail.com]
CC: 'Raymond JEANLOZ' [jeanloz@berkeley.edu]; Lowenthal, Micah [mlowenth@nas.edu]
Subject: RE: NASEM China Bio discussion
Attachments: U.S. China dialogue meetings v5-jwl.docx; Media Statement_UTMB and WIV-4-20-20.docx

Attached has some suggestions. Looks fine to me.

I had an hour plus telecon with the House Foreign Affairs subcommittee on Oversight & Investigations to discuss the Washington Post article about the possible leak from WIV and the State Department inspection and cable. 5-6 participants from their side and all engaged. I provided them with the attached summary before the meeting and we had a good discussion about our relationship. The NASEM-CAS ties were of interest to them and they seemed to appreciate our efforts at engagement. As much detail as you can provide on the posting will be useful I suspect.

Thanks, Jim

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Tuesday, April 21, 2020 3:04 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>; David Franz <davidrfranz@gmail.com>
Cc: 'Raymond JEANLOZ' <jeanloz@berkeley.edu>; Lowenthal, Micah <mlowenth@nas.edu>
Subject: RE: NASEM China Bio discussion
Importance: High

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Jim and Dave,

Here is the latest draft of the website text for your review.

Kind regards,

Ben

Benjamin Rusek
The U.S. National Academy of Sciences
1-202-334-3975

From: Raymond JEANLOZ <jeanloz@berkeley.edu>
Sent: Monday, April 20, 2020 4:38 PM
To: Lowenthal, Micah <mlowenth@nas.edu>
Cc: Rusek, Benjamin <BRusek@nas.edu>; LeDuc, James W. <jwleduc@utmb.edu>; David Franz <davidrfranz@gmail.com>
Subject: Re: NASEM China Bio discussion

I made a new copy of the transcript of the NPR interview -- attached.

Raymond

On Mon, Apr 20, 2020 at 8:46 AM Lowenthal, Micah <mlowenth@nas.edu> wrote:

> Hi there,
>
> Micah Lowenthal is inviting you to a scheduled Zoom meeting.

Join from PC, Mac, Linux, iOS or Android:
https://nasem.zoom.us/j/95438044518?pwd=Nm9Ha2V3dXpJeS9oREpMenY0WFJEZz09
Password: 042020

Would you like to test your Zoom connection? Please click on the link below.
https://nasem.zoom.us/test

NOTICE: The Zoom service allows audio and any materials exchanged or viewed during the session to be recorded and shared. Please be aware that by participating in this activity, you consent to your voice, likeness, and any materials you provide, being recorded for use and dissemination, without payment of any compensation for such use, in any language, format, or media now known or later devised, and you release the National Academies of Sciences, Engineering, and Medicine from any and all claims, liability, or damages arising from any such use. The Academies will proceed in reliance upon such consent and release. If you do not consent to the foregoing, please do not join the session.

Draft v5 _April 21, 2020

U.S. - China Bilateral Dialogue on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security

Since 2015, the National Academies of Sciences, Engineering, and Medicine (NASEM) has organized a series of meetings on the challenges of emerging infections, laboratory safety, and global health security with the Chinese Academy of Sciences (CAS), Chinese Center for Disease Control and Prevention (CCDC), and other Chinese life science and public health organizations. Academy members and other top-flight American researchers in human and animal virology and immunology participated, including current and former directors of BSL-4 laboratories, former CDC, and former uniform military biodefense experts. They have met with China's BSL-4 laboratory directors and researchers from top universities and research centers across China~~, among others~~. The topics discussed included basic and applied research on infectious ~~-~~diseases~~ research~~; the challenges of combating emerging infections; life-science collaboration and research-data sharing; high-containment biological laboratory management, safety and security; and responsible conduct in the use of gene editing in ~~viral~~ infectious disease research.

Comment [LJW1]: how many or list later the dates (yr)/sites.

The meetings enabled scientists from the United States and China to discuss research findings on diseases of mutual concern to China and the United States, to share best practices and lessons learned for managing and operating high containment biological laboratories, and to establish new collaborative research and institutional partnerships. NASEM promotes international scientific collaboration to address important issues for the United States and the world. These activities lead to better practices and increased transparency. Connecting scientists in China and the United States allows those working to combat emerging infectious disease to identify and implement the best management, safety, and security standards in their laboratories, and to create research collaboration and training partnerships to improve laboratory safety and security and to further basic and applied science on emerging infectious diseases.

Comment [RB2]: Maybe delete this part

Comment [LJW3]: Yes, I don't think it adds much.

~~***(First) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security*** (September 2015, Beijing, China)~~

~~***(Second) China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security*** (May 2017, Wuhan, China)~~

~~***(Third) U.S.-China Dialogue on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security*** (January 2018, Galveston, Texas, USA)~~

~~***(Fourth) China-U.S. Dialogue on the Challenges of Emerging Infections, Laboratory Safety, Global Health Security*** and workshop on ***Responsible Conduct in the Use of Gene Editing in Viral Infectious Disease Research*** (January 2019, Harbin, China)~~

Comment [RB4]: Raymond recommended that we delete the list of meetings but he wanted to hear your thoughts…

Ben Rusek, Senior Program Officer, PGA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002447

utmb Health
Galveston National Laboratory

Galveston National Laboratory's Role with International Laboratories; Including Chinese Laboratories

Dr. James W. Le Duc, Director
20 April 20

Introduction

The Galveston National Laboratory (GNL) held its grand opening in November 2008. It is one of 14 laboratories based on university campuses in the U.S. that belong to the NIAID Biodefense Laboratory Network.

The GNL has been fully operational at all levels of biocontainment (Biological Safety Level-2, BSL3 and BSL4) since 2010. Our faculty members are involved in basic and translational research on emerging and re-emerging infectious diseases that require purpose-built containment facilities and specially-trained staff to handle these high consequence pathogens. We have been heavily involved in research and diagnostic testing on the new coronavirus since it was first recognized, and we have had longstanding research programs for both Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronaviruses.

The GNL Training Mission

The Galveston National Laboratory benefited greatly in building the GNL workforce through two projects funded through the Department of Defense (W81XWH-09-2-0053 and W81XWH-11-2-0148) that allowed us to establish the National Biocontainment Training Center at UTMB. This Center provided individualized, hands-on training in biosafety, biosecurity and biocontainment laboratory operations to our own staff and to international partners from around the world who had built or were building new biocontainment laboratories. Parenthetically, during a World Health Organization (WHO) sponsored meeting in December 2017, representatives from more than 50 BSL4 laboratories were present. Each of these laboratories was presumably being built to conduct research on especially dangerous pathogens such as Ebola virus, and the need for high quality training from experienced instructors was obvious.

The DoD funding for the National Biocontainment Training Center ended in 2016, and by that time, the GNL had provided training through more than 10,000 encounters for participants from about 70 different countries, as well as from universities, government agencies and industry personnel throughout the U.S. Training was provided in the training center and laboratories at UTMB as well as on-site at international locations where a greater number of personnel could be reached and we could provide a customized learning experience for trainees within their own familiar laboratory setting.

FOIA Confidential Treatment Requested by Univ of Texas System

We continue to provide training to our own staff and faculty, but without dedicated funding we are now unable to provide training for international partners.

Training Support for China

In 2013 the Galveston National Laboratory began to engage with the staff of the BSL4 laboratories under construction in China, which included the Wuhan Institute of Virology (WIV) laboratory located in the outskirts of Wuhan and affiliated with the Chinese Academy of Sciences. A second BSL4 laboratory remains under construction in Kunming and is associated with the Chinese Academy of Medical Sciences, and the third BSL4 laboratory is now fully operational in Harbin, where it serves the Chinese Academy of Agricultural Sciences.

In addition to providing short-term training experiences to staff from the WIV, the GNL also hosted two Chinese post-doctoral scientists, who completed the nearly year-long training needed to gain independent access to our BSL4 facilities. This includes mentored work at BSL3 and at least 100 hours of mentored training at BSL4. Both young scientists worked on cutting-edge scientific projects on Crimean Congo hemorrhagic fever virus in partnership with GNL faculty members, and their results were published in high-impact international scientific journals. Both have since returned to WIV in China, where they were instrumental in establishing their biosafety and biosecurity training program for the new BSL4 laboratory and where they continue their independent research in the new facility. Our faculty and staff maintain contact and continue to collaborate scientifically with these two scientists.

These training efforts had two primary goals: To ensure that all scientists working in biocontainment anywhere in the world are exposed to proven best practices in biosafety and biosecurity as well as in the safe and secure operations of these complex facilities; and second to engage in scientific collaborations. The director of the Wuhan BSL4 laboratory, Zhiming Yuan and I jointly published an editorial on the need for global collaboration among biocontainment laboratories in [HYPERLINK "https://science.sciencemag.org/content/362/6412/267"] on 19 October 2018.

A second area of engagement has been an ongoing scientific dialogue facilitated by our U.S. National Academy of Sciences, Engineering and Medicine and the Chinese Academy of Sciences. Through this partnership, the Galveston National Lab has participated in joint meetings on emerging infectious diseases, biocontainment laboratory safety and security, and, more recently, gene editing. Meetings alternate between the US and China and have occurred about annually, with the first being held in Beijing in September 2015. The Galveston National Lab hosted one of the meetings in Galveston in January 2018.

Specific Coronavirus Discussions

Importantly, during each of these NASEM/CAS meetings, we have held a session on the coronaviruses with presentations by the foremost American leaders in this field. At each of these sessions, Dr. Zhengli Shi has presented her most recent work. During the September 2015 meeting, she described her studies of bat-associated coronaviruses

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_002449

and concluded that there was significant potential risk of transmission of some of these viruses to humans. She is the research scientist who discovered the link between bats and the original SARS virus that caused disease world-wide in 2003. She has participated in each of our dialogues; in every session, she has been fully engaged, very open and transparent about her work, and eager to collaborate.

There is convincing evidence that the new virus was not the result of intentional genetic engineering and that it almost certainly originated from nature given its high similarity to other known bat-associated coronaviruses. Dr Shi was among the first to identify the new virus, to determine its genetic sequence, and to share it publicly. She was also among the first to publish about the new virus in the international scientific literature.

The Wuhan Institute of Virology Lab

I have visited and toured the new BSL4 laboratory in Wuhan, prior to it starting operations in 2017. The facility was built in partnership with the French and it is modeled after the BSL4 laboratory in Lyon, France. It is of comparable quality and safety measures as any currently in operation in the US or Europe.

FOIA Confidential Treatment Requested by Univ of Texas System

To: james.areddy@wsj.com
Subject: RE: wsj

Zheng Li has been working on bat-associated coronaviruses since just after the original SARS outbreak in 2003. For at least the last 5 years she has been reporting the bat-associated coronaviruses may have the ability to infect humans and that we should be watching for their possible emergence. So she has been

From: James T. AREDDY <james.areddy@wsj.com>
Sent: Tuesday, April 14, 2020 3:54 PM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: Re: wsj

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim
It's really fascinating. Here's an interview with the reporter on that story where he describes how the State Dept was concerned two years ago about procedures in Wuhan early on. https://www.youtube.com/watch?v=cgnT2YK3BBI&feature=youtu.be He calls the link between the lab and the outbreak as a 'circumstantial' case. But do you know if Shi Zhengli's focus on bat coronavirus was a worry back a few years ago?

James T. Areddy
The Wall Street Journal
+86 1370 1700 594

james.areddy@wsj.com
james.areddy@shnq-news.com (中文)
(b)(6)
@jamestareddy
WeChat/Signal/Telegram/Facetime/WhatsApp

On Tue, Apr 14, 2020 at 11:09 AM LeDuc, James W. <jwleduc@utmb.edu> wrote:

> James,
>
> Thank you for sharing the report below. I had not seen this previously and I find it quite interesting, especially the comment about our laboratory working to help train scientists and building engineers from the new BSL4 laboratory. We clearly recognized this need but unfortunately, were unable to identify funding to support our efforts. I do believe that between our efforts on a lab-to-lab basis and the overarching dialogue maintained by the US National Academy of Sciences and the Chinese Academy of Sciences, we have had a positive impact, although admittedly limited.

I really do not have any information about the possibility that the new coronavirus was the result of a laboratory accident or accidental release. Further, I have no experience or association with the Hubei Province CDC located in Wuhan. Good luck with your continued investigations. Sorry to learn that you have been expelled from China.

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
(b)(6)


From: James T. AREDDY <james.areddy@wsj.com>
Sent: Tuesday, April 14, 2020 8:01 AM
To: LeDuc, James W. <jwleduc@UTMB.EDU>
Subject: wsj

WARNING: This email originated from outside of UTMB's email system. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Jim

Hi. We spoke several weeks ago when I did a story for The Wall Street Journal about BSL-4 labs. Since then the Washington Post has had two stories suggesting fears in USA that there could have been an accident in Wuhan. I'm curious to know what you think about these reports?

(FWIW. I, along with a number of American reporters, have been kicked out of China so I'm now working for WSJ in the U.S.)



Editorial-Opinion

State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses

Josh Rogin

By Josh **Rogin**

1480 words
14 April 2020
Washington Post.com
WPCOM
English
Copyright 2020, The Washington Post Co. All Rights Reserved.

Two years before the novel coronavirus pandemic upended the world, U.S. Embassy officials visited a Chinese research facility in the city of Wuhan several times and sent two official warnings back to Washington about inadequate safety at the lab, which was conducting risky studies on coronaviruses from bats. The cables have fueled discussions inside the U.S. government about whether this or another Wuhan lab was the source of the virus — even though conclusive proof has yet to emerge.

In January 2018, the U.S. Embassy in Beijing took the unusual step of repeatedly sending U.S. science diplomats to the Wuhan Institute of Virology (WIV), which had in 2015 become China's first laboratory to achieve the highest level of international bioresearch safety (known as BSL-4). WIV issued a news release in English about the last of these visits, which occurred on March 27, 2018. The U.S. delegation was led by Jamison Fouss, the consul general in Wuhan, and Rick Switzer, the embassy's counselor of environment, science, technology and health. Last week, WIV erased that statement from its website, though it remains archived on the Internet.

What the U.S. officials learned during their visits concerned them so much that they dispatched two diplomatic cables categorized as Sensitive But Unclassified back to Washington. The cables warned about safety and management weaknesses at the WIV lab and proposed more attention and help. The first cable, which I obtained, also warns that the lab's work on bat coronaviruses and their potential human transmission represented a risk of a new SARS-like pandemic.

"During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory," states the Jan. 19, 2018, cable, which was drafted by two officials from the embassy's environment, science and health sections who met with the WIV scientists. (The State Department declined to comment on this and other details of the story.)

The Chinese researchers at WIV were receiving assistance from the Galveston National Laboratory at the University of Texas Medical Branch and other U.S. organizations, but the Chinese requested additional help. The cables argued that the United States should give the Wuhan lab further support, mainly because its research on bat coronaviruses was important but also dangerous.

As the cable noted, the U.S. visitors met with Shi Zhengli, the head of the research project, who had been publishing studies related to bat coronaviruses for many years. In November 2017, just before the U.S. officials' visit, Shi's team had published research showing that horseshoe bats they had collected from a cave in Yunnan province were very likely from the same bat population that spawned the SARS coronavirus in 2003.

"Most importantly," the cable states, "the researchers also showed that various SARS-like coronaviruses can interact with ACE2, the human receptor identified for SARS-coronavirus. This finding strongly suggests that SARS-like coronaviruses from bats can be transmitted to

humans to cause SARS-like diseases. From a public health perspective, this makes the continued surveillance of SARS-like coronaviruses in bats and study of the animal-human interface critical to future emerging coronavirus outbreak prediction and prevention."

The research was designed to prevent the next SARS-like pandemic by anticipating how it might emerge. But even in 2015, other scientists questioned whether Shi's team was taking unnecessary risks. In October 2014, the U.S. government had imposed a moratorium on funding of any research that makes a virus more deadly or contagious, known as "gain-of-function" experiments.

As many have pointed out, there is no evidence that the virus now plaguing the world was engineered; scientists largely agree it came from animals. But that is not the same as saying it didn't come from the lab, which spent years testing bat coronaviruses in animals, said Xiao Qiang, a research scientist at the School of Information at the University of California at Berkeley.

"The cable tells us that there have long been concerns about the possibility of the threat to public health that came from this lab's research, if it was not being adequately conducted and protected," he said.

There are similar concerns about the nearby Wuhan Center for Disease Control and Prevention lab, which operates at biosecurity level 2, a level significantly less secure than the level-4 standard claimed by the Wuhan Insititute of Virology lab, Xiao said. That's important because the Chinese government still refuses to answer basic questions about the origin of the novel coronavirus while suppressing any attempts to examine whether either lab was involved.

Sources familiar with the cables said they were meant to sound an alarm about the grave safety concerns at the WIV lab, especially regarding its work with bat coronaviruses. The embassy officials were calling for more U.S. attention to this lab and more support for it, to help it fix its problems.

"The cable was a warning shot," one U.S. official said. "They were begging people to pay attention to what was going on."

No extra assistance to the labs was provided by the U.S. government in response to these cables. The cables began to circulate again inside the administration over the past two months as officials debated whether the lab could be the origin of the pandemic and what the implications would be for the U.S. pandemic response and relations with China.

Inside the Trump administration, many national security officials have long suspected either the WIV or the Wuhan Center for Disease Control and Prevention lab was the source of the novel coronavirus outbreak. According to the New York Times, the intelligence community has provided no evidence to confirm this. But one senior administration official told me that the cables provide one more piece of evidence to support the possibility that the pandemic is the result of a lab accident in Wuhan.

"The idea that is was just a totally natural occurrence is circumstantial. The evidence it leaked from the lab is circumstantial. Right now, the ledger on the side of it leaking from the lab is packed with bullet points and there's almost nothing on the other side," the official said.

As my colleague David Ignatius noted, the Chinese government's original story — that the virus emerged from a seafood market in Wuhan — is shaky. Research by Chinese experts published in the Lancet in January showed the first known patient, identified on Dec. 1, had

no connection to the market, nor did more than one-third of the cases in the first large cluster. Also, the market didn't sell bats.

Shi and other WIV researchers have categorically denied this lab was the origin for the novel coronavirus. On Feb. 3, her team was the first to publicly report the virus known as 2019-nCoV was a bat-derived coronavirus.
The Chinese government, meanwhile, has put a total lockdown on information related to the virus origins. Beijing has yet to provide U.S. experts with samples of the novel coronavirus collected from the earliest cases. The Shanghai lab that published the novel coronavirus genome on Jan. 11 was quickly shut down by authorities for "rectification." Several of the doctors and journalists who reported on the spread early on have disappeared.

On Feb. 14, Chinese President Xi Jinping called for a new biosecurity law to be accelerated. On Wednesday, CNN reported the Chinese government has placed severe restrictions requiring approval before any research institution publishes anything on the origin of the novel coronavirus.

The origin story is not just about blame. It's crucial to understanding how the novel coronavirus pandemic started because that informs how to prevent the next one. The Chinese government must be transparent and answer the questions about the Wuhan labs because they are vital to our scientific understanding of the virus, said Xiao.

We don't know whether the novel coronavirus originated in the Wuhan lab, but the cable pointed to the danger there and increases the impetus to find out, he said.

"I don't think it's a conspiracy theory. I think it's a legitimate question that needs to be investigated and answered," he said. "To understand exactly how this originated is critical knowledge for preventing this from happening in the future."

James T. Areddy

The Wall Street Journal

+86 1370 1700 594

james.areddy@wsj.com
james.areddy@shng-news.com (中文)
(b)(6)
@jamestareddy
WeChat/Signal/Telegram/Facetime/WhatsApp

From: Han Xia <(b)(6)
Sent: Thursday, February 28, 2013 3:47 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks for the things you do for me ! I think the last obstacle for me to work with you is the English test for me.
Only pass the exam, I can start the procedure of abroad. These months I will work hard to prepare for the test, and hope to get good news.

Prof. Zhi-ming Yuan is the head of the BSL-4 project in Wuhan now.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, February 27, 2013 12:55 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

This is great news! Congratulations on the visiting scholarship! All of us here are very excited that you got the funding. A start date in August would work very well for me. I will make sure that we will help you with everything including the (b)(6) as much as we can. I will talk to our international office to find out what steps we have to do to get the (b)(6) process started.

Thank you also for all the information. I will forward it to Dr. LeDuc. He told me today that he is very happy that you acquired the funding.

I will get back to you soon with more details on the (b)(6)

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Monday, February 25, 2013 6:01 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
Firstly, I have told to my boss about that you need the contact information of the institute directors. She said I can give you the web-link (http://english.whiov.cas.cn/au/ds/) of the directors and let me tell you the leadership and the division of responsibility.

FOIA Confidential Treatment Requested by Univ of Texas System

At the present time, the director of Wuhan institute of Virology is Prof.Xinwen Chen.He is in charge of the comprehensive work of the Institute. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100082.html
And the Secretary of the Party Committee of Wuhan institute of Virology is Prof. Zhi-ming Yuan. He is mainly in charge of the international cooperation and the bio-safety. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100080.html
Secondly, I am glad to tell you I have acquired the funding (ensure the basic cost of living in US) from Chinese Academy and Sciences to support me to UTMB. On January, I applied the visiting scholar sponsored by the Chinese Academy of Sciences. But at that time, I don't think the result could come out so quickly and not sure about whether I could acquire the support. This funding will not limit my work and I could spend all the time to do research with you.
But the time I go to US maybe after (b)(6). Due to I must to pass a English Test in China (need by the support) in June and the test result will come out in Aug. And need the invitation and (b)(6) form from you.
If you need any other informations please tell me.
Best wishes,
Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, February 19, 2013 10:29 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I hope you are doing well. I just wanted to see if your boss had a chance to talk to the director of the biocontainment lab. Are there any news?

Secondly, I wanted to ask you if you can send me the contact information (email) of the director of the institute of virology in Wuhan. Dr. LeDuc will be traveling to China soon and would like to talk to the director about a possible collaboration of our two universities.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 30, 2013 9:30 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

My boss thinks it may be better if she contacts with the Director of our biocontainment lab firstly.
And then she will give me some suggestions.

I will let you know soon about the progress.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, January 29, 2013 4:57 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010773

Hi,

I just wanted to emphasize again that we understand that you probably will not know if there is a position available at the biocontainment group in Wuhan. Dr. LeDuc wants to see some general statement that you would be welcome to return as a staff member working in biocontainment. Maybe it would make sense for the biocontainment group to contact Dr. LeDuc so that they can discuss the details. What do you think?

Don't hesitate to ask more questions!

Dennis

From: Han Xia (b)(6)
Sent: Sunday, January 27, 2013 8:28 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks. I will try my best to take the opportunity.

I talked to my boss, and she is willing to try to help me and contact with the biocontainment Group. Do you have the sample contract embodying all terms and the template of the letter need from biocontainment lab? We want to know if we sign the contract, what duties should be carry out in accordance with the contract. And this will help us to explain the situation of us to the leadership.

Then I will apply the the government funding to support me. However this way is time-consuming. After the complete of the apply, it is a long wait.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, January 25, 2013 1:19 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Let me start off by telling you that I can fully understand your concerns.

Let me tell you briefly about your opportunities with us:
I currently have 5 people working in my laboratory and I –at the moment- have no extra funding to hire more postdocs or students. I would be very excited to have you working in my laboratory, but I this point you I cannot hire an extra person. If you would decide to pay for your living expenses, you can certainly join us and work in my laboratory. I am aware that this is probably not possible and I fully understand why that might not be possible. Because of this situation, I decided to talk to Dr. LeDuc and see if there is another way of finding funding for you because I think you would be a great addition to our laboratory.

The fellowship that Dr. LeDuc suggested is specifically meant to improve the exchange between high biocontainment facilities around the world and our laboratory. We fully understand that at this point you don't know what you will do in 1 or 2 years or if there will be a job at the high containment laboratory in Wuhan. But you have to understand our requirements: we don't want to invest a lot of time and effort into training a candidate in high biocontainment for 2 years

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010774

and then the candidate goes back to their country and works in a completely different area of science. That would not increase the scientific exchange between us and other biocontainment laboratories. I hope you understand why we would like to see the candidates be somehow connect to their high biocontainment facility

At this point I would like to suggest two things:
1) would it be possible for your boss (or you) to get in touch with the biocontainment group at Wuhan and explain your situation? Maybe the leaders in that group could then contact Dr. LeDuc?
2) If all this fails, have you checked if there might be some Chinese funding (from the government or other organizations) that could pay for your time here with us?

Please do not hesitate to ask me questions and to tell me your thoughts and concerns.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 23, 2013 7:23 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

I am glad to receive Dr. James W. Le Duc's e-mail. Thank you very much for your and Dr. James W. Le Duc's good consideration
for me.I think before I reply to him, there are some details I want to discuss to you.

Personally, my long term career goals is to be a scientist like you. After complete my postdoctoral training, I will return to Wuhan
and prefer to find a faculty position in a University of Wuhan (do some research and convey the knowledge to students).

For the research, now I focus on the CCHFV and very interest to work to you with CCHFV. And I think the most important experience
I learn from you is the way of thinking and problem-solving in the progress of the research rather than the object of the study.
However, maybe I will expend or change my feild in future, and study other pathogens not only CCHFV. The experience to work in
your lab will very helpful to me in the other research not only limited in BSL-4.

And I talk to my boss, she is the PI of the Group of Virus Resources and Information Group and will retire in (b)(6) And She
said there could be carry out some cooperations to you in the level of Group, such as the help of the tick sample collection in
China. I think the power of my boss (limited in the Group) is very limited compare to your boss Director James W. Le Duc.

However in Dr. James W. Le Duc's e-mail, one rule of that fellowship is **on my return I will be working within the new
biocontainment laboratory of Wuhan Institute of Virology**. Is it means that after complete the postdoc work with you

FOIA Confidential Treatment Requested by Univ of Texas System

I must return back to work in the biocontainment laboratory of Wuhan Institute of Virology as soon as possible ? If yes, I think this will limit my career
in future. I remeber in the first email you reply to me, you asked me a quseation 'Will me return to Wuhan when I complete the postdoc
training?' My answer was 'I will return to Wuhan'. But in that time, I think the question is just about wether I will retrun to Wuhan
to find a job, not limited in insititue or univeristy. In addition, according to the management system of the institute, if I decide
to accept that postdoc positon, I have to quit my now job, and the Wuhan institute of Virology will not keep my position. And when
after 1 or 2 years I return to Wuhan, I must find a new job through applying the position.

I particularly wish to have the opportunity to work with you, and the experience will be very helpful to me in future. And are there any
other fundings could choice for the postdoc positon ?

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, January 17, 2013 12:14 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi Han,

I talked to Dr. LeDuc last week. There might be a possibility for you to come and work with us.
Dr. LeDuc is currently traveling in India and will be back next week. He will send you an email with all the details next week.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 16, 2013 7:05 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Have you talk to the director Dr. James LeDuc ? And could you tell me something about that ?

Looking forward to your reply. Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010776

Sent: Saturday, January 5, 2013 5:12 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

Thanks for the email and the presentation. You don't need to prepare a PPT for the call. It is just a casual Skype call.

How about I call you on Monday, 7th at 6:00pm my time through Skype. It will be Tuesday, 8:00am your time. Is this too early for you? If it is too early, than I can call 1 hour later. Let me know what you want to do.

I will have a student with me during the Skype call. Her name is (b)(6) and she is originally from the Wuhan region. Her parents still live in Wuhan. I thought it would be nice if you can talk to her about what to expect in Galveston and from the University.

Please let me know if this works for you.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Friday, January 04, 2013 12:11 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
I added you and left a message in the Skype.
The time in here is 14 hours earlier than Houston.
I don't know whether need to prepare a PPT in the interview, and I write a sample presentaion could help to increase the understanding to me.
Best wishes,
Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, December 26, 2012 12:17 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,
I found you on Skype and send you an invite. How about we talk Monday the 7th? How many hours ahead of us are you?
Best wishes,
Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 4:38 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,
Hi, our New Year holiday is Januray 1 to 3, and the work time in the first week is 4-11, these days is available.
I have a Skype account (b)(6) and we could use this to communicate.

Once again, wish you a happy holiday !

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010777

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Monday, December 24, 2012 3:36 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

Merry Christmas and Happy New Year to you too!
I would like to apologize that I did not get back to you sooner. We were thinking to have a phone conference and give you a phone call. However, we can use a different communication tool as well. Personally, I do not use MSN but I use Skype. Have you used this before?
We do not need your boss to join us during the conference call. I just thought she might like to join us, but it is not necessary. Whe would be a good time for you? Are you available the first week of January?

Best wishes,

Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 12:56 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,

Merry Christmas and Happy New year !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, December 21, 2012 6:26 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I met with the director of the Galveston National Laboratory, Dr. James LeDuc. He suggested setting up a teleconference with you and your mentor sometime after the first of the New Year. During the conference call we can discuss your interests and expectations of the post-doc experience. We can also discuss timelines and options for finances. Could you please tell me when would be a good day and time for you and your mentor to hold a teleconference?

Before the teleconference we can jointly develop an agenda of the topics that we want to discuss.
Would this work for you?

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development

FOIA Confidential Treatment Requested by Univ of Texas System

301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

"Working together to make wonderful"

From: Han Xia (b)(6)
Sent: Friday, December 14, 2012 12:28 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

Thank you for your reply.

1. My current position is an assistant research fellow (assist Principle Investigator to apply and complete the research projects and guide the MD or PhD students) in Virus Resource and information Group of Wuhan institute of virology.
My research work was focus on epidemiology and molecular biology of tick-boren virus (maily on CCHFV). There are three parts:
(1) Development of minigenome system for CCHFV YL04057. Now I have aquired the YL04057's completed cDNA clone, and construted the plasimd pcDNA/L,
pcDNA/S, pRF-LUTR-GFP, pRF-MUTR-GFP and pRF-SUTR-GFP. Currently, the result of the co-transfection of pcDNA/L, pcDNA/S and pRF-LUTR-GFP is the best. Next, I will optimization of the conditions to make the system more stable.

(2) Epidemiology survey of CCHFV in Yunnan and Xinjiang of China. In China, the main infected area is in Xinjiang, but there is no outbreak and patient in recent years.

We collected the human, livestock and tick samples in the areas which have been previously reported CCHF or isolated CCHFV. Then used the ELISA, qReal-time PCR, or 454 high-throughput sequencing to analysis this samples.

And recently, some tick samples from Yunnan were detected use 454 sequencing and there are some intersting data need to further analysis.

(3) Epidemiology and molecular biology of Influenza virus. Our group's traditional fields is influenza virus , and I occasionally participate in the project of influenza virus.

2. I don't work at BSL-4. I work maily in BSL-2 and partly in BSL-3. Firstly, now in Wuhan Insititue of Virology, the BSL-4 lab is under construction. Secondly,
according to China's biosafety regulations the operate of CCHFV in cell-level could be at BSL-3 lab. Lastly, due to my work about CCHFV was mainly
in molecular level and sample tested, not related to the animal experiment.

FOIA Confidential Treatment Requested by Univ of Texas System

3. Yes, I am planning on returning to Wuhan once I finish the work with you.

And I have a question, what fields of research do you want me to do if I work in you lab? Thank you.

Best wishes
Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: (b)(6)
Email: (b)(6)

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, December 13, 2012 11:25 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Thank you very much for your email and the interest in my work.

You have an excellent CV and we would be interested in working with you. Can you tell me a little bit more about your current position? Do you work at biosafety level 4? Do you collect patient and tick samples from the field?

Although there is currently no extra funding in my laboratory for a postdoc, we might have another possibility to find funding for you: our laboratory includes the National Biocontainment Training Center, which gives out fellowships to visiting scientists. The goal of this program is to establish a link between biocontainment laboratories from around the world.
My question for you is: are you planning on returning to Wuhan once you finish you work with us? If yes, than that would it easier for us to get you the fellowship.

Looking forward to hear from you,

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
Member, Institute for Human Infection and Immunity
301 University Blvd., Galveston, TX 77555-0610

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010780

P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

Working together to work wonders™

From: Han Xia (b)(6)
Sent: Tuesday, December 11, 2012 2:59 AM
To: Bente, Dennis A.
Subject: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

I am writing to you about the possibility of studying and researching in your lab as a visiting scholar or postdoc.

Your researches are of particular interest to me, especially tick-borne viruses (such as CCHF). Your group's research is so outstanding
that I believe that if given the opportunity to study and research under your guidance, the experience at your lab can improve my research capacity, learn technology that is more new, and enlarge my knowledge in this field,which will benefit me a lot.

I am a Research assistant at Wuhan institute of virology,Chinese academy of Science,China. I graduated from Chinese Academy of Sciences and got the Doctor degree of Biochemisty and Molecular Biology in (b)(6)

Since that time, I have been working in Development in the minigenome system and Epidemiological investigation for CCHFV. I have been completed the epidmiological survey of CCHFV in Yunnan, China,2008 (International journal of infectious diseases, 07/2011; 15(7): e459-63). And the establishment of minigenome system for China YL04057 is in progress and almost completed.

In recently, we developed the embryonated chicken egg model for CCHFV, the result was under reviewing in Virus research (Infection and propagation of CCHFV in embryonated chicken eggs).

My current research focuses on viral infection diesease.I am satisfied with my research work. However, due to the condition of the experiments and personal experiments are restricted, I would like to find an opportunity to go abroad for further study and research.

My CV is in the attachment. Your comments and consideration will be highly appreciated.
I am looking forward to hear from you.

Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

FOIA Confidential Treatment Requested by Univ of Texas System

Tel and Fax: +86-27-87199229
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010782

From: Han Xia (b)(6)
Sent: Sunday, March 3, 2013 8:01 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Could tell me the date range of the Dr. LeDuc in June in China (From Pfor. Xiao's e-mail, he said that Dr. LeDuc will come to Beijing to attend a meeting about Hantaan virus)? My boss let me to ask the date.

Maybe, there is a possible for us to invite Dr. LeDuc to give us a speech and talk the other things.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, February 27, 2013 12:55 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

This is great news! Congratulations on the visiting scholarship! All of us here are very excited that you got the funding. A start date in August would work very well for me. I will make sure that we will help you with everything including the visa (b)(6) as much as we can. I will talk to our international office to find out what steps we have to do to get the (b)(6) process started.

Thank you also for all the information. I will forward it to Dr. LeDuc. He told me today that he is very happy that you acquired the funding.

I will get back to you soon with more details on the (b)(6)

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Monday, February 25, 2013 6:01 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
Firstly, I have told to my boss about that you need the contact information of the institute directors. She said I can give you the web-link (http://english.whiov.cas.cn/au/ds/) of the directors and let me tell you the leadership and the division of responsibility.

FOIA Confidential Treatment Requested by Univ of Texas System

At the present time, the director of Wuhan institute of Virology is Prof.Xinwen Chen.He is in charge of the comprehensive work of the Institute. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100082.html
And the Secretary of the Party Committee of Wuhan institute of Virology is Prof. Zhi-ming Yuan. He is mainly in charge of the international cooperation and the bio-safety. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100080.html
Secondly, I am glad to tell you I have acquired the funding (ensure the basic cost of living in US) from Chinese Academy and Sciences to support me to UTMB. On January, I applied the visiting scholar sponsored by the Chinese Academy of Sciences. But at that time, I don't think the result could come out so quickly and not sure about whether I could acquire the support. This funding will not limit my work and I could spend all the time to do research with you.
But the time I go to US maybe after (b)(6) Due to I must to pass a English Test in China (need by the support) in June and the test result will come out in Aug. And need the invitation and (b)(6) form from you.
If you need any other informations please tell me.
Best wishes,
Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, February 19, 2013 10:29 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I hope you are doing well. I just wanted to see if your boss had a chance to talk to the director of the biocontainment lab. Are there any news?

Secondly, I wanted to ask you if you can send me the contact information (email) of the director of the institute of virology in Wuhan. Dr. LeDuc will be traveling to China soon and would like to talk to the director about a possible collaboration of our two universities.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 30, 2013 9:30 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

My boss thinks it may be better if she contacts with the Director of our biocontainment lab firstly.
And then she will give me some suggestions.

I will let you know soon about the progress.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, January 29, 2013 4:57 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010750

Hi,

I just wanted to emphasize again that we understand that you probably will not know if there is a position available at the biocontainment group in Wuhan. Dr. LeDuc wants to see some general statement that you would be welcome to return as a staff member working in biocontainment. Maybe it would make sense for the biocontainment group to contact Dr. LeDuc so that they can discuss the details. What do you think?

Don't hesitate to ask more questions!

Dennis

From: Han Xia (b)(6)
Sent: Sunday, January 27, 2013 8:28 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks. I will try my best to take the opportunity.

I talked to my boss, and she is willing to try to help me and contact with the biocontainment Group. Do you have the sample contract embodying all terms and the template of the letter need from biocontainment lab? We want to know if we sign the contract, what duties should be carry out in accordance with the contract. And this will help us to explain the situation of us to the leadership.

Then I will apply the the government funding to support me. However this way is time-consuming. After the complete of the apply, it is a long wait.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, January 25, 2013 1:19 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Let me start off by telling you that I can fully understand your concerns.

Let me tell you briefly about your opportunities with us:
I currently have 5 people working in my laboratory and I –at the moment- have no extra funding to hire more postdocs or students. I would be very excited to have you working in my laboratory, but I this point you I cannot hire an extra person. If you would decide to pay for your living expenses, you can certainly join us and work in my laboratory. I am aware that this is probably not possible and I fully understand why that might not be possible. Because of this situation, I decided to talk to Dr. LeDuc and see if there is another way of finding funding for you because I think you would be a great addition to our laboratory.

The fellowship that Dr. LeDuc suggested is specifically meant to improve the exchange between high biocontainment facilities around the world and our laboratory. We fully understand that at this point you don't know what you will do in 1 or 2 years or if there will be a job at the high containment laboratory in Wuhan. But you have to understand our requirements: we don't want to invest a lot of time and effort into training a candidate in high biocontainment for 2 years

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010751

and then the candidate goes back to their country and works in a completely different area of science. That would not increase the scientific exchange between us and other biocontainment laboratories. I hope you understand why we would like to see the candidates be somehow connect to their high biocontainment facility

At this point I would like to suggest two things:
1) would it be possible for your boss (or you) to get in touch with the biocontainment group at Wuhan and explain your situation? Maybe the leaders in that group could then contact Dr. LeDuc?
2) If all this fails, have you checked if there might be some Chinese funding (from the government or other organizations) that could pay for your time here with us?

Please do not hesitate to ask me questions and to tell me your thoughts and concerns.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 23, 2013 7:23 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

I am glad to receive Dr. James W. Le Duc's e-mail. Thank you very much for your and Dr. James W. Le Duc's good consideration
for me.I think before I reply to him, there are some details I want to discuss to you.

Personally, my long term career goals is to be a scientist like you. After complete my postdoctoral training, I will return to Wuhan
and prefer to find a faculty position in a University of Wuhan (do some research and convey the knowledge to students).

For the research, now I focus on the CCHFV and very interest to work to you with CCHFV. And I think the most important experience
I learn from you is the way of thinking and problem-solving in the progress of the research rather than the object of the study.
However, maybe I will expend or change my feild in future, and study other pathogens not only CCHFV. The experience to work in
your lab will very helpful to me in the other research not only limited in BSL-4.

And I talk to my boss, she is the PI of the Group of Virus Resources and Information Group and will retire in (b)(6) And She
said there could be carry out some cooperations to you in the level of Group, such as the help of the tick sample collection in
China. I think the power of my boss (limited in the Group) is very limited compare to your boss Director James W. Le Duc.

However in Dr. James W. Le Duc's e-mail, one rule of that fellowship is **on my return I will be working within the new
biocontainment laboratory of Wuhan Institute of Virology**. Is it means that after complete the postdoc work with you

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010752

I must return back to work in the biocontainment laboratory of Wuhan Institute of Virology as soon as possible ? If yes, I think this will limit my career
in future. I remeber in the first email you reply to me, you asked me a quseation 'Will me return to Wuhan when I complete the postdoc
training?' My answer was 'I will return to Wuhan'. But in that time, I think the question is just about wether I will retrun to Wuhan
to find a job, not limited in insititue or univeristy. In addition, according to the management system of the institute, if I decide
to accept that postdoc positon, I have to quit my now job, and the Wuhan institute of Virology will not keep my position. And when
after 1 or 2 years I return to Wuhan, I must find a new job through applying the position.

I particularly wish to have the opportunity to work with you, and the experience will be very helpful to me in future. And are there any
other fundings could choice for the postdoc positon ?

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, January 17, 2013 12:14 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi Han,

I talked to Dr. LeDuc last week. There might be a possibility for you to come and work with us.
Dr. LeDuc is currently traveling in India and will be back next week. He will send you an email with all the details next week.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 16, 2013 7:05 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Have you talk to the director Dr. James LeDuc ? And could you tell me something about that ?

Looking forward to your reply. Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System

Sent: Saturday, January 5, 2013 5:12 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

Thanks for the email and the presentation. You don't need to prepare a PPT for the call. It is just a casual Skype call.

How about I call you on Monday, 7th at 6:00pm my time through Skype. It will be Tuesday, 8:00am your time. Is this too early for you? If it is too early, than I can call 1 hour later. Let me know what you want to do.

I will have a student with me during the Skype call. Her name is Jia Wang and she is originally from the Wuhan region. Her parents still live in Wuhan. I thought it would be nice if you can talk to her about what to expect in Galveston and from the University.

Please let me know if this works for you.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Friday, January 04, 2013 12:11 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
I added you and left a message in the Skype.
The time in here is 14 hours earlier than Houston.
I don't know whether need to prepare a PPT in the interview, and I write a sample presentaion could help to increase the understanding to me.
Best wishes,
Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, December 26, 2012 12:17 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,
I found you on Skype and send you an invite. How about we talk Monday the 7th? How many hours ahead of us are you?
Best wishes,
Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 4:38 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,
Hi, our New Year holiday is Januray 1 to 3, and the work time in the first week is 4-11, these days is available.
I have a Skype account: (b)(6) and we could use this to communicate.

Once again, wish you a happy holiday !

FOIA Confidential Treatment Requested by Univ of Texas System

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Monday, December 24, 2012 3:36 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

Merry Christmas and Happy New Year to you too!
I would like to apologize that I did not get back to you sooner. We were thinking to have a phone conference and give you a phone call. However, we can use a different communication tool as well. Personally, I do not use MSN but I use Skype. Have you used this before?
We do not need your boss to join us during the conference call. I just thought she might like to join us, but it is not necessary. Whe would be a good time for you? Are you available the first week of January?

Best wishes,

Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 12:56 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,

Merry Christmas and Happy New year !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, December 21, 2012 6:26 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I met with the director of the Galveston National Laboratory, Dr. James LeDuc. He suggested setting up a teleconference with you and your mentor sometime after the first of the New Year. During the conference call we can discuss your interests and expectations of the post-doc experience. We can also discuss timelines and options for finances. Could you please tell me when would be a good day and time for you and your mentor to hold a teleconference?

Before the teleconference we can jointly develop an agenda of the topics that we want to discuss.
Would this work for you?

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010755

301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

"Working together to make excellence"

From: Han Xia (b)(6)
Sent: Friday, December 14, 2012 12:28 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

Thank you for your reply.

1. My current position is an assistant research fellow (assist Principle Investigator to apply and complete the research projects and guide the MD or PhD students) in Virus Resource and information Group of Wuhan institute of virology.
My research work was focus on epidemiology and molecular biology of tick-boren virus (maily on CCHFV). There are three parts:
(1) Development of minigenome system for CCHFV YL04057. Now I have aquired the YL04057's completed cDNA clone, and construted the plasimd pcDNA/L,
pcDNA/S, pRF-LUTR-GFP, pRF-MUTR-GFP and pRF-SUTR-GFP. Currently, the result of the co-transfection of pcDNA/L, pcDNA/S and pRF-LUTR-GFP is the best. Next, I will optimization of the conditions to make the system more stable.

(2) Epidemiology survey of CCHFV in Yunnan and Xinjiang of China. In China, the main infected area is in Xinjiang, but there is no outbreak and patient in recent years.

We collected the human, livestock and tick samples in the areas which have been previously reported CCHF or isolated CCHFV. Then used the ELISA, qReal-time PCR, or 454 high-throughput sequencing to analysis this samples.

And recently, some tick samples from Yunnan were detected use 454 sequencing and there are some intersting data need to further analysis.

(3) Epidemiology and molecular biology of Influenza virus. Our group's traditional fields is influenza virus , and I occasionally participate in the project of influenza virus.

2. I don't work at BSL-4. I work maily in BSL-2 and partly in BSL-3. Firstly, now in Wuhan Insititue of Virology, the BSL-4 lab is under construction. Secondly,
according to China's biosafety regulations the operate of CCHFV in cell-level could be at BSL-3 lab. Lastly, due to my work about CCHFV was mainly
in molecular level and sample tested, not related to the animal experiment.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010756

3. Yes, I am planning on returning to Wuhan once I finish the work with you.

And I have a question, what fields of research do you want me to do if I work in you lab? Thank you.

Best wishes
Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: +86-27-87199229
Email:(b)(6)

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia(b)(6)
Sent: Thursday, December 13, 2012 11:25 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Thank you very much for your email and the interest in my work.

You have an excellent CV and we would be interested in working with you. Can you tell me a little bit more about your current position? Do you work at biosafety level 4? Do you collect patient and tick samples from the field?

Although there is currently no extra funding in my laboratory for a postdoc, we might have another possibility to find funding for you: our laboratory includes the National Biocontainment Training Center, which gives out fellowships to visiting scientists. The goal of this program is to establish a link between biocontainment laboratories from around the world.
My question for you is: are you planning on returning to Wuhan once you finish you work with us? If yes, than that would it easier for us to get you the fellowship.

Looking forward to hear from you,

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
Member, Institute for Human Infection and Immunity
301 University Blvd., Galveston, TX 77555-0610

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010757

P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

Working together to work wonders™

From: Han Xia (b)(6)
Sent: Tuesday, December 11, 2012 2:59 AM
To: Bente, Dennis A.
Subject: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

I am writing to you about the possibility of studying and researching in your lab as a visiting scholar or postdoc.

Your researches are of particular interest to me, especially tick-borne viruses (such as CCHF). Your group's research is so outstanding
that I believe that if given the opportunity to study and research under your guidance, the experience at your lab can improve my research capacity, learn technology that is more new, and enlarge my knowledge in this field,which will benefit me a lot.

I am a Research assistant at Wuhan institute of virology,Chinese academy of Science,China. I graduated from Chinese Academy of Sciences and got the Doctor degree of Biochemisty and Molecular Biology in July 2011.

Since that time, I have been working in Development in the minigenome system and Epidemiological investigation for CCHFV. I have been completed the epidmiological survey of CCHFV in Yunnan, China,2008 (International journal of infectious diseases, 07/2011; 15(7): e459-63). And the establishment of minigenome system for China YL04057 is in progress and almost completed.

In recently, we developed the embryonated chicken egg model for CCHFV, the result was under reviewing in Virus research (Infection and propagation of CCHFV in embryonated chicken eggs).

My current research focuses on viral infection diesease.I am satisfied with my research work. However, due to the condition of the experiments and personal experiments are restricted, I would like to find an opportunity to go abroad for further study and research.

My CV is in the attachment. Your comments and consideration will be highly appreciated.
I am looking forward to hear from you.

Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010758

Tel and Fax: +86-27-87199229
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010759

From: LeDuc, James W.
Sent: Tuesday, March 5, 2013 10:00 AM
To: Bente, Dennis A (b)(6)
Subject: RE: China visit

Dennis, Han,

I plan to attend the international hantavirus meetings to be held in Beijing 5-7 June 2013, then a small group from the conference will fly to Xian to see the warriors from 8-10 June. I was thinking that it might be convenient for me to go on then to Wuhan for a day of discussions on possible collaborations, traveling on June 10 and spending the day of 11 June in discussions at the Institute, then return to the USA on 12 June. That said, I am still very much at the exploratory phase, since I have not developed a real concept plan yet, nor have I sought any official support from UTMB. My basic thought is that both our organizations are working on similar research topics in virology and both of us have biocontainment facilities, so there should be many topics of common interest and opportunities for collaboration. It would be interesting and useful to informally explore how we might work together more closely in the future. Based on these very preliminary discussions, perhaps we could then develop a more structured plan for the future.

Thanks, Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: Bente, Dennis A.
Sent: Monday, March 04, 2013 11:00 PM
To: LeDuc, James W.
Subject: China visit

Dear Jim,
Please see below.
Dennis

From: Han Xia (b)(6)
Sent: Sunday, March 03, 2013 8:01 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

FOIA Confidential Treatment Requested by Univ of Texas System

Could tell me the date range of the Dr. LeDuc in June in China (From Pfor. Xiao's e-mail, he said that Dr. LeDuc will come to Beijing to attend a meeting about Hantaan virus)? My boss let me to ask the date.

Maybe, there is a possible for us to invite Dr. LeDuc to give us a speech and talk the other things.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, February 27, 2013 12:55 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

This is great news! Congratulations on the visiting scholarship! All of us here are very excited that you got the funding. A start date in August would work very well for me. I will make sure that we will help you with everything including the (b)(6) as much as we can. I will talk to our international office to find out what steps we have to do to get the (b)(6) process started.

Thank you also for all the information. I will forward it to Dr. LeDuc. He told me today that he is very happy that you acquired the funding.

I will get back to you soon with more details on the (b)(6)

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Monday, February 25, 2013 6:01 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
Firstly, I have told to my boss about that you need the contact information of the institute directors. She said I can give you the web-link (http://english.whiov.cas.cn/au/ds/) of the directors and let me tell you the leadership and the division of responsibility.
At the present time, the director of Wuhan institute of Virology is Prof.Xinwen Chen.He is in charge of the comprehensive work of the Institute. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100082.html
And the Secretary of the Party Committee of Wuhan institute of Virology is Prof. Zhi-ming Yuan. He is mainly in charge of the international cooperation and the bio-safety. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100080.html
Secondly, I am glad to tell you I have acquired the funding (ensure the basic cost of living in US) from Chinese Academy and Sciences to support me to UTMB. On January, I applied the visiting scholar sponsored by the Chinese Academy of Sciences. But at that time, I don't think the result could come out so quickly and not sure

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010761

about whether I could acquire the support. This funding will not limit my work and I could spend all the time to do research with you.
But the time I go to US maybe (b)(6) Due to I must to pass a English Test in China (need by the support) in June and the test result will come out in Aug. And need the invitation and (b)(6) form from you.
If you need any other informations please tell me.
Best wishes,
Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, February 19, 2013 10:29 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I hope you are doing well. I just wanted to see if your boss had a chance to talk to the director of the biocontainment lab. Are there any news?

Secondly, I wanted to ask you if you can send me the contact information (email) of the director of the institute of virology in Wuhan. Dr. LeDuc will be traveling to China soon and would like to talk to the director about a possible collaboration of our two universities.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 30, 2013 9:30 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

My boss thinks it may be better if she contacts with the Director of our biocontainment lab firstly.
And then she will give me some suggestions.

I will let you know soon about the progress.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, January 29, 2013 4:57 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

I just wanted to emphasize again that we understand that you probably will not know if there is a position available at the biocontainment group in Wuhan. Dr. LeDuc wants to see some general statement that you would be welcome to return as a staff member working in biocontainment. Maybe it would make sense for the biocontainment group to contact Dr. LeDuc so that they can discuss the details. What do you think?

Don't hesitate to ask more questions!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010762

Dennis

From: Han Xia (b)(6)
Sent: Sunday, January 27, 2013 8:28 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks. I will try my best to take the opportunity.

I talked to my boss, and she is willing to try to help me and contact with the biocontainment Group. Do you have the sample contract embodying all terms and the template of the letter need from biocontainment lab? We want to know if we sign the contract, what duties should be carry out in accordance with the contract. And this will help us to explain the situation of us to the leadership.

Then I will apply the the government funding to support me. However this way is time-consuming. After the complete of the apply, it is a long wait.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, January 25, 2013 1:19 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Let me start off by telling you that I can fully understand your concerns.

Let me tell you briefly about your opportunities with us:
I currently have 5 people working in my laboratory and I –at the moment- have no extra funding to hire more postdocs or students. I would be very excited to have you working in my laboratory, but I this point you I cannot hire an extra person. If you would decide to pay for your living expenses, you can certainly join us and work in my laboratory. I am aware that this is probably not possible and I fully understand why that might not be possible. Because of this situation, I decided to talk to Dr. LeDuc and see if there is another way of finding funding for you because I think you would be a great addition to our laboratory.

The fellowship that Dr. LeDuc suggested is specifically meant to improve the exchange between high biocontainment facilities around the world and our laboratory. We fully understand that at this point you don't know what you will do in 1 or 2 years or if there will be a job at the high containment laboratory in Wuhan. But you have to understand our requirements: we don't want to invest a lot of time and effort into training a candidate in high biocontainment for 2 years and then the candidate goes back to their country and works in a completely different area of science. That would not increase the scientific exchange between us and other biocontainment laboratories. I hope you understand why we would like to see the candidates be somehow connect to their high biocontainment facility

At this point I would like to suggest two things:
1) would it be possible for your boss (or you) to get in touch with the biocontainment group at Wuhan and explain your situation? Maybe the leaders in that group could then contact Dr. LeDuc?
2) If all this fails, have you checked if there might be some Chinese funding (from the government or other organizations) that could pay for your time here with us?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010763

Please do not hesitate to ask me questions and to tell me your thoughts and concerns.

Best wishes,

Dennis

From: Han Xia(b)(6)
Sent: Wednesday, January 23, 2013 7:23 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

I am glad to receive Dr. James W. Le Duc's e-mail. Thank you very much for your and Dr. James W. Le Duc's good consideration
for me.I think before I reply to him, there are some details I want to discuss to you.

Personally, my long term career goals is to be a scientist like you. After complete my postdoctoral training, I will return to Wuhan
and prefer to find a faculty position in a University of Wuhan (do some research and convey the knowledge to students).

For the research, now I focus on the CCHFV and very interest to work to you with CCHFV. And I think the most important experience
I learn from you is the way of thinking and problem-solving in the progress of the research rather than the object of the study.
However, maybe I will expend or change my feild in future, and study other pathogens not only CCHFV. The experience to work in
your lab will very helpful to me in the other research not only limited in BSL-4.

And I talk to my boss, she is the PI of the Group of Virus Resources and Information Group and will retire in July, 2014. And She
said there could be carry out some cooperations to you in the level of Group, such as the help of the tick sample collection in
China. I think the power of my boss (limited in the Group) is very limited compare to your boss Director James W. Le Duc.

However in Dr. James W. Le Duc's e-mail, one rule of that fellowship is **on my return I will be working within the new
biocontainment laboratory of Wuhan Institute of Virology**. Is it means that after complete the postdoc work with you
I must return back to work in the biocontainment laboratory of Wuhan Institute of Virology as soon as possible ? If yes, I think this will limit my career
in future. I remeber in the first email you reply to me, you asked me a quseation 'Will me return to Wuhan when I complete the postdoc
training?' My answer was 'I will return to Wuhan'. But in that time, I think the question is just about wether I will retrun to Wuhan
to find a job, not limited in insititue or univeristy. In addition, according to the management system of the institute, if I decide

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010764

to accept that postdoc positon, I have to quit my now job, and the Wuhan institute of Virology will not keep my position. And when
after 1 or 2 years I return to Wuhan, I must find a new job through applying the position.

I particularly wish to have the opportunity to work with you, and the experience will be very helpful to me in future. And are there any
other fundings could choice for the postdoc positon ?

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, January 17, 2013 12:14 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi Han,

I talked to Dr. LeDuc last week. There might be a possibility for you to come and work with us.
Dr. LeDuc is currently traveling in India and will be back next week. He will send you an email with all the details next week.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 16, 2013 7:05 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Have you talk to the director Dr. James LeDuc ? And could you tell me something about that ?

Looking forward to your reply. Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Saturday, January 5, 2013 5:12 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

Thanks for the email and the presentation. You don't need to prepare a PPT for the call. It is just a casual Skype call.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010765

How about I call you on Monday, 7th at 6:00pm my time through Skype. It will be Tuesday, 8:00am your time. Is this too early for you? If it is too early, than I can call 1 hour later. Let me know what you want to do.

I will have a student with me during the Skype call. Her name is (b)(6) and she is originally from the Wuhan region. Her parents still live in Wuhan. I thought it would be nice if you can talk to her about what to expect in Galveston and from the University.

Please let me know if this works for you.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Friday, January 04, 2013 12:11 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
I added you and left a message in the Skype.
The time in here is 14 hours earlier than Houston.
I don't know whether need to prepare a PPT in the interview, and I write a sample presentaion could help to increase the understanding to me.
Best wishes,
Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia <(b)(6)
Sent: Wednesday, December 26, 2012 12:17 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,
I found you on Skype and send you an invite. How about we talk Monday the 7th? How many hours ahead of us are you?
Best wishes,
Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 4:38 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,
Hi, our New Year holiday is Januray 1 to 3, and the work time in the first week is 4-11, these days is available.
I have a Skype account: (b)(6), and we could use this to communicate.

Once again, wish you a happy holiday !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia <(b)(6)>
Sent: Monday, December 24, 2012 3:36 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010766

Merry Christmas and Happy New Year to you too!
I would like to apologize that I did not get back to you sooner. We were thinking to have a phone conference and give you a phone call. However, we can use a different communication tool as well. Personally, I do not use MSN but I use Skype. Have you used this before?
We do not need your boss to join us during the conference call. I just thought she might like to join us, but it is not necessary. Whe would be a good time for you? Are you available the first week of January?

Best wishes,

Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 12:56 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,

Merry Christmas and Happy New year !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, December 21, 2012 6:26 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I met with the director of the Galveston National Laboratory, Dr. James LeDuc. He suggested setting up a teleconference with you and your mentor sometime after the first of the New Year. During the conference call we can discuss your interests and expectations of the post-doc experience. We can also discuss timelines and options for finances. Could you please tell me when would be a good day and time for you and your mentor to hold a teleconference?

Before the teleconference we can jointly develop an agenda of the topics that we want to discuss.
Would this work for you?

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 (b)(6)
F 409.266.6810 E dabente@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010767

utmb Health

"Working together to make wonders"

From: Han Xia (b)(6)
Sent: Friday, December 14, 2012 12:28 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

Thank you for your reply.

1. My current position is an assistant research fellow (assist Principle Investigator to apply and complete the research projects and guide the MD or PhD students) in Virus Resource and information Group of Wuhan institute of virology.
My research work was focus on epidemiology and molecular biology of tick-boren virus (maily on CCHFV). There are three parts:
(1) Development of minigenome system for CCHFV YL04057. Now I have aquired the YL04057's completed cDNA clone, and construted the plasimd pcDNA/L,
pcDNA/S, pRF-LUTR-GFP, pRF-MUTR-GFP and pRF-SUTR-GFP. Currently, the result of the co-transfection of pcDNA/L, pcDNA/S and pRF-LUTR-GFP is the best. Next, I will optimization of the conditions to make the system more stable.

(2) Epidemiology survey of CCHFV in Yunnan and Xinjiang of China. In China, the main infected area is in Xinjiang, but there is no outbreak and patient in recent years.

We collected the human, livestock and tick samples in the areas which have been previously reported CCHF or isolated CCHFV. Then used the ELISA, qReal-time PCR, or 454 high-throughput sequencing to analysis this samples.

And recently, some tick samples from Yunnan were detected use 454 sequencing and there are some intersting data need to further analysis.

(3) Epidemiology and molecular biology of Influenza virus. Our group's traditional fields is influenza virus , and I occasionally participate in the project of influenza virus.

2. I don't work at BSL-4. I work maily in BSL-2 and partly in BSL-3. Firstly, now in Wuhan Insititue of Virology, the BSL-4 lab is under construction. Secondly,
according to China's biosafety regulations the operate of CCHFV in cell-level could be at BSL-3 lab. Lastly, due to my work about CCHFV was mainly
in molecular level and sample tested, not related to the animal experiment.

3. Yes, I am planning on returning to Wuhan once I finish the work with you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010768

And I have a question, what fields of research do you want me to do if I work in you lab? Thank you.

Best wishes
Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: (b)(6)
Email: (b)(6)

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, December 13, 2012 11:25 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Thank you very much for your email and the interest in my work.

You have an excellent CV and we would be interested in working with you. Can you tell me a little bit more about your current position? Do you work at biosafety level 4? Do you collect patient and tick samples from the field?

Although there is currently no extra funding in my laboratory for a postdoc, we might have another possibility to find funding for you: our laboratory includes the National Biocontainment Training Center, which gives out fellowships to visiting scientists. The goal of this program is to establish a link between biocontainment laboratories from around the world.
My question for you is: are you planning on returning to Wuhan once you finish you work with us? If yes, than that would it easier for us to get you the fellowship.

Looking forward to hear from you,

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
Member, Institute for Human Infection and Immunity
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010769

utmb Health

"Working together to work wonders!"

From: Han Xia (b)(6)
Sent: Tuesday, December 11, 2012 2:59 AM
To: Bente, Dennis A.
Subject: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

I am writing to you about the possibility of studying and researching in your lab as a visiting scholar or postdoc.

Your researches are of particular interest to me, especially tick-borne viruses (such as CCHF). Your group's research is so outstanding
that I believe that if given the opportunity to study and research under your guidance, the experience at your lab can improve my research capacity, learn technology that is more new, and enlarge my knowledge in this field,which will benefit me a lot.

I am a Research assistant at Wuhan institute of virology,Chinese academy of Science,China. I graduated from Chinese Academy of Sciences and got the Doctor degree of Biochemisty and Molecular Biology in July 2011.

Since that time, I have been working in Development in the minigenome system and Epidemiological investigation for CCHFV. I have been completed the epidmiological survey of CCHFV in Yunnan, China,2008 (International journal of infectious diseases, 07/2011; 15(7): e459-63). And the establishment of minigenome system for China YL04057 is in progress and almost completed.

In recently, we developed the embryonated chicken egg model for CCHFV, the result was under reviewing in Virus research (Infection and propagation of CCHFV in embryonated chicken eggs).

My current research focuses on viral infection diesease.I am satisfied with my research work. However, due to the condition of the experiments and personal experiments are restricted, I would like to find an opportunity to go abroad for further study and research.

My CV is in the attachment. Your comments and consideration will be highly appreciated.
I am looking forward to hear from you.

Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: +86-27-87199229
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010771

From: Han Xia (b)(6)
Sent: Sunday, March 10, 2013 8:31 PM
To: Bente, Dennis A.
Cc: LeDuc, James W.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

About the Dr. Leduc's China visit. My boss tell the date and the conditions to the our center's Director, and hope could invite Dr. Leduc to visit our institute and then could have a meet to the institute's Director. However, in June the Director of our center will in abroad.
And another way is to apply the Gehong Forum which support the experts to do an academic report in our institute, but the person responsible for the reception were just the ordinary staff. I think this will not reach the purpose to discuss cooperation.

I am very sorry for this situation. My boss has to do the things within her able, her administrative powers is very limited.

And please convey our apologies to Dr.Leduc. Maybe Dr.Leduc could directly contact to the Prof. Zhiming Yuan(his information in the website in the pre-email).

In addition, I have received the Ms. Ramos e-mail about (b)(6) Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, March 8, 2013 2:43 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

My secretary, Ms. Ramos, will contact you very shortly about (b)(6)
(b)(6)

Nevertheless, if you have questions or something is not clear to you please do not hesitate to contact me.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Thursday, February 28, 2013 3:47 AM

FOIA Confidential Treatment Requested by Univ of Texas System

To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks for the things you do for me ! I think the last obstacle for me to work with you is the English test for me.
Only pass the exam, I can start the procedure of abroad. These months I will work hard to prepare for the test, and hope to get good news.

Prof. Zhi-ming Yuan is the head of the BSL-4 project in Wuhan now.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, February 27, 2013 12:55 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

This is great news! Congratulations on the visiting scholarship! All of us here are very excited that you got the funding. A start date in August would work very well for me. I will make sure that we will help you with everything including the (b)(6) as much as we can. I will talk to our international office to find out what steps we have to do to get the (b)(6) process started.

Thank you also for all the information. I will forward it to Dr. LeDuc. He told me today that he is very happy that you acquired the funding.

I will get back to you soon with more details on the (b)(6)

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Monday, February 25, 2013 6:01 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
Firstly, I have told to my boss about that you need the contact information of the institute directors. She said I can give you the web-link (http://english.whiov.cas.cn/au/ds/) of the directors and let me tell you the leadership and the division of responsibility.
At the present time, the director of Wuhan institute of Virology is Prof.Xinwen Chen.He is in charge of the comprehensive work of the Institute. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100082.html
And the Secretary of the Party Committee of Wuhan institute of Virology is Prof. Zhi-ming Yuan. He is mainly in charge of the international cooperation and the bio-safety. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100080.html

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010738

Secondly, I am glad to tell you I have acquired the funding (ensure the basic cost of living in US) from Chinese Academy and Sciences to support me to UTMB. On January, I applied the visiting scholar sponsored by the Chinese Academy of Sciences. But at that time, I don't think the result could come out so quickly and not sure about whether I could acquire the support. This funding will not limit my work and I could spend all the time to do research with you.
But the time I go to US maybe after (b)(6) Due to I must to pass a English Test in China (need by the support) in June and the test result will come out in Aug. And need the invitation and (b)(6) from you.
If you need any other informations please tell me.
Best wishes,
Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, February 19, 2013 10:29 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I hope you are doing well. I just wanted to see if your boss had a chance to talk to the director of the biocontainment lab. Are there any news?

Secondly, I wanted to ask you if you can send me the contact information (email) of the director of the institute of virology in Wuhan. Dr. LeDuc will be traveling to China soon and would like to talk to the director about a possible collaboration of our two universities.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 30, 2013 9:30 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

My boss thinks it may be better if she contacts with the Director of our biocontainment lab firstly.
And then she will give me some suggestions.

I will let you know soon about the progress.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, January 29, 2013 4:57 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

I just wanted to emphasize again that we understand that you probably will not know if there is a position available at the biocontainment group in Wuhan. Dr. LeDuc wants to see some general statement that you would be welcome to return as

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010739

a staff member working in biocontainment. Maybe it would make sense for the biocontainment group to contact Dr. LeDuc so that they can discuss the details. What do you think?

Don't hesitate to ask more questions!

Dennis

From: Han Xia (b)(6)
Sent: Sunday, January 27, 2013 8:28 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks. I will try my best to take the opportunity.

I talked to my boss, and she is willing to try to help me and contact with the biocontainment Group. Do you have the sample contract embodying all terms and the template of the letter need from biocontainment lab? We want to know if we sign the contract, what duties should be carry out in accordance with the contract. And this will help us to explain the situation of us to the leadership.

Then I will apply the the government funding to support me. However this way is time-consuming. After the complete of the apply, it is a long wait.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, January 25, 2013 1:19 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Let me start off by telling you that I can fully understand your concerns.

Let me tell you briefly about your opportunities with us:
I currently have 5 people working in my laboratory and I –at the moment- have no extra funding to hire more postdocs or students. I would be very excited to have you working in my laboratory, but I this point you I cannot hire an extra person. If you would decide to pay for your living expenses, you can certainly join us and work in my laboratory. I am aware that this is probably not possible and I fully understand why that might not be possible. Because of this situation, I decided to talk to Dr. LeDuc and see if there is another way of finding funding for you because I think you would be a great addition to our laboratory.

The fellowship that Dr. LeDuc suggested is specifically meant to improve the exchange between high biocontainment facilities around the world and our laboratory. We fully understand that at this point you don't know what you will do in 1 or 2 years or if there will be a job at the high containment laboratory in Wuhan. But you have to understand our requirements: we don't want to invest a lot of time and effort into training a candidate in high biocontainment for 2 years and then the candidate goes back to their country and works in a completely different area of science. That would not increase the scientific exchange between us and other biocontainment laboratories. I hope you understand why we would like to see the candidates be somehow connect to their high biocontainment facility

At this point I would like to suggest two things:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010740

1) would it be possible for your boss (or you) to get in touch with the biocontainment group at Wuhan and explain your situation? Maybe the leaders in that group could then contact Dr. LeDuc?
2) If all this fails, have you checked if there might be some Chinese funding (from the government or other organizations) that could pay for your time here with us?

Please do not hesitate to ask me questions and to tell me your thoughts and concerns.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 23, 2013 7:23 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

I am glad to receive Dr. James W. Le Duc's e-mail. Thank you very much for your and Dr. James W. Le Duc's good consideration
for me.I think before I reply to him, there are some details I want to discuss to you.

Personally, my long term career goals is to be a scientist like you. After complete my postdoctoral training, I will return to Wuhan
and prefer to find a faculty position in a University of Wuhan (do some research and convey the knowledge to students).

For the research, now I focus on the CCHFV and very interest to work to you with CCHFV. And I think the most important experience
I learn from you is the way of thinking and problem-solving in the progress of the research rather than the object of the study.
However, maybe I will expend or change my feild in future, and study other pathogens not only CCHFV. The experience to work in
your lab will very helpful to me in the other research not only limited in BSL-4.

And I talk to my boss, she is the PI of the Group of Virus Resources and Information Group and will retire in (b)(6) And She
said there could be carry out some cooperations to you in the level of Group, such as the help of the tick sample collection in
China. I think the power of my boss (limited in the Group) is very limited compare to your boss Director James W. Le Duc.

However in Dr. James W. Le Duc's e-mail, one rule of that fellowship is **on my return I will be working within the new
biocontainment laboratory of Wuhan Institute of Virology**. Is it means that after complete the postdoc work with you
I must return back to work in the biocontainment laboratory of Wuhan Institute of Virology as soon as possible ? If yes, I think this will limit my career
in future. I remeber in the first email you reply to me, you asked me a quseation 'Will me return to Wuhan when I complete the postdoc

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010741

training?' My answer was 'I will return to Wuhan'. But in that time, I think the question is just about wether I will retrun to Wuhan
to find a job, not limited in insititue or univeristy. In addition, according to the management system of the institute, if I decide
to accept that postdoc positon, I have to quit my now job, and the Wuhan institute of Virology will not keep my position. And when
after 1 or 2 years I return to Wuhan, I must find a new job through applying the position.

I particularly wish to have the opportunity to work with you, and the experience will be very helpful to me in future. And are there any
other fundings could choice for the postdoc positon ?

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, January 17, 2013 12:14 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi Han,

I talked to Dr. LeDuc last week. There might be a possibility for you to come and work with us.
Dr. LeDuc is currently traveling in India and will be back next week. He will send you an email with all the details next week.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 16, 2013 7:05 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Have you talk to the director Dr. James LeDuc ? And could you tell me something about that ?

Looking forward to your reply. Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Saturday, January 5, 2013 5:12 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

FOIA Confidential Treatment Requested by Univ of Texas System

Thanks for the email and the presentation. You don't need to prepare a PPT for the call. It is just a casual Skype call.

How about I call you on Monday, 7th at 6:00pm my time through Skype. It will be Tuesday, 8:00am your time. Is this too early for you? If it is too early, than I can call 1 hour later. Let me know what you want to do.

I will have a student with me during the Skype call. Her name is (b)(6) and she is originally from the Wuhan region. Her parents still live in Wuhan. I thought it would be nice if you can talk to her about what to expect in Galveston and from the University.

Please let me know if this works for you.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Friday, January 04, 2013 12:11 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
I added you and left a message in the Skype.
The time in here is 14 hours earlier than Houston.
I don't know whether need to prepare a PPT in the interview, and I write a sample presentaion could help to increase the understanding to me.
Best wishes,
Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia <(b)(6)
Sent: Wednesday, December 26, 2012 12:17 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,
I found you on Skype and send you an invite. How about we talk Monday the 7th? How many hours ahead of us are you?
Best wishes,
Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 4:38 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,
Hi, our New Year holiday is Januray 1 to 3, and the work time in the first week is 4-11, these days is available.
I have a Skype account: (b)(6), and we could use this to communicate.

Once again, wish you a happy holiday !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia <(b)(6)>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010743

Sent: Monday, December 24, 2012 3:36 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

Merry Christmas and Happy New Year to you too!
I would like to apologize that I did not get back to you sooner. We were thinking to have a phone conference and give you a phone call. However, we can use a different communication tool as well. Personally, I do not use MSN but I use Skype. Have you used this before?
We do not need your boss to join us during the conference call. I just thought she might like to join us, but it is not necessary. Whe would be a good time for you? Are you available the first week of January?

Best wishes,

Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 12:56 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,

Merry Christmas and Happy New year !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, December 21, 2012 6:26 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I met with the director of the Galveston National Laboratory, Dr. James LeDuc. He suggested setting up a teleconference with you and your mentor sometime after the first of the New Year. During the conference call we can discuss your interests and expectations of the post-doc experience. We can also discuss timelines and options for finances. Could you please tell me when would be a good day and time for you and your mentor to hold a teleconference?

Before the teleconference we can jointly develop an agenda of the topics that we want to discuss.
Would this work for you?

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 (b)(6)
F 409.266.6810 E dabente@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010744

utmb Health

"Working together to make wonders"

From: Han Xia(b)(6)
Sent: Friday, December 14, 2012 12:28 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

Thank you for your reply.

1. My current position is an assistant research fellow (assist Principle Investigator to apply and complete the research projects and guide the MD or PhD students) in Virus Resource and information Group of Wuhan institute of virology.
My research work was focus on epidemiology and molecular biology of tick-boren virus (maily on CCHFV). There are three parts:
(1) Development of minigenome system for CCHFV YL04057. Now I have aquired the YL04057's completed cDNA clone, and construted the plasimd pcDNA/L,
pcDNA/S, pRF-LUTR-GFP, pRF-MUTR-GFP and pRF-SUTR-GFP. Currently, the result of the co-transfection of pcDNA/L, pcDNA/S and pRF-LUTR-GFP is the best. Next, I will optimization of the conditions to make the system more stable.

(2) Epidemiology survey of CCHFV in Yunnan and Xinjiang of China. In China, the main infected area is in Xinjiang, but there is no outbreak and patient in recent years.

We collected the human, livestock and tick samples in the areas which have been previously reported CCHF or isolated CCHFV. Then used the ELISA, qReal-time PCR, or 454 high-throughput sequencing to analysis this samples.

And recently, some tick samples from Yunnan were detected use 454 sequencing and there are some intersting data need to further analysis.

(3) Epidemiology and molecular biology of Influenza virus. Our group's traditional fields is influenza virus , and I occasionally participate in the project of influenza virus.

2. I don't work at BSL-4. I work maily in BSL-2 and partly in BSL-3. Firstly, now in Wuhan Insititue of Virology, the BSL-4 lab is under construction. Secondly,
according to China's biosafety regulations the operate of CCHFV in cell-level could be at BSL-3 lab. Lastly, due to my work about CCHFV was mainly
in molecular level and sample tested, not related to the animal experiment.

3. Yes, I am planning on returning to Wuhan once I finish the work with you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010745

And I have a question, what fields of research do you want me to do if I work in you lab? Thank you.

Best wishes
Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: +86-27-87199229
Email:(b)(6)

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia(b)(6)
Sent: Thursday, December 13, 2012 11:25 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Thank you very much for your email and the interest in my work.

You have an excellent CV and we would be interested in working with you. Can you tell me a little bit more about your current position? Do you work at biosafety level 4? Do you collect patient and tick samples from the field?

Although there is currently no extra funding in my laboratory for a postdoc, we might have another possibility to find funding for you: our laboratory includes the National Biocontainment Training Center, which gives out fellowships to visiting scientists. The goal of this program is to establish a link between biocontainment laboratories from around the world.
My question for you is: are you planning on returning to Wuhan once you finish you work with us? If yes, than that would it easier for us to get you the fellowship.

Looking forward to hear from you,

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
Member, Institute for Human Infection and Immunity
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 M(b)(6)
F 409.266.6810 E dabente@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010746

utmb Health

"Working together to work wonders!"

From: Han Xia (b)(6)
Sent: Tuesday, December 11, 2012 2:59 AM
To: Bente, Dennis A.
Subject: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

I am writing to you about the possibility of studying and researching in your lab as a visiting scholar or postdoc.

Your researches are of particular interest to me, especially tick-borne viruses (such as CCHF). Your group's research is so outstanding
that I believe that if given the opportunity to study and research under your guidance, the experience at your lab can improve my research capacity, learn technology that is more new, and enlarge my knowledge in this field,which will benefit me a lot.

I am a Research assistant at Wuhan institute of virology,Chinese academy of Science,China. I graduated from Chinese Academy of Sciences and got the Doctor degree of Biochemisty and Molecular Biology in July 2011.

Since that time, I have been working in Development in the minigenome system and Epidemiological investigation for CCHFV. I have been completed the epidmiological survey of CCHFV in Yunnan, China,2008 (International journal of infectious diseases, 07/2011; 15(7): e459-63). And the establishment of minigenome system for China YL04057 is in progress and almost completed.

In recently, we developed the embryonated chicken egg model for CCHFV, the result was under reviewing in Virus research (Infection and propagation of CCHFV in embryonated chicken eggs).

My current research focuses on viral infection diesease.I am satisfied with my research work. However, due to the condition of the experiments and personal experiments are restricted, I would like to find an opportunity to go abroad for further study and research.

My CV is in the attachment. Your comments and consideration will be highly appreciated.
I am looking forward to hear from you.

Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: (b)(6)
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010748

From: LeDuc, James W.
Sent: Monday, March 11, 2013 4:04 PM
To: Han Xia;Bente, Dennis A.
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

Thank you for the additional information regarding the availability of your director during June. Given that he will not be available, I will not plan on visiting Wuhan at this time. This is not a problem and I will follow up with a message directly to Professor Xinwen Chen to explore alternate dates and to extend an invitation to him to visit UTMB should he have the occasion to be in the USA.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: Han Xia (b)(6)
Sent: Sunday, March 10, 2013 8:31 PM
To: Bente, Dennis A.
Cc: LeDuc, James W.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

About the Dr. Leduc's China visit. My boss tell the date and the conditions to the our center's Director, and hope could invite Dr. Leduc to visit our institute and then could have a meet to the institute's Director. However, in June the Director of our center will in abroad.
And another way is to apply the Gehong Forum which support the experts to do an academic report in our institute, but the person responsible for the reception were just the ordinary staff. I think this will not reach the purpose to discuss cooperation.

I am very sorry for this situation. My boss has to do the things within her able, her administrative powers is very limited.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010725

And please convey our apologies to Dr.Leduc. Maybe Dr.Leduc could directly contact to the Prof. Zhiming Yuan(his information in the website in the pre-email).

In addition, I have received the Ms. Ramos e-mail about (b)(6). Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, March 8, 2013 2:43 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

My secretary, Ms. Ramos, will contact you very shortly about (b)(6)

(b)(6)

Nevertheless, if you have questions or something is not clear to you please do not hesitate to contact me.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Thursday, February 28, 2013 3:47 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks for the things you do for me ! I think the last obstacle for me to work with you is the English test for me.
Only pass the exam, I can start the procedure of abroad. These months I will work hard to prepare for the test, and hope to get good news.

Prof. Zhi-ming Yuan is the head of the BSL-4 project in Wuhan now.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, February 27, 2013 12:55 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010726

This is great news! Congratulations on the visiting scholarship! All of us here are very excited that you got the funding. A start date in August would work very well for me. I will make sure that we will help you with everything including the (b)(6) as much as we can. I will talk to our international office to find out what steps we have to do to get the (b)(6) process started.

Thank you also for all the information. I will forward it to Dr. LeDuc. He told me today that he is very happy that you acquired the funding.

I will get back to you soon with more details on the (b)(6)

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Monday, February 25, 2013 6:01 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
Firstly, I have told to my boss about that you need the contact information of the institute directors. She said I can give you the web-link (http://english.whiov.cas.cn/au/ds/) of the directors and let me tell you the leadership and the division of responsibility.
At the present time, the director of Wuhan institute of Virology is Prof.Xinwen Chen.He is in charge of the comprehensive work of the Institute. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100082.html
And the Secretary of the Party Committee of Wuhan institute of Virology is Prof. Zhi-ming Yuan. He is mainly in charge of the international cooperation and the bio-safety. His information is below:
http://sourcedb.cas.cn/sourcedb_whiov_cas/yw/rck/200907/t20090718_2100080.html
Secondly, I am glad to tell you I have acquired the funding (ensure the basic cost of living in US) from Chinese Academy and Sciences to support me to UTMB. On January, I applied the visiting scholar sponsored by the Chinese Academy of Sciences. But at that time, I don't think the result could come out so quickly and not sure about whether I could acquire the support. This funding will not limit my work and I could spend all the time to do research with you.
But the time I go to US maybe after (b)(6) Due to I must to pass a English Test in China (need by the support) in June and the test result will come out in Aug. And need the invitation and (b)(6) form from you.
If you need any other informations please tell me.
Best wishes,
Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, February 19, 2013 10:29 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I hope you are doing well. I just wanted to see if your boss had a chance to talk to the director of the biocontainment lab. Are there any news?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010727

Secondly, I wanted to ask you if you can send me the contact information (email) of the director of the institute of virology in Wuhan. Dr. LeDuc will be traveling to China soon and would like to talk to the director about a possible collaboration of our two universities.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 30, 2013 9:30 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

My boss thinks it may be better if she contacts with the Director of our biocontainment lab firstly.
And then she will give me some suggestions.

I will let you know soon about the progress.

Best wishes,

Han
From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Tuesday, January 29, 2013 4:57 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

I just wanted to emphasize again that we understand that you probably will not know if there is a position available at the biocontainment group in Wuhan. Dr. LeDuc wants to see some general statement that you would be welcome to return as a staff member working in biocontainment. Maybe it would make sense for the biocontainment group to contact Dr. LeDuc so that they can discuss the details. What do you think?

Don't hesitate to ask more questions!

Dennis

From: Han Xia (b)(6)
Sent: Sunday, January 27, 2013 8:28 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Thanks. I will try my best to take the opportunity.

I talked to my boss, and she is willing to try to help me and contact with the biocontainment Group. Do you have the sample contract embodying all terms and the template of the letter need from biocontainment lab? We want to know if we sign the contract, what duties should be carry out in accordance with the contract. And this will help us to explain the situation of us to the leadership.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010728

Then I will apply the the government funding to support me. However this way is time-consuming. After the complete of the apply, it is a long wait.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, January 25, 2013 1:19 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

Let me start off by telling you that I can fully understand your concerns.

Let me tell you briefly about your opportunities with us:
I currently have 5 people working in my laboratory and I –at the moment- have no extra funding to hire more postdocs or students. I would be very excited to have you working in my laboratory, but I this point you I cannot hire an extra person. If you would decide to pay for your living expenses, you can certainly join us and work in my laboratory. I am aware that this is probably not possible and I fully understand why that might not be possible. Because of this situation, I decided to talk to Dr. LeDuc and see if there is another way of finding funding for you because I think you would be a great addition to our laboratory.

The fellowship that Dr. LeDuc suggested is specifically meant to improve the exchange between high biocontainment facilities around the world and our laboratory. We fully understand that at this point you don't know what you will do in 1 or 2 years or if there will be a job at the high containment laboratory in Wuhan. But you have to understand our requirements: we don't want to invest a lot of time and effort into training a candidate in high biocontainment for 2 years and then the candidate goes back to their country and works in a completely different area of science. That would not increase the scientific exchange between us and other biocontainment laboratories. I hope you understand why we would like to see the candidates be somehow connect to their high biocontainment facility

At this point I would like to suggest two things:
1) would it be possible for your boss (or you) to get in touch with the biocontainment group at Wuhan and explain your situation? Maybe the leaders in that group could then contact Dr. LeDuc?
2) If all this fails, have you checked if there might be some Chinese funding (from the government or other organizations) that could pay for your time here with us?

Please do not hesitate to ask me questions and to tell me your thoughts and concerns.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 23, 2013 7:23 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

I am glad to receive Dr. James W. Le Duc's e-mail. Thank you very much for your and Dr. James W. Le Duc's good consideration
for me.I think before I reply to him, there are some details I want to discuss to you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010729

Personally, my long term career goals is to be a scientist like you. After complete my postdoctoral training, I will return to Wuhan
and prefer to find a faculty position in a University of Wuhan (do some research and convey the knowledge to students).

For the research, now I focus on the CCHFV and very interest to work to you with CCHFV. And I think the most important experience
I learn from you is the way of thinking and problem-solving in the progress of the research rather than the object of the study.
However, maybe I will expend or change my feild in future, and study other pathogens not only CCHFV. The experience to work in
your lab will very helpful to me in the other research not only limited in BSL-4.

And I talk to my boss, she is the PI of the Group of Virus Resources and Information Group and will retire in July, 2014. And She
said there could be carry out some cooperations to you in the level of Group, such as the help of the tick sample collection in
China. I think the power of my boss (limited in the Group) is very limited compare to your boss Director James W. Le Duc.

However in Dr. James W. Le Duc's e-mail, one rule of that fellowship is **on my return I will be working within the new
biocontainment laboratory of Wuhan Institute of Virology**. Is it means that after complete the postdoc work with you
I must return back to work in the biocontainment laboratory of Wuhan Institute of Virology as soon as possible ? If yes, I think this will limit my career
in future. I remeber in the first email you reply to me, you asked me a quseation 'Will me return to Wuhan when I complete the postdoc
training?' My answer was 'I will return to Wuhan'. But in that time, I think the question is just about wether I will retrun to Wuhan
to find a job, not limited in insititue or univeristy. In addition, according to the management system of the institute, if I decide
to accept that postdoc positon, I have to quit my now job, and the Wuhan institute of Virology will not keep my position. And when
after 1 or 2 years I return to Wuhan, I must find a new job through applying the position.

I particularly wish to have the opportunity to work with you, and the experience will be very helpful to me in future. And are there any
other fundings could choice for the postdoc positon ?

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, January 17, 2013 12:14 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010730

Hi Han,

I talked to Dr. LeDuc last week. There might be a possibility for you to come and work with us.
Dr. LeDuc is currently traveling in India and will be back next week. He will send you an email with all the details next week.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Wednesday, January 16, 2013 7:05 PM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,

Have you talk to the director Dr. James LeDuc ? And could you tell me something about that ?

Looking forward to your reply. Thank you.

Best wishes,

Han

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Saturday, January 5, 2013 5:12 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,

Thanks for the email and the presentation. You don't need to prepare a PPT for the call. It is just a casual Skype call.

How about I call you on Monday, 7th at 6:00pm my time through Skype. It will be Tuesday, 8:00am your time. Is this too early for you? If it is too early, than I can call 1 hour later. Let me know what you want to do.

I will have a student with me during the Skype call. Her name is Jia Wang and she is originally from the Wuhan region. Her parents still live in Wuhan. I thought it would be nice if you can talk to her about what to expect in Galveston and from the University.

Please let me know if this works for you.

Best wishes,

Dennis

From: Han Xia (b)(6)
Sent: Friday, January 04, 2013 12:11 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Hi Prof. Dennis,
I added you and left a message in the Skype.
The time in here is 14 hours earlier than Houston.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010731

I don't know whether need to prepare a PPT in the interview, and I write a sample presentaion could help to increase the understanding to me.
Best wishes,
Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Wednesday, December 26, 2012 12:17 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Hi,
I found you on Skype and send you an invite. How about we talk Monday the 7th? How many hours ahead of us are you?
Best wishes,
Dennis Bente

From: Han Xia (b)(6)
Sent: Monday, December 24, 2012 4:38 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,
Hi, our New Year holiday is Januray 1 to 3, and the work time in the first week is 4-11, these days is available.
I have a Skype account: (b)(6) and we could use this to communicate.

Once again, wish you a happy holiday !

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Monday, December 24, 2012 3:36 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han,

Merry Christmas and Happy New Year to you too!
I would like to apologize that I did not get back to you sooner. We were thinking to have a phone conference and give you a phone call. However, we can use a different communication tool as well. Personally, I do not use MSN but I use Skype. Have you used this before?
We do not need your boss to join us during the conference call. I just thought she might like to join us, but it is not necessary. Whe would be a good time for you? Are you available the first week of January?

Best wishes,

Dennis Bente

From: Han Xia [mailto: (b)(6)
Sent: Monday, December 24, 2012 12:56 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Bente, Dennis A,

Merry Christmas and Happy New year !

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010732

Han Xia

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Friday, December 21, 2012 6:26 AM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

I met with the director of the Galveston National Laboratory, Dr. James LeDuc. He suggested setting up a teleconference with you and your mentor sometime after the first of the New Year. During the conference call we can discuss your interests and expectations of the post-doc experience. We can also discuss timelines and options for finances. Could you please tell me when would be a good day and time for you and your mentor to hold a teleconference?

Before the teleconference we can jointly develop an agenda of the topics that we want to discuss.
Would this work for you?

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

"Working together to work wonders"

From: Han Xia (b)(6)
Sent: Friday, December 14, 2012 12:28 AM
To: Bente, Dennis A.
Subject: Re: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

Thank you for your reply.

1. My current position is an assistant research fellow (assist Principle Investigator to apply and complete the research projects and guide the MD or PhD students) in Virus Resource and information Group of Wuhan institute of virology.
My research work was focus on epidemiology and molecular biology of tick-boren virus (maily on CCHFV).
There are three parts:
(1) Development of minigenome system for CCHFV YL04057. Now I have aquired the YL04057's completed cDNA clone, and construted the plasimd pcDNA/L,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010733

pcDNA/S, pRF-LUTR-GFP, pRF-MUTR-GFP and pRF-SUTR-GFP. Currently, the result of the co-transfection of pcDNA/L, pcDNA/S and pRF-LUTR-GFP is the best. Next, I will optimization of the conditions to make the system more stable.

(2) Epidemiology survey of CCHFV in Yunnan and Xinjiang of China. In China, the main infected area is in Xinjiang, but there is no outbreak and patient in recent years.

We collected the human, livestock and tick samples in the areas which have been previously reported CCHF or isolated CCHFV. Then used the ELISA, qReal-time PCR, or 454 high-throughput sequencing to analysis this samples.

And recently, some tick samples from Yunnan were detected use 454 sequencing and there are some intersting data need to further analysis.

(3) Epidemiology and molecular biology of Influenza virus. Our group's traditional fields is influenza virus , and I occasionally participate in the project of influenza virus.

2. I don't work at BSL-4. I work maily in BSL-2 and partly in BSL-3. Firstly, now in Wuhan Insititue of Virology, the BSL-4 lab is under construction. Secondly,
according to China's biosafety regulations the operate of CCHFV in cell-level could be at BSL-3 lab. Lastly, due to my work about CCHFV was mainly
in molecular level and sample tested, not related to the animal experiment.

3. Yes, I am planning on returning to Wuhan once I finish the work with you.

And I have a question, what fields of research do you want me to do if I work in you lab? Thank you.

Best wishes
Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax: (b)(6)
Email: (b)(6)

From: "Bente, Dennis A." <dabente@UTMB.EDU>
To: Han Xia (b)(6)
Sent: Thursday, December 13, 2012 11:25 PM
Subject: RE: apply postdoc or visiting scholar in your lab about CCHF

Dear Han Xia,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010734

Thank you very much for your email and the interest in my work.

You have an excellent CV and we would be interested in working with you. Can you tell me a little bit more about your current position? Do you work at biosafety level 4? Do you collect patient and tick samples from the field?

Although there is currently no extra funding in my laboratory for a postdoc, we might have another possibility to find funding for you: our laboratory includes the National Biocontainment Training Center, which gives out fellowships to visiting scientists. The goal of this program is to establish a link between biocontainment laboratories from around the world.
My question for you is: are you planning on returning to Wuhan once you finish you work with us? If yes, than that would it easier for us to get you the fellowship.

Looking forward to hear from you,

Best wishes,

Dennis

Dennis Bente, D.V.M., Ph.D.
Assistant Professor, Department of Microbiology & Immunology
Member, Center for Biodefense and Emerging Infectious Diseases
Member, Sealy Center for Vaccine Development
Member, Institute for Human Infection and Immunity
301 University Blvd., Galveston, TX 77555-0610
P 409.266.6935 M (b)(6)
F 409.266.6810 E dabente@utmb.edu

utmb Health

"Working together to work wonders"

From: Han Xia (b)(6)
Sent: Tuesday, December 11, 2012 2:59 AM
To: Bente, Dennis A.
Subject: apply postdoc or visiting scholar in your lab about CCHF

Dear Prof. Dennis A Bente,

I am writing to you about the possibility of studying and researching in your lab as a visiting scholar or postdoc.

Your researches are of particular interest to me, especially tick-borne viruses (such as CCHF). Your group's research is so outstanding
that I believe that if given the opportunity to study and research under your guidance, the experience at your lab can improve my research capacity, learn technology that is more new, and enlarge my knowledge in this field,which will benefit me a lot.

I am a Research assistant at Wuhan institute of virology,Chinese academy of Science,China. I graduated from Chinese Academy of Sciences and got the Doctor degree of Biochemisty and Molecular Biology in July 2011.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010735

Since that time, I have been working in Development in the minigenome system and Epidemiological investigation for CCHFV. I have been completed the epidmiological survey of CCHFV in Yunnan, China,2008 (International journal of infectious diseases, 07/2011; 15(7): e459-63). And the establishment of minigenome system for China YL04057 is in progress and almost completed.

In recently, we developed the embryonated chicken egg model for CCHFV, the result was under reviewing in Virus research (Infection and propagation of CCHFV in embryonated chicken eggs).

My current research focuses on viral infection diesease.I am satisfied with my research work. However, due to the condition of the experiments and personal experiments are restricted, I would like to find an opportunity to go abroad for further study and research.

My CV is in the attachment. Your comments and consideration will be highly appreciated.
I am looking forward to hear from you.

Sincerely yours,

Han Xia

Virus Resource and information Group
Wuhan institute of virology
Chinese academy of Science

No.44, Xiao Hong Shan, Wuhan, P.R.China

Tel and Fax:(b)(6)
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_010736

Full Name: Xinwen Chen
Last Name: Chen
First Name: Xinwen
Job Title: Director
Company: Institute of Virology, Wuhan, China

E-mail: chenxw@wh.iov.cn
E-mail Display As: Xinwen Chen (chenxw@wh.iov.cn)

Details of the Faculty or Staff			
Name	chenxinwen	Title	N/A
Highest Education	N/A	Office	Address:Xiao Hong Shan No.44,Wu Han,P.R.China.
Phone	N/A	Zip Code	430071
Fax	N/A	Email	chenxw@wh.iov.cn



Education and Appointments :

Xinwen Chen,PhD,Professor.He obtained his BSc and MSc from the Department of Biology, Central China Normal University in 1986 and Henan University of Technology in 1988, respectively. In 1998, he obtained his PhD from Wageningen University in 2001. He subsequently worked at the University of California at Berkeley and Wageningen University as a visiting scientist.Dr. Chen is one of the scientists in "Hundred-talent Project" CAS and one of the awardees of the "National Outstanding Youth Fund". Dr. Chen's current positions include Director of WIV, member of the institute's Scientific Advaisory Board and WIV's Academic Degree Committee , member of WIOV Academic Degree Committee.He is also the Head of the department of Virology and Principal of Hepatitis Virus lab. In addition, Dr. Chen is also Editor- in-Chef of Virologica Sinica and editor of Chinese Biological Abstracts. He is a permanent member of the Chinese Society of Microbiology, a member of the council of the Hubei Society of Microbiology and a member of the council of the Hubei Society of Biotechnology. Dr. Chen has more than 90 publications,of which 40 are registered in the SCI indes.He was also awarded the second prize in the "National Innovation Award".

Represented Wuhan Institute of Virology during NAS-CAS meeting in Galveston GNL, Jan 2018

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_001817

From: Kingsley, Ashley M.
Sent: Tuesday, April 2, 2013 10:13 AM
To: Fawcett, Steve
Subject: FW: Remote Access Request (UTMB/FDA Pilot Course)

Sorry for the delay……

Ashley Marie Kingsley, M.S., CHLS
Assistant Training Manager
Institutional Office of Regulated Nonclinical Studies
Office: 409.747.8136
Mail Stop 0184
Location: 2.810 Rebecca Sealy

From: Kingsley, Ashley M.
Sent: Friday, March 29, 2013 12:18 PM
To: Rexrode, Jeffery (Jeffery.Rexrode@fda.hhs.gov)
Cc: Kingsley, Ashley M. (amkingsl@UTMB.EDU)
Subject: Remote Access Request (UTMB/FDA Pilot Course)

Remote Access List (UTMB/FDA Pilot Course)

FDA Faculty

Vernon Toelle	Vernon.Toelle@fda.hhs.gov	Day 4, April 4, 2013 – 2:45-3:30pm

The following have access for Day 1 only:

Pierre Formenty	formentyp@who.int	WHO
Nicoletta Previsani	previsanin@who.int	WHO
Yuan Zhiming	yzm@pentium.whiov.ac.cn	China, Note: Yuan is last name
Shi Zhengli	zlshi@wh.iov.cn	China, Note: Shi is last name
Radha K. Maheshwari	radha.maheshwari@usuhs.edu	Coordinator for India

The following have access for the entire course (Day 1-5):

Peter Jahrling	jahrlingp@niaid.nih.gov	NIAID
Nicolette Devore	nicolette.devore@fda.hhs.gov	FDA
Louise Pitt	louise.pitt@us.army.mil	USAMRIID
Amy Fix	(b)(6) com	Novavax

Please cc the assistance listed below the UTMB Provost and President when sending access.

Dr. Danny Jacobs	djacobs@utmb.edu	UTMB, Provost
Jandee Alarid	jalarid@utmb.edu	
Dr. David Callender	dlc@utmb.edu	UTMB, President
Karin Little, Robin Rhone	klittle@utmb.edu, rrhone@utmb.edu	

Can you also cc me on the emails sent for log in access just in case I need to resend if lost in their emails?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_084715

Thanks,

Ashley Marie Kingsley, M.S., CHLS
Assistant Training Manager
Institutional Office of Regulated Nonclinical Studies (ORNcS)
University of Texas Medical Branch
Mail Stop 0184
301 University Blvd.
Galveston, TX 77555-0184

Office: 409.747.8163
Fax: 409-266.9565
Email: amkingsl@utmb.edu
Location: 2.810 Rebecca Sealy

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_084716

From: Wang, Tian
Sent: Tuesday, June 4, 2013 9:54 AM
To: zlshi
Subject: RE: Recommendation letter for Miss Luo Huanle

Dear Dr. Shi,

Thank you for the reference letter.

Best Regards,

Tian Wang, PhD.

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, June 03, 2013 10:39 PM
To: Wang, Tian
Subject: Recommendation letter for Miss Luo Huanle

Dear Dr. Wang,

Could you please see attached recommendation letter for Miss Luo Huanle. Please let me know if you have any questions.

Best regards,

2013-06-04

Zhengli Shi, Ph D.
Senior scientist
Wuhan Institute of Virology, Chinese Academy of Sciences.
430071, Wuhan
China
Tel/Fax: (86-27) 87197240

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_085859

CURRICULUM VITAE

PERSONAL INFORMATION

Name HuanleLuo

(b)(6)

Page 087

Withheld pursuant to exemption

(b)(6)

of the Freedom of Information and Privacy Act

Page 088

Withheld pursuant to exemption

(b)(6)

of the Freedom of Information and Privacy Act

From: LeDuc, James W.
Sent: Monday, July 28, 2014 8:28 AM
To: Bente, Dennis A.;Ksiazek, Thomas G.
Subject: FW: validation for virus antibody detection
Attachments: 2012 Yuan JF.pdf; 2008 Li Y-EID-Niv antibody.pdf; 2013 Ge et al_nature12711-print.pdf; 2005 Li et al.Science SARS in bats.pdf

Dennis,

Please see letter of inquiry from Wuhan. I'm wondering if Han Xia knows this person and might be interested in attempting to develop this potential collaboration. This might be a good opportunity to position her for sustain collaborations between our organizations. We can check with the Toms to see if we have the critical immune sera to validate their observations.

Please check with Han and then we can discuss. I replied to Dr Zhengli that we would discuss here and get back to him soon.

Thanks, Jim

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016764

Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System

Yuan et al. Virology Journal 2012, 9:236
http://www.virologyj.com/content/9/1/236

VIROLOGY JOURNAL

SHORT REPORT Open Access

Serological evidence of ebolavirus infection in bats, China

Junfa Yuan[1,2], Yuji Zhang[1], Jialu Li[1], Yunzhi Zhang[3], Lin-Fa Wang[4] and Zhengli Shi[1*]

Abstract

Background: The genus *Ebolavirus* of the family Filoviridae currently consists of five species. All species, with the exception of *Reston ebolavirus*, have been found in Africa and caused severe human diseases. Bats have been implicated as reservoirs for ebolavirus. *Reston ebolavirus*, discovered in the Philippines, is the only ebolavirus species identified in Asia to date. Whether this virus is prevalent in China is unknown.

Findings: In this study, we developed an enzyme linked immunosorbent assay (ELISA) for ebolavirus using the recombinant nucleocapsid protein and performed sero-surveillance for the virus among Chinese bat populations. Our results revealed the presence of antibodies to ebolavirus in 32 of 843 bat sera samples and 10 of 16 were further confirmed by western blot analysis.

Conclusion: To our knowledge, this is the first report of any filovirus infection in China.

Keywords: Ebolavirus, Antibody detection, Bats

Findings

Filoviruses are associated with acute fatal hemorrhagic diseases of humans and/or nonhuman primates when they spill over from their wildlife reservoir hosts. The family consists of two genera: *Marburgvirus* and *Ebolavirus* [1,2]. Five species of ebolavirus have been identified: *Ivory Coast ebolavirus*, *Sudan ebolavirus*, *Zaire ebolavirus* (EBOV), *Reston ebolavirus* (RESTV) and *Bundibugyo ebolavirus*. RESTV is the only known filovirus that does not cause severe disease in humans; however, it can be fatal in monkeys [3]. In 2009, infection of domestic pigs by RESTV was reported in the Philippines [4]. It was speculated that RESTV infected monkeys and pigs from an as yet unidentified host. Bats have been implicated as reservoirs for Marburgvirus [5] and Ebolavirus [6] in Africa and Asian country, the Philippines [7]. Previously, we have detected antibodies to the severe acute respiratory syndrome virus [8] and henipavirus [9] in bat sera in China. In this study, we conducted a surveillance study for the presence of ebolavirus in Chinese bat populations.

From 2006–2009, 843 bats were trapped within their natural habitat from several provinces in mainland China in accordance with animal ethics protocols approved by the Wuhan Institute of Virology, Chinese Academy of Sciences. Serum, pharyngeal and fecal swab samples were collected and stored as described previously [8]. Most animals were released back into their habitat. Those did not survive underwent necropsy.

The codon optimized nucleocapsid (NP) gene fragments (aa 410–653) of RESTV and EBOV were synthesized based on reference sequences downloaded from GenBank with reference numbers FJ621583 and L11365, respectively, and subcloned into pFastBac-HTb. The His-tagged truncated NP of RESTV (Reston-NP) or EBOV (Zaire-NP) were expressed in insect cells using the Bac-to-bac system (Invitrogen) and purified with a His.Bind Kit (Novagen) (Figure 1A & B) following the manufacturer's instructions. Both the truncated Zaire-NP and Reston-NP strongly reacted to hyperimmune rabbit sera raised against the full-length NP protein of RESTV [10] by ELISA, although the optical density (OD_{450}) readings to Reston-NP were higher than those to Zaire-NP under the same dilution (Figure 1C). The results indicated that both of these antigens were suitable for detection of ebolavirus antibodies.

* Correspondence: zlshi@wh.iov.cn
[1]State Key Laboratory of Virology, Wuhan Institute of Virology-Chinese Academy of Sciences, Wuhan, Hubei 430071, P R, China
Full list of author information is available at the end of the article

BioMed Central

© 2012 Yuan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016766




Figure 1 Characterization of the truncated recombinant nucleocapsid protein of RESTV (Reston-NP) and EBOV (Zaire-NP). Coomassie staining (**A**) and western blot analysis (**B**) of purified proteins separated by 10% SDS-PAGE. Lane M: molecular weight markers from Fermentas; Lane 1: Reston-NP; Lane 2: Zaire-NP. (**C**) ELISA analysis of Reston-NP and Zaire-NP using hyperimmune rabbit sera raised against the full-length Reston-NP.




Figure 2 Distribution of OD_{450} readings and antibody titers among different positive bat sera. The left panel shows the corrected OD_{450} readings at a serum dilution of 1:100. The right panel displays the antibody titers at an OD_{450} reading equal or greater than 0.19 (> 2-fold – ve sera). The number of sera at each OD_{450} or titer reading is shown to the right of the proportionally sized dots.

Considering the close geographical relationship of Chinese and Philippine bats, Reston-NP was used for the initial screening. ELISA plates were coated with the recombinant Reston-NP at approximately 100 ng/well and bat sera were tested in triplicates at a dilution of 1:100, followed by detection with horseradish peroxidase (HRP) conjugated Protein A/G (Pierce) at 1:20,000. Samples with a mean optical density 2.1-fold or higher than that of the negative control (OD_{450} value: 0.19) were considered positive. Positive serum samples were retested at dilutions of 1:100, 1:400, and 1:1600 against both Reston-NP and Zaire-NP (Figure 2).

A summary of the initial screening results is shown in Table 1. Of the 843 bat sera screened for antibodies to Reston-NP by ELISA, 32 were positive. These were from 10 of the 23 bat species collected from 5 different locations. Among the positive sera, 17 had OD_{450} readings higher than 0.19 at 1:400 and 3 at 1:1600 (Figure 2). These positive sera were further tested with the Zaire-NP protein and 25 were positive, and 10 samples had OD_{450} values higher than 0.19 at a 1:400 and 4 at a 1:1600. Sixteen bat sera with sufficient remaining quantity were further confirmed by western blot analysis with the recombinant NP expressed in *Escherichia coli*, and 10 were reactive to both the Reston- and Zaire-NP proteins (Figure 3, Table 2).

A surrogate virus neutralization test was conducted using a recombinant env$^-$ HIV-1 virus containing the luciferase reporter gene pseudotyped with spike glycoprotein proteins (GP) of EBOV (Zaire-GP) or RESTV (Reston-GP [11]). The plasmid encoding Zaire-GP (L11365) was kindly provided by Prof. Lijun Rong (University of Illinois at Chicago, USA). The Reston-GP gene was synthesized based on the RESTV genome sequence (FJ621583). Serum was serially diluted at 1:20 to 1:640 in 30 μl of medium and mixed with 30 μl of pseudovirus solution. The mixture was incubated for 1 h at 37°C and subsequently added, in triplicate, to 293T cells grown in a 96-well plate. The plate was incubated for 1 h at 37°C before being replenished with fresh medium and incubated for 48 h. Cells were lysed in 30 μl of lysis reagent (Progema) and luciferase activity was measured using a

FOIA Confidential Treatment Requested by Univ of Texas System

UTSystem_016767

Table 1 Detection of antibody to RESTV nucleocapsid protein by ELISA

Bat species	No. positive / No. tested (percent)
Megachiroptera	
Rousettus leschenaulti	11/126(8.73%)
Cynopterus sphinx	2/2(100%)
Microchiroptera	
Hipposideridae	
Hipposideros Pomona	3/39(7.69%)
Hipposideros spp.	1/15(6.67%)
Hipposideros cineraceus	0/111
Hipposideros armiger	0/41
Hipposideros larvatus	0/21
Rhinolophidae	
Rhinolophus affinis	1/69(1.45%)
Rhinolophus ferrumequinum	0/15
Rhinolophus sinics	0/6
Rhinolophus pusillus	0/14
Rhinolophus pearsonii	0/3
Rhinolophus spp.	0/15
Vespertilionidae	
Miniopterus schreibersii	2/23(8.7%)
Pipistrellus pipistrellus	4/35(11.43%)
Myotis ricketti	4/83(4.82%)
Myotis davidii	0/5
Myotis chinensis	0/6
Myotis daubentonii	0/24
Myotis fimbriatus	0/2
Myotis spp.	3/118(2.54%)
Scotophilus kuhli	1/25(4%)
Unknown	0/2
Total	32/843(3.8%)

Luciferase assay kit (Promega). None of the positive bat serum inhibited entry of Reston-GP or Zaire-GP pseudotyped virus.

The Invitrogen OneStep RT-PCR Kit was used to screen ebolavirus RNA using the universal primers against the Filovirus L gene or N gene as described previously [12,13]. RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen) following the manufacturer's instructions. No filovirus-specific RNA was detected by one step RT-PCR among 143 tissue samples (spleen, liver or fecal swab) tested, therefore, virus isolation was not attempted.

In this paper, we presented serological evidence of ebolavirus infection in several bat populations in China. To our knowledge, this is the first report of any ebolavirus infection in this part of the world. The most significant prevalence of ebolavirus antibody was found among the *Rousettus leschenaulti, Pipistrellus pipistrellus and Myotis* species. Several serum samples have relatively high titer to both Reston-and Zaire-NP.

There are several possibilities to account for the failure in detecting neutralizing antibodies. In general, bats seem to produce lower level of neutralizing antibodies in response to viral infection, possibly due to the lower affinity of the bat antibodies [14]. Alternatively, it is possible that one or more as-yet-unknown ebolaviruses are circulating among the bat populations sampled in this study, producing antibodies cross-reactive with, but not neutralizing EBOV or RESTV. Also, a new ebolavirus species closely-related with EBOV but not the RESTV might be missed during the initial screening using Reston-NP solely. An initial screening for eboalvirus antibodies should be conducted by using ELISA with a 1:1 mixture of recombinant NP of EBOV and RESTV to detect wider range of ebolavirus species. Recently, a genetically distinct filovirus was found in dead insectivorous bats in Spain [15], suggesting that filoviruses have a wider host range and geographical




Figure 3 Western-blot analysis of ELISA positive serum samples with recombinant Reston-NP and Zaire-NP expressed in *E. coli*. The polyclonal antibody against the full-length nucleocapsid protein of RESTV was used as positive control. Sample no. 2195 was ELISA negative and used as negative control. The other 5 samples were western blot positive. Note: western blot no.1487, 1552, 1689, 1973 and 2166 is not presented due to the absence of signal in the scanned photograph.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016768

Table 2 Determination of ELISA titer and western blot reactivity against the truncated nucleocapsid proteins of RESTV (Reston-NP) and EBOV (Zaire-NP)

Bat species and sample ID	Titer in ELISA		Western blot	
	Reston-NP	Zaire-NP	Reston-NP	Zaire-NP
Miniopterus schreibersii (no:849)*	1600	1600	+	+
Rousettus leschenaulti (no:1263)	100	100	N	N
Rousettus leschenaulti (no:1276)	400	400	N	N
Cynopterus sphinx (no:1487)	400	400	+	+
Hipposideros Pomona (no:1552)	100	100	+	+
Rousettus leschenaulti (no:1688)*	100	100	+	+
Rousettus leschenaulti (no:1689)	400	N	+	+
Pipistrellus pipistrellus (no:1973)	400	400	+	+
Pipistrellus pipistrellus (no:1977)*	400	N	+	+
*Myotis spp. (no:2114)**	400	400	+	+
Rousettus leschenaulti (no:2158)	400	100	N	N
Rousettus leschenaulti (no:2166)	100	N	+	+
Rousettus leschenaulti (no:2169)*	100	100	+	+
Rousettus leschenaulti (no:2183)	400	400	N	N
Rousettus leschenaulti (no:2190)	100	100	N	N
Rousettus leschenaulti (no:2211)	100	400	N	N

+: positive; N: no signal was detected; *: The results of western blot are shown in Figure 3.

location than previously thought. The unsuccessful identification of ebolavirus-related genes in the samples is likely attributable to the often low-level of virus replication, the similarly transient nature of the infection in bats or the sequence mis-match of the PCR primers used and the target sequence of the potential unknown ebolavirus genomes.

There are approximately 120 species of bats distributed throughout China. Bat species in the genera *Rousettus*, *Hipposideros*, *Myotis*, *Miniopterus* and *Pipistrellus* naturally reside in trees, buildings and caves that can be in close proximity to human residential areas, increasing the potential of zoonotic transmission from bats to humans. There is evidence of human infection of ebolavirus in central Africa as a result of direct bat-to-human transmission [16]. In the Guangdong and Hainan provinces of China, local populations customarily eat large bats, such as Leschenault's rousette. The preliminary results presented in this study highlight the need to continue and expand surveillance for ebolavirus or related viruses in China and elsewhere in the Asian continent.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JY and YZ independently performed protein expression and ELISA. JL performed the RNA extraction and RT-PCR. YZ provided samples and information about bats. LFW and ZS conceived the project and provided overall scientific oversight. All authors contributed to the preparation of the final manuscript. All authors read and approved the final manuscript.

Acknowledgments

This work was funded by a State Key Program for Basic Research Grant (2011CB504701). We thank Prof. Lijun Rong for kindly providing the Zaire G protein gene.

Author details

[1]State Key Laboratory of Virology, Wuhan Institute of Virology-Chinese Academy of Sciences, Wuhan, Hubei 430071, P R, China. [2]Huazhong Agriculture University, Wuhan, Hubei 430070, P R, China. [3]Yunnan Institute of Endemic Diseases Control and Prevention, Dali, Yunnan 671000, P R, China. [4]Commonwealth Scientific and Industrial Research Organization Livestock Industries, Geelong, Victoria 3220, , Australia.

Received: 1 May 2012 Accepted: 2 October 2012
Published: 13 October 2012

References

1. Barrette RW, Xu L, Rowland JM, McIntosh MT: **Current perspectives on the phylogeny of Filoviridae.** *Infect Genet Evol* 2011, **11:**1514–1519.
2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, *et al*: **Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.** *Arch Virol* 2010, **155:**2083–2103.
3. Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, Fulhorst CF, Rollin PE, Calaor AB, Manalo DL, Roces MC, *et al*: **Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996.** *J Infect Dis* 1999, **179**(Suppl 1):S115–S119.
4. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, Rollin PE, Towner JS, Shieh WJ, Batten B, *et al*: **Discovery of swine as a host for the Reston ebolavirus.** *Science* 2009, **325:**204–206.
5. Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, Grard G, Ksiazek TG, Gonzalez JP, Nichol ST, Leroy EM: **Marburg virus infection detected in a common African bat.** *PLoS One* 2007, **2:**e764.
6. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Delicat A, Paweska JT, Gonzalez JP, Swanepoel R: **Fruit bats as reservoirs of Ebola virus.** *Nature* 2005, **438:**575–576.
7. Taniguchi S, Watanabe S, Masangkay JS, Omatsu T, Ikegami T, Alviola P, Ueda N, Iha K, Fujii H, Ishii Y, *et al*: **Reston Ebolavirus antibodies in bats, the Philippines.** *Emerg Infect Dis* 2011, **17:**1559–1560.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016769

8. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, *et al*: **Bats are natural reservoirs of SARS-like coronaviruses.** *Science* 2005, **310:**676–679.
9. Li Y, Wang J, Hickey AC, Zhang Y, Li Y, Wu Y, Zhang H, Yuan J, Han Z, McEachern J, *et al*: **Antibodies to Nipah or Nipah-like viruses in bats, China.** *Emerg Infect Dis* 2008, **14:**1974–1976.
10. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA, Payne J, White J, Yu M, Bingham J, *et al*: **Ebola Reston virus infection of pigs: clinical significance and transmission potential.** *J Infect Dis* 2011, **204**(Suppl 3):S804–S809.
11. Manicassamy B, Wang J, Jiang H, Rong L: **Comprehensive analysis of ebola virus GP1 in viral entry.** *J Virol* 2005, **79:**4793–4805.
12. Ogawa H, Miyamoto H, Ebihara H, Ito K, Morikawa S, Feldmann H, Takada A: **Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene.** *J Virol Methods* 2011, **171:**310–313.
13. Panning M, Laue T, Olschlager S, Eickmann M, Becker S, Raith S, Courbot MC, Nilsson M, Gopal R, Lundkvist A, *et al*: **Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories.** *J Infect Dis* 2007, **196**(Suppl 2):S199–S204.
14. Baker ML, Tachedjian M, Wang LF: **Immunoglobulin heavy chain diversity in Pteropid bats: evidence for a diverse and highly specific antigen binding repertoire.** *Immunogenetics* 2010, **62:**173–184.
15. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martinez M, *et al*: **Discovery of an ebolavirus-like filovirus in europe.** *PLoS Pathog* 2011, **7:**e1002304.
16. Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM: **Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species.** *J Infect Dis* 2007, **196**(Suppl 2):S176–S183.

doi:10.1186/1743-422X-9-236
Cite this article as: Yuan *et al.*: Serological evidence of ebolavirus infection in bats, China. *Virology Journal* 2012 **9**:236.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central

FOIA Confidential Treatment Requested by Univ of Texas System

UTSystem_016770

Acknowledgments

We thank Brad Biggerstaff and Becky Eisen for statistical analyses used in this study. S.E.K. was supported by The Oak Ridge Institute for Science and Education.

Cherilyn Sackal, Anne Laudisoit, Michael Kosoy, Robert Massung, Marina E. Eremeeva, Sandor E. Karpathy, Kristen Van Wyk, Elizabeth Gabitzsch, and Nordin S. Zeidner

Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (C. Sackal, M. Kosoy, K. Van Wyk, N. Zeidner); University of Antwerp, Antwerp, Belgium (A. Laudisoit); University of Liege, Liege, Belgium (A. Laudisoit); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R. Massung, M.E. Eremeeva, S.E. Karpathy); and Etubics Corporation, Seattle, Washington, USA (E. Gabitzsch)

DOI: 10.3201/eid1412.080610

References

1. Parola P, Davoust B, Raoult D. Tick and flea-borne rickettsial emerging zoonoses. Vet Res. 2005;36:469–92. DOI: 10.1051/vetres:2005004
2. Perez-Osorio CE, Zavala-Velazquez JE, Leon JJ, Zavala-Castro J. *Rickettsia felis* as emergent global threat for humans. Emerg Infect Dis. 2008;14:1019–22. DOI: 10.3201/eid1407.071656
3. Schmidt A., editor. Contributions to microbiology. Basel (Switzerland): Karger; 1998.
4. Koehler JE. *Bartonella* infections. Adv Pediatr Infect Dis. 1996;11:1–27.
5. Schwartzman W. *Bartonella* (*Rochalimaea*) infections: beyond cat scratch. Annu Rev Med. 1996;47:355–64. DOI: 10.1146/annurev.med.47.1.355
6. Chanteau S, Rahalison L, Ralafiarisoa L, Foulon J, Ratsitorahina M, Ratsifasoamanana L, et al. Development and testing of a rapid diagnostic test for bubonic and pneumonic plague. Lancet. 2003;361:211–6. DOI: 10.1016/S0140-6736(03)12270-2
7. Laudisoit A, Leirs H, Makundi RH, Van Dongen S, Davis S, Neerinckx S, et al. Plague and the human flea, Tanzania. Emerg Infect Dis. 2007;13:687–93.
8. Norman AF, Regnery PL, Jameson P, Greene C, Krause DC. Differentiation of *Bartonella*-like isolates at the species level by PCR-restriction fragment length polymorphism in the citrate synthase gene. J Clin Microbiol. 1995;33:1797–803.
9. Kettle DS, editor. Medical and veterinary entomology. 2nd ed. Wallingford (MA): CABI Publishing; 1995.
10. Bitam I, Parola P, De La Cruz K, Matsumoto K, Bazia B, Rolain JM, et al. First molecular detection of *Rickettsia felis* in fleas from Algeria. Am J Trop Med Hyg. 2006;74:532–5.

Address for correspondence: Nordin S. Zeidner, Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases, 3150 Rampart Rd, Foothills Campus, Fort Collins, CO 80521, USA; email: naz2@cdc.gov

Antibodies to Nipah or Nipah-like Viruses in Bats, China

To the Editor: *Hendra virus* (HeV) and *Nipah virus* (NiV), the only known members of the genus *Henipavirus,* are 2 emerging paramyxoviruses that are highly pathogenic in a variety of vertebrate animals, including humans (*1*). Since the initial discovery of the viruses in Australia and Malaysia (*2*,*3*), sporadic HeV outbreaks have been reported from 1995 to 2007 in Australia (*4*), and regular NiV outbreaks have occurred in Bangladesh (*5*) and India (*6*). Numerous frugivorous bat species (genus *Pteropus*), and some insectivous bat species have been found to be reservoir hosts of henipaviruses in Australia and Asian countries (*7*–*9*).

In this study conducted during 2004–2007, bats were trapped within their natural habitat from 10 provinces in mainland People's Republic of China. Serum, pharyngeal, and fecal swab samples were collected and stored as described previously (*10*). An ELISA was developed to detect antibodies to the NiV nucleocapsid (N) and attachment glycoprotein (G) proteins. For confirmation, ELISA-positive samples were tested by using Western blot against a recombinant NiV G fragment (aa 71–193) fused with the maltose-binding protein. Virus neutralization tests were conducted with live NiV and HeV under Biosaftey Level 4 containment in Australia. In addition, a surrogate neutralization test was developed by using recombinant *env*$^-$ HIV-1, pseudotyped with NiV G and F. RNA was extracted by using the QIA amp Viral RNA Mini Kit (QIAGEN, Hilden, Germany). Reverse transcription–PCR (RT-PCR) was performed by using primers against the NiV N gene as described previously (*3*).

In total, 692 bat serum specimens were screened for antibody to NiV N or G protein (or both) by ELISA, and 33 were positive (online Appendix Table, available from www.cdc.gov/EID/content/14/12/1974-appT.htm). These specimens were from 9 of the 23 bat species examined in this study. Of the 33 serum samples reactive in ELISA, 25 with sufficient quantity left were further tested by Western blot, and 17 of 25 serum samples were reactive with MBP-NiV G fusion fragment, but not with the control MBP. None of the samples inhibited entry of NiV F/G-pseudotyped virus or neutralized either HeV or NiV. No NiV-specific RNA was detected by RT-PCR among 479 fecal swab samples and 67 throat swab samples tested; therefore, virus isolation was not attempted.

This study systematically investigated NiV presence among bats in China. The detection of henipavirus antibody suggests that several bat species have been exposed to NiV or a closely related virus. The prevalence of antibody was especially prominent among *Myotis* species from Yunnan

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016782

Province. Antibody was detected in samples from 3 of 4 *Myotis* species captured in the same location in 2006 and 2007. A relatively high prevalence of henipavirus antibody was also found among *Rousettus leschenaultia* samples from Hainan Province in 2007. Notably, Yunnan and Hainan are both located in southern China. Although pteropid bats are not found in China, these data suggest henipaviruses could be introduced into China by other susceptible bat species that overlap their habitat with pteropid bats in neighboring countries.

Several possibilities may explain the failure to detect neutralizing antibodies. One might be the unique immune response among those nonpteropid bats, which results in a low level of neutralizing antibodies that are difficult to detect in the current assay systems. Alternatively, and perhaps more likely, ≥1 Nipah-like viruses could be circulating among the bat populations sampled in this study, producing antibodies that cross-react with, but do not neutralize, the prototype Malaysian NiV virus isolate. This phenomenon has been observed previously by our group for severe acute respiratory syndrome (SARS)–like viruses in horseshoe bats, whose sera cross-reacted with, but did not neutralize, the SARS virus in humans (*10*).

Obtaining serologic evidence of viruses in bat populations is typically more successful as a screening tool than either nucleic acid based assays or virus isolation; this is likely attributable to the often low-level of virus replication, the transient nature of the infection in bats, or both. The inability to amplify NiV sequences may have been attributable to the viral RNA present among these samples being below the threshold of detection in our assay or to the absence of infection in the population at the time of sampling. In addition, the primers used in the PCR may target regions of the NiV N protein that exhibit substantial sequence divergence in a Nipah-like virus.

Bat species in the genera *Rousettus, Myotis*, *Miniopterus,* and *Hipposideros* naturally reside in trees, buildings, and caves that can be in close proximity to human residential areas, which increases the potential of transmission of zoonotic pathogens from bats to humans. The increased risk for these zoonotic infections to spread from bats to humans in areas of cohabitation is best illustrated by the repeated spillover events involving NiV in Bangladesh (*5*). Given the present initial evidence of exposure among bats in mainland China shown here, there is an urgent need to continue and expand surveillance studies for henipaviruses in China and elsewhere on the Asian continent.

This work was jointly funded by State Key Program for Basic Research grant 2005CB523004 from the Chinese Ministry of Science and Technology, the Knowledge Innovation Program Key Project administered by the Chinese Academy of Sciences (KSCX1-YW-R-07), the Australian Biosecurity Cooperative Research Centre for Emerging Infectious Diseases, Project 1.026RE (L.-F. W.), The Middle Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Disease Research, National Institutes of Health grant AI057168 (C.C.B.), and the East Asia and Pacific Summer Institutes program administered by the United States National Science Foundation (A.C.H).

Yan Li, Jianmin Wang, Andrew C. Hickey, Yunzhi Zhang, Yuchun Li, Yi Wu, Huajun Zhang, Junfa Yuan, Zhenggang Han, Jennifer McEachern, Christopher C. Broder, Lin-Fa Wang, and Zhengli Shi

Author affiliations: State Key Laboratory of Virology–Chinese Academy of Sciences, Wuhan, People's Republic of China (Y. Li, J. Wang, Y. Zhang, H. Zhang, J. Yuan, Z. Han, Z. Shi); Uniformed Services University, Bethesda, Maryland, USA (A.C. Hickey, C.C. Broder); Yunnan Institute of Endemic Diseases Control and Prevention, Dali, People's Republic of China (Y. Zhang); Shandong University at Weihai, Weihai, People's Republic of China (Y. Li); University of Guangzhou, Guangzhou, People's Republic of China (Y. Wu); and Commonwealth Scientific and Industrial Research Organisation Livestock Industries, Geelong, Victoria, Australia (J. McCachern, L.-F. Wang)

DOI: 10.3201/eid1412.080359

References

1. Eaton BT, Mackenzie JS, Wang LF. Henipaviruses. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1587–1600.
2. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, et al. A morbillivirus that caused fatal disease in horses and humans. Science. 1995;268:94–7. DOI: 10.1126/science.7701348

Erratum—Vol. 14, No. 9

The article Obligations to Report Outbreaks of Foodborne Disease under the International Health Regulations (2005) (M.D. Kirk et al.) contained incorrect figures in the abstract and conclusion. The text stated that 7 (50%) of 14 outbreaks would have required notification to the World Health Organization (WHO). The correct proportion is 6 (43%) of 14 outbreaks that would have required notification to the WHO. The article has been corrected online (www.cdc.gov/eid/content/14/9/1440.htm).

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016783

3. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288:1432–5. DOI: 10.1126/science.288.5470.1432
4. Field HE, Breed AC, Shield J, Hedlefs RM, Pittard K, Pott B, et al. Epidemiological perspectives on Hendra virus infection in horses and flying foxes. Aust Vet J. 2007;85:268–70. DOI: 10.1111/j.1751-0813.2007.00170.x
5. Epstein JH, Field HE, Luby S, Pulliam JR, Daszak P. Nipah virus: impact, origins, and causes of emergence. Curr Infect Dis Rep. 2006;8:59–65. DOI: 10.1007/s11908-006-0036-2
6. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, et al. Nipah virus–associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis. 2006;12:235–40.
7. Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, et al. Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. Emerg Infect Dis. 2001;7:439–41.
8. Reynes JM, Counor D, Ong S, Faure C, Seng V, Molia S, et al. Nipah virus in Lyle's flying foxes, Cambodia. Emerg Infect Dis. 2005;11:1042–7.
9. Wacharapluesadee S, Lumlertdacha B, Boongird K, Wanghongsa S, Chanhome L, Rollin P, et al. Bat Nipah virus, Thailand. Emerg Infect Dis. 2005;11:1949–51.
10. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676–9. DOI: 10.1126/science.1118391

Address for correspondence. Zhengli Shi, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, People's Republic of China; email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016784

8. W. D. Lawton, M. J. Surgalla, *J. Infect. Dis.* **113**, 39 (1963).
9. A. V. Philipovskiy *et al.*, *Infect. Immun.* **73**, 1532 (2005).
10. T. Kubori *et al.*, *Science* **280**, 602 (1998).
11. F. S. Cordes *et al.*, *J. Biol. Chem.* **278**, 17103 (2003).
12. E. Hoiczyk, G. Blobel, *Proc. Natl. Acad. Sci. U.S.A.* **98**, 4669 (2001).
13. L. Journet, C. Agrain, P. Broz, G. R. Cornelis, *Science* **302**, 1757 (2003).
14. *Yersinia* builds injectisomes when the temperature reaches 37°C, the host's body temperature. Yop secretion is triggered by contact with a target cell or artificially by chelation of Ca^{2+} ions (*15*).
15. Materials and methods are available as supporting material on *Science* Online.
16. Removal of *lcrV* leads to reduced synthesis of YopB and YopD because of a regulatory effect of LcrV on their expression. This undesired effect can be compensated by deleting *yopQ* (*5*).
17. C. A. Mueller *et al.*, unpublished data.
18. W. L. Picking *et al.*, *Infect. Immun.* **73**, 1432 (2005).
19. S. J. Daniell *et al.*, *Cell. Microbiol.* **3**, 865 (2001).
20. D. Chakravortty, M. Rohde, L. Jager, J. Deiwick, M. Hensel, *EMBO J.* **24**, 2043 (2005).
21. We thank P. Jenö for mass spectrometry analyses, M. Duerrenberger for use of the TEM facility, and J. M. Meyer and J. Frey for supplying *P. aeruginosa* PAO1 and *A. salmonicida* JF2267. Supported by the Swiss National Science Foundation (grant nos. 32-65393.01 to G.C. and 3100-059415 to A.E.) and by the Maurice E. Müller Foundation of Switzerland.

Supporting Online Material
www.sciencemag.org/cgi/content/full/310/5748/674/DC1
Materials and Methods
Figs. S1 to S8
Tables S1 and S2
References and Notes

5 August 2005; accepted 4 October 2005
10.1126/science.1118476

Bats Are Natural Reservoirs of SARS-Like Coronaviruses

Wendong Li,[1,2] Zhengli Shi,[2]* Meng Yu,[3] Wuze Ren,[2] Craig Smith,[4] Jonathan H. Epstein,[5] Hanzhong Wang,[2] Gary Crameri,[3] Zhihong Hu,[2] Huajun Zhang,[2] Jianhong Zhang,[2] Jennifer McEachern,[3] Hume Field,[4] Peter Daszak,[5] Bryan T. Eaton,[3] Shuyi Zhang,[1,6]* Lin-Fa Wang[3]*

Severe acute respiratory syndrome (SARS) emerged in 2002 to 2003 in southern China. The origin of its etiological agent, the SARS coronavirus (SARS-CoV), remains elusive. Here we report that species of bats are a natural host of coronaviruses closely related to those responsible for the SARS outbreak. These viruses, termed SARS-like coronaviruses (SL-CoVs), display greater genetic variation than SARS-CoV isolated from humans or from civets. The human and civet isolates of SARS-CoV nestle phylogenetically within the spectrum of SL-CoVs, indicating that the virus responsible for the SARS outbreak was a member of this coronavirus group.

Severe acute respiratory syndrome (SARS) was caused by a newly emerged coronavirus, now known as SARS coronavirus (SARS-CoV) (*1*, *2*). In spite of the early success of etiological studies and molecular characterization of this virus (*3*, *4*), efforts to identify the origin of SARS-CoV have been less successful. Without knowledge of the reservoir host distribution and transmission routes of SARS-CoV, it will be difficult to prevent and control future outbreaks of SARS.

Studies conducted previously on animals sampled from live animal markets in Guangdong, China, indicated that masked palm civets (*Paguma larvata*) and two other species had been infected by SARS-CoV (*5*). This led to a large-scale culling of civets to prevent further SARS outbreaks. However, subsequent studies have revealed no widespread infection in wild or farmed civets (*6*, *7*). Experimental infection of civets with two different human isolates of SARS-CoV resulted in overt clinical symptoms, rendering them unlikely to be the natural reservoir hosts (*8*). These data suggest that although *P. larvata* may have been the source of the human infection that precipitated the SARS outbreak, infection in this and other common species in animal markets was more likely a reflection of an "artificial" market cycle in naïve species than an indication of the natural reservoir of the virus.

Bats are reservoir hosts of several zoonotic viruses, including the Hendra and Nipah viruses, which have recently emerged in Australia and East Asia, respectively (*9*–*11*). Bats may be persistently infected with many viruses but rarely display clinical symptoms (*12*). These characteristics and the increasing presence of bats and bat products in food and traditional medicine markets in southern China and elsewhere in Asia (*13*) led us to survey bats in the search for the natural reservoir of SARS-CoV.

In this study, conducted from March to December of 2004, we sampled 408 bats representing nine species, six genera, and three families from four locations in China (Guangdong, Guangxi, Hubei, and Tianjin) after trapping them in their native habitat (Table 1). Blood, fecal, and throat swabs were collected; serum samples and cDNA from fecal or throat samples were independently analyzed, double-blind, with different methods in our laboratories in Wuhan and Geelong (*14*).

Among six genera of bat species surveyed (*Rousettus*, *Cynopterus*, *Myotis*, *Rhinolophus*, *Nyctalus*, and *Miniopterus*), three communal, cave-dwelling species from the genus *Rhinolophus* (horseshoe bats) in the family *Rhinolophidae* demonstrated a high SARS-CoV antibody prevalence: 13 out of 46 bats (28%) in *R. pearsoni* from Guangxi, 2 out of 6 bats (33%) in *R. pussilus* from Guangxi, and 5 out of 7 bats (71%) in *R. macrotis* from Hubei. The high seroprevalence and wide distribution of seropositive bats is expected for a wildlife reservoir host for a pathogen (*15*).

The serological findings were corroborated by poylmerase chain reaction (PCR) analyses with primer pairs derived from the nucleocapsid (N) and polymerase (P) genes (table S1). Five fecal samples tested positive, all of them from the genus *Rhinolophus*: three in *R. pearsoni* from Guangxi and one each in *R. macrotis* and *R. ferrumequinum*, respectively, from Hubei. No virus was isolated from an inoculation of Vero E6 cells with fecal swabs of PCR-positive samples.

A complete genome sequence was determined directly from PCR products from one of the fecal samples (sample Rp3) that contained relatively high levels of genetic material. The genome organization of this virus (Fig. 1), tentatively named SARS-like coronavirus isolate Rp3 (SL-CoV Rp3), was essentially identical to that of SARS-CoV, with the exception of three regions (Fig. 1, shaded boxes). The overall nucleotide sequence identity between SL-CoV Rp3 and SARS-CoV Tor2 was 92% and increased to ~94% when the three variable regions were excluded. The variable regions are located at the 5′ end of the S gene (equivalent to the S1 coding region of coronavirus S protein) and the region immediately upstream of the N gene. These regions have been identified as "high mutation" regions among different SARS-CoVs (*5*, *16*, *17*). The region upstream of the N gene is known to be prone to deletions of various sizes (*5*, *16*, *18*).

Predicted protein products from each gene or putative open reading frame (ORF) of SL-CoV Rp3 and SARS-CoV Tor2 were com-

[1]Institute of Zoology, Chinese Academy of Sciences (CAS), Beijing, China. [2]State Key Laboratory of Virology, Wuhan Institute of Virology, CAS, Wuhan, China. [3]Commonwealth Scientific and Industrial Research Organization (CSIRO) Livestock Industries, Australian Animal Health Laboratory, Geelong, Australia. [4]Department of Primary Industries and Fisheries, Queensland, Australia. [5]The Consortium for Conservation Medicine, New York, USA. [6]Guangzhou Institute of Biomedicine and Health, Guangzhou, China.

*To whom correspondence should be addressed. E-mail: zlshi@wh.iov.cn (Z.S.); zhangsy@ioz.ac.cn (S.Z.); linfa.wang@csiro.au (L.-F.W.)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016801

Table 1. Detection of antibodies to SARS-CoV and PCR amplification of N and P gene fragments with SARS-CoV–specific primers. ND, not determined because of poor sample quality or unavailability of specimens from individual animals.

Sampling		Bat species	Antibody test: positive/total (%)	PCR analysis: positive/total (%)	
Time	Location			Fecal swabs	Respiratory swabs
Mar 04	Nanning, Guangxi	*Rousettus leschenaulti*	1/84 (1.2%)	0/110	ND
	Maoming, Guangdong	*Rousettus leschenaulti*	0/42	0/45	ND
		Cynopterus sphinx	0/17	0/27	ND
July 04	Nanning, Guangxi	*Rousettus leschenaulti*	ND	0/55	0/55
	Tianjin	*Myotis ricketti*	ND	0/21	0/21
Nov 04	Yichang, Hubei	*Rhinolophus pusillus*	ND	0/15	ND
		Rhinolophus ferrumequinum	0/4	1/8 (12.5%)*	ND
		Rhinolophus macrotis	5/7 (71%)	1/8 (12.5%)†	0/3
		Nyctalus plancyi	0/1	0/1	ND
		Miniopterus schreibersi	0/1	0/1	ND
		Myotis altarium	0/1	0/1	ND
Dec 04	Nanning, Guangxi	*Rousettus leschenaulti*	1/58 (1.8)	ND	ND
		Rhinolophus pearsoni	13/46 (28.3%)	3/30 (10%)‡	0/11
		Rhinolophus pussilus	2/6 (33.3%)	0/6	0/2

*Positive fecal sample designated Rf1 †Positive fecal sample designated Rm1 ‡Positive fecal samples designated Rp1, Rp2, and Rp3, respectively.




Fig. 1. Genome organization of, and comparison between, SL-CoV and SARS-CoV. (**A**) Overall genome organization of SL-CoV Rp3. (**B**) Expanded diagram of the 3′ region of the genome in comparison with SARS-CoV strains Tor2 and SZ3, following the same nomenclature used by Marra *et al.* (*4*). The genes (named by letters P, S, E, M, and N) present in all coronaviruses are shown in dark-colored arrows, whereas the SARS-CoV–specific ORFs are numbered and illustrated in light-colored arrows. ORF10′ follows the nomenclature by Guan *et al.* (*5*) to indicate that the single ORF present between ORF9 and N in SL-CoV is equivalent to the fusion of ORF10 and ORF11 in the same region in SARS-CoV Tor2. The shaded boxes mark the only three regions displaying significant sequence difference between the two viruses (table S2).

pared (table S2). The P, S, E, M, and N proteins, which are present in all coronaviruses, were similarly sized in the two viruses, with sequence identities ranging from 96% to 100%. The only exception was the S1 domain of the S protein, where sequence identity fell to 64%. The S1 domain is involved in receptor binding, whereas the S2 domain is responsible for the fusion of virus and host cell membranes (*19*). The sequence divergence in the S1 domain corroborated our serum neutralization studies, which indicated that although bat sera have a high level of cross-reactive antibodies (with enzyme-linked immunosorbent assay titers ranging from 1:100 to 1:6400), they failed to neutralize SARS-CoV when tested on Vero E6 cells. This finding suggests that S1 is the main target for antibody-mediated neutralization of this group of viruses, which is consistent with previous reports indicating that major SARS-CoV neutralization epitopes are located in the S1 region (*20*, *21*).

In addition to the five genes present in all coronavirus genomes, coronaviruses also have several ORFs between the P gene and the 3′ end of the genome that code for nonstructural proteins. The function of these nonstructural proteins is largely unknown. The location and sequence of ORFs are group- or virus-specific and hence can serve as important molecular markers for studying virus evolution and classification (*19*, *22*). SARS-CoV has a unique set of ORFs not shared by any of the known coronaviruses (*3*, *4*). Most of these ORFs were also present in SL-CoV, confirming the extremely close genetic relationship between SARS-CoV and SL-CoV (Fig. 1 and table S2).

Coronaviruses produce subgenomic mRNAs through a discontinuous transcription process not fully characterized (*19*). Conserved nucleotide sequences functioning as transcription regulatory sequences (TRSs) are required for the production of the subgenomic mRNAs. In SARS-CoV, such TRSs were identified at each of the predicted gene start sites (*3*, *4*). All of these TRSs were absolutely conserved between SARS-CoV Tor2 and SL-CoV Rp3 (table S3), further demonstrating that these two viruses are very closely related.

SL-CoV is completely different from a bat coronavirus (bat-CoV) recently identified by Poon *et al.* (*7*) from species of bats in the genus *Miniopterus* during a wildlife surveillance study in Hong Kong (Fig. 2). Because the complete genome sequence was not available for bat-CoV, only the trees covering the common sequences (i.e., parts of the P1b and S2 proteins) are shown. The phylogenetic analysis demonstrated that SL-CoV Rp3 and SARS-CoVs are clustered together but that bat-CoV is placed among the relatively distant group 1 viruses. Hereafter, SARS-CoVs and SL-CoVs will be collectively called the SARS cluster of coronaviruses.

In addition to the complete genome sequence of SL-CoV Rp3, partial genome sequences for the other four PCR-positive bat samples were also determined. Phylogenetic analysis based on the N protein sequences (Fig. 3A) revealed that the genetic variation among the SL-CoV sequences was much greater than that exhibited by SARS-CoVs (for simplicity, only three human and civet SARS-CoV isolates were used; the remainder are almost identical to those shown). This was especially obvious when SL-CoVs isolated from different bat species were compared. Moreover, the results suggested that SARS-CoVs nestle phylogenetically within the spectrum of SL-CoVs.

We also compared the "high mutation" regions in samples Rf1, Rm1, and Rp3. For the region upstream of the N gene, SL-CoVs from all three bat species contained a single ORF (ORF10′), similar to that found in SARS-CoV isolates from civets (*5*) and patients in the early phase of the outbreaks (*16*, *18*) but different from that in most human isolates, which

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016802




Fig. 2. Phylogenetic trees. (**A**) and (**B**) are trees based on deduced amino acid sequences of the same regions in P1b and S, respectively, as used by Poon *et al.* (*7*) for bat-CoV. Tor2 and SZ3, SARS-CoV strains Tor2 and SZ3; Rp3, SL-CoV Rp3; HCoV, human coronavirus; MHV, mouse hepatitis virus; PEDV, porcine epidemic diarrhea virus; IBV, avian infectious bronchitis virus.




Fig. 3. Phylogenetic trees based on deduced amino acid sequences of (**A**) N, (**B**) ORF10′, and (**C**) S1 proteins. Tor2, SZ3, and GD01, different SARS-CoV strains; Rf1, Rm1, and Rp1-3, different SL-CoV sequences. The genetic distance scale shown for (A) is different from those for (B) and (C).

have a 29-nucleotide deletion in this region (*3*, *4*, *16*). ORF10′ in Rf1 codes for a protein having the same size (122 amino acids) as and more than 80% sequence identity to ORF10′ proteins of SARS-CoVs, but those in Rm1 and Rp3 code for a 121–amino acid protein with only 35% sequence identity (Fig. 3B and fig. S2). By contrast, analysis of the S1 protein regions (Fig. 3C and fig. S3) indicated that Rf1 was more closely related to SL-CoVs from two other bat species than to SARS-CoVs, suggesting that the SARS cluster of coronaviruses could recombine to increase genetic diversity and fitness, as is well documented for other coronaviruses (*19*). We were unable to sequence these regions for Rp1 or Rp2, owing to the poor quality of the fecal materials from these two animals. The limited amount of cDNA available was used up for N gene analysis and in initial sequencing trials with SARS-CoV–derived primers, which were largely unsuccessful. Judging from the close relationship of the N genes between Rp1, Rp2, and Rp3 (fig. S1), it is unlikely that Rp1 or Rp2 will have major sequence differences from Rp3 in the S1 or ORF10′ regions. This is not unexpected, considering that these three positive samples were obtained from the same bat species in the same location.

The genetic diversity of bat-derived sequences supports the notion that bats are a natural reservoir host of the SARS cluster of coronaviruses. A similar observation has been made for henipaviruses, another important group of emerging zoonotic viruses of bat origin, which show greater genetic diversity in bats than was observed among viruses isolated during the initial Nipah outbreaks in Malaysia (*23*–*26*). The overall nucleotide sequence identity of 92% between SL-CoVs and SARS-CoVs is very similar to that observed between Nipah viruses isolated from Malaysia and Bangladesh in 1999 and 2004, respectively (*25*) (fig. S4). SL-CoVs present a new challenge to the diagnosis and treatment of future disease outbreaks. The current tests and therapeutic strategies may not work effectively against all viruses in this group, owing to their great genetic variability in the S1 domain region of the S gene.

The genus *Rhinolophus* contains 69 species and has a wide distribution from Australia to Europe (*27*). They roost primarily in caves and feed mainly on moths and beetles. However, notwithstanding the predominant *Rhinolophus* findings in this study, it is highly likely that there are more SARS-related coronaviruses to be discovered in bats. Indeed, our positive serological findings in the cave-dwelling fruit bat *Rousettus leschenaulti* indicate that infection by a related virus could occur in fruit bats as well, albeit at a much lower frequency. A plausible mechanism for emergence from a natural bat reservoir can be readily envisaged. Fruit bats including *R. leschenaulti*, and less frequently insectivorous bats, are found in markets in southern China. An infectious consignment of bats serendipitously juxtaposed with a susceptible amplifying species, such as *P. larvata*, at some point in the wildlife supply chain could result in spillover and establishment of a market cycle while susceptible animals are available to maintain infection. Further studies in field epidemiology, laboratory infection, and receptor distribution and usage are being conducted to assess potential roles played by different bat species in SARS emergence.

These findings on coronaviruses, together with data on henipaviruses (*23*–*25*, *28*), suggest that genetic diversity exists among zoonotic viruses in bats, increasing the possibility of variants crossing the species barrier and causing outbreaks of disease in human populations. It is therefore essential that we enhance our knowledge and understanding of reservoir host distribution, animal-animal and human-animal interaction (particularly within the wet-market system), and the genetic diversity of bat-borne viruses to prevent future outbreaks.

References and Notes

1. J. S. M. Peiris *et al.*, *Lancet* **361**, 1319 (2003).
2. T. G. Ksiazek *et al.*, *N. Engl. J. Med.* **348**, 1953 (2003).
3. P. A. Rota *et al.*, *Science* **300**, 1394 (2003).
4. M. A. Marra *et al.*, *Science* **300**, 1399 (2003).
5. Y. Guan *et al.*, *Science* **302**, 276 (2003).
6. C. Tu *et al.*, *Emerg. Infect. Dis.* **10**, 2244 (2004).
7. L. L. M. Poon *et al.*, *J. Virol.* **79**, 2110 (2005).
8. D. Wu *et al.*, *J. Virol.* **79**, 2620 (2005).
9. K. Murray *et al.*, *Science* **268**, 94 (1995).
10. K. B. Chua *et al.*, *Science* **288**, 1432 (2000).
11. L.-F. Wang, B. T. Eaton, *Infect. Dis. Rev.* **3**, 52 (2001).
12. S. E. Sulkin, R. Allen, *Monograph Virol.* **8**, 170 (1974).
13. S. P. Mickleburgh, A. M. Huston, P. A. Racey, *Oryx* **36**, 18 (2002).
14. Materials and methods are available as supporting material on *Science* Online.
15. P. J. Hudson, A. Rizzoli, B. T. Grenfell, H. Heesterbeek, A. P. Dobson, Eds., *The Ecology of Wildlife Diseases* (Oxford Univ. Press, Oxford, 2002).
16. Chinese SARS Molecular Epidemiology Consortium, *Science* **303**, 1666 (2004).
17. P. Liò, N. Goldman, *Trends Microbiol.* **12**, 106 (2004).
18. H.-D. Song *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2430 (2005).
19. M. C. Lai, K. V. Holmes, in *Fields Virology*, D. M. Knipe *et al.*, Eds. (Lippincott, Williams & Wilkins, Philadelphia, 2001), vol. 2, chap. 35.
20. R. A. Tripp *et al.*, *J. Virol. Methods* **128**, 21 (2005).
21. Y. He, H. Lu, P. Siddiqui, Y. Zhou, S. Jiang, *J. Immunol.* **174**, 4908 (2005).
22. D. A. Brian, R. S. Baric, *Curr. Top. Microbiol. Immunol.* **287**, 1 (2005).
23. S. AbuBakar *et al.*, *Emerg. Infect. Dis.* **10**, 2228 (2004).
24. J.-M. Reynes *et al.*, *Emerg. Infect. Dis.* **11**, 1042 (2005).
25. B. H. Harcourt *et al.*, *Emerg. Infect. Dis.* **11**, 1594 (2005).
26. V. P. Hsu *et al.*, *Emerg. Infect. Dis.* **10**, 2082 (2004).
27. T. H. Kunz, M. B. Fenton, Eds., *Bat Ecology* (Univ. of Chicago Press, Chicago, 2003).
28. L.-F. Wang, K. B. Chua, M. Yu, B. T. Eaton, *Curr. Genomics* **4**, 263 (2003).
29. This work was jointly funded by a special grant for "Animal Reservoir of SARS-CoV," State Key Program for Basic Research Grant 2005CB523004, and State High Technology Development Program grant no.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016803

2005AA219070 from the Ministry of Science and Technology, People's Republic of China; the Sixth Framework Program "EPISARS" from the European Commission (no. 51163); the Australian Biosecurity Cooperative Research Centre for Emerging Infectious Disease (Project 1.007R); and an NIH/NSF "Ecology of Infectious Diseases" award (no. R01-TW05869) from the John E. Fogarty International Center and the V. Kann Rasmussen Foundation. For the full-length genome sequence of SL-CoV Rp3, see GenBank accession no. DQ71615. Additional GenBank accession numbers are given in the supporting material.

Supporting Online Material
www.sciencemag.org/cgi/content/full/1118391/DC1
Materials and Methods
Figs. S1 to S4
Tables S1 to S3
References and Notes

4 August 2005; accepted 20 September 2005
Published online 29 September 2005;
10.1126/science.1118391
Include this information when citing this paper.

Neurogenesis in the Hypothalamus of Adult Mice: Potential Role in Energy Balance

Maia V. Kokoeva, Huali Yin, Jeffrey S. Flier*

Ciliary neurotrophic factor (CNTF) induces weight loss in obese rodents and humans, and for reasons that are not understood, its effects persist after the cessation of treatment. Here we demonstrate that centrally administered CNTF induces cell proliferation in feeding centers of the murine hypothalamus. Many of the newborn cells express neuronal markers and show functional phenotypes relevant for energy-balance control, including a capacity for leptin-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3). Co-administration of the mitotic blocker cytosine-β-D-arabinofuranoside (Ara-C) eliminates the proliferation of neural cells and abrogates the long-term, but not the short-term, effect of CNTF on body weight. These findings link the sustained effect of CNTF on energy balance to hypothalamic neurogenesis and suggest that regulated hypothalamic neurogenesis in adult mice may play a previously unappreciated role in physiology and disease.

The obesity epidemic has prompted major efforts to develop safe and effective therapies (*1*, *2*). However, approved drugs for obesity have limited efficacy and act only acutely, with patients rapidly regaining weight after terminating treatment (*3*). Only the neurocytokine ciliary neurotrophic factor (CNTF) and Axokine, an analog of CNTF developed as a drug candidate for the treatment of obesity, appear to deviate from this paradigm. Rodents and patients treated with Axokine were reported to maintain lowered body weights weeks to months after the cessation of treatment (*4*, *5*). This feature of Axokine/CNTF action is unexplained and suggests that CNTF induces long-lasting changes in one or more elements of the energy-balance circuitry.

In rodents, CNTF is most potent when administered directly into the cerebrospinal fluid (*6*) and activates signaling cascades in hypothalamic nuclei involved in feeding control (*5*, *7*, *8*). For instance, CNTF activates phosphorylation of signal transducer and activator of transcription 3 (STAT3) in a population of hypothalamic neurons that substantially overlaps with those activated by leptin (*5*). However, in contrast to CNTF, leptin-treated animals do not maintain their lowered body weight after the cessation of treatment. We thus sought a CNTF-specific mechanism to explain this long-term effect.

CNTF supports the survival of neurons in vitro and in vivo (*9*) and has also been implicated in the maintenance of adult neural stem cells (*10*). Furthermore, other trophic factors, such as epidermal growth factor and fibroblast growth factor 2, are known to act as mitogens on adult neuronal progenitors (*11*, *12*), and they promote the functional regeneration of hippocampal pyramidal neurons (*13*). Neurogenesis in the adult brain is most clearly defined in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the hippocampal formation (*14*). However, recent reports indicate that the neuroproliferative potency in the adult extends to other brain structures, including the hypothalamus (*15*–*17*). On the basis of these findings, we hypothesized that the long-term effect of CNTF on body-weight regulation might involve neurogenesis in the hypothalamus, which is the brain region most relevant for energy-balance regulation.

To assess the mitogenic potency of CNTF in the adult nervous system in vivo, we delivered the cell-proliferation marker bromodeoxyuridine (BrdU) alone (vehicle treatment) or together with CNTF directly into the cerebrospinal fluid of mouse brains (*18*). CNTF and BrdU were continuously infused for 7 days into the right lateral ventricle using osmotic minipumps. Mice were switched to a high-fat diet two months before surgery and were kept on this diet throughout the experiments. In accordance with previous results (*5*), CNTF-treated mice showed a marked reduction in body weights (Fig. 1A), which persisted after termination of CNTF delivery. Mice were killed 22 days after surgery, and brain sections were immunostained with an antibody against BrdU. Because BrdU incorporates into DNA of dividing cells, BrdU-positive ($BrdU^+$) cells are thought to represent newborn cells. Figure 1B shows coronal sections of vehicle- and CNTF-infused animals at the level of the arcuate, ventromedial, and dorsomedial nuclei, well-known hypothalamic centers for energy-balance regulation (*19*). In vehicle-infused animals, few $BrdU^+$ cells were detected in the parenchyma surrounding the third ventricle (Fig. 1B, left). Administration with CNTF led to a dramatic increase of BrdU+ cells (Fig. 1B, right). Note the higher density of $BrdU^+$ cells at the base of the third ventricle, which is part of the arcuate nucleus/median eminence.

The pattern of CNTF receptor (CNTFR) mRNA expression is consistent with this observation. In situ hybridization using a riboprobe against CNTFR mRNA revealed strong staining in the walls of the basal third ventricle and surrounding arcuate nucleus parenchyma (Fig. 1C). Because this section originated from an animal treated with both CNTF and BrdU, we colabeled with antibodies to BrdU. Many $BrdU^+$ cells were positive for CNTFR expression, indicating that CNTF, at least in part, directly promotes cell division by binding to CNTFR on putative neural progenitor cells (Fig. 1D, inset). By counting all newly generated cells in the caudal hypothalamus, CNTF treatment led to a marked increase of $BrdU^+$ cells over vehicle-infused animals (Fig. 1E). The total number of $BrdU^+$ cells in CNTF-treated animals remained constant for at least 2 weeks after the infusion period. Subsequently, the numbers decreased but plateaued at a high level. Vehicle-infused animals showed a similar fractional decrease over time. Thus it appears that the majority of hypothalamic $BrdU^+$ cells do not die or migrate to distant areas as reported for newborn neurons of the SVZ, which follow the rostral migratory stream toward the olfactory bulb (*20*).

To investigate the origin of adult-born cells in the hypothalamus, we examined CNTF and vehicle-infused brains every 12 hours starting 48 hours after surgery, a time when the infused CNTF/BrdU should just reach the ventricular system (*18*). Hypothalamic BrdU incorporation was first detected 60 to 72 hours

Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA.

*To whom correspondence should be addressed. E-mail: jflier@bidmc.harvard.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_016804

From: Bente, Dennis A.
Sent: Monday, July 28, 2014 11:36 AM
To: LeDuc, James W.;Ksiazek, Thomas G.
Subject: RE: validation for virus antibody detection

I talked to Han. She knows the scientist (it is a woman). In fact, the collaborated on a project years ago. Han said that her group is scientifically very strong (nature paper, etc.). We would be happy to collaborate and help as much as we can.

Dennis

From: LeDuc, James W.
Sent: Monday, July 28, 2014 8:28 AM
To: Bente, Dennis A.; Ksiazek, Thomas G.
Subject: FW: validation for virus antibody detection

Dennis,

Please see letter of inquiry from Wuhan. I'm wondering if Han Xia knows this person and might be interested in attempting to develop this potential collaboration. This might be a good opportunity to position her for sustain collaborations between our organizations. We can check with the Toms to see if we have the critical immune sera to validate their observations.

Please check with Han and then we can discuss. I replied to Dr Zhengli that we would discuss here and get back to him soon.

Thanks, Jim

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070876

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_070877

From: LeDuc, James W.
Sent: Monday, July 28, 2014 8:46 PM
To: zlshi
Cc: 袁 志明;Bente, Dennis A.;Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

FOIA Confidential Treatment Requested by Univ of Texas System

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064366

From: zlshi [zlshi@wh.iov.cn]
Sent: 7/28/2014 8:51:40 PM
To: LeDuc, James W. [jwleduc@UTMB.EDU]
CC: 袁 志明 [yzm@wh.iov.cn]; Bente, Dennis A. [dabente@UTMB.EDU]; Xia, Han [haxia@UTMB.EDU]
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Le Duc,

Thank you very much for your prompt and positive reply. I'll discuss the details with Dr. Bente and Dr. Xia Han for the next step.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi <zlshi@wh.iov.cn>
Sent: Tuesday, July 29, 2014 4:55 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.;Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064360

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064361

From: zlshi [zlshi@wh.iov.cn]
Sent: 7/31/2014 2:58:37 AM
To: Bente, Dennis A. [dabente@UTMB.EDU]
CC: Xia, Han [haxia@UTMB.EDU]
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you very much for your positive reply. Your suggestion to use non-human primate sera against the viruses is very good.

Regarding the project of CCHFV, I'm happy to share with you our experience. I'll talk the details with Han at her available time through QQ (b)(6) or Skype (b)(6)

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi [zlshi@wh.iov.cn]
Sent: 8/31/2014 8:51:40 PM
To: Bente, Dennis A. [dabente@UTMB.EDU]
CC: Xia, Han [haxia@UTMB.EDU]; Zhang Bo [zhangbo@wh.iov.cn]
Subject: Re: RE: validation for virus antibody detection
Attachments: Invitation letter for invited speaker.doc

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM

To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System

The 6th Symposium on Emerging Viral Diseases
Address: Xiaohongshan 44, Wuchang, Wuhan 430071, Hubei, P.R. China
Tel: +86-27-87198921 Fax: +86-27-87198921 http://www.whiov.ac.cn

Dr. Dennis Bente
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610

Dear Dr. Bente,

The 6th International Symposium on Emerging Viral Diseases will be held in October 29-31, 2014 in Wuhan, China. The symposium will be organized by the Wuhan Institute of Virology, Chinese Academy of Sciences. The symposium will cover various topics of emerging viruses, including epidemiology, molecular biology, evolution, immunology, and pathogenesis. This biennial symposium has become an important event for leading Chinese and international virologists to discuss cutting-edge science as well as to foster global collaborations.

It is our great pleasure to invite you as a plenary speaker to present your work at this symposium. Your accommodation and expenses in Wuhan will be covered by the conference. In addition, *Virologica Sinica*, the official journal of Chinese Society for Microbiology, will delicate a special issue for this symposium. Your contribution of an article to this open-access issue will be greatly appreciated. However, due to budget constrain, we are unfortunately not able to cover your travel expenses.

Please send the attached Reply Form together with your abstract to our secretary Mrs. Li-Ping Li by July 31, 2014 and indicate whether you request travel assistance.

We look forward to seeing you in Wuhan.

Sincerely Yours,

[SHAPE * MERGEFORMAT]
Pei-Yong SHI
Novartis Institute for Tropical Diseases

(b)(6)

Bo ZHANG
Wuhan Institute of Virology
Chinese Academy of Sciences

6th International Symposium on Emerging Viral Diseases
Oct. 29-31, Wuhan, China

Reply Form for Invited Speakers

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_039251

Name of invited Speaker	
Contact email	
Are you able to attend the symposium?	
Title of your presentation	

Please send your reply form together with your abstract (see attached sample or template) to our secretary by July 31, 2014:

Ms Li-Ping LI
Wuhan Institute of Virology
Chinese Academy of Sciences
Wuhan 430071, P.R.China
Tel/Fax: +86-27-87198921
Email: llp@wh.iov.cn

Abstract template

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_039252

Difference in receptor usage between SARS coronavirus and SARS-like coronavirus of bat origin

Wuze Ren[1], Xiuxia Qu[2], Wendong Li[1], Zhenggang Han[1], Meng Yu, Peng Zhou, Shuyi Zhang, Lin-Fa Wang[3], Hongkui Deng[2], Zhengli Shi[1]

[1]State key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China; [2]Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of Life Sciences, Peking University, Beijing, China; [3]CSIRO Livestock Industries, Australian Animal Health Laboratory and Australian Biosecurity Cooperative Research Center for Emerging Infectious Diseases, Geelong, Australia; and School of Life Science, [4]East China Normal University, Shanghai, China

Severe acute respiratory syndrome (SARS) was caused by the SARS-associated coronavirus (SARS-CoV), which uses the angiotensin converting enzyme 2 (ACE2) as its receptor for cell entry. A group of SARS-like coronaviruses (SL-CoVs) has been identified in horseshoe bats. SL-CoVs and SARS-CoVs share an identical genome organization and high sequence identities with the main exception of the N-terminus of the spike protein (S), known to be responsible for receptor binding in coronaviruses. In this study, we investigated the receptor usage of the SL-CoV S by combining an HIV-based pseudovirus system with cell lines expressing the ACE2 molecules of human, civet or horseshoe bat. In addition to full-length S of SL-CoV and SARS-CoV, a series of S chimeras was constructed by inserting different sequences of the SARS-CoV S into the SL-CoV S backbone. Several important observations were made from this study. First, the SL-CoV S was unable to use any of the three ACE2 molecules as its receptor. Second, the SARS-CoV S failed to enter cells expressing the bat ACE2. Third, the chimeric S covering the previously defined receptor-binding domain gained their ability to enter cells via human ACE2, albeit with different efficiency for different constructs. Fourth, a minimal insert region (aa 310-518) was found to be sufficient to convert the SL-CoV S from ACE2-non-binding to human ACE2-binding, indicating that the SL-CoV S is largely compatible to SARS-CoV S protein both in structure and function.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_039253

From: zlshi <zlshi@wh.iov.cn>
Sent: Monday, September 1, 2014 7:51 PM
To: Bente, Dennis A.
Cc: Zhang Bo
Subject: Re: meeting confirmation

Dear Dennis,

Thank you very much for your confirmation.

All topics of your work is relevant for the meeting. Whatever you talk will be interesting. But my personal opinion would be pathogensis as it is more intriguing and cross-over with the backgroud of most of us in the Institute.

Looking forward to meeting you.

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-09-02 08:28
To: zlshi
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Thank you very much for the letter. It is definitely not too late to get the visa. Collegues of mine here are the Galveston National Laboratory got their visa from the Chinese Consulate in Houston within a week.

I am very excited to able to join your symposium on Emerging Viral Diseases. As you probably have heard from Han Xia, we work on tick-borne hemorrhagic fever viruses (bunyaviruses and flaviruses). My lab works on a range of different projects from molecular virology, diagnostics, pathogenesis and immunology, to vaccine development. I was wondering what topic would be most relevant for the meeting. Please let me know what would be good topics.

Thank you and best wishes,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064356

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection

Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064357

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064358

Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064359

From: zhangbo <zhangbo@wh.iov.cn>
Sent: Friday, October 3, 2014 8:07 PM
To: zlshi;Bente, Dennis A.
Cc: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Attachments: _Template for CV.doc

Dear Dennis

We still accept the abstract. Please send me the abstract directly. The agenda is going to be finished, I would like to have your abstract by Oct. 7th.
At same time, I would like to have your update CV. The template for CV is attached.
It will be fine if you arrive Wuhan on Oct. 29th which is used for registration. We have presentation on 30th and 31st of Oct.
We are looking forward to seeing you in Wuhan.
All best,
Bo

Bo Zhang
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Xiao Hong Shan Zhong Qu 44
Wuhan, Hubei 430071, P.R.China
Tel:(+)86-27-87197822
email: zhangbo@wh.iov.cn

原始邮件

发件人: Dennis A." <dabente@UTMB.EDU>
收件人: zlshi<zlshi@wh.iov.cn>
抄送: Han" <haxia@UTMB.EDU>; Zhang Bo<zhangbo@wh.iov.cn>
发送时间: 2014年10月4日(周六) 06:06
主题: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

I will go to the Chinese embassy on Monday. I should be able to get the visa within a week. I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

Please let me know,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064351

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064352

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064353

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064354

From:	(b)(6)
Sent:	Saturday, October 11, 2014 3:34 AM
To:	dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; Bente, Dennis A.; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
Cc:	zhangbo; llp
Subject:	Program of 6th International Symposium on Emerging Viral Diseases
Attachments:	2014-Agenda 6th ISEVD-10-11.doc

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014	**09:00-21:00**	**Registration**
Thursday, Oct. 30, 2014	**08:30-12:00**	**Session 1: Emerging viruses and viral epidemiology**
	12:00-14:00	**Lunch**
	14:00-18:00	**Session 2: Antiviral and Vaccine**
	18:00-20:00	**Dinner**
Friday, Oct. 31, 2014	**08:30-12:00**	**Session 3: Emerging viruses and viral therapeutic**
	12:00-14:00	**Lunch**
	14:00-17:25	**Session 4: Viral replication**
	18:00-19:00	**Dinner**

Details about AGENDA are listed in the attached file.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125712

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125713

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 **Oct. 29, 2014** **10 月 29 日**	**Venue** 地点 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
	Day 1, Morning Session /第一天上午	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs**: **Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
Thursday 星期四 **Oct. 30, 2014** **10 月 30 日**	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125714

12:00-14:00	Lunch/午餐
	Day 1, Afternoon Session /第一天下午
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2, Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125716

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125717

	18:00-19:00	Dinner/晚餐

From: (b)(6)
Sent: Saturday, October 11, 2014 3:34 AM
To: dimitrdi;pei_yong.shi;cbroder;christopher.broder;kuhnjens;gdliang;lijun;Linfa.wang;linfa.wang;michlai;changchun_tu;zhangyongzhen;zlshi;mko2;michael.lo;gaof;gaofu;chengfeng_qin;zheng_yin;ouyangsy;louzy;louzy;yuanan;Andrew.Davidson;daszak;chmura;zchenai;kecw1965;avidguan811;chen_ling;chen002;chenmz;yee_sin_leo;linda_k_lee;angela_chow;axiong;chenhualan;jwu;dguo;ywu8;tcyang2014;Bente, Dennis A.;qing_yin.wang;liusw;guang.yang;liflit;wanglih9755;caiy;lmy2014;13811876613;wfshi;shiwf;liurong19840901;532389467;heb-001001;xjsyzhang;sr_sun2005;zhoudg
Cc: zhangbo;llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: 2014-Agenda 6th ISEVD-10-11.doc

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014	**09:00-21:00**	**Registration**
Thursday, Oct. 30, 2014	**08:30-12:00**	**Session 1: Emerging viruses and viral epidemiology**
	12:00-14:00	**Lunch**
	14:00-18:00	**Session 2: Antiviral and Vaccine**
	18:00-20:00	**Dinner**
Friday, Oct. 31, 2014	**08:30-12:00**	**Session 3: Emerging viruses and viral therapeutic**
	12:00-14:00	**Lunch**
	14:00-17:25	**Session 4: Viral replication**
	18:00-19:00	**Dinner**

Details about AGENDA are listed in the attached file.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064408

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064409

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 **Oct. 29, 2014** **10 月 29 日**	**Venue** 地点 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
	Day 1, Morning Session /第一天上午	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs**: **Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
Thursday 星期四 **Oct. 30, 2014** **10 月 30 日**	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064410

12:00-14:00	Lunch/午餐
	Day 1, Afternoon Session /第一天下午
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064411

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2, Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064412

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064413

	18:00-19:00	Dinner/晚餐

From: (b)(6)
Sent: Saturday, October 11, 2014 3:34 AM
To: dimitrdi;pei_yong.shi;cbroder;christopher.broder;kuhnjens;gdliang;lijun;Linfa.wang;linfa.wang;michlai;changchun_tu;zhangyongzhen;zlshi;mko2;michael.lo;gaof;gaofu;chengfeng_qin;zheng_yin;ouyangsy;louzy;louzy;yuanan;Andrew.Davidson;daszak;chmura;zchenai;kecw1965;avidguan811;chen_ling;chen002;chenmz;yee_sin_leo;linda_k_lee;angela_chow;axiong;chenhualan;jwu;dguo;ywu8;tcyang2014;Bente, Dennis A.;qing_yin.wang;liusw;guang.yang;liflit;wanglih9755;caiy;lmy2014;13811876613;wfshi;shiwf;liurong19840901;532389467;heb-001001;xjsyzhang;sr_sun2005;zhoudg
Cc: zhangbo;llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: 2014-Agenda 6th ISEVD-10-11.doc

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014	**09:00-21:00**	**Registration**
Thursday, Oct. 30, 2014	**08:30-12:00**	**Session 1: Emerging viruses and viral epidemiology**
	12:00-14:00	**Lunch**
	14:00-18:00	**Session 2: Antiviral and Vaccine**
	18:00-20:00	**Dinner**
Friday, Oct. 31, 2014	**08:30-12:00**	**Session 3: Emerging viruses and viral therapeutic**
	12:00-14:00	**Lunch**
	14:00-17:25	**Session 4: Viral replication**
	18:00-19:00	**Dinner**

Details about AGENDA are listed in the attached file.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094126

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email:(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094127

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 **Oct. 29, 2014** **10 月 29 日**	**Venue** 地点 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
	Day 1, Morning Session /第一天上午	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs**: **Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
Thursday 星期四 **Oct. 30, 2014** **10 月 30 日**	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094128

12:00-14:00	Lunch/午餐
	Day 1, Afternoon Session /第一天下午
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094129

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2, Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094130

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_094131

	18:00-19:00	Dinner/晚餐

From: zhangbo [zhangbo@wh.iov.cn]
Sent: 10/13/2014 8:49:18 AM
To: Bente, Dennis A. [dabente@UTMB.EDU]
CC: 刘思情 (b)(6)
Subject: RE: RE: validation for virus antibody detection
Attachments: 2014-Agenda 6th ISEVD-10-11.doc

Hi Dennis
We only have presentation on both 30th and 31st.
Si-Qing Liu sent you agenda of the symposium to you last weekend. I think you may miss it. Please check the attachment for the agenda.
At same time, we would like to have you itinerary?
All best,
Bo

Bo Zhang
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Xiao Hong Shan Zhong Qu 44
Wuhan, Hubei 430071, P.R.China
Tel:(+)86-27-87197822
email: zhangbo@wh.iov.cn

原始邮件
发件人: Dennis A." <dabente@UTMB EDU>
收件人: zhangbo<zhangbo@wh.iov.cn>
发送时间: 2014年10月13日(周一) 21.27
主题: RE: RE: validation for virus antibody detection

Dear Bo,

I was just wondering if I present on the 30th or on the 31st. I would like to visit the new BSL4 lab being built in Wuhan and my host, Xia Han, is trying to coordinate my visit.

Could you also please tell me how long the presentation should be?

Thank you,

Dennis

From: zhangbo [mailto:zhangbo@wh.iov.cn]
Sent: Friday, October 3, 2014 8:07 PM
To: zlshi; Bente, Dennis A.
Cc: Xia, Han
Subject: RE: RE: validation for virus antibody detection

Dear Dennis

We still accept the abstract. Please send me the abstract directly. The agenda is going to be finished, I would like to have your abstract by Oct. 7th.

FOIA Confidential Treatment Requested by Univ of Texas System

At same time, I would like to have your update CV. The template for CV is attached.
It will be fine if you arrive Wuhan on Oct. 29th which is used for registration. We have presentation on 30th and 31st of Oct.
We are looking forward to seeing you in Wuhan.
All best,
Bo

Bo Zhang

Flavivirus Infection and Prevention

Wuhan Institute of Virology

Chinese Academy of Sciences

Xiao Hong Shan Zhong Qu 44

Wuhan, Hubei 430071, P.R.China

Tel:(+)86-27-87197822

email: zhangbo@wh.iov.cn

原始邮件

发件人: Dennis A." <dabente@UTMB.EDU>

收件人: zlshi<zlshi@wh.iov.cn>

抄送: Han" <haxia@UTMB.EDU>; Zhang Bo<zhangbo@wh.iov.cn>

发送时间: 2014年10月4日(周六) 06:06

主题: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

I will go to the Chinese embassy on Monday. I should be able to get (b)(6) within a week. I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

Please let me know,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late fo (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection

Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

FOIA Confidential Treatment Requested by Univ of Texas System

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500

FOIA Confidential Treatment Requested by Univ of Texas System

(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 Oct. 29, 2014 10 月 29 日	**Venue 地点** 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
Thursday 星期四 Oct. 30, 2014 10 月 30 日	**Day 1, Morning Session /第一天上午**	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs: Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064426

12:00-14:00	Lunch/午餐
Day 1, Afternoon Session /第一天下午	
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064427

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2. Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064428

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064429

	18:00-19:00	Dinner/晚餐

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo;llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: 2014-Agenda 6th ISEVD-10-11.doc

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064400

Thursday, Oct. 30, 2014 08:30-12:00 Session 1: Emerging viruses and viral epidemiology

12:00-14:00 Lunch

14:00-18:00 Session 2: Antiviral and Vaccine

18:00-20:00 Dinner

Friday, Oct. 31, 2014 08:30-12:00 Session 3: Emerging viruses and viral therapeutic

12:00-14:00 Lunch

14:00-17:25 Session 4: Viral replication

18:00-19:00 Dinner

Details about AGENDA are listed in the attached file.

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.

We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,

Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064401

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064402

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 **Oct. 29, 2014** **10 月 29 日**	**Venue** 地点 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
	Day 1, Morning Session /第一天上午	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs**: **Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
Thursday 星期四 **Oct. 30, 2014** **10 月 30 日**	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064403

12:00-14:00	Lunch/午餐
	Day 1, Afternoon Session /第一天下午
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064404

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2, Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064405

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064406

	18:00-19:00	Dinner/晚餐

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: 2014-Agenda 6th ISEVD-10-11.doc

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125704

Thursday, Oct. 30, 2014 08:30-12:00 Session 1: Emerging viruses and viral epidemiology

12:00-14:00 Lunch

14:00-18:00 Session 2: Antiviral and Vaccine

18:00-20:00 Dinner

Friday, Oct. 31, 2014 08:30-12:00 Session 3: Emerging viruses and viral therapeutic

12:00-14:00 Lunch

14:00-17:25 Session 4: Viral replication

18:00-19:00 Dinner

Details about AGENDA are listed in the attached file.
We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125705

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125706

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Wednesday 星期三 **Oct. 29, 2014** **10 月 29 日**	**Venue** 地点 09:00-21:00	**Registration**/报到注册 Ground Floor, Hongshan Hotel/洪山宾馆一楼大厅 Ground Floor, Shuaifu Hotel（Marshal Palace Hotel）/帅府饭店一楼大厅
	Day 1, Morning Session /第一天上午	
	Venue 地点	Conference Hall of the Wuhan Institute of Virology, CAS 2nd floor of the Institute Building 中国科学院武汉病毒研究所学术报告厅（研究所大楼二层）
	08:30-08:45	**Opening Address/开幕式致词**
	08:45-12:00	**Session 1: Emerging viruses and viral epidemiology** **Session Chairs**: **Xinwen CHEN, Pei-Yong Shi**
	08:45-09:15 IS-01	**Title:** Receptor-binding adaptation for human CD26 by lineage C betacoronaviruses **Speaker: George F. Gao** Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	09:15-09:45 IS-02	**Title:** Bats, Emerging Zoonotic Viruses and a One-Health Vaccine for Hendra Virus **Speaker: Lin-Fa Wang** Duke-NUS Graduate Medical School, 8 College Road, Singapore
Thursday 星期四 **Oct. 30, 2014** **10 月 30 日**	09:45-10:15	Group Photo of Symposium Participants/与会代表合影 Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:40 IS-03	**Title:** Emerging viral outbreaks in Singapore **Speaker: Leo Yee Sin** Institute of Infectious Diseases & Epidemiology/Communicable Disease Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
	10:40-11:00 IS-04	**Title:** Novel tick-borne viruses discovered in China **Speaker: Yong-Zhen Zhang** Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
	11:00-11:20 IS-05	**Title:** USAID-EPT-PREDICT – A new approach to preventing pandemics and targeting control by detecting potentially zoonotic pathogens before they spillover from wildlife **Speaker: Peter Daszak** EcoHealth Alliance, New York, NY 10001, USA
	11:20-11:40 IS-06	**Title:** Influenza A/H7N9 virus emergence in poultry and humans in Guangdong China **Speaker: Changwen Ke** Institute of Microbiology, Center for Diseases Control and Prevention of Guangdong Province, China
	11:40-12:00 IS-07	**Title:** Overview of the diversity, cross-species transmission, and pathologic potential of taxonomically distinct simian arteriviruses **Speaker: Jens Kuhn** Integrated Research Facility at Fort Detrick (IRF-Frederick) Frederick, MD 21702, USA

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125707

12:00-14:00	Lunch/午餐
Day 1, Afternoon Session /第一天下午	
14:00-18:00	**Session 2: Antiviral and Vaccine** **Session Chairs: Hong TANG, Linfa WANG**
14:00-14:30 IS-08	**Title:** Protein ubiquitination regulates multiple steps in the life of influenza virus **Speaker: Michael Lai** Institute of Molecular Biology and National RNAi Core Facility, Academia Sinica, Taipei, Taiwan, China
14:30-15:00 IS-09	**Title:** Discovery of novel methyltransferases of coronaviruses and their use as antiviral drug targets **Speaker: Deyin Guo** School of Basic Medical Sciences, Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-10	**Title:** A lesson learned from the clinical trial of Balapiravir in dengue patients **Speaker: Pei-Yong Shi** Novartis Institute for Tropical Diseases, Singapore
15:20-15:40 IS-11	**Title:** The challenge in drug discovery of antivirals for RNA viruses **Speaker: Zheng Yin** College of Pharmacy, Nankai University, Tianjin, China
15:40-16:00 IS-12	**Title:** New Opportunities in Dengue Drug Discovery: Targeting NS4B **Speaker: Qingyin Wang** Novartis Institute for Tropical Diseases, Singapore
16:00-16:20	Coffee Break and Poster Presentation/茶歇和展板
16:20-16:40 IS-13	**Title:** Identification of entry inhibitors of emerging viral pathogens **Speaker: Lijun Rong** Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA
16:40-17:00 IS-14	**Title:** Human monoclonal antibodies against emerging and biodefense-related viruses **Speaker: Dimiter S Dimitrov** Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702, USA
17:00-17:20 IS-15	**Title:** Vaccine-elicited CD8+ T cells in HIV/AIDS control **Speaker: Zhiwei Chen** AIDS Institute/Department of Microbiology/Li Ka Shing Faculty of Medicine, University of Hong, Pokfulam, Hong Kong, China
17:20-17:40 IS-16	**Title:** Rational design of a thermotolerant virus vaccine by bioinspired silicification **Speaker: Cheng-Feng Qin** Department of Virology, Beijing Institute of Microbiology and Epidemiology, Beijing, China
17:40-18:00 IS-17	**Title:** Cell Mediated Novel Gene Therapy for Neuro AIDS **Speaker: Yuanan Lu** Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, USA
18:00-20:00	Dinner/晚餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125708

Program of

6th International Symposium on Emerging Viral Diseases

Date 日期	Time 时间	Content 议程
Friday 星期五 Oct. 31, 2014 10 月 31 日		**Day 2, Morning Session /第二天上午**
	08:30-12:00	**Session 3: Emerging viruses and viral therapeutic** **Session Chairs: JianGuo Wu, Zheng-Li SHI**
	08:30-08:55 IS-18	**Title:** Threat to human health posed by avian influenza viruses **Speaker: Hualan Chen** Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China
	08:55-09:15 IS-19	**Title:** Novel bat viruses identified in Yunnan province **Speaker: Chang-Chun Tu** Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun, China
	09:15-09:35 IS-20	**Title:** Isolation and identification of bat viruses closely related to human and porcine orthoreoviruses **Speaker: Zheng-Li Shi** Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
	09:35-09:55 IS-21	**Title:** Structural insights into Phlebovirus and Orthobunyavirus nucleocapsid protein complexes **Speaker: Songying Ouyang** Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
	09:55-10:15	Coffee Break and Poster Presentation/茶歇和展板
	10:15-10:35 IS-22	**Title:** Rapid generation of anti-virus antibodies in responding to emerging and virulent viral infectious diseases **Speaker: Ling Chen** Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guang Zhou, China
	10:35-10:55 IS-23	**Title:** Envelope Glycoproteins of Henipaviruses, Australian Bat Lyssavirus and Rabies Virus as Targets of Neutralizing Human Monoclonal Antibodies **Speaker: Christopher C Broder** Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
	10:55-11:20 IS-24	**Title:** Achieving the Impossible? Vaccine Strategies for the Control and Prevention of Japanese Encephalitis in Mainland China, 1951–2011 **Speaker: Guo-Dong Liang** State Key Laboratory for Infectious Diseases Prevention and Control, Institute for Viral Disease Control and Prevention, CDC, Beijing, China
	11:20-11:40 IS-25	**Title:** Analysis of Hazardous Characteristics of Mosquito-borne Diseases and Vectors Mosquitoes at Ningbo Port **Speaker: Tian-Ci Yang** Beilun Entry-Exit Inspection and Quarantine Bureau, Ningbo, Zhejiang, China
	12:00-14:00	Lunch/午餐

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125709

Day 2, Afternoon Session /第二天下午	
14:00-17:20	**Session 4: Viral replication** **Session Chairs: Zhihong HU, George F. GAO**
14:00-14:20 IS-26	**Title:** System Mapping of HIV-mediated CCR5 Signaling Critical for Viral Infection of Primary Target Cells **Speaker: Yuntao Wu** Department of Molecular and Microbiology, George Mason University, Manassas, Virginia, USA
14:20-14:40 IS-27	**Title:** Early Pathogenesis of Crimean-Congo Hemorrhagic Fever: Tick saliva immunomodulate cutaneous antigen presenting cell response to infection **Speaker: Bente, Dennis A** Galveston National Laboratory, Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, Texas, USA
14:40-15:00 IS-28	**Title:** Replication, Pathogenesis, and Immune Evasion of HBV and HCV **Speaker: Jianguo Wu** Wuhan University, Wuhan 430071, PR China
15:00-15:20 IS-29	**Title:** Function and formation of Crimean-Congo hemorrhagic fever virus ribonucleoprotein complex **Speaker: Zhi-Yong Lou** School of Medicine, Tsinghua University, Tsinghua University, Beijing 100084, China
15:20-15:40	Coffee Break and Poster Presentation/茶歇和展板
15:40-16:00 IS-30	**Title:** Monitoring influenza virus receptor binding changes by biophysical and structural analyses **Speaker: Alex Xiaoli Xiong** Division of Virology, MRC National Institute for Medical Research, Mill Hill, London, UK
16:00-16:20 IS-31	**Title:** Engaging Nipah virus on multiple fronts: from molecular characterization to pathogenesis to potential therapeutics **Speaker: Michael Lo** US Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, USA
16:20-16:40 IS-32	**Title:** Phosphoprotein of Human Parainfluenza Virus Type 3 Blocks Autophagosome-Lysosome Fusion **Speaker: Mingzhou Chen** State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
16:40-17:00 IS-33	**Title:** High throughput quantitative proteomic analysis of dengue virus-host cell interaction **Speaker: Andrew Davidson** Medical Sciences and Veterinary Sciences, University of Bristol, UK
17:00-17:20 IS-34	**Title:** Conserved functional regions of hemagglutinin as drug targets to develop influenza virus entry inhibitors **Speaker: Shuwen Liu** School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
17:20-17:25	**Closing Remarks**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125710

	18:00-19:00	Dinner/晚餐

From: zlshi <zlshi@wh.iov.cn>
Sent: Sunday, October 19, 2014 8:36 AM
To: Bente, Dennis A.
Cc: Xia, Han;Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

I hope you have already (b)(6) Can you please send me the information if you have booked your flight? I'll send one of my students to pick you up at Wuhan airport.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-04 06:06
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

I will go to the Chinese embassy on Monday. I should be able to get the visa within a week. I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

Please let me know,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064444

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection

Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064445

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064446

(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064447

From: Xia, Han
Sent: Tuesday, October 21, 2014 9:54 PM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: who is who.doc

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

Han

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125719

发自我的 iPhone

在 Oct 20, 2014，11:06，Bente, Dennis A. <dabente@UTMB.EDU> 写道：

Dear Bo and Si-qing,

Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.

My (b)(6)

Looking forward to meet you,

Dennis

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125720

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

Thursday, Oct. 30, 2014 08:30-12:00 Session 1: Emerging viruses and viral epidemiology

12:00-14:00 Lunch

14:00-18:00 Session 2: Antiviral and Vaccine

18:00-20:00 Dinner

Friday, Oct. 31, 2014 08:30-12:00 Session 3: Emerging viruses and viral therapeutic

12:00-14:00 Lunch

14:00-17:25 Session 4: Viral replication

18:00-19:00 Dinner

Details about AGENDA are listed in the attached file. We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125721

Please send the reply to Si-Qing Liu **by Oct. 18, 2014**.
If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email:(b)(6)

<Travel Reservation October 27 for BENTE.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125722

Beijing

Dr. Mifang Liang

Genetic recombinant antibody developing, pathogenesis of hemorrhagic virus, vaccine and diagnosis method developing.



FOIA Confidential Treatment Requested by Univ of Texas System

Wuhan

Dr. Zhiming Yuan, Director of Chinese Academic and Science, Wuhan Branch, Director of Wuhan BSL-4. Arbovirus diagnosis, bio-control and molecular epidemiology.



Dr. Dongli Song, engineering director of BSL-4



FOIA Confidential Treatment Requested by Univ of Texas System

Dr. Xinwen Chen, Director of Wuhan institute of virology.
Hepatitis virus



Dr. Zhengli Shi
emerging viruses and the infection, including the virus isolation and characterization, diagnostic method development and genomic studies, epidemiology and molecular mechanism of interspecies infection of zoonotic viruses, and viral metagenomics.



FOIA Confidential Treatment Requested by Univ of Texas System

Dr. Bo Zhang

Replication, pathogenesis and virus-host interaction, vaccine development and antiviral drug screen (West Nile virus, Dengue virus, EV71,epidemic encephalitis B).



Dr. Hanzhong Wang

Zoonosis virus, Interaction between virus infection and innate immunity, Dynamic tracing of virus infection



Dr. Tianxian Li

My ex-supervisor. Viral collection, isolation, classify.



FOIA Confidential Treatment Requested by Univ of Texas System

From: Xia, Han
Sent: Tuesday, October 21, 2014 9:54 PM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases
Attachments: who is who.doc

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

Han

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064431

发自我的 iPhone

在 Oct 20, 2014，11:06，Bente, Dennis A. <dabente@UTMB.EDU> 写道：

Dear Bo and Si-qing,

Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.

My (b)(6)

Looking forward to meet you,

Dennis

From (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064432

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

Thursday, Oct. 30, 2014 08:30-12:00 Session 1: Emerging viruses and viral epidemiology

12:00-14:00 Lunch

14:00-18:00 Session 2: Antiviral and Vaccine

18:00-20:00 Dinner

Friday, Oct. 31, 2014 08:30-12:00 Session 3: Emerging viruses and viral therapeutic

12:00-14:00 Lunch

14:00-17:25 Session 4: Viral replication

18:00-19:00 Dinner

Details about AGENDA are listed in the attached file. We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064433

Please send the reply to Si-Qing Liu **by Oct. 18, 2014**.
If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email:(b)(6)

<Travel Reservation October 27 for BENTE.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064434

Beijing

Dr. Mifang Liang

Genetic recombinant antibody developing, pathogenesis of hemorrhagic virus, vaccine and diagnosis method developing.



FOIA Confidential Treatment Requested by Univ of Texas System

Wuhan

Dr. Zhiming Yuan, Director of Chinese Academic and Science, Wuhan Branch, Director of Wuhan BSL-4. Arbovirus diagnosis, bio-control and molecular epidemiology.



Dr. Dongli Song, engineering director of BSL-4



FOIA Confidential Treatment Requested by Univ of Texas System

Dr. Xinwen Chen, Director of Wuhan institute of virology.
Hepatitis virus



Dr. Zhengli Shi
emerging viruses and the infection, including the virus isolation and characterization, diagnostic method development and genomic studies, epidemiology and molecular mechanism of interspecies infection of zoonotic viruses, and viral metagenomics.



FOIA Confidential Treatment Requested by Univ of Texas System

Dr. Bo Zhang

Replication, pathogenesis and virus-host interaction, vaccine development and antiviral drug screen (West Nile virus, Dengue virus, EV71,epidemic encephalitis B).



Dr. Hanzhong Wang

Zoonosis virus, Interaction between virus infection and innate immunity, Dynamic tracing of virus infection



Dr. Tianxian Li

My ex-supervisor. Viral collection, isolation, classify.



FOIA Confidential Treatment Requested by Univ of Texas System

From: Xia, Han
Sent: Thursday, October 23, 2014 8:09 AM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Thank you! I don't need anything from U.S.

Before I left, Dr. Leduc asked me to come to his office and talked about the GNL-Wuhan institute collaboration program (he said he have $25,000 can be used).
The epidimiology of tick-borne virus or arborvirus in Yunnan is my interested, do you think we can start the collaboration from this point?

So, this week I met my ex-supervisior and talked about the sample collection from Yunnan. She said she can help us and very glad to see you in Wuhan (her friend is the director of Menglian CDC, a region of Yunnan). The human sera sample, tick sample I got and analyzed before was from that region. During the time you stay in Wuhan, when you have time can you meet my ex-supervisior and we can talk about the possibility of the program?

Han

From: Bente, Dennis A.
Sent: Tuesday, October 21, 2014 11:57 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

exactly what I wanted! Well done. thank you.
is there anything I can bring you from the USA?
Dennis

Sent from a mobile device. Excuse brevity and typos.

-------- Original message --------
From: "Xia, Han" <haxia@UTMB.EDU>
Date:10/21/2014 9:53 PM (GMT-06:00)
To: "Bente, Dennis A." <dabente@UTMB.EDU>
Cc:
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

Han

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125692

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

发自我的 iPhone

在 Oct 20, 2014，11:06，Bente, Dennis A. <dabente@UTMB.EDU> 写道：

> Dear Bo and Si-qing,
>
> Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
> I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
> The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.
>
> My (b)(6)
>
> Looking forward to meet you,
>
> Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125693

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125694

Thursday, Oct. 30, 2014 **08:30-12:00** **Session 1: Emerging viruses and viral epidemiology**

12:00-14:00 **Lunch**

14:00-18:00 **Session 2: Antiviral and Vaccine**

18:00-20:00 **Dinner**

Friday, Oct. 31, 2014 **08:30-12:00** **Session 3: Emerging viruses and viral therapeutic**

12:00-14:00 **Lunch**

14:00-17:25 **Session 4: Viral replication**

18:00-19:00 **Dinner**

Details about AGENDA are listed in the attached file.
We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**.
Please send the reply to Si-Qing Liu **by Oct. 18, 2014**.
If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125695

Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

<Travel Reservation October 27 for BENTE.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125696

From: Xia, Han
Sent: Thursday, October 23, 2014 8:09 AM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Thank you! I don't need anything from U.S.

Before I left, Dr. Leduc asked me to come to his office and talked about the GNL-Wuhan institute collaboration program (he said he have $25,000 can be used).
The epidimiology of tick-borne virus or arborvirus in Yunnan is my interested, do you think we can start the collaboration from this point?

So, this week I met my ex-supervisior and talked about the sample collection from Yunnan. She said she can help us and very glad to see you in Wuhan (her friend is the director of Menglian CDC, a region of Yunnan). The human sera sample, tick sample I got and analyzed before was from that region. During the time you stay in Wuhan, when you have time can you meet my ex-supervisior and we can talk about the possibility of the program?

Han

From: Bente, Dennis A.
Sent: Tuesday, October 21, 2014 11:57 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

exactly what I wanted! Well done. thank you.
is there anything I can bring you from the USA?
Dennis

Sent from a mobile device. Excuse brevity and typos.

-------- Original message --------
From: "Xia, Han" <haxia@UTMB.EDU>
Date:10/21/2014 9:53 PM (GMT-06:00)
To: "Bente, Dennis A." <dabente@UTMB.EDU>
Cc:
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

Han

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064439

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

发自我的 iPhone

在 Oct 20, 2014，11:06，Bente, Dennis A. <dabente@UTMB.EDU> 写道：

> Dear Bo and Si-qing,
>
> Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
> I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
> The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.
>
> My (b)(6)
>
> Looking forward to meet you,
>
> Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064440

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064441

Thursday, Oct. 30, 2014 **08:30-12:00** **Session 1: Emerging viruses and viral epidemiology**

12:00-14:00 **Lunch**

14:00-18:00 **Session 2: Antiviral and Vaccine**

18:00-20:00 **Dinner**

Friday, Oct. 31, 2014 **08:30-12:00** **Session 3: Emerging viruses and viral therapeutic**

12:00-14:00 **Lunch**

14:00-17:25 **Session 4: Viral replication**

18:00-19:00 **Dinner**

Details about AGENDA are listed in the attached file.
We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**.
Please send the reply to Si-Qing Liu **by Oct. 18, 2014**.
If you have updated the information before, please skip the request.
We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064442

Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email:(b)(6)

<Travel Reservation October 27 for BENTE.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064443

From: Xia, Han [haxia@UTMB.EDU]
Sent: 10/24/2014 6:45:24 AM
To: Bente, Dennis A. [dabente@UTMB.EDU]
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Right, Xinjiang is not safe, because the terrorist in there.

1. Like the tick biologist said, few information on tick species is available. Maybe we can add the tick species taxonomy identification, because I know no one is a tick expert, and no one can do systemic identification in Wuhan institute.

2. The money can be met with money from Wuhan. My ex-supervisor is still a PI in Wuhan institute untill July, 2015. If we want go to Yunnan for sample collection, we have to use her social relationship in there.
When Dr. Zhengli Shi asked you to help her to test the Ebola antibody, I asked her if she can help us collect tick sample in Yunnan (she has some sample collection sites in Yunnan too), she said she can't.

3. Sure, you and me can go to Yunnan, and the local people will guide us for tick sample collection. At the same time, they can help us get some human or animal sera sample.

4. The material can leave China, but I have to figure out the detail for how to bring them out of China, especilly the live ticks.
When you visited Turkey, did you bring some live ticks from Turkey to the U.S.? How to bring live ticks into the U.S.is my concern.

5. Does the collabration have to relate to BSL-4? I am not sure we can isolate BSL-4 virus in tick from there. Because for the CCHFV, most of the proof is the sera antibody.For the other pathogens we don't need the BSL-4.

Han

(P.S. You will stay in Hongshan hotel)

From: Bente, Dennis A.
Sent: Thursday, October 23, 2014 12:48 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Han,

When I talked to Dr. LeDuc he said that $50,000 would be available. Anyway, at least some money.

In terms of the project we can propose whatever you and I would like to do. I think Yunnan is a good idea.
I remember that you said Xinjiang province is difficult to go to, right? We just know that CCHFV is there.

I talked to a tick biologist who is an expert on tick-borne pathogen epidemiology and ask him for his opinion on where to go in China to find new viruses. He said that not a lot of information on tick species is available from China so it is hard to say.
He said we should go to an area with great biological diversity: so warm/tropical weather. Different landscapes, lots of different animals. He suggested the southern/tropical parts of China. So Yunnan seems to be a great idea.

Here are some points that I want you to think about for the collaboration:
1. Dr. Le Duc wants that part of the work is done here the other part has to be done in China. How can we accomplish that? What would be a good topic? Because just collecting ticks and finding new pathogens can all be done in China.
2. Dr. LeDuc wants that our money that we invest will be met with money from Wuhan. Do you think that is possible?
3. Who would do the tick collection (can I help with the tick collection?)?
4. Do you think that material/data could leave China, for example, sequences or other data or maybe live ticks?

FOIA Confidential Treatment Requested by Univ of Texas System

5. How can we integrate this into the BSL4?

Dennis

---

m: Xia, Han
Sent: Thursday, October 23, 2014 8:09 AM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Thank you! I don't need anything from U.S.

Before I left, Dr. Leduc asked me to come to his office and talked about the GNL-Wuhan institute collaboration program (he said he have $25,000 can be used).
The epidimiology of tick-borne virus or arborvirus in Yunnan is my interested, do you think we can start the collaboration from this point?

So, this week I met my ex-supervisior and talked about the sample collection from Yunnan. She said she can help us and very glad to see you in Wuhan (her friend is the director of Menglian CDC, a region of Yunnan). The human sera sample, tick sample I got and analyzed before was from that region. During the time you stay in Wuhan, when you have time can you meet my ex-supervisior and we can talk about the possibility of the program?

Han

From: Bente, Dennis A.
Sent: Tuesday, October 21, 2014 11:57 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

exactly what I wanted! Well done. thank you.
is there anything I can bring you from the USA?
Dennis

Sent from a mobile device. Excuse brevity and typos.

-------- Original message --------
From: "Xia, Han" <haxia@UTMB.EDU>
Date:10/21/2014 9:53 PM (GMT-06:00)
To: "Bente, Dennis A." <dabente@UTMB.EDU>
Cc:
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

FOIA Confidential Treatment Requested by Univ of Texas System

Han

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

(b)(6) iPhone

在 Oct 20, 2014， 11:06， Bente, Dennis A. <dabente@UTMB.EDU> 写道：

Dear Bo and Si-qing,

Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.

My (b)(6)

Looking forward to meet you,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014	**09:00-21:00**	**Registration**
Thursday, Oct. 30, 2014	**08:30-12:00**	**Session 1: Emerging viruses and viral epidemiology**
	12:00-14:00	**Lunch**
	14:00-18:00	**Session 2: Antiviral and Vaccine**
	18:00-20:00	**Dinner**

Friday, Oct. 31, 2014 and viral therapeutic	**08:30-12:00**	**Session 3: Emerging viruses**
	12:00-14:00	**Lunch**
	14:00-17:25	**Session 4: Viral replication**
	18:00-19:00	**Dinner**

Details about AGENDA are listed in the attached file.

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.

We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.
Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

<Travel Reservation October 27 for BENTE.pdf>

From: Xia, Han [/O=UTMB/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=XIA, HANB82]
Sent: 10/24/2014 6:45:24 AM
To: Bente, Dennis A. [dabente@UTMB.EDU]
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Right, Xinjiang is not safe, because the terrorist in there.

1. Like the tick biologist said, few information on tick species is available. Maybe we can add the tick species taxonomy identification, because I know no one is a tick expert, and no one can do systemic identification in Wuhan institute.

2. The money can be met with money from Wuhan. My ex-supervisor is still a PI in Wuhan institute untill July, 2015. If we want go to Yunnan for sample collection, we have to use her social relationship in there.
When Dr. Zhengli Shi asked you to help her to test the Ebola antibody, I asked her if she can help us collect tick sample in Yunnan (she has some sample collection sites in Yunnan too), she said she can't.

3. Sure, you and me can go to Yunnan, and the local people will guide us for tick sample collection. At the same time, they can help us get some human or animal sera sample.

4. The material can leave China, but I have to figure out the detail for how to bring them out of China, especilly the live ticks.
When you visited Turkey, did you bring some live ticks from Turkey to the U.S.? How to bring live ticks into the U.S.is my concern.

5. Does the collabration have to relate to BSL-4? I am not sure we can isolate BSL-4 virus in tick from there. Because for the CCHFV, most of the proof is the sera antibody.For the other pathogens we don't need the BSL-4.

Han

(P.S. You will stay in Hongshan hotel)

From: Bente, Dennis A.
Sent: Thursday, October 23, 2014 12:48 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Han,

When I talked to Dr. LeDuc he said that $50,000 would be available. Anyway, at least some money.

In terms of the project we can propose whatever you and I would like to do. I think Yunnan is a good idea.
I remember that you said Xinjiang province is difficult to go to, right? We just know that CCHFV is there.

I talked to a tick biologist who is an expert on tick-borne pathogen epidemiology and ask him for his opinion on where to go in China to find new viruses. He said that not a lot of information on tick species is available from China so it is hard to say.
He said we should go to an area with great biological diversity: so warm/tropical weather. Different landscapes, lots of different animals. He suggested the southern/tropical parts of China. So Yunnan seems to be a great idea.

Here are some points that I want you to think about for the collaboration:
1. Dr. Le Duc wants that part of the work is done here the other part has to be done in China. How can we accomplish that? What would be a good topic? Because just collecting ticks and finding new pathogens can all be done in China.
2. Dr. LeDuc wants that our money that we invest will be met with money from Wuhan. Do you think that is possible?
3. Who would do the tick collection (can I help with the tick collection?)?

FOIA Confidential Treatment Requested by Univ of Texas System

4. Do you think that material/data could leave China, for example, sequences or other data or maybe live ticks?
5. How can we integrate this into the BSL4?

Dennis

---

m: Xia, Han
Sent: Thursday, October 23, 2014 8:09 AM
To: Bente, Dennis A.
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Thank you! I don't need anything from U.S.

Before I left, Dr. Leduc asked me to come to his office and talked about the GNL-Wuhan institute collaboration program (he said he have $25,000 can be used).
The epidimiology of tick-borne virus or arborvirus in Yunnan is my interested, do you think we can start the collaboration from this point?

So, this week I met my ex-supervisior and talked about the sample collection from Yunnan. She said she can help us and very glad to see you in Wuhan (her friend is the director of Menglian CDC, a region of Yunnan). The human sera sample, tick sample I got and analyzed before was from that region. During the time you stay in Wuhan, when you have time can you meet my ex-supervisior and we can talk about the possibility of the program?

Han

From: Bente, Dennis A.
Sent: Tuesday, October 21, 2014 11:57 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

exactly what I wanted! Well done. thank you.
is there anything I can bring you from the USA?
Dennis

Sent from a mobile device. Excuse brevity and typos.

-------- Original message --------
From: "Xia, Han" <haxia@UTMB.EDU>
Date:10/21/2014 9:53 PM (GMT-06:00)
To: "Bente, Dennis A." <dabente@UTMB.EDU>
Cc:
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

The introduction of person who you will meet is attached (Sorry, I can't find information for Ping Chen).

Do you have PPT which contains BSL-4 operation, managment, training? It seem like they will ask you make a report about BSL-4 when you visit the BSL-4.

Thank you,

Han

From: Bente, Dennis A.
Sent: Sunday, October 19, 2014 10:56 PM
To: Xia, Han
Subject: RE: Program of 6th International Symposium on Emerging Viral Diseases

Yes, the 30th would for to meet with Dr. Yuan.

Han, can you help me with something? There are now so many names of people that I am supposed to meet that I am getting confused. For example, in Beijing I have Drs. Mifang Liang and Ping Chen in addition to the scientists in Wuhan. Can you prepare a "who is who". Their name, a photo, a short description of who they are and what they work on? Maybe even scientists that I have not corresponed with by email but that I will likely meet when I am there?

Thanks,
Dennis

From: Xia, Han
Sent: Sunday, October 19, 2014 10:30 PM
To: Bente, Dennis A.
Subject: Re: Program of 6th International Symposium on Emerging Viral Diseases

Hi Dennis,

Dr. Yuan told me, he will meet you in New BSl-4 on Oct. 30th. He will tell me the exactly time then. Is that Ok for you!

By the way, I saw you replied to Si-Qing's email that you don't need the student to pick you up from the airport. However, the Zhengli Shi is the one who said she will send a student to pick up you. Do you need me to tell Zhengli, I will pick up you?

Han

(b)(6) Phone

在 Oct 20, 2014，11:06，Bente, Dennis A. <dabente@UTMB.EDU> 写道：

> Dear Bo and Si-qing,
>
> Please find attached my flight itinerary. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. My postdoctoral fellow, Han Xia, who is currently in Wuhan will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.
> I saw that you listed two hotels, Hongshan Hotel and Shuaifu Hotel. Which one will I be staying at?
> The meeting ends on the 31st of October, but I won't be leaving Wuhan until the 2nd of November. Is there a way that I can extend my stay in the hotel for two more nights? I will certainly pay for it myself.
>
> My (b)(6)
>
> Looking forward to meet you,
>
> Dennis

FOIA Confidential Treatment Requested by Univ of Texas System

From: (b)(6)
Sent: Sunday, October 19, 2014 8:31 AM
To: Bente, Dennis A.
Cc: zhangbo; llp
Subject: Fw: Program of 6th International Symposium on Emerging Viral Diseases

Dear Dr. Bente

We have not received your itinerary information. Would you please send it to me? We will make a room reservation for you during the meeting.

All the best,
Si-qing

From: (b)(6)
Date: 2014-10-11 16:33
To: dimitrdi; pei_yong.shi; cbroder; christopher.broder; kuhnjens; gdliang; lijun; Linfa.wang; linfa.wang; michlai; changchun_tu; zhangyongzhen; zlshi; mko2; michael.lo; gaof; gaofu; chengfeng_qin; zheng_yin; ouyangsy; louzy; louzy; yuanan; Andrew.Davidson; daszak; chmura; zchenai; kecw1965; avidguan811; chen_ling; chen002; chenmz; yee_sin_leo; linda_k_lee; angela_chow; axiong; chenhualan; jwu; dguo; ywu8; tcyang2014; dabente; qing_yin.wang; liusw; guang.yang; liflit; wanglih9755; caiy; lmy2014; 13811876613; wfshi; shiwf; liurong19840901; 532389467; heb-001001; xjsyzhang; sr_sun2005; zhoudg
CC: zhangbo; llp
Subject: Program of 6th International Symposium on Emerging Viral Diseases

Dear Speakers

We look forward to having you at **the 6th International Symposium on Emerging Viral Diseases being held in October 29-31, 2014 in Wuhan, China**. This conference will take place in the Wuhan Institute of Virology, Chinese Academy of Sciences at Xiao Hong Shan Zhong Qu 44, Wuhan, Hubei 430071. Below is an agenda for the conference:

AGENDA

Wednesday, Oct. 29, 2014 09:00-21:00 Registration

Thursday, Oct. 30, 2014 **08:30-12:00** **Session 1: Emerging viruses and viral epidemiology**

12:00-14:00 **Lunch**

14:00-18:00 **Session 2: Antiviral and Vaccine**

18:00-20:00 **Dinner**

Friday, Oct. 31, 2014 **08:30-12:00** **Session 3: Emerging viruses and viral therapeutic**

12:00-14:00 **Lunch**

14:00-17:25 **Session 4: Viral replication**

18:00-19:00 **Dinner**

Details about AGENDA are listed in the attached file.

We will appreciate that all attendees and speakers **tell us your Arrival and Departure dates**. Please send the reply to Si-Qing Liu **by Oct. 18, 2014**. If you have updated the information before, please skip the request.

We hope fervently that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.

FOIA Confidential Treatment Requested by Univ of Texas System

Flavivirus Infection and Prevention
Wuhan Institute of Virology
Chinese Academy of Sciences
Tel: (+)86-27-87197822
Email: (b)(6)

<Travel Reservation October 27 for BENTE.pdf>

FOIA Confidential Treatment Requested by Univ of Texas System

From: (b)(6)
Sent: Friday, October 24, 2014 11:20 AM
To: gaof;gaofu;Linfa.wang;linfa.wang;yee_sin_leo;zhangyongzhen;daszak;kecw1965;louzy;louzy;michlai;dguo;pei_yong.shi;zheng_yin;qing_yin.wang;lijun;dimitrdi;zchenai;chengfeng_qin;yuanan;chenhualan;changchun_tu;zlshi;ouyangsy;chen_ling;chen002;cbroder;christopher.broder;gdliang;ywu8;Bente, Dennis A.;jwu;kuhnjens;axiong;mko2;michael.lo;chenmz;Andrew.Davidson;liusw;hongping.dong;caiy;luguangwen2001;davidguan811;chmura;angela_chow
Cc: zhangbo;llp
Subject: Advices of Registration for 6th International Symposium on Emerging Viral Diseases
Attachments: Conference Guide_HongShan Hotel.pdf

Dear Speakers

We have some advices about the registration for you. Please find them in the attached file.
Again, we hope that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.

Flavivirus Infection and Prevention

Wuhan Institute of Virology

Chinese Academy of Sciences

Tel: (+)86-27-87197822

Email (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_090239

From: (b)(6)
Sent: Friday, October 24, 2014 11:20 AM
To: gaof; gaofu; Linfa.wang; linfa.wang; yee_sin_leo; zhangyongzhen; daszak; kecw1965; louzy; louzy; michlai; dguo; pei_yong.shi; zheng_yin; qing_yin.wang; lijun; dimitrdi; zchenai; chengfeng_qin; yuanan; chenhualan; changchun_tu; zlshi; ouyangsy; chen_ling; chen002; cbroder; christopher.broder; gdliang; ywu8; Bente, Dennis A.; jwu; kuhnjens; axiong; mko2; michael.lo; chenmz; Andrew.Davidson; liusw; hongping.dong; caiy; luguangwen2001; davidguan811; chmura; angela_chow
Cc: zhangbo; llp
Subject: Advices of Registration for 6th International Symposium on Emerging Viral Diseases
Attachments: Conference Guide_HongShan Hotel.pdf

Dear Speakers

We have some advices about the registration for you. Please find them in the attached file.
Again, we hope that you are going to enjoy the conference and the city of Wuhan!

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.

Flavivirus Infection and Prevention

Wuhan Institute of Virology

Chinese Academy of Sciences

Tel: (+)86-27-87197822

Email:(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125727

From: (b)(6)
Sent: Thursday, November 13, 2014 5:47 AM
To: Linfa.wang;linfa.wang;yee_sin_leo;zhangyongzhen;daszak;kecw1965;louzy;michlai;dguo;pei_yong.shi;qing_yin.wang;lijun;dimitrdi;zchenai;chengfeng_qin;yuanan;chenhualan;changchun_tu;chenxw;zlshi;huzh;xiaogf;ouyangsy;chen_ling;chen002;cbroder;christopher.broder;ywu8;Bente, Dennis A.;jwu;kuhnjens;axiong
Cc: zhangbo;llp
Subject: Photo of the 6th Symposium on Emerging Viral Diseases
Attachments: Photo of the 6th Symposium on Emerging Viral Diseases.jpg

Dear Attendees

Thanks for your supports and contributions to the 6th Symposium on Emerging Viral Diseases. We hope that you would have had a happy trip in Wuhan. The photo taken in the conference is sent. Please find the attachment.
We look forward to meeting you in the next meeting.

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.

Flavivirus Infection and Prevention

Wuhan Institute of Virology

Chinese Academy of Sciences

Tel: (+)86-27-87197822

Email: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064398

From: (b)(6)
Sent: Thursday, November 13, 2014 5:47 AM
To: Linfa.wang; linfa.wang; yee_sin_leo; zhangyongzhen; daszak; kecw1965; louzy; michlai; dguo; pei_yong.shi; qing_yin.wang; lijun; dimitrdi; zchenai; chengfeng_qin; yuanan; chenhualan; changchun_tu; chenxw; zlshi; huzh; xiaogf; ouyangsy; chen_ling; chen002; cbroder; christopher.broder; ywu8; Bente, Dennis A.; jwu; kuhnjens; axiong
Cc: zhangbo; llp
Subject: Photo of the 6th Symposium on Emerging Viral Diseases
Attachments: Photo of the 6th Symposium on Emerging Viral Diseases.jpg

Dear Attendees

Thanks for your supports and contributions to the 6th Symposium on Emerging Viral Diseases. We hope that you would have had a happy trip in Wuhan. The photo taken in the conference is sent. Please find the attachment.
We look forward to meeting you in the next meeting.

Sincerely,
Si-Qing Liu

Si-Qing Liu, Ph.D.

Flavivirus Infection and Prevention

Wuhan Institute of Virology

Chinese Academy of Sciences

Tel: (+)86-27-87197822

Email (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125702

From: zlshi <zlshi@wh.iov.cn>
Sent: Monday, November 17, 2014 8:11 PM
To: Bente, Dennis A.
Cc: Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you again for your coming to our meeting.

We have prepared the following kits for validation:
1. Sandwich ELISA based on nucleocapsid protein (IgG+IgM of aminals and humans).
2. Indirect ELISA based on nucleocapsid protein (IgG or IgM) or envelop membrane glycoprotein (IgG or IgM of humans).
3. Capture ELISA based on nucleocapsid protein (IgM of humans).

For the first one, we have done the specific test using sera from health bats, pigs,monkeys and human and rabbit sera immunized with other virus proteins.
For the 2nd and 3rd, we have done the specific test using sera from health human.

We much appreciate if you have positive sera for testing out kits.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-20 11:35
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

My visa was approved last week. I will pick it up from the Chinese embassy tomorrow. I will be arriving in Wuhan on the 29th at 9:20pm in the evening. Han Xia will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064393

Best wishes,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, October 19, 2014 8:36 AM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

I hope you have (b)(6) Can you please send me the information if you have booked your flight? I'll send one of my students to pick you up at Wuhan airport.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-04 06:06
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

I will go to the Chinese embassy on Monday. I should be able to get the visa within a week. I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

Please let me know,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064394

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064395

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064396

Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064397

From: zlshi <zlshi@wh.iov.cn>
Sent: Sunday, December 21, 2014 5:20 AM
To: Bente, Dennis A.
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you for your update information.

Yes, I'm still interested in testing our sandwich ELISA kit. This kit can be used for screening virus infection in animals if it's proved useful. Please let me know how can I send you the kit.

For human samples, we are trying to find other way to test out kits. I think it'll be very complicated even though CDC agree to test our Kits.

Best regards,

Zhengli,

Zheng-Li Shi
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Hubei
China
Tel & Fax 86-27 87197240

From: Bente, Dennis A.
Date: 2014-12-18 05:41
To: zlshi
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for the very late reply to your email.

In the meantime have done some research on the topic: we do have non-human primate sera against ebola zaire but not against ebola reston. I talked to Dr. Tom Ksiazek who is very experienced with ELISA assays and he emphasized that the results that you are getting for non-human primate sera could be different to human samples. I do know that the CDC in Atlanta has a range of human sera. Please let me know if you still want us to test the ELISA with the primate samples or if you want us to put you in touch with the group at the CDC.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064369

Best wishes,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, November 17, 2014 8:11 PM
To: Bente, Dennis A.
Cc: Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you again for your coming to our meeting.

We have prepared the following kits for validation:
1. Sandwich ELISA based on nucleocapsid protein (IgG+IgM of aminals and humans).
2. Indirect ELISA based on nucleocapsid protein (IgG or IgM) or envelop membrane glycoprotein (IgG or IgM of humans).
3. Capture ELISA based on nucleocapsid protein (IgM of humans).

For the first one, we have done the specific test using sera from health bats, pigs,monkeys and human and rabbit sera immunized with other virus proteins.
For the 2nd and 3rd, we have done the specific test using sera from health human.

We much appreciate if you have positive sera for testing out kits.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-20 11:35
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064370

My (b)(6) I will be arriving in Wuhan on the 29th at 9:20pm in the evening. Han Xia will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.

Best wishes,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, October 19, 2014 8:36 AM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

I hope you have (b)(6) Can you please send me the information if you have booked your flight? I'll send one of my students to pick you up at Wuhan airport.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-04 06:06
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

(b)(6) I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064371

Please let me know,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6)

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection
Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064372

should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064373

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064374

COLLABORATION AGREEMENT

This Collaboration Agreement ("Agreement") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926 and Wuhan Institute of Virology, Chinese Academy of Sciences, ("Collaborator") located at _Xiaohognshan Zhongqu 44, Wuhan 430071, China_individually a "party" and collectively, the "parties" to this Agreement.

RECITALS

WHEREAS, UTMB and Collaborator wish to collaborate on a research effort of mutual interest in the area of emerging disease control and laboratory biosafety management_ as described in the "Research Program", set forth as Exhibit A , which is a part of this Agreement.

WHEREAS, UTMB desires to participate in the collaboration by providing technical expertise to Collaborator;

WHEREAS, Collaborator desires to participate in the collaboration by providing technical expertise to UTMB; and

WHEREAS, the parties wish to memorialize in writing all of the terms and conditions that shall govern the parties' prior and present acts involving the collaboration as follows.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties hereto agree as follows:

TERMS AND CONDITIONS

1. **Definitions.**
   - 1.1 TRANSFEROR: A party providing Materials and/or Technical Data to the other party as defined herein. All parties hereto are Transferors.
   - 1.2 UTMB: University of Texas Medical Branch, a component institution of the University of Texas System, and its employees.
   - 1.3 MATERIALS: Deliverables, products, items, or goods of the Transferor that is transferred to Recipient for use in the performance of this Agreement, as identified in *Exhibit B. Materials.*
   - 1.4 RECIPIENT: A party in receipt of Material and Technical Data as defined herein. All parties hereto are Recipients.
   - 1.5 RESEARCH PROGRAM: As defined in *Exhibit A. Research Program.*
   - 1.6 RESULTS: All and any results developed from the Research Program under this Agreement by either party.
   - 1.7 TECHNICAL DATA: All prior technical knowledge, know-how, and information, including scientific data, laboratory records and books, software, patent applications, descriptive materials, and other oral and written information disclosed directly or indirectly by Transferor to Recipient for use in the performance of this Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064382

2. **Research Program.** University will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "UTMB Principal Investigator").

   Collaborator will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "Collaborator Principal Investigator").

   The parties may extend the Research Program under mutually agreeable terms. Collaborator understands that University's primary mission is education and advancement of knowledge and the Research Program will be designed to carry out that mission. The manner of performance of the Research Program shall be determined solely by the Principal Investigator. University does not guarantee specific results.

   Collaborator understands that University may be involved in similar Research Programs or similar research through other researchers on behalf of itself and others. University shall be free to continue such research provided that it is conducted separately and by different investigators from the Research Program, and Collaborator shall not gain any rights via this Agreement to other research.

3. **Communication and Reports.** Each party will promptly and fully inform the other party of the Results developed from the Research Program conducted hereunder. UTMB and Collaborator will consult with one another at mutually agreed times and intervals regarding the progress of the Research Program.

4. **Use of Materials and Technical Data**. The Materials and Technical Data shall be used by the Recipient's Principal Investigators and only for the purposes of the Research Program, as described in *Exhibit A: Research Program.* Recipients shall at all times use the Materials and Technical Data in a safe manner, and shall at all times comply with all state, federal and other applicable laws, rules and regulations pertaining to use, export, or re-export of the Materials and/or Technical Data. Nothing herein shall obligate a Transferor to transfer or disclose any Materials and/or Technical Data to a Recipient. This Agreement will apply to all Materials and/or Technical Data actually transferred or disclosed to a Recipient. Neither the Recipient nor the Recipient Principal Investigator shall distribute, release, or in any way disclose the Material to any person or entity other than laboratory personnel under the Recipient Principal Investigator's direct supervision, and the Recipient and Recipient Principal Investigator shall ensure that no one will be allowed to take or send Material to any other location. Material is made available for investigational use only in laboratory animals or in vitro experiments. Neither Material nor any biological materials treated therewith will be used in human beings. Further, no Materials as identified in Exhibit B of this Agreement or any other Material shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. In the event that Materials and/or Technical Data not initially listed in Exhibit B need to be sent by or to any Party in pursuit of the Research Plan, the attached Material Transfer Agreement Letter ("MTA Letter") will be utilized, identified as an amendment to this Agreement, and signed by authorized officials of all Parties.

5. **Protection of Material and Technical Data**. Upon completion of the Research Program, and in the absence of further written agreement of the parties, Recipient shall cease all use and make no further use of the Material or Technical Data. Upon completion of the Research Program or at Transferor's request, all Technical Data in tangible form and copies thereof in whole or in part, shall be returned to Transferor by Recipient except that Recipient shall be permitted to retain one copy in its files which copy shall be used only by Recipient and its legal advisors in connection with review of its obligations hereunder. In addition, upon completion of the Research Program or at Transferor's earlier request, all Material unused by Recipient will be, at Transferor's direction, properly disposed of or returned to Transferor. Recipient agrees that any distribution of Technical Data or the disclosure of Confidential Information without Transferor's express written permission may cause Transferor irreparable harm and that any breach or threatened breach of this Agreement by Recipient or Investigator will entitle Transferor to injunctive relief, in addition to any other legal remedies available to it in any court of competent jurisdiction.

6. **Permitted Transfer and Disclosure**. Recipient shall have the right to disclose Transferor's Technical Data and allow access to Transferor's Materials only to Recipient's employees who are working on this Agreement. Recipient will take all other reasonable steps, including, but not limited to, those steps taken to protect information, data or other tangible or intangible property of its own of a highly confidential nature, to insure that the Transferor's Material and Technical Data are not disclosed or duplicated or in any manner delivered or disseminated to others, and to prevent its officers, directors, employees, subcontractors, and others from violating this Agreement. Transferor's Material is made available for internal research use only in laboratory animals or in vitro experiments. Except as provided for by this Agreement, Recipient shall not distribute, transfer, or release Transferor's Material to any person or entity other than laboratory personnel under Recipient's Investigator, unless written permission is obtained from Transferor. Recipient agrees that all of its employees involved in the Research Program will have read the terms and conditions of this Agreement and abide by the terms and conditions of this Agreement. Recipient must acknowledge the Transferor as the source of the Transferor's Materials in publications, grant proposals, or other related documents.

7. **Good Faith Submissions and Negotiations.** The Parties may jointly apply for external funding in order to establish the Research Program. In the event that an award is made for the funding of the Research Program, the parties shall enter a comprehensive agreement setting forth their rights and obligations. The Parties agree to negotiate the terms of any such agreement in good faith.

8. **No License from Transferor**. Except as stated in this Agreement, nothing in this Agreement is to be construed as granting a license to Recipient to utilize the Material or Technical Data except as expressly provided in this Agreement, in any way whatsoever or under any patent owned by Transferor, unless a separate license agreement for such right is executed or has been by Recipient and Transferor. Any modification of this Agreement, and any further contract or license agreement between the parties hereto, shall be in writing.

9. **Title, License.** All discoveries, know-how, techniques, ideas or intellectual property, whether patented or patentable or not, that are owned and controlled by a party to this Agreement and that were existing or conceived prior to the date of this Agreement will continue to be

owned and controlled by the relevant party and are not affected by this Agreement. Any new invention, development, or discovery resulting from the Research Program ("Invention") shall be promptly and confidentially disclosed in writing by the inventive party to the other party. Ownership of Inventions shall reflect inventorship as determined by U.S. patent law, if patentable, and shall be determined by mutual consent between the parties, if not patentable. In the event of joint ownership of an Invention, the parties shall enter into an agreement for the subject Invention concerning the sharing of all invention management responsibilities, i.e., based upon the parties' relative contributions to the subject Invention. Each party shall retain a nonexclusive royalty-free license to use any Inventions developed hereunder for its own internal research purposes only.

10. **Publication**. All parties shall be entitled to publish with respect of the outcomes of the Research Program. In the event that either Party wishes to publish in relation to its respective contributions in facilitating the Research Program, a copy of the proposed publication shall be submitted to the other party for prior review and comment no later than sixty (60) days before planned submission. Upon request from the non-publishing party, the publishing party shall remove any of the non-publishing party's Confidential Information from the proposed publication, or the publishing party shall agree to delay submission of the proposed publication for an additional forty-five (45) days to allow for the non-publishing party to pursue patent protection.

11. **Confidentiality**. Recipient shall treat all information confidential ("Confidential Information"), as identified by Transferor, for a period of three (3) years and shall not use any Confidential Information except for purposes of the Research Program, or disclose any of said Confidential Information to any third party or personnel except for the Investigator without the prior written approval of Transferor; provided, however, Confidential Information shall not include information that: (a) was publicly known and generally available in the public domain prior to the time of disclosure to Recipient by Transferor; (b) becomes publicly known and made generally available in the public domain after disclosure to Recipient by Transferor, except by breach of this Agreement by Recipient; (c) was in Recipient's possession at the time of disclosure by Transferor as established by contemporaneous written records and was not acquired directly or indirectly from Transferor or from any other party under an obligation of confidentiality to Transferor; (d) is received by Recipient from a third party with the legal right to provide Recipient with such information; and (e) is required by law to be disclosed, provided however that the Recipient shall provide reasonable advance notice thereof to enable Transferor to seek a protective order or other legal means prevent such disclosure.

12. **Waiver of Warranties**. TRANSFEROR SUPPLIES THE MATERIAL AND TECHNICAL DATA WITHOUT ANY WARRANTY, REPRESENTATION OR UNDERTAKING WHATSOEVER, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY RESPECTING THE EFFICIENCY, PERFORMANCE, WORKMANSHIP, CONDITION, MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR SAFETY FOR ANY USE OR TREATMENT BY RECIPIENT. TRANSFEROR MAKES NO REPRESENTATION OR WARRANTY THAT USE OF THE TECHNICAL DATA OR MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. IT IS UNDERSTOOD THAT TRANSFEROR, ITS OFFICERS, DIRECTORS, AGENTS AND EMPLOYEES SHALL HAVE NO LIABILITY IN CONNECTION WITH RECIPIENT'S USE OF THE MATERIAL AND/OR TECHNICAL DATA.

13. **Indemnity**. To the extent authorized by the indemnifying party's state law, each party ("Indemnitor") shall indemnify the other ("Indemnitee") for any claims, demands, or losses that arise out of the Indemnitor's use of the Indemnitee's Results, Technical Data, or Materials under this Agreement.

14. **Benefit and Binding Effect**. This Agreement shall be binding upon and for the benefit of the parties hereto.

15. **Assignment**. This Agreement shall not be assigned by a Party without the prior written approval of the other Party.

16. **Authority**. Except as otherwise provided herein, each party hereto certifies that it has the full right, power and authority to enter into this Agreement. This Agreement shall be construed and enforced in accordance with the laws of the United States of America and the State of Texas without regard to their principles of conflicts of law. This Agreement sets forth the entire agreement between the parties with respect to the subject matter contained herein and supersedes any previous understandings, commitments or agreements, whether oral or written. This Agreement may only be amended with a writing signed by authorized representatives of both parties hereto.

17. **Independent Contractor.** For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not agents or employees of the other party. Neither party shall have authority to make any statements, representations nor commitments of any kind, nor to take any action which shall be binding on the other party, except as may be expressly provided for herein or authorized in writing.

18. **Use of Name.** Each party agrees that it shall not use the name and/or logo of the other Party in any advertising or publicity material without having obtained prior written authorization from that Party.

19. **Export Control.** Both parties acknowledge and agree that no classified information or research will be used or developed under this Agreement. All information and results under this Agreement is deemed fundamental research. All parties acknowledge that this Agreement and the performance thereof are subject to compliance with any and all applicable United States laws, regulations, or orders, including those that may relate to the export of technical data, and both Parties agree to comply with all such laws, regulations and orders, including, if applicable, all requirements of the International Traffic in Arms Regulations and/or the Export Administration Act, as may be amended. All parties further agree that if the export laws are applicable, it will not disclose or re-export any technical data received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless the disclosing party has obtained prior written authorization from authority responsible for such matters. Further, no Materials as identified in Exhibit B of this Agreement shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. The MTA letter shall act as an amendment to this Agreement.

20. **Visitor Scientist.** This Agreement does not authorize on-site visitation by the other party to the hosting party's campuses. Any decision that consists of the personnel of one party to train, work, or visit the campuses of the other party must be evidenced by the execution of a separate Visitor Scientist Agreement mutually signed by the authorized representatives of both parties.

21. **Term and Termination.** This Agreement shall be effective from 1 January 2015 until 31 December 2019. At that time, if Research Program in not completed and upon mutual written agreement of the parties, the Agreement may be extended for an additional (1) year. However, either party may terminate this Agreement for any reason upon giving thirty (30) days written notice to the other party.

22. **Funding.** It is understood and agreed that UTMB and Collaborator will each be responsible for their own expenses incurred in the performance of the Collaborative Research Program. Neither party is under obligation to fund the portion of the Collaborative Research Research Program conducted by the other party.

23. **Notices**. Any notice required by this Agreement shall be given by prepaid, first class, certified mail, return receipt requested, addressed to the Parties' authorized signatory:

The University of Texas Medical Branch at Galveston
Suite 1.200, 1700
301 University Blvd., Galveston, TX 77555-0926
ATTN: Sundeep Mattamana

or in the case of Collaborator, to:

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiaohongshan Zhongqu 44, Wuhan 430071, China

ATTN: Chen Xinwen
Title: General Director

or at such other addresses as may be given from time to time in accordance with the terms of this notice provision.

In Witness Whereof, the parties have caused this Agreement to be executed by their duly authorized representatives.

UNIVERSITY OF TEXAS MEDICAL BRANCH	**WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES**
_____	_____
Carolee King, JD Sr. VP and General Counsel	Authorized Signatory Chen Xinwen Title: General Director
Date: _____	Date: _____
Read and understood:	Read and understood:
_____	_____
Signature of UTMB Investigator	Signature of Collaborator Investigator

EXHIBIT A: RESEARCH PROGRAM

EXHIBIT B: MATERIALS

UTMB Materials:

Collaborator Materials:

MATERIAL TRANSFER AGREEMENT LETTER

This Material Transfer Agreement Letter ("MTA Letter") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926, and the [redacted] ("Collaborator") located at [redacted], individually a "party" and collectively, the "parties" to this Agreement.

WHEREAS, UTMB and Collaborator have entered into a Collaboration Agreement ("Agreement") effective [redacted];

WHEREAS, unless specifically described in this MTA Letter, the terms of the Agreement shall govern the relationship between the parties;

NOW THERFORE, The parties agree as follows:

1. UTMB will provide Collaborator with Materials described in Exhibit B. Collaborator will provide UTMB with Materials described in Exhibit B ("Material")

2. The Material is not for use in human subjects.

3. Except as provided for by the Agreement, Recipent shall not distribute, transfer or release the Material to any person or entity other than laboratory personnel under Recipient Scientist's direct supervision, unless written permission is obtained from Transferor. RECIPENT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

4. Recipient agrees to use the MATERIAL in compliance with all applicable statutes and regulations.

5. Recipient further agrees that if the U.S. export laws are or become applicable, it will not export any Materials received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless Recipient has obtained prior written authorization from the appropriate authority responsible for such matters.

6. Except as stated herein, all other terms of the Agreement shall remain unchanged and in full force and effect.

UNIVERSITY OF TEXAS MEDICAL BRANCH

Collaborator

Carolee King, JD
Sr. VP and General Counsel

Name: _____
Title: _____

Date: _____

Date: _____

From: zlshi <zlshi@wh.iov.cn>
Sent: Monday, January 12, 2015 7:03 PM
To: Bente, Dennis A.
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you for your information.

This article was published by another group. I don't think they have an optimized ELISA kit.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2015-01-13 01:03
To: zlshi
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

I saw this article online. Is this the ELISA that you are referring to?

Let me make sure we have all the approvals to ship the kits so that they don't get stuck at customs.

Thanks,

Dennis

Nucleoprotein-based indirect enzyme-linked immunosorbent assay (indirect ELISA) for detecting antibodies specific to Ebola virus and Marbug virus

Free Full Text (HTML)  ***Free*** Full Text (PDF)

Yi Huang, Youjie Zhu, Mengshi Yang, Zhenqing Zhang, Donglin Song, Zhiming Yuan

Full-length nucleoproteins from Ebola and Marburg viruses were expressed as His-tagged recombinant proteins in *Escherichia coli* and nucleoprotein-based enzyme-linked immunosorbent assays (ELISAs) were established for the detection of antibodies specific to Ebola and Marburg viruses. The ELISAs were evaluated by testing antisera

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064339

collected from rabbit immunized with Ebola and Marburg virus nucleoproteins. Although little cross-reactivity of antibodies was observed in anti- Ebola virus nucleoprotein rabbit antisera, the highest reactions to immunoglobulin G (IgG) were uniformly detected against the nucleoprotein antigens of homologous viruses. We further evaluated the ELISA's ability to detect antibodies to Ebola and Marburg viruses using human sera samples collected from individuals passing through the Guangdong port of entry. With a threshold set at the mean plus three standard deviations of average opti! cal densities of sera tested, the ELISA systems using these two recombinant nucleoproteins have good sensitivity and specificity. These results demonstrate the usefulness of ELISA for diagnostics as well as ecological and serosurvey studies of Ebola and Marburg virus infection.

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, December 21, 2014 5:20 AM
To: Bente, Dennis A.
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you for your update information.

Yes, I'm still interested in testing our sandwich ELISA kit. This kit can be used for screening virus infection in animals if it's proved useful. Please let me know how can I send you the kit.

For human samples, we are trying to find other way to test out kits. I think it'll be very complicated even though CDC agree to test our Kits.

Best regards,

Zhengli,

Zheng-Li Shi
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Hubei
China
Tel & Fax 86-27 87197240

From: Bente, Dennis A.
Date: 2014-12-18 05:41
To: zlshi

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064340

Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for the very late reply to your email.

In the meantime have done some research on the topic: we do have non-human primate sera against ebola zaire but not against ebola reston. I talked to Dr. Tom Ksiazek who is very experienced with ELISA assays and he emphasized that the results that you are getting for non-human primate sera could be different to human samples. I do know that the CDC in Atlanta has a range of human sera. Please let me know if you still want us to test the ELISA with the primate samples or if you want us to put you in touch with the group at the CDC.

Best wishes,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, November 17, 2014 8:11 PM
To: Bente, Dennis A.
Cc: Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Thank you again for your coming to our meeting.

We have prepared the following kits for validation:
1. Sandwich ELISA based on nucleocapsid protein (IgG+IgM of aminals and humans).
2. Indirect ELISA based on nucleocapsid protein (IgG or IgM) or envelop membrane glycoprotein (IgG or IgM of humans).
3. Capture ELISA based on nucleocapsid protein (IgM of humans).

For the first one, we have done the specific test using sera from health bats, pigs,monkeys and human and rabbit sera immunized with other virus proteins.
For the 2nd and 3rd, we have done the specific test using sera from health human.

We much appreciate if you have positive sera for testing out kits.

Best regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064341

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-20 11:35
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

(b)(6) I will be arriving in Wuhan on the 29th at 9:20pm in the evening. Han Xia will pick me up from the airport and take me to the hotel. There is no need to send a student. Thank you very much for the offer.

Best wishes,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, October 19, 2014 8:36 AM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

I hope you have (b)(6) Can you please send me the information if you have booked your flight? I'll send one of my students to pick you up at Wuhan airport.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064342

Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-10-04 06:06
To: zlshi
CC: Xia, Han; Zhang Bo
Subject: RE: RE: validation for virus antibody detection

Dear Zhengli,

Please accept my apologies for getting back to you so late. I was traveling out of the country. I was planning on submitting my abstract as soon as possible but I was wondering if it is too late now or if my abstract can still get accepted in the program.

(b)(6) I will also book my flights next week. Do you suggest that I get to Wuhan on the 29th or earlier or later?

Please let me know,

Dennis

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Sunday, August 31, 2014 8:52 PM
To: Bente, Dennis A.
Cc: Xia, Han; Zhang Bo
Subject: Re: RE: validation for virus antibody detection

Dear Dennis,

Can you please see attached invitation letter. Sorry for this delay because of some information confusing. Hope it's not too late for (b)(6).

Please let me know if you need any other information.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064343

Email: zlshi@wh.iov.cn

From: Bente, Dennis A.
Date: 2014-07-31 13:45
To: zlshi
CC: Xia, Han
Subject: RE: RE: validation for virus antibody detection

Dear Dr. Zhengli,

Thank you very much for your email. We are very excited and honored to help you as much as we can with your project. It sounds like that the first step would be to test sera from zaire and reston infected individulas against these peptides in an ELISA (or another assay that you prefer). As you can probably imagine, getting samples from humans is extremely difficult. However, we should be able to get sera from reston and zaire infected non-human primates. I will initiate the steps to get these samples.

I am also curious if you would consider expanding your project and if you could help us with your experise. We are currently trying to distinguish serologically two different strains of Crimean-Congo hemorrhagic fever virus. A peptide ELISA would be extremely helpful, yet, we could use expertise designing these peptides.

Please let me know your thoughts. I talked to Han Xia, a postdoc from Wuhan in my lab, today and told her that she should be the connection between our two labs. If necessary, she can call you anytime to discuss details, for example, of the peptide shipment.

Looking forward to working with you!

Dennis

From: zlshi [zlshi@wh.iov.cn]
Sent: Tuesday, July 29, 2014 4:54 AM
To: Bente, Dennis A.
Cc: LeDuc, James W.; Xia, Han
Subject: Re: RE: validation for virus antibody detection

Dear Dr. Dennis,

Thank you very much for your positive reply to our requiry of collaboration.

As I metioned in the previous email, we have identified three peptides within the nucleocapsid protein which can be used for distinguish the infection between the Reston and zaire viral species. The peptides we expressed are in soluable form. We can prepare these peptides and send to you for your testing. Please let me know what's your thought.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064344

From: LeDuc, James W.
Date: 2014-07-29 09:46
To: zlshi
CC: 袁 志明; Bente, Dennis A.; Xia, Han
Subject: RE: validation for virus antibody detection

Dear Dr Zhengli,

I have spoken to my colleagues, including Dr Han Xia that I understand you know, and they would be pleased to collaborate with you on your proposed project. They are copied here and I ask them to communicate directly with you to determine next steps.

We look forward to working with you.

With best regards,

Jim

James W. Le Duc, Ph.D.
Director
Galveston National Laboratory
University of Texas Medical Branch
Galveston, TX 77555-0610
(t) 409-266-6500
(f) 409-266-6810
jwleduc@utmb.edu

From: zlshi [mailto:zlshi@wh.iov.cn]
Sent: Monday, July 28, 2014 2:51 AM
To: LeDuc, James W.
Cc: 袁 志明
Subject: validation for virus antibody detection

Dear Dr. Le duc,

May I intruduce myself. I'm a senior researcher at Wuhan Institute of Virology. I was absent during your visit in Wuhan in 2013 and missed your presentation.

I've been working on bat viruses since 2004 and discovered a variety of bat viruses inlcuding SARS-like coronaviruses. In addtion, we have developed antibody detection methods for henipavirus and ebolaviruses and found serological evidences of related viruses (sse papers attached). Recently, we

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064345

have found three peptides within ebolavirus nucleocapsid protein which can be used to differentiate the infection between reston ebolavirus and zaire ebolavirus. However, due to lacking positive sera of ebolavirus infection, we were not able to validate the methods for ebolavirus detection. I'm wondering if your lab could help us to test our methods. Your help will be greatly appreciated.

Best regards,

Zhengli,

SHI Zhengli, Ph. D
Senior Scientist & Professor
Wuhan Institute of Virology, Chinese Academy of Sciences
44 Xiao Hong Shan
430071 Wuhan, Hubei
China
Tel & Fax: (0086) 27 87197240
Email: zlshi@wh.iov.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064346

From: zhangxin [zhangxin@wh.iov.cn]
Sent: 1/21/2015 9:45:09 PM
To: Lawal, Adeola [adlawal@UTMB.EDU]
CC: yzm [yzm@wh.iov.cn]; Bente, Dennis A. [dabente@UTMB.EDU]
Subject: Collaboration Agreement between UTMB and WIV
Attachments: WIV & UTMB Collaboration Agreement.pdf

Dear Dr. Lawal, Adeola

Thank you for your inquiry of the status of the agreement between you and Prof. Zhiming YUAN. I'm Xin ZHANG, in charge of international collaboration of Wuhan Institute of Virology.

Please find attached a copy of Collaboration Agreement, which have been signed by Prof. Zhiming YUAN and our Institute's Deputy Director General, Prof. Hong TANG.

Should you have any questions, please let me know.

Have a nice day!

Best regards

Sincerely
Xin

Xin ZHANG
Office of Research and Development
Wuhan Institute of Virology
Chinese Academy of Sciences
The People's Republic of China
Tel: (0086)027-87197115
Fax: (0086) 027-87198209
Email: zhangxin@wh.iov.cn; ky@wh.iov.cn
Website: http://english.whiov.cas.cn/

发件人： Yuan Zhiming
发送时间： 2015-01-14 15:33
收件人： Lawal, Adeola
抄送： zhangxin
主题： Re: FW: UTMB
Dear Dr.Lawal, Adeola,

I have finalized the draft and have it a check by the General Director of institute. I hope the revised Agreement will send to you very soon.

I have accepted the invitation of Dr. LeDuc, the director of GNL, to visit your place from 16-20 March, 2015. I hope to meet you and your colleagues to further discuss the program for our future coopearation.

Best regards

Yuan Zhiming

======= 2015-01-09 03:31:29 您在来信中写道：=======

>Hello Dr. Zhiming and Happy New Year!

FOIA Confidential Treatment Requested by Univ of Texas System

>
>Are you able to update me as to the status of Agreement? Please know that we look forward to getting this agreement in pl
ace.
>
>Best,
>
>
>Ade Lawal, JD
>Associate Legal Officer
>Office of Technology Transfer
>
>
>
>
>-----Original Message-----
>From: Yuan Zhiming [mailto:yzm@wh.iov.cn]
>Sent: Thursday, December 18, 2014 4:07 AM
>To: Lawal, Adeola
>Subject: Re: UTMB
>Importance: High
>
>DEar Ade Lawal,
>
>It is my pleasure to have received your MTA draft. We generally have no objection to the MTA and hopefully we could ha
ve it signed in near future.
>
>I schedule to visit your laboratory in March 2015, I hope to discuss with you and Dr. Bente for our cooperation program.
>
>Best regards
>
>
>Yuan Zhiming
>
>
>
>======= 2014-12-15 23:20:29 您在来信中写道：=======
>
>>Dear Dr. Yuan,
>>
>>Please find attached UTMB's standard Collaboration MTA for use in working with our investigator, Dr. Bente. Once co
mpleted, have signed by your authorized signatory and return to me for further processing. We look forward to getting this
agreement in place.
>>
>>Best,
>>
>>
>>Ade Lawal, JD
>>Associate Legal Officer
>>Office of Technology Transfer
>
>==========
>
>
>   致
>礼！
>
>
>   Yuan Zhiming
>   yzm@wh.iov.cn

> 2014-12-18
>

==========

致

礼！

Yuan Zhiming
yzm@wh.iov.cn
2015-01-14

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012817

COLLABORATION AGREEMENT

This Collaboration Agreement ("Agreement") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926 and Wuhan Institute of Virology, Chinese Academy of Sciences, ("Collaborator") located at _Xiaohognshan Zhongqu 44, Wuhan 430071, China individually a "party" and collectively, the "parties" to this Agreement.

RECITALS

WHEREAS, UTMB and Collaborator wish to collaborate on a research effort of mutual interest in the area of emerging disease control and laboratory biosafety management as described in the "Research Program", set forth as Exhibit A, which is a part of this Agreement.

WHEREAS, UTMB desires to participate in the collaboration by providing technical expertise to Collaborator;

WHEREAS, Collaborator desires to participate in the collaboration by providing technical expertise to UTMB; and

WHEREAS, the parties wish to memorialize in writing all of the terms and conditions that shall govern the parties' prior and present acts involving the collaboration as follows.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties hereto agree as follows:

TERMS AND CONDITIONS

1. **Definitions.**
   - 1.1 TRANSFEROR: A party providing Materials and/or Technical Data to the other party as defined herein. All parties hereto are Transferors.
   - 1.2 UTMB: University of Texas Medical Branch, a component institution of the University of Texas System, and its employees.
   - 1.3 MATERIALS: Deliverables, products, items, or goods of the Transferor that is transferred to Recipient for use in the performance of this Agreement, as identified in *Exhibit B. Materials.*
   - 1.4 RECIPIENT: A party in receipt of Material and Technical Data as defined herein. All parties hereto are Recipients.
   - 1.5 RESEARCH PROGRAM: As defined in *Exhibit A. Research Program.*
   - 1.6 RESULTS: All and any results developed from the Research Program under this Agreement by either party.
   - 1.7 TECHNICAL DATA: All prior technical knowledge, know-how, and information, including scientific data, laboratory records and books, software, patent applications, descriptive materials, and other oral and written information disclosed directly or indirectly by Transferor to Recipient for use in the performance of this Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012818

2. **Research Program.** University will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "UTMB Principal Investigator").

   Collaborator will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "Collaborator Principal Investigator").

   The parties may extend the Research Program under mutually agreeable terms. Collaborator understands that University's primary mission is education and advancement of knowledge and the Research Program will be designed to carry out that mission. The manner of performance of the Research Program shall be determined solely by the Principal Investigator. University does not guarantee specific results.

   Collaborator understands that University may be involved in similar Research Programs or similar research through other researchers on behalf of itself and others. University shall be free to continue such research provided that it is conducted separately and by different investigators from the Research Program, and Collaborator shall not gain any rights via this Agreement to other research.

3. **Communication and Reports.** Each party will promptly and fully inform the other party of the Results developed from the Research Program conducted hereunder. UTMB and Collaborator will consult with one another at mutually agreed times and intervals regarding the progress of the Research Program.

4. **Use of Materials and Technical Data**. The Materials and Technical Data shall be used by the Recipient's Principal Investigators and only for the purposes of the Research Program, as described in *Exhibit A: Research Program.* Recipients shall at all times use the Materials and Technical Data in a safe manner, and shall at all times comply with all state, federal and other applicable laws, rules and regulations pertaining to use, export, or re-export of the Materials and/or Technical Data. Nothing herein shall obligate a Transferor to transfer or disclose any Materials and/or Technical Data to a Recipient. This Agreement will apply to all Materials and/or Technical Data actually transferred or disclosed to a Recipient. Neither the Recipient nor the Recipient Principal Investigator shall distribute, release, or in any way disclose the Material to any person or entity other than laboratory personnel under the Recipient Principal Investigator's direct supervision, and the Recipient and Recipient Principal Investigator shall ensure that no one will be allowed to take or send Material to any other location. Material is made available for investigational use only in laboratory animals or in vitro experiments. Neither Material nor any biological materials treated therewith will be used in human beings. Further, no Materials as identified in Exhibit B of this Agreement or any other Material shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. In the event that Materials and/or Technical Data not initially listed in Exhibit B need to be sent by or to any Party in pursuit of the Research Plan, the attached Material Transfer Agreement Letter ("MTA Letter") will be utilized, identified as an amendment to this Agreement, and signed by authorized officials of all Parties.

5. **Protection of Material and Technical Data**. Upon completion of the Research Program, and in the absence of further written agreement of the parties, Recipient shall cease all use and make no further use of the Material or Technical Data. Upon completion of the Research Program or at Transferor's request, all Technical Data in tangible form and copies thereof in whole or in part, shall be returned to Transferor by Recipient except that Recipient shall be permitted to retain one copy in its files which copy shall be used only by Recipient and its legal advisors in connection with review of its obligations hereunder. In addition, upon completion of the Research Program or at Transferor's earlier request, all Material unused by Recipient will be, at Transferor's direction, properly disposed of or returned to Transferor. Recipient agrees that any distribution of Technical Data or the disclosure of Confidential Information without Transferor's express written permission may cause Transferor irreparable harm and that any breach or threatened breach of this Agreement by Recipient or Investigator will entitle Transferor to injunctive relief, in addition to any other legal remedies available to it in any court of competent jurisdiction.

6. **Permitted Transfer and Disclosure**. Recipient shall have the right to disclose Transferor's Technical Data and allow access to Transferor's Materials only to Recipient's employees who are working on this Agreement. Recipient will take all other reasonable steps, including, but not limited to, those steps taken to protect information, data or other tangible or intangible property of its own of a highly confidential nature, to insure that the Transferor's Material and Technical Data are not disclosed or duplicated or in any manner delivered or disseminated to others, and to prevent its officers, directors, employees, subcontractors, and others from violating this Agreement. Transferor's Material is made available for internal research use only in laboratory animals or in vitro experiments. Except as provided for by this Agreement, Recipient shall not distribute, transfer, or release Transferor's Material to any person or entity other than laboratory personnel under Recipient's Investigator, unless written permission is obtained from Transferor. Recipient agrees that all of its employees involved in the Research Program will have read the terms and conditions of this Agreement and abide by the terms and conditions of this Agreement. Recipient must acknowledge the Transferor as the source of the Transferor's Materials in publications, grant proposals, or other related documents.

7. **Good Faith Submissions and Negotiations.** The Parties may jointly apply for external funding in order to establish the Research Program. In the event that an award is made for the funding of the Research Program, the parties shall enter a comprehensive agreement setting forth their rights and obligations. The Parties agree to negotiate the terms of any such agreement in good faith.

8. **No License from Transferor**. Except as stated in this Agreement, nothing in this Agreement is to be construed as granting a license to Recipient to utilize the Material or Technical Data except as expressly provided in this Agreement, in any way whatsoever or under any patent owned by Transferor, unless a separate license agreement for such right is executed or has been by Recipient and Transferor. Any modification of this Agreement, and any further contract or license agreement between the parties hereto, shall be in writing.

9. **Title, License.** All discoveries, know-how, techniques, ideas or intellectual property, whether patented or patentable or not, that are owned and controlled by a party to this Agreement and that were existing or conceived prior to the date of this Agreement will continue to be

owned and controlled by the relevant party and are not affected by this Agreement. Any new invention, development, or discovery resulting from the Research Program ("Invention") shall be promptly and confidentially disclosed in writing by the inventive party to the other party. Ownership of Inventions shall reflect inventorship as determined by U.S. patent law, if patentable, and shall be determined by mutual consent between the parties, if not patentable. In the event of joint ownership of an Invention, the parties shall enter into an agreement for the subject Invention concerning the sharing of all invention management responsibilities, i.e., based upon the parties' relative contributions to the subject Invention. Each party shall retain a nonexclusive royalty-free license to use any Inventions developed hereunder for its own internal research purposes only.

10. **Publication**. All parties shall be entitled to publish with respect of the outcomes of the Research Program. In the event that either Party wishes to publish in relation to its respective contributions in facilitating the Research Program, a copy of the proposed publication shall be submitted to the other party for prior review and comment no later than sixty (60) days before planned submission. Upon request from the non-publishing party, the publishing party shall remove any of the non-publishing party's Confidential Information from the proposed publication, or the publishing party shall agree to delay submission of the proposed publication for an additional forty-five (45) days to allow for the non-publishing party to pursue patent protection.

11. **Confidentiality**. Recipient shall treat all information confidential ("Confidential Information"), as identified by Transferor, for a period of three (3) years and shall not use any Confidential Information except for purposes of the Research Program, or disclose any of said Confidential Information to any third party or personnel except for the Investigator without the prior written approval of Transferor; provided, however, Confidential Information shall not include information that: (a) was publicly known and generally available in the public domain prior to the time of disclosure to Recipient by Transferor; (b) becomes publicly known and made generally available in the public domain after disclosure to Recipient by Transferor, except by breach of this Agreement by Recipient; (c) was in Recipient's possession at the time of disclosure by Transferor as established by contemporaneous written records and was not acquired directly or indirectly from Transferor or from any other party under an obligation of confidentiality to Transferor; (d) is received by Recipient from a third party with the legal right to provide Recipient with such information; and (e) is required by law to be disclosed, provided however that the Recipient shall provide reasonable advance notice thereof to enable Transferor to seek a protective order or other legal means prevent such disclosure.

12. **Waiver of Warranties**. TRANSFEROR SUPPLIES THE MATERIAL AND TECHNICAL DATA WITHOUT ANY WARRANTY, REPRESENTATION OR UNDERTAKING WHATSOEVER, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY RESPECTING THE EFFICIENCY, PERFORMANCE, WORKMANSHIP, CONDITION, MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR SAFETY FOR ANY USE OR TREATMENT BY RECIPIENT. TRANSFEROR MAKES NO REPRESENTATION OR WARRANTY THAT USE OF THE TECHNICAL DATA OR MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. IT IS UNDERSTOOD THAT TRANSFEROR, ITS OFFICERS, DIRECTORS, AGENTS AND EMPLOYEES SHALL HAVE NO LIABILITY IN CONNECTION WITH RECIPIENT'S USE OF THE MATERIAL AND/OR TECHNICAL DATA.

13. **Indemnity**. To the extent authorized by the indemnifying party's state law, each party ("Indemnitor") shall indemnify the other ("Indemnitee") for any claims, demands, or losses that arise out of the Indemnitor's use of the Indemnitee's Results, Technical Data, or Materials under this Agreement.

14. **Benefit and Binding Effect**. This Agreement shall be binding upon and for the benefit of the parties hereto.

15. **Assignment**. This Agreement shall not be assigned by a Party without the prior written approval of the other Party.

16. **Authority**. Except as otherwise provided herein, each party hereto certifies that it has the full right, power and authority to enter into this Agreement. This Agreement shall be construed and enforced in accordance with the laws of the United States of America and the State of Texas without regard to their principles of conflicts of law. This Agreement sets forth the entire agreement between the parties with respect to the subject matter contained herein and supersedes any previous understandings, commitments or agreements, whether oral or written. This Agreement may only be amended with a writing signed by authorized representatives of both parties hereto.

17. **Independent Contractor.** For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not agents or employees of the other party. Neither party shall have authority to make any statements, representations nor commitments of any kind, nor to take any action which shall be binding on the other party, except as may be expressly provided for herein or authorized in writing.

18. **Use of Name.** Each party agrees that it shall not use the name and/or logo of the other Party in any advertising or publicity material without having obtained prior written authorization from that Party.

19. **Export Control.** Both parties acknowledge and agree that no classified information or research will be used or developed under this Agreement. All information and results under this Agreement is deemed fundamental research. All parties acknowledge that this Agreement and the performance thereof are subject to compliance with any and all applicable United States laws, regulations, or orders, including those that may relate to the export of technical data, and both Parties agree to comply with all such laws, regulations and orders, including, if applicable, all requirements of the International Traffic in Arms Regulations and/or the Export Administration Act, as may be amended. All parties further agree that if the export laws are applicable, it will not disclose or re-export any technical data received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless the disclosing party has obtained prior written authorization from authority responsible for such matters. Further, no Materials as identified in Exhibit B of this Agreement shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. The MTA letter shall act as an amendment to this Agreement.

20. **Visitor Scientist.** This Agreement does not authorize on-site visitation by the other party to the hosting party's campuses. Any decision that consists of the personnel of one party to train, work, or visit the campuses of the other party must be evidenced by the execution of a separate Visitor Scientist Agreement mutually signed by the authorized representatives of both parties.

21. **Term and Termination.** This Agreement shall be effective from 1 January 2015 until 31 December 2019. At that time, if Research Program in not completed and upon mutual written agreement of the parties, the Agreement may be extended for an additional (1) year. However, either party may terminate this Agreement for any reason upon giving thirty (30) days written notice to the other party.

22. **Funding.** It is understood and agreed that UTMB and Collaborator will each be responsible for their own expenses incurred in the performance of the Collaborative Research Program. Neither party is under obligation to fund the portion of the Collaborative Research Research Program conducted by the other party.

23. **Notices**. Any notice required by this Agreement shall be given by prepaid, first class, certified mail, return receipt requested, addressed to the Parties' authorized signatory:

The University of Texas Medical Branch at Galveston
Suite 1.200, 1700
301 University Blvd., Galveston, TX 77555-0926
ATTN: Sundeep Mattamana

or in the case of Collaborator, to:

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiaohongshan Zhongqu 44, Wuhan 430071, China

ATTN: Hong TANG
Title: Deputy Director General

or at such other addresses as may be given from time to time in accordance with the terms of this notice provision.

In Witness Whereof, the parties have caused this Agreement to be executed by their duly authorized representatives.

UNIVERSITY OF TEXAS MEDICAL BRANCH

Carolee King, JD
Sr. VP and General Counsel

Date: _____

Read and understood:

_____
Signature of UTMB Investigator

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

(b)(6)

Hong TANG (b)(6) (b)(6)
Deputy Director General

Date: Feb. 22, 2015

Read and understood: YUAN ZHIMING

(b)(6)

Signature of Collaborator Investigator

EXHIBIT A: RESEARCH PROGRAM

EXHIBIT B: MATERIALS

UTMB Materials:

Collaborator Materials:

MATERIAL TRANSFER AGREEMENT LETTER

This Material Transfer Agreement Letter ("MTA Letter") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926, and the Wuhan Institute of Virology, Chinese Academy of Sciences, ("Collaborator") located at _Xiaohognshan Zhongqu 44, Wuhan 430071, individually a "party" and collectively, the "parties" to this Agreement.

WHEREAS, UTMB and Collaborator have entered into a Collaboration Agreement ("Agreement") effective from 1 January 2015 until 31 December 2019;

WHEREAS, unless specifically described in this MTA Letter, the terms of the Agreement shall govern the relationship between the parties;

NOW THERFORE, The parties agree as follows:

1. UTMB will provide Collaborator with Materials described in Exhibit B. Collaborator will provide UTMB with Materials described in Exhibit B ("Material")
2. The Material is not for use in human subjects.
3. Except as provided for by the Agreement, Recipient shall not distribute, transfer or release the Material to any person or entity other than laboratory personnel under Recipient Scientist's direct supervision, unless written permission is obtained from Transferor. RECIPENT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.
4. Recipient agrees to use the MATERIAL in compliance with all applicable statutes and regulations.
5. Recipient further agrees that if the U.S. export laws are or become applicable, it will not export any Materials received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless Recipient has obtained prior written authorization from the appropriate authority responsible for such matters.
6. Except as stated herein, all other terms of the Agreement shall remain unchanged and in full force and effect.

FOIA Confidential Treatment Requested by Univ of Texas System

UNIVERSITY OF TEXAS MEDICAL BRANCH

Carolee King, JD
Sr. VP and General Counsel

Date: _____

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

(b)(6)

Hong TANG (b)(6)
Deputy Director General

Date: Feb. 22, 2015

Proposal Evaluation Form

EUROPEAN COMMISSION

Horizon 2020 - Research and Innovation Framework Programme

Evaluation Summary Report - Research and innovation actions/Innovation actions

Call: H2020-INFRAIA-2014-2015
Funding scheme: Research and Innovation action
Proposal number: 653316
Proposal acronym: EVAg
Duration (months): 48
Proposal title: European Virus Archive goes global
Activity: RANKING LIST

N.	Proposer name	Country	Total Cost	%	Grant Requested	%
1	UNIVERSITE D'AIX MARSEILLE	FR	2,904,961	24.13%	2,806,425	26.00%
2	BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN	DE	670,215	5.57%	670,215	6.21%
3	THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS	UK	807,276	6.70%	807,276	7.48%
4	UNIVERSITAETSKLINIKUM BONN	DE	603,250	5.01%	603,250	5.59%
5	Department of Health	UK	373,524	3.10%	373,524	3.46%
6	UNIVERSITAET BASEL	CH	460,910	3.83%	0	0.00%
7	UNIVERZA V LJUBLJANI	SI	534,175	4.44%	534,175	4.95%
8	VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED	SK	313,500	2.60%	313,500	2.90%
9	ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI - IRCCS	IT	476,404	3.96%	476,404	4.41%
10	ROBERT KOCH-INSTITUT	DE	434,688	3.61%	434,688	4.03%
11	ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM	NL	539,345	4.48%	539,345	5.00%
12	ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM	NL	296,373	2.46%	296,373	2.75%
13	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	FR	181,175	1.50%	181,175	1.68%
14	INSTITUT PASTEUR	FR	625,454	5.19%	625,454	5.80%
15	FRIEDRICH LOEFFLER INSTITUT - BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT	DE	605,997	5.03%	605,997	5.61%
16	THE PIRBRIGHT INSTITUTE LBG	UK	1,054,667	8.76%	972,803	9.01%
17	The University of Texas Medical Branch at Galveston	US	50,000	0.42%	50,000	0.46%
18	AGRICULTURAL RESEARCH COUNCIL (ARC)	ZA	145,440	1.21%	145,440	1.35%
19	NATIONAL HEALTH LABORATORY SERVICES	ZA	40,750	0.34%	40,750	0.38%
20	Chumakov Institute of Poliomyelitis and Viral Encephalitides	RU	15,100	0.13%	15,100	0.14%
21	SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION	RU	187,696	1.56%	50,000	0.46%
22	I.I.Mechnikov Scientific Research Institute for Vaccines and Sera	RU	15,100	0.13%	15,100	0.14%
23	NATINAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION	CN	175,000	1.45%	112,500	1.04%
24	Wuhan Institute of Virology	CN	480,250	3.99%	73,375	0.68%
25	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION	AU	50,000	0.42%	50,000	0.46%
	Total:		12,041,250		10,792,869	

Abstract:
The overall objective will be to create and mobilise an International network of high calibre centres around a strong European group of institutes selected for their appropriate expertises, to collect, amplify, characterise, standardise, authenticate, distribute and track, mammalian and other exotic viruses. The network of EVAg laboratories including 25 institutions represents an extensive range of virological disciplines. The architecture of the consortium is based on the association of capacities accessible to the partners but also to any end-users through the EVAg web-based catalogue. This concept has been elaborated and tested for its efficiency during the successful EVA project (FP7). The project will integrate more facilities dedicated to high risk pathogen (HRP) manipulation (1 in EVA, 13 in EVAg) The access to products derived from those HRP will be enhanced and for instance the production of diagnostic reagents will be facilitated. The new project will also provide access to high containment biosafety facilities to carry out in vivo studies of infectious disease using natural or models hosts, to look at prophylactic or therapeutic control measures and to develop materials for the evaluation of diagnostic tests, meaning an extensive capacity to service and to training. EVAg will also link up with other network-based virus-associated programmes that exist globally. However, looking further ahead, EVAg is conceived ultimately to be an open entity aiming at developing synergies and complementarity capabilities in such a way as to offer an improved access to researchers. This project will generate the largest collection of mammalian viruses in the world and move beyond the current state-of-the-art to provide an increasingly valuable resource and service to the world's scientific community, including government health departments, higher education institutes, industry and, through information systems, the general public.

Evaluation Summary Report

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_006834

Evaluation Result

Total score: 15.00 (Threshold: 10.00)

Form information

SCORING

Scores must be in the range 0-5.

Interpretation of the score:

- ***0–*** *The* ***proposal fails to address the criterion*** *or cannot be assessed due to missing or incomplete information.*
- ***1– Poor.*** *The criterion is inadequately addressed, or there are serious inherent weaknesses.*
- ***2– Fair.*** *The proposal broadly addresses the criterion, but there are significant weaknesses.*
- ***3– Good.*** *The proposal addresses the criterion well, but a number of shortcomings are present.*
- ***4– Very good.*** *The proposal addresses the criterion very well, but a small number of shortcomings are present.*
- ***5– Excellent.*** *The proposal successfully addresses all relevant aspects of the criterion.Any shortcomings are minor.*

Criterion 1 - Excellence

Score: **5.00** (Threshold: 3.00/5.00 , Weight: 100.00%)

Note: The following aspects will be taken into account, to the extent that the proposed work corresponds to the topic description in the work programme: .
Clarity and pertinence of the objectives;
Credibility of the proposed approach;
Soundness of the concept, including trans-disciplinary considerations, where relevant;
Extent that proposed work is ambitious, has innovation potential, and is beyond the state of the art (e.g. ground-breaking objectives, novel concepts and approaches).
The extent to which the Networking Activities will foster a culture of co-operation between the participants and other relevant stakeholders.
The extent to which the Access Activities (Trans-national Access and/or Virtual Access activities) will offer access to state-of-the-art infrastructures, high quality services, and will enable users to conduct excellent research.
The extent to which the Joint Research Activities will contribute to quantitative and qualitative improvements of the services provided by the infrastructures.

The proposal is a logical continuation of a highly successful FP7 initiative, EVA, which, as evidenced by documented number of users , has indeed already achieved 'flagship' status in the field of European initiatives. However, the RI proposed is not just a simple follow-up of the EVA project but a strong enhancement enlarging objectives, excellence, partnership and involvement of third parties at a global level. The proposing Consortium has significantly grown to become more inclusive and to create a critical mass required to achieve the ambitious objectives of the proposal. Networking, Trans National Access and Joint Research Activities are integrated into the proposal that benefits from a very clear vision for the future of this initiative. The concept, objectives and proposed activities, including access to information and products, along with the work plan, show a high potential for addressing the requirements of the call. The EVAg infrastructure will provide access to a) the world's largest collection of animal and human viruses, derived products of high quality standard for research and development purposes and services, b) open access to a unique documented virus list, c) well-defined standards for quality assurance and security measures, d) specific training with a particular focus on the new generation of researchers to exploit and adapt innovative tools for their research.

Linking the proposed project to existing ESFRIs is a strength, with the EVAg archive potentially forming a service unit within the BBMRI and close involvement with ERINHA. Furthermore, the potential to form a repository for EU-funded virology is clear as highlighted by the number of EU-funded initiatives that EVA members are involved in. Thus, the consortium is embedded into the EU framework and current functions very well as a network. The integration of high risk pathogen manipulation and access to the platforms for in vivo studies, including state-of-the-art high containment, further strengthens the proposal, as does the plan to harmonize standards and drive toward the development of diagnostic reagents and the inclusion of emergency response strategies. Significant interaction with World Health Organization is also evident, while absence of a Centers of Disease Control and Prevention participation was felt to represent a minor shortcoming.

Criterion 2 - Impact

Score: **5.00** (Threshold: 3.00/5.00 , Weight: 100.00%)

Note: The following aspects will be taken into account, to the extent to which the outputs of the project should contribute at the European and/or International level:
The expected impacts listed in the work programme under the relevant topic;
Enhancing innovation capacity and integration of new knowledge;
Strengthening the competitiveness and growth of companies by developing innovations meeting the needs of European and global markets, and where relevant, by delivering such innovations to the markets *
Any other environmental and socially important impacts;
Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant.

The expected impact of the proposed project is well described. If EVAg is able to create the world's largest collection of viruses/pathogens, it will be a major achievement that will support ongoing progress in the fields of animal and human health. From the project's predecessor's progress this appears realistic, with the current catalogue already being considered as a cornerstone for human health research. Building upon this archive will provide the opportunity of improving and organizing new knowledge and providing rapid access to critically important materials.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_006835

The JRAs proposed will clearly impact the community based on the outlined quality of access that will be achieved through a controlled and validated set of resources. The EVAg initiative will increase competitiveness and, as highlighted in the proposal, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry. The incorporation of multiple world class installations and the major world health organizations ensures a very strong impact from this EU-led initiative. The IPR management set out in the proposal is acceptable and clear. The initiative has an important social impact with particular emphasis on human disease. The efforts made by the scientific community are well represented by this advanced group, therefore impacting very effectively and positively on EU citizens and EU competitiveness.

Criterion 3 - Quality and efficiency of the implementation

Score: **5.00** (Threshold: 3.00/5.00 , Weight: 100.00%)

Note: The following aspects will be taken into account:
Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources;
Complementarity of the participants within the consortium (when relevant);
Appropriateness of the management structures and procedures, including risk and innovation management.

The quality and transparency of the implementation plan are at high level. The work plan is composed of 9 WPs organized in an effective structure that are presented in a thoughtful manner (tasks, subtasks, responsible leader etc.). The JRAs reflect a good balance of partners/time and resources providing a coherent collaborative structure. Importantly, the JRAs are very clearly aimed toward the community and the development of novel and innovative tools and processes. The JRAs successfully scale across all key areas in virology and associated scientific disciplines. This reflects the complementarity of partners and infrastructures indeed creating a very effective critical mass for scientific excellence.

The expertise of participants covers all relevant and related fields necessary to execute the planned activities. In addition, the plan to establish a global level of networking and joint research activities are based on the 25 partners from 13 countries including 9 non-European institutions from Australia, China, Russia, South Africa and the US. The TNAs are well described highlighting good coordination with 55 installations partnering in this initiative. The criteria for access are clearly set out and are supported by a robust selection concepts that are based on the significant previous experience of the consortium.

The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide, and the outreach to interact with new user communities is credible. Management structures are built upon the previous successful project and appear robust. Risk management is also based on previous experience and well-presented. Risk mitigation measures provided are both functional and viable. Security issue, as well as ethical and legal aspects are well addressed in the proposal.

Operational Capacity

Status: **Operational Capacity: Yes**

Not provided

Proposal content corresponds, wholly or in part, to the topic description against which it is submitted, in the relevant work programme part

Status: **Yes**

Not provided

Overall comments

The proposed global partners are considered essential and their contribution is fundamental. EU partners get access to resources which translates into a clear added value to the European partners and community.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_006836

From: zhangxin <zhangxin@wh.iov.cn>
Sent: Wednesday, March 4, 2015 8:06 PM
To: Bente, Dennis A.
Subject: Re: RE: Collaboration Agreement between UTMB and WIV

Dear Dennis,

I am really sorry for the delay of response due to our Spring Festival Holiday.

The agreement has been sent to Prof. Zhiming YUAN for his modification. Upon completing, I will email to you as soon as possible.

Thank you!

Sincerely
Xin

Xin ZHANG
Office of Research and Development
Wuhan Institute of Virology
Chinese Academy of Sciences
The People's Republic of China
Tel: (0086)027-87197115
Fax: (0086) 027-87198209
Email: zhangxin@wh.iov.cn; ky@wh.iov.cn
Website: http://english.whiov.cas.cn/

From: Bente, Dennis A.
Date: 2015-02-21 01:41
To: zhangxin
Subject: RE: Collaboration Agreement between UTMB and WIV

Dear Ade,

My last question for today, I promise!

Has this agreement been completed?

Thanks,

Dennis

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012796

From: zhangxin [mailto:zhangxin@wh.iov.cn]
Sent: Wednesday, January 21, 2015 9:45 PM
To: Lawal, Adeola
Cc: yzm; Bente, Dennis A.
Subject: Collaboration Agreement between UTMB and WIV

Dear Dr. Lawal, Adeola

Thank you for your inquiry of the status of the agreement between you and Prof. Zhiming YUAN. I'm Xin ZHANG, in charge of international collaboration of Wuhan Institute of Virology.

Please find attached a copy of Collaboration Agreement, which have been signed by Prof. Zhiming YUAN and our Institute's Deputy Director General, Prof. Hong TANG.

Should you have any questions, please let me know.

Have a nice day!

Best regards

Sincerely
Xin

Xin ZHANG
Office of Research and Development
Wuhan Institute of Virology
Chinese Academy of Sciences
The People's Republic of China
Tel: (0086)027-87197115
Fax: (0086) 027-87198209
Email: zhangxin@wh.iov.cn; ky@wh.iov.cn
Website: http://english.whiov.cas.cn/

发件人： Yuan Zhiming
发送时间： 2015-01-14 15:33
收件人： Lawal, Adeola
抄送： zhangxin
主题： Re: FW: UTMB

Dear Dr.Lawal, Adeola,

I have finalized the draft and have it a check by the General Director of institute. I hope the revised Agreement will send to you very soon.

I have accepted the invitation of Dr. LeDuc, the director of GNL, to visit your place from 16-20 March, 2015. I hope to meet you and your colleagues to further discuss the program for our future coopearation.

Best regards

Yuan Zhiming

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012797

======= 2015-01-09 03:31:29 您在来信中写道：=======

>Hello Dr. Zhiming and Happy New Year!
>
>Are you able to update me as to the status of Agreement? Please know that we look forward to getting this agreement in pl ace.
>
>Best,
>
>
>Ade Lawal, JD
>Associate Legal Officer
>Office of Technology Transfer
>
>
>
>
>-----Original Message-----
>From: Yuan Zhiming [mailto:yzm@wh.iov.cn]
>Sent: Thursday, December 18, 2014 4:07 AM
>To: Lawal, Adeola
>Subject: Re: UTMB
>Importance: High
>
>DEar Ade Lawal,
>
>It is my pleasure to have received your MTA draft. We generally have no objection to the MTA and hopefully we could ha ve it signed in near future.
>
>I schedule to visit your laboratory in March 2015, I hope to discuss with you and Dr. Bente for our cooperation program.
>
>Best regards
>
>
>Yuan Zhiming
>
>
>
>======= 2014-12-15 23:20:29 您在来信中写道：=======
>
>>Dear Dr. Yuan,
>>
>>Please find attached UTMB's standard Collaboration MTA for use in working with our investigator, Dr. Bente. Once co mpleted, have signed by your authorized signatory and return to me for further processing. We look forward to getting this agreement in place.
>>
>>Best,
>>
>>
>>Ade Lawal, JD
>>Associate Legal Officer
>>Office of Technology Transfer
>
>= = = = = = = = = = = = = = = = = = = =
>
>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012798

> 致

>礼！

>

>

> Yuan Zhiming

> yzm@wh.iov.cn

> 2014-12-18

>

==========

致

礼！

Yuan Zhiming

yzm@wh.iov.cn

2015-01-14

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012799

From: zhangxin <zhangxin@wh.iov.cn>
Sent: Thursday, March 5, 2015 12:28 AM
To: Lawal, Adeola
Cc: Bente, Dennis A.;yzm
Subject: Re: RE: Collaboration Agreement between UTMB and WIV
Attachments: collaboration agreement.pdf

Dear Dr. Lawal, Adeola

Sorry for the delay of response to your email due to our Spring Festival Holiday.

I've contacted with Prof. Zhiming YUAN to confirm the questions put forward in your last email. Since this is a collaboration agreement, Prof. Zhiming YUAN hoped further collaboration plans and some detailed terms such as, the Scope of Research and Materials, could probabaly be discussed during his visit to UTMB this March.

Please find attached a copy of Collaboration Agreement, which has been reprinted.

Have a good day!

Best regards

Sincerely
Xin

Xin ZHANG
Office of Research and Development
Wuhan Institute of Virology
Chinese Academy of Sciences
The People's Republic of China
Tel: (0086)027-87197115
Fax: (0086) 027-87198209
Email: zhangxin@wh.iov.cn; ky@wh.iov.cn
Website: http://english.whiov.cas.cn/

From: Lawal, Adeola
Date: 2015-02-10 10:20
To: 'zhangxin'
CC: yzm
Subject: RE: Collaboration Agreement between UTMB and WIV

Hello –

Thank you for the partially executed agreement. On review, we've noted the following:

1. The Collaboration Agreement and accompany MTA contain no Scope of Research – Please provide a scope of research.
2. Will materials be provided under this Agreement? If so, please indicate.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012800

3. Your signature appears pre-dated – Perhaps this is an oversight. In any event please correct this to reflect the date of your actual signature
4. The document is somewhat difficult to read as there appears to be some background print. Please reprint so that the Agreement is clear.

Thank you for your attention to these items. We look forward to getting an agreement in place for your collaboration with Dr. Bente.

Best,

Ade

From: zhangxin [mailto:zhangxin@wh.iov.cn]
Sent: Wednesday, January 21, 2015 9:45 PM
To: Lawal, Adeola
Cc: yzm; Bente, Dennis A.
Subject: Collaboration Agreement between UTMB and WIV

Dear Dr. Lawal, Adeola

Thank you for your inquiry of the status of the agreement between you and Prof. Zhiming YUAN. I'm Xin ZHANG, in charge of international collaboration of Wuhan Institute of Virology.

Please find attached a copy of Collaboration Agreement, which have been signed by Prof. Zhiming YUAN and our Institute's Deputy Director General, Prof. Hong TANG.

Should you have any questions, please let me know.

Have a nice day!

Best regards

Sincerely
Xin

Xin ZHANG
Office of Research and Development
Wuhan Institute of Virology
Chinese Academy of Sciences
The People's Republic of China
Tel: (0086)027-87197115
Fax: (0086) 027-87198209
Email: zhangxin@wh.iov.cn; ky@wh.iov.cn
Website: http://english.whiov.cas.cn/

发件人： Yuan Zhiming
发送时间： 2015-01-14 15:33
收件人： Lawal, Adeola

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012801

抄送： zhangxin

主题： Re: FW: UTMB

Dear Dr.Lawal, Adeola,

I have finalized the draft and have it a check by the General Director of institute. I hope the revised Agreement will send to you very soon.

I have accepted the invitation of Dr. LeDuc, the director of GNL, to visit your place from 16-20 March, 2015. I hope to meet you and your colleagues to further discuss the program for our future coopearation.

Best regards

Yuan Zhiming

======= 2015-01-09 03:31:29 您在来信中写道：=======

>Hello Dr. Zhiming and Happy New Year!
>
>Are you able to update me as to the status of Agreement? Please know that we look forward to getting this agreement in pl ace.
>
>Best,
>
>
>Ade Lawal, JD
>Associate Legal Officer
>Office of Technology Transfer
>
>
>
>
>-----Original Message-----
>From: Yuan Zhiming [mailto:yzm@wh.iov.cn]
>Sent: Thursday, December 18, 2014 4:07 AM
>To: Lawal, Adeola
>Subject: Re: UTMB
>Importance: High
>
>DEar Ade Lawal,
>
>It is my pleasure to have received your MTA draft. We generally have no objection to the MTA and hopefully we could ha ve it signed in near future.
>
>I schedule to visit your laboratory in March 2015, I hope to discuss with you and Dr. Bente for our cooperation program.
>
>Best regards
>
>
>Yuan Zhiming
>
>
>
>=======2014-12-15 23:20:29 您在来信中写道：=======
>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012802

>>Dear Dr. Yuan,
>>
>>Please find attached UTMB's standard Collaboration MTA for use in working with our investigator, Dr. Bente. Once co mpleted, have signed by your authorized signatory and return to me for further processing. We look forward to getting this agreement in place.
>>
>>Best,
>>
>>
>>Ade Lawal, JD
>>Associate Legal Officer
>>Office of Technology Transfer
>
>==========
>
>
> 致

>礼！
>
>
> Yuan Zhiming
> yzm@wh.iov.cn
> 2014-12-18
>

==========

致

礼！

Yuan Zhiming
yzm@wh.iov.cn
2015-01-14

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012803

COLLABORATION AGREEMENT

This Collaboration Agreement ("Agreement") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926 and Wuhan Institute of Virology, Chinese Academy of Sciences, ("Collaborator") located at _Xiaohognshan Zhongqu 44, Wuhan 430071, China individually a "party" and collectively, the "parties" to this Agreement.

RECITALS

WHEREAS, UTMB and Collaborator wish to collaborate on a research effort of mutual interest in the area of emerging disease control and laboratory biosafety management as described in the "Research Program", set forth as Exhibit A, which is a part of this Agreement.

WHEREAS, UTMB desires to participate in the collaboration by providing technical expertise to Collaborator;

WHEREAS, Collaborator desires to participate in the collaboration by providing technical expertise to UTMB; and

WHEREAS, the parties wish to memorialize in writing all of the terms and conditions that shall govern the parties' prior and present acts involving the collaboration as follows.

NOW THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties hereto agree as follows:

TERMS AND CONDITIONS

1. **Definitions.**
   - 1.1 TRANSFEROR: A party providing Materials and/or Technical Data to the other party as defined herein. All parties hereto are Transferors.
   - 1.2 UTMB: University of Texas Medical Branch, a component institution of the University of Texas System, and its employees.
   - 1.3 MATERIALS: Deliverables, products, items, or goods of the Transferor that is transferred to Recipient for use in the performance of this Agreement, as identified in *Exhibit B. Materials.*
   - 1.4 RECIPIENT: A party in receipt of Material and Technical Data as defined herein. All parties hereto are Recipients.
   - 1.5 RESEARCH PROGRAM: As defined in *Exhibit A. Research Program.*
   - 1.6 RESULTS: All and any results developed from the Research Program under this Agreement by either party.
   - 1.7 TECHNICAL DATA: All prior technical knowledge, know-how, and information, including scientific data, laboratory records and books, software, patent applications, descriptive materials, and other oral and written information disclosed directly or indirectly by Transferor to Recipient for use in the performance of this Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_012804

2. **Research Program.** University will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "UTMB Principal Investigator").

   Collaborator will use its own facilities and its reasonable best efforts to conduct the collaboration described in Attachment A ("Research Program") under the direction of emerging disease control research and laboratory biosafety management (the "Collaborator Principal Investigator").

   The parties may extend the Research Program under mutually agreeable terms. Collaborator understands that University's primary mission is education and advancement of knowledge and the Research Program will be designed to carry out that mission. The manner of performance of the Research Program shall be determined solely by the Principal Investigator. University does not guarantee specific results.

   Collaborator understands that University may be involved in similar Research Programs or similar research through other researchers on behalf of itself and others. University shall be free to continue such research provided that it is conducted separately and by different investigators from the Research Program, and Collaborator shall not gain any rights via this Agreement to other research.

3. **Communication and Reports.** Each party will promptly and fully inform the other party of the Results developed from the Research Program conducted hereunder. UTMB and Collaborator will consult with one another at mutually agreed times and intervals regarding the progress of the Research Program.

4. **Use of Materials and Technical Data**. The Materials and Technical Data shall be used by the Recipient's Principal Investigators and only for the purposes of the Research Program, as described in *Exhibit A: Research Program.* Recipients shall at all times use the Materials and Technical Data in a safe manner, and shall at all times comply with all state, federal and other applicable laws, rules and regulations pertaining to use, export, or re-export of the Materials and/or Technical Data. Nothing herein shall obligate a Transferor to transfer or disclose any Materials and/or Technical Data to a Recipient. This Agreement will apply to all Materials and/or Technical Data actually transferred or disclosed to a Recipient. Neither the Recipient nor the Recipient Principal Investigator shall distribute, release, or in any way disclose the Material to any person or entity other than laboratory personnel under the Recipient Principal Investigator's direct supervision, and the Recipient and Recipient Principal Investigator shall ensure that no one will be allowed to take or send Material to any other location. Material is made available for investigational use only in laboratory animals or in vitro experiments. Neither Material nor any biological materials treated therewith will be used in human beings. Further, no Materials as identified in Exhibit B of this Agreement or any other Material shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. In the event that Materials and/or Technical Data not initially listed in Exhibit B need to be sent by or to any Party in pursuit of the Research Plan, the attached Material Transfer Agreement Letter ("MTA Letter") will be utilized, identified as an amendment to this Agreement, and signed by authorized officials of all Parties.

5. **Protection of Material and Technical Data**. Upon completion of the Research Program, and in the absence of further written agreement of the parties, Recipient shall cease all use and make no further use of the Material or Technical Data. Upon completion of the Research Program or at Transferor's request, all Technical Data in tangible form and copies thereof in whole or in part, shall be returned to Transferor by Recipient except that Recipient shall be permitted to retain one copy in its files which copy shall be used only by Recipient and its legal advisors in connection with review of its obligations hereunder. In addition, upon completion of the Research Program or at Transferor's earlier request, all Material unused by Recipient will be, at Transferor's direction, properly disposed of or returned to Transferor. Recipient agrees that any distribution of Technical Data or the disclosure of Confidential Information without Transferor's express written permission may cause Transferor irreparable harm and that any breach or threatened breach of this Agreement by Recipient or Investigator will entitle Transferor to injunctive relief, in addition to any other legal remedies available to it in any court of competent jurisdiction.

6. **Permitted Transfer and Disclosure**. Recipient shall have the right to disclose Transferor's Technical Data and allow access to Transferor's Materials only to Recipient's employees who are working on this Agreement. Recipient will take all other reasonable steps, including, but not limited to, those steps taken to protect information, data or other tangible or intangible property of its own of a highly confidential nature, to insure that the Transferor's Material and Technical Data are not disclosed or duplicated or in any manner delivered or disseminated to others, and to prevent its officers, directors, employees, subcontractors, and others from violating this Agreement. Transferor's Material is made available for internal research use only in laboratory animals or in vitro experiments. Except as provided for by this Agreement, Recipient shall not distribute, transfer, or release Transferor's Material to any person or entity other than laboratory personnel under Recipient's Investigator, unless written permission is obtained from Transferor. Recipient agrees that all of its employees involved in the Research Program will have read the terms and conditions of this Agreement and abide by the terms and conditions of this Agreement. Recipient must acknowledge the Transferor as the source of the Transferor's Materials in publications, grant proposals, or other related documents.

7. **Good Faith Submissions and Negotiations.** The Parties may jointly apply for external funding in order to establish the Research Program. In the event that an award is made for the funding of the Research Program, the parties shall enter a comprehensive agreement setting forth their rights and obligations. The Parties agree to negotiate the terms of any such agreement in good faith.

8. **No License from Transferor**. Except as stated in this Agreement, nothing in this Agreement is to be construed as granting a license to Recipient to utilize the Material or Technical Data except as expressly provided in this Agreement, in any way whatsoever or under any patent owned by Transferor, unless a separate license agreement for such right is executed or has been by Recipient and Transferor. Any modification of this Agreement, and any further contract or license agreement between the parties hereto, shall be in writing.

9. **Title, License.** All discoveries, know-how, techniques, ideas or intellectual property, whether patented or patentable or not, that are owned and controlled by a party to this Agreement and that were existing or conceived prior to the date of this Agreement will continue to be

owned and controlled by the relevant party and are not affected by this Agreement. Any new invention, development, or discovery resulting from the Research Program ("Invention") shall be promptly and confidentially disclosed in writing by the inventive party to the other party. Ownership of Inventions shall reflect inventorship as determined by U.S. patent law, if patentable, and shall be determined by mutual consent between the parties, if not patentable. In the event of joint ownership of an Invention, the parties shall enter into an agreement for the subject Invention concerning the sharing of all invention management responsibilities, i.e., based upon the parties' relative contributions to the subject Invention. Each party shall retain a nonexclusive royalty-free license to use any Inventions developed hereunder for its own internal research purposes only.

10. **Publication**. All parties shall be entitled to publish with respect of the outcomes of the Research Program. In the event that either Party wishes to publish in relation to its respective contributions in facilitating the Research Program, a copy of the proposed publication shall be submitted to the other party for prior review and comment no later than sixty (60) days before planned submission. Upon request from the non-publishing party, the publishing party shall remove any of the non-publishing party's Confidential Information from the proposed publication, or the publishing party shall agree to delay submission of the proposed publication for an additional forty-five (45) days to allow for the non-publishing party to pursue patent protection.

11. **Confidentiality**. Recipient shall treat all information confidential ("Confidential Information"), as identified by Transferor, for a period of three (3) years and shall not use any Confidential Information except for purposes of the Research Program, or disclose any of said Confidential Information to any third party or personnel except for the Investigator without the prior written approval of Transferor; provided, however, Confidential Information shall not include information that: (a) was publicly known and generally available in the public domain prior to the time of disclosure to Recipient by Transferor; (b) becomes publicly known and made generally available in the public domain after disclosure to Recipient by Transferor, except by breach of this Agreement by Recipient; (c) was in Recipient's possession at the time of disclosure by Transferor as established by contemporaneous written records and was not acquired directly or indirectly from Transferor or from any other party under an obligation of confidentiality to Transferor; (d) is received by Recipient from a third party with the legal right to provide Recipient with such information; and (e) is required by law to be disclosed, provided however that the Recipient shall provide reasonable advance notice thereof to enable Transferor to seek a protective order or other legal means prevent such disclosure.

12. **Waiver of Warranties**. TRANSFEROR SUPPLIES THE MATERIAL AND TECHNICAL DATA WITHOUT ANY WARRANTY, REPRESENTATION OR UNDERTAKING WHATSOEVER, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY RESPECTING THE EFFICIENCY, PERFORMANCE, WORKMANSHIP, CONDITION, MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR SAFETY FOR ANY USE OR TREATMENT BY RECIPIENT. TRANSFEROR MAKES NO REPRESENTATION OR WARRANTY THAT USE OF THE TECHNICAL DATA OR MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. IT IS UNDERSTOOD THAT TRANSFEROR, ITS OFFICERS, DIRECTORS, AGENTS AND EMPLOYEES SHALL HAVE NO LIABILITY IN CONNECTION WITH RECIPIENT'S USE OF THE MATERIAL AND/OR TECHNICAL DATA.

13. **Indemnity**. To the extent authorized by the indemnifying party's state law, each party ("Indemnitor") shall indemnify the other ("Indemnitee") for any claims, demands, or losses that arise out of the Indemnitor's use of the Indemnitee's Results, Technical Data, or Materials under this Agreement.

14. **Benefit and Binding Effect**. This Agreement shall be binding upon and for the benefit of the parties hereto.

15. **Assignment**. This Agreement shall not be assigned by a Party without the prior written approval of the other Party.

16. **Authority**. Except as otherwise provided herein, each party hereto certifies that it has the full right, power and authority to enter into this Agreement. This Agreement shall be construed and enforced in accordance with the laws of the United States of America and the State of Texas without regard to their principles of conflicts of law. This Agreement sets forth the entire agreement between the parties with respect to the subject matter contained herein and supersedes any previous understandings, commitments or agreements, whether oral or written. This Agreement may only be amended with a writing signed by authorized representatives of both parties hereto.

17. **Independent Contractor.** For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not agents or employees of the other party. Neither party shall have authority to make any statements, representations nor commitments of any kind, nor to take any action which shall be binding on the other party, except as may be expressly provided for herein or authorized in writing.

18. **Use of Name.** Each party agrees that it shall not use the name and/or logo of the other Party in any advertising or publicity material without having obtained prior written authorization from that Party.

19. **Export Control.** Both parties acknowledge and agree that no classified information or research will be used or developed under this Agreement. All information and results under this Agreement is deemed fundamental research. All parties acknowledge that this Agreement and the performance thereof are subject to compliance with any and all applicable United States laws, regulations, or orders, including those that may relate to the export of technical data, and both Parties agree to comply with all such laws, regulations and orders, including, if applicable, all requirements of the International Traffic in Arms Regulations and/or the Export Administration Act, as may be amended. All parties further agree that if the export laws are applicable, it will not disclose or re-export any technical data received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless the disclosing party has obtained prior written authorization from authority responsible for such matters. Further, no Materials as identified in Exhibit B of this Agreement shall be sent without a material transfer letter ("MTA letter") signed by authorized officials of both parties and the obtainment of any export licenses as required by U.S. laws. The MTA letter shall act as an amendment to this Agreement.

20. **Visitor Scientist.** This Agreement does not authorize on-site visitation by the other party to the hosting party's campuses. Any decision that consists of the personnel of one party to train, work, or visit the campuses of the other party must be evidenced by the execution of a separate Visitor Scientist Agreement mutually signed by the authorized representatives of both parties.

21. **Term and Termination.** This Agreement shall be effective from 1 January 2015 until 31 December 2019. At that time, if Research Program in not completed and upon mutual written agreement of the parties, the Agreement may be extended for an additional (1) year. However, either party may terminate this Agreement for any reason upon giving thirty (30) days written notice to the other party.

22. **Funding.** It is understood and agreed that UTMB and Collaborator will each be responsible for their own expenses incurred in the performance of the Collaborative Research Program. Neither party is under obligation to fund the portion of the Collaborative Research Research Program conducted by the other party.

23. **Notices**. Any notice required by this Agreement shall be given by prepaid, first class, certified mail, return receipt requested, addressed to the Parties' authorized signatory:

The University of Texas Medical Branch at Galveston
Suite 1.200, 1700
301 University Blvd., Galveston, TX 77555-0926
ATTN: Sundeep Mattamana

or in the case of Collaborator, to:

Wuhan Institute of Virology, Chinese Academy of Sciences
Xiaohongshan Zhongqu 44, Wuhan 430071, China

ATTN: Hong TANG
Title: Deputy Director General

or at such other addresses as may be given from time to time in accordance with the terms of this notice provision.

In Witness Whereof, the parties have caused this Agreement to be executed by their duly authorized representatives.

UNIVERSITY OF TEXAS MEDICAL BRANCH

Carolee King, JD
Sr. VP and General Counsel

Date: _____

Read and understood:

_____
Signature of UTMB Investigator

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

(b)(6)

Hong TANG (b)(6)
Deputy Director General

Date: Feb. 22, 2015

Read and understood: YUAN ZHIMING

(b)(6)

Signature of Collaborator Investigator

EXHIBIT A: RESEARCH PROGRAM

EXHIBIT B: MATERIALS

UTMB Materials:

Collaborator Materials:

MATERIAL TRANSFER AGREEMENT LETTER

This Material Transfer Agreement Letter ("MTA Letter") is made between The University of Texas Medical Branch at Galveston, d/b/a UTMB Health ("UTMB"), a health institution of The University of Texas System ("System"), an agency of the state of Texas, located at 301 University Blvd., Galveston, TX 77555-0926, and the Wuhan Institute of Virology, Chinese Academy of Sciences, ("Collaborator") located at _Xiaohognshan Zhongqu 44, Wuhan 430071, individually a "party" and collectively, the "parties" to this Agreement.

WHEREAS, UTMB and Collaborator have entered into a Collaboration Agreement ("Agreement") effective from 1 January 2015 until 31 December 2019;

WHEREAS, unless specifically described in this MTA Letter, the terms of the Agreement shall govern the relationship between the parties;

NOW THERFORE, The parties agree as follows:

1. UTMB will provide Collaborator with Materials described in Exhibit B. Collaborator will provide UTMB with Materials described in Exhibit B ("Material")

2. The Material is not for use in human subjects.

3. Except as provided for by the Agreement, Recipient shall not distribute, transfer or release the Material to any person or entity other than laboratory personnel under Recipient Scientist's direct supervision, unless written permission is obtained from Transferor. RECIPENT MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

4. Recipient agrees to use the MATERIAL in compliance with all applicable statutes and regulations.

5. Recipient further agrees that if the U.S. export laws are or become applicable, it will not export any Materials received under this Agreement to any countries for which the United States government requires an export license or other supporting documentation at the time of export or transfer, unless Recipient has obtained prior written authorization from the appropriate authority responsible for such matters.

6. Except as stated herein, all other terms of the Agreement shall remain unchanged and in full force and effect.

UNIVERSITY OF TEXAS MEDICAL BRANCH

Carolee King, JD
Sr. VP and General Counsel

Date: _____

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES

(b)(6)

Hong TANG (b)(6)
Deputy Director General

Date: Feb. 22, 2015

Full Name: Hong Tang
Last Name: Tang
First Name: Hong
Job Title: Deputy Dir General
Company: Wuhan Institute of Virology

Business: +86 (27) 87197727
Business 2: +86 (10) 64888438

E-mail: tangh@wh.iov.cn
E-mail Display As: Hong Tang (tangh@wh.iov.cn)
E-mail 2: tanghong@moon.ibp.ac.cn
E-mail2 Display As: Hong Tang (tanghong@moon.ibp.ac.cn)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_059321

utmb Health
Galveston National Laboratory

301 University Boulevard
Galveston, Texas 77555-0610
P 409.266.6500 **F** 409.266.6810

Zhiming Yuan, PhD

Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan, CHINA

NOTE: Please bring a photo ID to gain entrance into the GNL and ask security to call ext 66500 to request an escort to your designated area.

Monday, April 27, 2015

9:30 - 10:00	***Dr. Dennis Bente will pick up Dr. Yuan from Hotel Galvez and escort to UTMB.***	***Hotel Galvez*** 2100 Seawall Blvd
10:00 - 12:00	***Meeting with:*** ***Dennis Bente, DVM, PhD*** Assistant Professor, Department of Microbiology and Immunology Member, Center for Biodesense and Emerging Diseases Member, Sealy Center for Vaccination Member, Institute of Human Infection and Immunity ***Thomas G. Ksiazek, DVM*** Professor, Departments of Pathology and Microbiology and Immunology Director, National Biocontainment Training Center Director, High Containment Operations Core, GNL ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	6.200U, GNL
12:00 – 1:15	***Lunch with*** ***Dennis Bente, DVM, PhD*** Assistant Professor, Department of Microbiology and Immunology Member, Center for Biodesense and Emerging Diseases Member, Sealy Center for Vaccination Member, Institute of Human Infection and Immunity ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	***Farley Girls Café*** 801 Post Office Street
1:30 – 2:30	***GNL Tour with:*** ***Miguel Grimaldo, M Eng*** Assitant Professor, Department of Pathology Director of Institutional Biocontinamnet Resources	

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_064449

	Thomas G. Ksiazek, DVM Professor, Departments of Pathology and Microbiology and Immunology Director, National Biocontainment Training Center Director, High Containment Operations Core, GNL	
2:30 – 3:30	***Biocontainment Maintenance and Operations Meeting with:*** ***Miguel Grimaldo, M Eng*** Assitant Professor, Department of Pathology Director of Institutional Biocontinamnet Resources	6.200U, GNL
3:30 – 4:00	***Wrap up with:*** ***Miguel Grimaldo, M Eng*** Assitant Professor Director of Institutional Biocontinamnet Resources Departmentof Pathology ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	6.200U, GNL
4:00	***Dr. Bente will escort Dr. Yuan to the Hotel Galvez.***	
5:30	***Dr. Bente will pick up Dr. Yuan from Hotel Galvez and transport to Willie G's Restaurant.***	
6:00 p.m.	***Dinner with:*** ***Dennis Bente, DVM, PhD*** Assistant Professor, Department of Microbiology & Immunology Member, Center for Biodesense and Emerging Diseases Member, Sealy Center for Vaccination Member, Institute of Human Infection and Immunity ***Yingzi Cong, PhD*** Associate Professor, Microbiology and Immunology and Pathology ***Lynn Soong, MD, PhD*** Professor, Departments of Microbiology and Immunology and Pathology Director, Microbiology & Immunology Graduate Program ***Jiaren Sun, MD, PhD*** Associate Professor, Microbiology and Immunology ***Chien-Te (Kent) Tseng, PhD*** Associate Professor, Microbiology and Immunology ***Tian (Tina) Wang, PhD*** Associate Professor, Microbiology and Immunology ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	***Willie G's Restaurant*** 2100 Harborside Galveston, TX 409 -762-3030 *Reservation in Dr. Bente name.*

FOIA Confidential Treatment Requested by Univ of Texas System

utmb Health
Galveston National Laboratory

301 University Boulevard
Galveston, Texas 77555-0610
P 409.266.6500 **F** 409.266.6810

Zhiming Yuan, PhD

Professor of Wuhan Institute of Virology
President of Wuhan Branch
Chinese Academy of Sciences
Wuhan, CHINA

Tuesday, April 28, 2015

9:00	***Dr. Dennis Bente will pick up Dr. Yuan from Hotel Galvez and escort to UTMB.***	***Hotel Galvez*** 2100 Seawall Blvd
9:30-10:30	***Meeting with Environmental Health and Safety:*** ***Belinda Rivera*** Lab Bio Training Consultant Environmental Health and Safety ***Jason Hardcastle*** Sr Lab Biosafety Training Specialist Environmental Health and Safety	***Materials Management Warehouse,*** 2nd Floor 13th and Mechanic
10:30 – 11:00	***Dr. Xia will escort Dr. Yuan to the GNL.***	
11:00 – 11:30	***Meeting with:*** ***Yingzi Cong, PhD*** Associate Professor, Microbiology and Immunology and Pathology	6.200U, GNL
11:30 – 12:00	***Meeting with:*** ***Chien-Te (Kent) Tseng, PhD*** Associate Professor, Microbiology and Immunology	6.200U, GNL
12:00 - 1:15	***Lunch with:*** ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	***Smooth Tony's*** 415 – 9th Street
1:15-2:00	***Meeting with:*** ***James W. Le Duc, PhD*** John Sealy Distinguished University Chair in Tropical and Emerging Virology Director, Galveston National Laboratory Professor, Department of Microbiology and Immunology	6.200C, GNL
2:00 – 2:30	***Meeting with:*** ***Jiaren Sun, MD, PhD*** Associate Professor, Microbiology and Immunology	6.200U, GNL

FOIA Confidential Treatment Requested by Univ of Texas System

2:30 – 3:00	***Meeting with:*** ***Tian (Tina) Wang, PhD*** Associate Professor, Microbiology and Immunology	6.200U, GNL
3:00 - 3:30	***Break***	
3:30 – 4:00	***Meeting with:*** ***Alexander Freiberg, PhD*** Director, Robert E. Shope BSL-4 Laboratory Associate Professor, Department of Pathology	6.200U, GNL
4:00 - 4:30	***Wrap up with:*** ***James W. Le Duc, PhD*** John Sealy Distinguished University Chair in Tropical and Emerging Virology Director, Galveston National Laboratory Professor, Department of Microbiology and Immunology ***Dennis Bente, DVM, PhD*** Assistant Professor, Department of Microbiology & Immunology Member, Center for Biodesense and Emerging Diseases Member, Sealy Center for Vaccination Member, Institute of Human Infection and Immunity ***Han Xia, PhD*** Post-Doctoral Fellow I Galveston National Laboratory Department of Microbiology and Immunology	
4:30	***Dr. Xia will escort Dr. Yuan to the Hotel Galvez.***	
6:00	***Dr. Xia will escort Dr. Yuan to the Shearn's Restaurant***	
6:30	***Dinner with:*** Dr. and Mrs. James W. Le Duc Dr. Han Xia and Dr. Cheng Hu	***Shearn's Restaurant*** 7 Hope Blvd Galveston, TX 77554 409-741-8484

Wednesday, April 29, 2015

12:00pm	***Texas Totally Limousine will pick up Dr. Yuan from Hotel Galvez and transport to Bush Intercontinental Airport***	***Texas Totally Limousine (281) 338-7825*** ***Confirmation #11046891***

FOIA Confidential Treatment Requested by Univ of Texas System

Produced in Native

MINUTES - 1st EVAg MEETING
European Virus Archive goes global
01.04.2015 – 02.04.2015
INSTITUT PASTEUR

Participant list

FIRST NAME	FAMILY NAME	EMAIL	ORGANISATION	
Tatjana	**AVSIC-ZUPANC**	tatjana.avsic@mf.uni-lj.si	Institute of Microbiology and Immunology	UL
Glaucia	**BACCALA**	glaucia.baccala@fondation-merieux.org	Fondation Mérieux - Centre International de Recherche en Infectiologie	CIRI
Maurice	**BARDSLEY**	Maurice.Bardsley@apha.gsi.gov.uk	Animal and Plant Health Agency	APHA
Cécile	**BARONTI**	cecile.baronti@ird.fr	Institut de recherche pour le développement	IRD
Danielle	**BAYLIS**	Daniele.Bayliss@apha.gsi.gov.uk	Animal and Plant Health Agency	APHA
Hervé	**BOURHY**	herve.bourhy@pasteur.fr	Institut Pasteur	IP
Daniel	**BOURQUAIN**	BourquainD@rki.de	Robert Koch Institute	RKI
Jean-Pierre	**CAMINADE**	jean-pierre.caminade@recherche.gouv.fr	Ministère de l'Education Nationale, de l'Enseignement Supérieur et de le Recherche	M.E.N.E.S.R.
Bryan	**CHARLESTON**	bryan.charleston@pirbright.ac.uk	The Pirbright Institute	TPI
Valérie	**CHOUMET**	vchoumet@pasteur.fr	Institut Pasteur	IP
Bruno	**COUTARD**	Bruno.coutard@afmb.univ-mrs.fr	Aix-Marseille University	AMU
Laurent	**DACHEUX**	Laurent.dacheux@pasteur.fr	Institut Pasteur	IP
Céline	**DAMON**	celine.damon@univ-amu.fr	Aix-Marseille University	AMU
Xavier	**DE LAMBALLERIE**	Xavier.De-Lamballerie@univ-amu.fr	Aix-Marseille University	AMU
Francis	**DELPEYROUX**	francis.delpeyroux@pasteur.fr	Institut Pasteur	IP
Antonino	**DI CARO**	antonino.dicaro@inmi.it	National Institute for Infectious Diseases LazzaroSpallanzani	INMI

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007186

FIRST NAME	FAMILY NAME	EMAIL	ORGANISATION	
Stuart	**DOWALL**	Stuart.Dowall@phe.gov.uk	Public HealthEngland	DH PHE
Jan Felix	**DREXLER**	drexler@virology-bonn.de	Universitaetsklinikum Bonn	UKB
Vincent	**ENOUF**	venouf@pasteur.fr	Institut Pasteur	IP
Elisabeth	**ERLACHER-VINDEL**	e.erlacher-vindel@oie.int	World Organisation for Animal Health	OIE
Anna-Bella	**FAILLOUX**	anna-bella.failloux@pasteur.fr	Institut Pasteur	IP
Tony	**FOOKS**	Tony.Fooks@apha.gsi.gov.uk	Animal and Plant Health Agency	APHA
Pierre B.H.	**FORMENTY**	formentyp@who.int	World HealthOrganization	WHO
Dominique	**GILLET**	dominique.gillet@pasteur.fr	Institut Pasteur	IP
Alexander	**GORBALENYA**	A.E.Gorbalenya@lumc.nl	Academischzeikenhuis Leiden - Leids Universitairmedishcentrum	LUMC
Ernest	**GOULD**	eag@ceh.ac.uk	Aix-Marseille University	AMU
Bart	**HAAGMANS**	b.haagmans@erasmusmc.nl	Erasmus universitairmedish centrum Rotterdam	EMC
Roger	**HEWSON**	Roger.Hewson@phe.gov.uk	Public HealthEngland	DH PHE
Zhihong	**HU**	huzh@wh.iov.cn	Chinese Academy of Science Wuhan	WIV
Sara	**HURST**	sara.hurst@pirbright.ac.uk	The Pirbright Institute	TPI
Giuseppe	**IPPOLITO**	giuseppe.ippolito@inmi.it	National Institute for Infectious Diseases LazzaroSpallanzani	INMI
David	**ITIER**	david.itier@pasteur.fr	Institut Pasteur	IP
Nadia	**KHELEF**	nkhelef@pasteur.fr	Institut Pasteur	IP
Boris	**KLEMPA**	boris.klempa@savba.sk	Institute of Virology	IVSAS
Thomas	**KLIMKAIT**	thomas.klimkait@unibas.ch	University of Basel	UNIBAS
Misa	**KORVA**	misa.korva@mf.uni-lj.si	Institute of Microbiology and Immunology	UL
Florence	**LARROUS**	Florence.larrous@pasteur.fr	Institut Pasteur	IP

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007187

FIRST NAME	FAMILY NAME	EMAIL	ORGANISATION	
Philippe	**LIEUTAUD**	Philippe.Lieutaud@afmb.univ-mrs.fr	Aix-Marseille University	AMU
Jan Eric	**LITTON**	jan-eric.litton@bbmri-eric.eu	Biobanking and BioMolecular resources Research Infrastructure	BBMRI-ERIC
Denise	**MARSTON**	Denise.Marston@apha.gsi.gov.uk	Animal and Plant Health Agency	APHA
Sam	**MCCULLOUGH**	Sam.Mccullough@csiro.au	Commonwealth Scientific and Industrial Research Organisation	CSIRO
Marianne	**PABION**	marianne.pabion@univ-amu.fr	Aix-Marseille University	AMU
Nathalie	**PARDIGON**	nathalie.pardigon@pasteur.fr	Institut Pasteur	IP
Daniel	**PINSCHEWER**	daniel.pinschewer@unibas.ch	University of Basel	UNIBAS
Florence	**PRADEL**	florence.pradel@fondation-merieux.org	Fondation Mérieux - Centre International de Recherche en Infectiologie	CIRI
Christine	**PRAT**	(b)(6)	Aix-Marseille University	AMU
Hervé	**RAOUL**	herve.raoul@inserm.fr	Institut national de la santé et de la recherche médicale	INSERM
Sven	**REICHE**	Sven.Reiche@fli.bund.de	Friedrich-Loeffler-Institut	FLI
Toni	**RIEGER**	rieger@bni-hamburg.de	Bernhard Nocht Institute	BNI
Jean-Louis	**ROMETTE**	jean-louis.romette@univ-amu.fr	Aix-Marseille University	AMU
Claude	**SABETA**	SabetaC@arc.agric.za	Agricultural Research Council	ARC-OVI
Frédéric	**SGARD**	Frederic.SGARD@oecd.org	Organisation for Economic Co-operation and Development	OECD
Sameera	**SURI**	suris@who.int	World HealthOrganization	WHO
Sylvie	**VAN DER WERF**	Sylvie.van-der-werf@pasteur.fr	Institut Pasteur	IP
Nikos	**VASILAKIS**	nivasila@utmb.edu	University of Texas Medical Branch	UTMB
Kathleen	**VICTOIR**	kathleen.victoir@pasteur.fr	Institut Pasteur	IP
Emma	**WISE**	Emma.Wise@apha.gsi.gov.uk	Animal and Plant Health Agency	APHA
Vitaly	**ZVEREV**	zverev@bioservice.ru	Mechnikov Scientific Research Institute for Vaccines and Sera	Mechnikov

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007188

❖ *1st of April 2015 from 13:30 to 19:30*

Welcome	
Jean-Louis ROMETTE, AMU, presented the two days agenda and the new EVAg project highlighting: - The success of the proposal (Final note 15/15) - The structure of the project: 16 partners from Europe, 10 partners from non-European Countries build up the consortium of the project with the support of 20 associated partners. The EVAg consortium has several extensions to other scientific networks (CDC's, WHO, OIE, ESFRI). **Q&A and Notes:** - AMU requested a fixed start date on the 1st of April 2015, but the consortium is waiting for the Grant Agreement signature to formalize the approval of the European Commission. As a consequence, it is highly recommended to engage only small sums on the project.	"Introduction and Welcome – On the footprints of EVA" by Jean-Louis ROMETTE (ppt available)
Financial and Administrative Information	
Marianne PABION, AMU presented the Grant Agreement preparation: - The Grant Agreement Data preparation is based on an electronic-only grant management. - Most beneficiaries signed the declaration of honour (DOH) and are about to sign the Accession Forms. - Five beneficiaries still need to sign the DOH (P17 UTMB, P19 NICD/NHLS, P20 IPVE, P22 Mechnikov, P23 China CDC). - The project will last 48 months and will be divided in 3 reporting periods (M18, M36, M48). **Q&A and Notes:** - Partners who did not sign the DOH are strongly invited to accomplish the requested administrative steps as soon as possible.	"Signature of the Grant Agreement" by Marianne PABION (ppt available)
Jean-Louis ROMETTE, AMU & Marianne PABION, AMU offered an overview of the structure of the Consortium Agreement: - The CA will be based on the DESCA 2020 Model Consortium Agreement - The CA is an internal document and will specify the relationship among the parties concerning the organisation of the work, the management of the project and the partner's rights/obligations. - The CA will be divided in four pillars (General issues, governance, Finance, Intellectual Property Rights). - The CA will circulate during the month of April between the beneficiaries of the consortium. **Q&A and Notes:** - The coordination proposed to annex a Model of MTA to the CA to be used and modified during the lifetime of the project. A scaffold of MTA could be also made available on the website with the possibility to modify a few paragraphs. - Action: When the project starts each institution could submit the MTA they wish to use. They would then be reviewed by the management team, and accepted for the rest of the project. If approved, each PI could have a delegation of signature.	"Preparation of the Consortium Agreement" by Jean-Louis ROMETTE & Marianne PABION (ppt available)
Boards compositions	
Jean-Louis ROMETTE, AMU presented the role and composition of the Executive Board and ask who is willing to be part of it: - Executive Board has two distinct roles: ○ It will prepare and propose political and strategic orientations of the project to the General Assembly. ○ I will implement the strategy adopted for the Project by the General Assembly, controlling the execution of the project in line with its agreed work plan, and monitoring corrective actions, including review of the deliverables, budget reallocation and allocation of the contingency fund **Q&A and Notes:** - After discussions, the consortium voted and decided that all WP Leaders would be part of the Executive Board to favor the operational decisions and the achievement of the tasks.	"Nomination of the Executive Board" by Jean-Louis ROMETTE (ppt available)
Christine PRAT, AMU presented the role of the Selection Panel and asked who would be willing to be a part of it: - Trans-National access (TNA) provides access « free of charge" to selected scientists working in a country other than the country where the provider is located - TNA can give access to viruses, derived products, or access to facility - The Selection Panel will recommend the benefit of free of charge to those that qualify and possibly assist each partner providing access to an end user - The composition will be: ○ 5 experts in the field ○ 3 external to the consortium ○ 2 among the partners' team members ○ The quality manager will be an extra member of this panel ○ The Selection panel will be assisted by the Business Developer and TNA manager	"Constitution of the Selection Panel" by Christine PRAT (ppt available)
Ernest GOULD, AMU presented the Workgroups for Advancement Validation and Exchanges (WAVE): - It is a specific feature implemented to initiate enhanced scientific communication inside the consortium (WP8) and to ensure an efficient contribution to EVAg Response to emergency situation (WP6) - It's goal is to overcome difficulties arising in monitoring, and ensuring rapid progress of targets, down the pipeline **Q&A and Notes:** - Partners can be part in several WAVE groups - In case of emergency, the EB will decide for the distribution of budget	"Constitution of the WAVE groups" by Ernest GOULD (ppt available)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007189

Access to users	
Jean-Louis ROMETTE, AMU & Marianne PABION, AMU presented Trans-national Access under H2020: - A new way to report based on actual costs with eligible costs actually and solely incurred for providing access to the selected user groups (Hours worked for the grant must be recorded) ○ Direct costs (personnel, sub-contracts, goods, services) are reimbursed up to 100% of the eligible costs ○ Indirect costs are reimbursed up to 25% of direct costs excluding subcontracting costs - Trans-national Access eligibility conditions and provider obligations **Q&A and Notes:** Third country users: up to 20% of the access can be provided to user teams with a majority of users working in third countries	"TNA & associated budget (WP7)" by Jean-Louis ROMETTE & Marianne PABION (ppt available)
A new system of web tools, using new programming technologies, is under development for the EVAg project. Waiting for the availability of the first functional releases of these tools, the system developed during the previous project will be in use (EVA). The EVAg system will be composed by 4 layers that will be implemented in the following order: • A Website (public and restricted area dedicated to consortium members) • A Portal (a database with interfaces that lists the products available in the consortium) • A system of orders management (including a cart system, a user area, tracking orders and vote for TNAs capabilities) • A local sample management system software that will be compatible with EVAg structure These parts will be improved from their first release till the end of the project. To achieve the development of these tools, the contribution of the members of the consortium will be important so that the developed tools will benefit from available skills in the consortium regarding textual content & illustration of the website, Beta testing, integration of prices & shipping fees, creation of new categories of products, Quality of data entered, development of an ontology extending BBMRI ontology… It was decided that partners will reply to calls for help on these subjects when needed. A first release of the public part of the EVAg website (pre-release, non-referenced by search engines) is available at http://global.european-virus-archive.com **Q&A and Notes:** **Participants interested in the website can contact Philippe LIEUTAUD (Philippe.Lieutaud@afmb.univ-mrs.fr) and give their feedback on the new layout, structure and content of the EVAg website.**	"EVAg Website& Portal, constitution of a work group (WP7)" Philippe LIEUTAUD & Christine PRAT
Giuseppe IPPOLITO, INMI & Christine PRAT, AMU presented the action plan linked to the WP8 "transfer of knowledge: dissemination and communication activities within and outside the consortium": - The internal communication activities - The external dissemination towards the industrial and scientific community and diverse audiences ○ scientific audience: through publications in peer-review jounals, e-learning, meetings, workshop etc... ○ end-users: through presentations of EVAg at specific conferences, and the website interface etc... ○ public at large: through social media, interactive e-platforms etc...	"Promotional documentation (WP8)" by Giuseppe IPPOLITO & Christine PRAT (ppt available)
Capacities set up (Round table)	
Xavier de Lamballerie, AMU presented work-plan and actions for WP1 "Developing a repository of quality controlled virus stocks and the associated metadata": - This WP encompasses all research and development relating directly to virus isolation, characterization, taxonomic assignment and preservation - The main objective is to integrate into the EVAg collection a large number of viruses relevant to fundamental, epidemiology and public health research, with the highest standards of quality, characterisation and standardisation. - It also implies significant research activities to develop and/or improve methodological tools that can serve this objective **Q&A and Notes:** A question was raised on the inactivation of samples before shipping. Regulations vary for different types of sample and different geographical localisations.	Action plan including scientific development and capacity building of the WP1, by Xavier de Lamballerie (ppt available)
Bruno Coutard, AMU presented work-plan and actions for WP2 "Derived material platform": - the recombinant virus generation platform (AMU 1a) - the recombinant proteins platform (AMU 1b) - The molecular diagnostics platform (UKB) - The serological diagnostics platform (EMC) - Innovative tools for shipment (APHA)	Action plan including scientific development and capacity building of the WP2, by Bruno Coutard (ppt available)
Sven Reiche, FLI presented work-plan and actions for WP3 "In vivo studies platform": - Providing expertise on a large number of animal models with ○ The *in vivo* vertebrate hosts platform (FLI) ○ The *in vivo* invertebrate hosts platform (IVSAS)	Action plan including scientific development and capacity building of the WP3, by Sven Reiche (ppt available)
Maurice Bardsley, APHA presented work-plan and actions for WP4 "Quality management systems": - Address the "inscription criteria" for new products on the catalog (UL) - Address the EVAg Quality Management System implementation	Action plan including scientific development and capacity building of the WP4, by Maurice Bardsley (ppt available)
Jan Felix Drexler, UKB presented work-plan and actions for WP6 "Support to response" - In response to an outbreak, a specific WAVE will be implemented - One task will be to distribute and develop reagents and protocols for molecular detection - One task will be to distribute and develop reagents and protocols for serological detection of antibodies - A mobile laboratory capacity will be deployed to assist in an outbreak	Action plan including scientific development and capacity building of the WP6, by Jan Felix Drexler (ppt available)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007190

❖ *2nd of April 2015 from 09:30 to 13:30*

Collaboration with Scientific & Health networks (Round table) **Round table chaired by Herve BOURHY (WP5)**	
Florence PRADEL, Fondation Mérieux presented GABRIEL an international network of scientists and research laboratories by focusing on the: - History of the networklaunched in January 2008 as pillar of the Research Platform of the Fondation Mérieux - Composition, structure and localisation - Activities (Collaborative research, Technology transfer, Training and Knowledge sharing, Quality Assurance) and objectives **Q&A and Notes:** GABRIEL &EVAg - Haiti, Paraguay, Mali, China and Bangladesh expressed their will to collaborate with the EVAg project and would need training to join the project	"Presentation of the GABRIEL network", by Florence PRADEL (ppt available)
Kathleen VICTOIR, Institut Pasteur presented the Institut Pasteur International Network regarding the following aspects: - The structure and expertise - The objectives, research areas and key partnerships	"Presentation of Pasteur Institutes Network", by Kathleen VICTOIR (ppt available)
Elisabeth ERLACHER-VINDEL, OIE, Scientific and Technical Service presented the World Organisation for Animal Health (OIE) regarding the following aspects: - Structure, and localisation - History of the intergovernmental organisation founded in 1924, created to prevent the spread of animal diseases throughout the world. WTO's reference organisation for international trade and surveillance and control of animaldiseases and zoonoses - Objectives and 5th Strategic plan (2011-2015) – 6th Strategic Plan to be adopted in May 2015 - New projects: OIE Genomic Sequences Platform and Creation of a biobank - Composition (247 Reference Laboratories in 38 countries - Opportunities for collaboration with EVAg	"OIE and EVAg: A future for a collaboration", by Elisabeth ERLACHER-VINDEL (ppt available)
Pierre FORMENTY, EDPLN & GOARN, WHOpresented the World Health Organization, the Global Outbreak and Response Network (GOARN) and the Emerging and Dangerous Pathogens Laboratory Network (EDPLN). EVAg is considered as an active partner of the WHO networks based on common activities and collaboration	"EVAg as an active partner of the GOARN", by Pierre FORMENTY (ppt available)
Long term sustainability: Roundtable **Round table chaired by Jean-Louis ROMETTE (WP9)**	
Jean-Louis ROMETTE, AMU presented the foreseeable plans for a long term sustainability after the 4 years presenting: - The networks and related infrastructures with whom EVAg could enter into formal collaborations (BBMRI-ERIC, ERINHA, MIRRI, G20) - The next steps to come are to: ○ Design conceptually and legally the future form of the infrastructure ○ Establish a business model to prepare a long term sustainable funding for the consortium ○ Build up a proposal for a project structure eligible to the GSF roadmap **Q&A and Notes:** - AMU would accept to host the legal entity of the International Large Infrastructure. All the EVAg beneficiaries could be attached to the legal entity. - All partners have to start national negotiations with their own Ministries and Funding authorities in order to secure their participation - A question was raised concerning the nonprofit status of EVAg: if partners receive money from companies, is it possible to secure it for later? Do we have to declare 0 at the end of the year? - A commercial or development contract with a company will not be declared in the Form C. The partner will have to verify that there is no double financing. The money received in this case for the development of the product or of a result is not concerning the consortium.	"After the 4 years", by Jean-Louis ROMETTE (ppt available)
Jan-Eric LITTON, BBMRI presented the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC): - The 7 pillars, the structure and the legal basis - The will to build one of Europe's Largest Health Infrastructure with a New Biobank catalogue for research in Europe ○ 20 million human biological samples during BBMRI Preparatory Phase catalogued ○ Estimated tissue samples in Europe: 1.6 Billion **Q&A and Notes:** - EVAg could join the BBMRI but remains the fact that Non-Europeans countries are only observers and cannot vote. - BBMRI could also be a full partner of EVAg.	"BBMRI-ERIC", by Jan-Eric LITTON (ppt available)
Frédéric SGARD, OECD presented the Global Science Forum and the perspectives for large research infrastructure funding on the long term: - The sustainability of a large research infrastructure depends on the type of infrastructure and is strongly related to the financial viability on the long term - The international collaboration is producing an added cost (15 to 20 %) - During the establishment phase the provision of funds is feasible. But once the operational phase has started financial issues can raise - The quality of the infrastructure's secretariat is crucial, to help and to respond to the beneficiaries to respond to the calls for proposals - Frédéric SGARD presented options of structures that could be adopted: ○ ERIC is a European Entity where non-European Countries don't have the same rights ○ A Belgium association is flexible but doesn't have the prefect legal system neither	"Presentation of the GSF" by Frédéric SGARD (No ppt available)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007191

Q&A and Notes: - EVAg has to work from the start on the best legal and financial framework to adopt on the long term, with a business plan on the next ten years, identifying the national structures able to leverage funding opportunities - The Members need to convince the Ministries support the network to that national priorities and roadmaps fit with the project objectives	
Conclusions	
Christian BRECHOT - Institut Pasteur, President& Jean-Louis ROMETTE – AMU	

Focus on equal opportunities

Gender balance at the 1st EVAgMeeting:

41% women – 59% men

- **Glossary**

Gender: – a socio-cultural process – refers to cultural and social attitudes that together shape and sanction "feminine" and "masculine" behaviours, products, technologies, environments, and knowledge[1].

Gender equality: gender equality is the result of the absence of discrimination on the basis of a person's sex in opportunities and the allocation of resources or benefits or in access to services[2].

Equal opportunities for women and men: equal opportunities indicate the absence of barriers to economic, political and social participation on the grounds of sex[3].

Gender dimension in research: is a concept regrouping the various elements concerning biological characteristics and social/cultural factors of both women and men into the development of research policies, programmes and projects.

- **Promoting Gender Equality in Research and Innovation**

In Horizon 2020 Gender is a cross-cutting issue and is mainstreamed in each of the different parts of the Work Programme, ensuring a more integrated approach to research and innovation.

- **Three objectives underpin the strategy on gender equality in Horizon 2020:**
  - Fostering gender balance in research teams, in order to close the gaps in the participation of women.
  - Ensuring gender balance in decision-making, in order to reach the target of 40% of the under-represented sex in panels and groups and of 50% in advisory groups.
  - Integrating the gender dimension in research and innovation (R&I) content, helps improve the scientific quality and societal relevance of the produced knowledge, technology and/or innovation.
- **More information**
  - Policy: http://ec.europa.eu/research/swafs/index.cfm?pg=policy&lib=gender
  - Promoting Gender Equality in Research and Innovation: http://ec.europa.eu/programmes/horizon2020/en/h2020-section/promoting-gender-equality-research-and-innovation

TO DO LIST		
Who	**What**	**When**
AMU	▪ Finalise the GA signature; ▪ Circulate the CA.	Before 31/05/2015
Admin	▪ Update the contact list circulated by AMU ▪ Send the Participant bank details of their organisation to marianne.pabion@univ-amu.fr &nadia.benmammar@univ-amu.fr ▪ Send the logo of your organisation to marianne.pabion@univ-amu.fr	Before 31/05/2015
LEAR	▪ Assign the FSIGN (Financial Signatory)to the project in the participant portal	Before 31/05/2015
PLSIGN	▪ Sign the accession Form to the Grant Agreement	Within 1 week after reception of the invitation
ALL	▪ Save the dates for the 2nd EVAg Meeting in Rome on the 1st and 2nd of October 2015	Asap

[1] Cf. Gendered Innovations, How gender analysis contributes to research
[2] Cf. Strategy for equality between women and men 2010-2015
[3] Cf. Gender Toolkit in EU-funded research

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_007192

From: LeDuc, James W.
Sent: Tuesday, June 2, 2015 3:31 PM
To: Ksiazek, Thomas G.
Subject: FW: Next steps on the CAS NAS bio workshop?
Attachments: Draft CAS NAS invite letter.docx

Tom, are you interested in participating in this meeting in Beijing, 29-30 Sept 2015? Will be similar to the India meeting last fall. I'll stop past later today to discuss. You would cover Ebola.

Thanks, Jim

From: David Franz (b)(6)
Sent: Tuesday, June 02, 2015 2:46 PM
To: Diane Griffin; LeDuc, James W.
Subject: Fwd: Next steps on the CAS NAS bio workshop?

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

(b)(6)

Begin forwarded message:

From: "Rusek, Benjamin" <BRusek@nas.edu>
Subject: Next steps on the CAS NAS bio workshop?
Date: May 6, 2015 5:40:30 PM EDT
To: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, 吴莹 <wuying@im.ac.cn>
Cc: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, Zhang Lei <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, 'Jinghua Cao' <jh-cao@cashq.ac.cn>, 张清泉 <qqzhang@cashq.ac.cn>, 高福 <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later

FOIA Confidential Treatment Requested by Univ of Texas System

this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044499

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044500

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044501

主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Dr. Hui,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044502

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (b)(6)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone (b)(6) (b)(6) office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044503

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044504

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)
David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044505

security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)
Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼！

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044506

DRAFT **5/6/15**

INVITATION: China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety & Global Health Security

Greetings___,

The U.S. National Academy of Sciences (NAS) and the Chinese Academy of Sciences (CAS) in partnership with representatives from other Chinese institutions are organizing a joint workshop between Chinese and American experts on the challenges of emerging infections, laboratory safety, and global health security. The meeting will take place on September 29-30, 2015 at a CAS institute in Beijing, China. The purpose of this letter is to formally invite you to speak at the upcoming workshop and ask you to hold the workshop dates open on your calendar.

The workshop will touch on both human and animal health issues associated with the global life-sciences revolution and today's challenges with respect to emerging infections and epidemics. Of particular relevance to life-science communities in China and the United States is the challenge of achieving the right balance of regulation to make laboratory research safe and secure and yet minimally impact progress in the life sciences for the good of all people. The sessions would be designed to allow scientists from China and the United States to jointly share lessons learned regarding biological safety, laboratory leadership and management, staff education and training, and the efficient and sustainable maintenance and operation of laboratories for animal and public health research. Together we might also consider clinical applications for improving global health security and encouraging collaborative partnerships between Chinese and American scientists in areas identified during the workshop.

NAS and CAS have set up an informal joint committee to plan the workshop and invite workshop speakers and participants (all subject to mutual agreement by our Academies). We hope that you can attend and speak about ___ during a session on___.

If you are available to attend, NAS will fund your travel to China, and provide lodging and meals for the duration of the workshop. Unless you already possess a valid Chinese Visa you will need to work with NAS staff in advance of the meeting to obtain a visa, please make sure that your passport is valid for at least six months from the date of the meeting. Visa processing will be performed by NAS staff members with invitation letters provided by CAS.

We look forward to receiving your reply and any thoughts that you wish to share regarding the organization, content, and substance of this joint workshop. Thank you for your consideration.

Sincerely,

(b)(6)

Yaping Zhang
Vice President, CAS

(b)(6)

Diane E. Griffin
Vice President, NAS
dgriffin@jhsph.edu

NAS points of contact:

David R. Franz DVM, Ph.D.
Former Commander, USAMRIID
davidrfranz@gmail.com

Benjamin J. Rusek, Senior Program Officer
U.S. National Academy of Sciences
brusek@nas.edu (b)(6)

CAS points of contact:

Hui Sun, Director, Division of American and Oceanian Affairs, Bureau of International Cooperation
Chinese Academy of Sciences
sunhui@cashq.ac.cn +86-10-6859750

DRAFT

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044507

From: Dave Franz <davidrfranz@gmail.com>
Sent: Tuesday, June 2, 2015 4:35 PM
To: LeDuc, James W.
Cc: Diane Griffin;Benjamin Rusek (BRusek@nas.edu);Lowenthal, Micah;Guenther, Rita;Ksiazek, Thomas G.
Subject: Re: Next steps on the CAS NAS bio workshop?

Excellent!! Thanks Tom. Dave

Sent from my iPhone

On Jun 2, 2015, at 5:13 PM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

> I spoke to Tom Ksiazek and he is willing to join us in the China meeting in September and to speak on Ebola, details to be determined.
>
> Thanks, Jim
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Tuesday, June 02, 2015 2:46 PM
> **To:** Diane Griffin; LeDuc, James W.
> **Subject:** Fwd: Next steps on the CAS NAS bio workshop?
>
> David R. Franz DVM, Ph.D
>
> Assistant: (b)(6)
> (b)(6)
>
> Begin forwarded message:
>
> **From:** "Rusek, Benjamin" <BRusek@nas.edu>
> **Subject: Next steps on the CAS NAS bio workshop?**
> **Date:** May 6, 2015 5:40:30 PM EDT

FOIA Confidential Treatment Requested by Univ of Texas System

To: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, 吴莹 <wuying@im.ac.cn>
Cc: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, Zhang Lei <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, 'Jinghua Cao' <jh-cao@cashq.ac.cn>, 张清泉 <qqzhang@cashq.ac.cn>, 高福 <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004684

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004685

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004686

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax: +86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004687

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004688

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone ([redacted]office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004689

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert Davi
Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including
CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it i
possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use whil
we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meetin
between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda
year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan
experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004690

David Franz (Independent Consultant, United States)
David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute o Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)
Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. Nationa Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including th Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops o nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurit Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked o international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member c the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. H previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. i political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004691



653316 — EVAg

Consortium agreement

Version 1, 2015/06/09



Version 1.1 - May 2014

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124946

Table of Content

CONSORTIUM AGREEMENT

Section 1: Definitions 4
Section 2: Purpose 5
Section 3: Entry into force, duration and termination 5
Section 4: Responsibilities of Parties 6
Section 5: Liability towards each other 7
Section 6: Governance structure 8
Section 7: Financial provisions 15
Section 8: Results 17
Section 9: Access Rights 19
Section 10: Non-disclosure of information 22
Section 11: Miscellaneous 23
Section 12: Signatures 26
Attachment 1: Background included 51
Attachment 2: Accession document 60
Attachment 3: List of Third Parties for simplified transfer according to Section 8.2.2 61
Attachment 4: Identified Affiliated Entities according to Section 9.5 62
Attachment 5: Identified Third Parties with a link to a Party 63
Attachment 6: Trans-national access costs 63

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124947

CONSORTIUM AGREEMENT

THIS CONSORTIUM AGREEMENT is based upon
REGULATION (EU) No 1290/2013 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 11 December 2013 laying down the rules for the participation and dissemination in "Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020)" (hereinafter referred to as "the Rules"), and the European Commission Multi-beneficiary General Model Grant Agreement and its Annexes, and is made on 1st of April 2015, hereinafter referred to as the Effective Date

BETWEEN:

1. **UNIVERSITE D'AIX-MARSEILLE (AMU), the COORDINATOR**
   1.a. INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (IRD)
   Linked Third Party of AMU, acting on behalf of the AMU Laboratory EPV (Emergence des Pathologies Virales - UMR D190)
   1.b. CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
   Linked Third Party of AMU, acting on behalf of the AMU Laboratory AFMB (Architecture et Fonction des Macromolécules Biologiques - UMR 7257)
2. BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)
3. ANIMAL AND PLANT HEALTH AGENCY (APHA)
4. UNIVERSITAETSKLINIKUM BONN (UKB)
5. DEPARTMENT OF HEALTH (DH PHE)
6. UNIVERSITAT BASEL (UNIBAS)
7. UNIVERZA V LJUBLJANI (UL)
8. VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)
9. ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)
10. ROBERT KOCH-INSTITUT (RKI)
11. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)
12. ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)
13. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
14. INSTITUT PASTEUR (IP)
15. FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)
16. THE PIRBRIGHT INSTITUTE LBG (TPI)
17. THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)
18. AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)
19. NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)
20. FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)
21. SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)
22. I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)
23. NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)
24. WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)
25. COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

hereinafter, jointly or individually, referred to as "Parties" or "Party"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124948

relating to the Action entitled

"European Virus Archive goes global"

in short

EVAg

hereinafter referred to as "Project"

WHEREAS:
The Parties, having considerable experience in the field concerned, have submitted a proposal for the Project to the Funding Authority as part of the Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020).
The Parties wish to specify or supplement binding commitments among themselves in addition to the provisions of the specific Grant Agreement to be signed by the Parties and the EC (hereinafter "Grant Agreement").
The Parties are aware that this Consortium Agreement is based upon the DESCA model consortium agreement.

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

Section 1: Definitions

1.1 Definitions

Words beginning with a capital letter shall have the meaning defined either herein or in the Rules or in the Grant Agreement including its Annexes.

1.2 Additional Definitions

"Consortium Plan"

Consortium Plan means the description of the action and the related agreed budget as first defined in the Grant Agreement and which may be updated by the General Assembly.

"Funding Authority"

Funding Authority means the body awarding the grant for the Project.

"Defaulting Party"

Defaulting Party means a Party which the General Assembly has identified to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.2 of this Consortium Agreement.

"Needed" means:

For the implementation of the Project:
Access Rights are needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be impossible, significantly delayed, or require significant additional financial or human resources.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124949

For exploitation of own Results:
Access Rights are needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible.

"Resource" means:
Material, data, know-how or information

"Third Party Linked to a Beneficiary" means:
Legal entities, either public or private, represented in the Grant Agreement by a Signatory Party according to the terms of the Article 14 of the Grant Agreement. This Signatory Party and the Third Party Linked to a Beneficiary it represents shall be partners in a "Joint Research Unit".

"Joint Research Unit"means:
Unincorporated entity created by a written contract between a Signatory Party and the legally linked Third Party to a Beneficiary it represents and listed, if any, in the Article 14 of the Grant Agreement and in the Attachment 5.
According to the Article 14 and Article 26.3 of the Grant Agreement, CNRS is a Linked Third Party of UNIVERSITE D'AIX-MARSEILLE (AMU) with rights on results of AMU AFMB (UMR 7257) and IRD is a Linked Third Party of UNIVERSITE D'AIX-MARSEILLE (AMU) with rights on results of AMU EPV (UMR D190).

"Member" means:
The Principal Investigator of each Benecifiarie's team involved in the project.

"Research Infrastructure", (RI) means:
Facilities, resources and services used by the scientific community for conducting research and innovation in their fields.

"Installation" means:
A part or a service of a research infrastructure that could be used independently from the rest. A research infrastructure consists of one or more installations.

"Trans-national Access", (TNA) means:
A "free of charge" provision of access to a research infrastructure to selected researchers or research teams working in a country other than the country where the research infrastructure is located. (Specific provisions for Access to RI are defined in Article 16 of the Grant Agreement).

Section 2: Purpose

The purpose of this Consortium Agreement is to specify with respect to the Project the relationship among the Parties, in particular concerning the organisation of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution.

Section 3: Entry into force, duration and termination

3.1 Entry into force

An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124950

This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this Consortium Agreement.

An entity becomes a Party to the Consortium Agreement upon signature of the accession document (Attachment 2) by the new Party and the Coordinator. Such accession shall have effect from the date identified in the accession document.

3.2 Duration and termination

This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the Parties under the Grant Agreement and under this Consortium Agreement.
However, this Consortium Agreement or the participation of one or more Parties to it may be terminated in accordance with the terms of this Consortium Agreement.

If the Grant Agreement is not signed by the Funding Authority or a Party, or is terminated, or if a Party's participation in the Grant Agreement is terminated, this Consortium Agreement shall automatically terminate in respect of the affected Party/ies, subject to the provisions surviving the expiration or termination under Section 3.3 of this Consortium Agreement.

3.3 Survival of rights and obligations

The provisions relating to Access Rights and Confidentiality, for the time period mentioned therein, as well as for Liability, Applicable law and Settlement of disputes shall survive the expiration or termination of this Consortium Agreement.
Termination shall not affect any rights or obligations of a Party leaving the Consortium incurred prior to the date of termination, unless otherwise agreed between the General Assembly and the leaving Party. This includes the obligation to provide all input, deliverables and documents for the period of its participation.

In case of one Party's withdrawal, the other Parties shall use reasonable endeavours to reach a timely agreement on how to reallocate the requesting Party's tasks so that the overall objectives of the Project can still be met after the Party's withdrawal. Following the decisions above the Coordinator shall promptly notify the Funding Authority, for its approval.

Section 4: Responsibilities of Parties

4.1 General principles

Each Party undertakes :

- to take part in the efficient implementation of the Project, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by Belgian law.
- to notify promptly, in accordance with the governance structure of the Project, any significant information, fact, problem or delay likely to affect the Project.

Each Party shall:

- promptly provide all information reasonably required by a Consortium Body or by the Coordinator to carry out its tasks.
- take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Parties.

4.2 Breach

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124951

In the event that the Executive Board (EB) identifies a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed by the General Assembly, will give formal notice to such Party requiring that such breach will be remedied within 30 calendar days.

If such breach is substantial and is not remedied within that period or is not capable of remedy, the General Assembly may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof which may include termination of its participation.

4.3 Involvement of third parties

A Party that enters into a subcontract or otherwise involves third parties (including but not limited to Affiliated Entities and Third Parties with a link to a Party) in the Project remains responsible for carrying out its relevant part of the Project and for such third party's compliance with the provisions of this Consortium Agreement and of the Grant Agreement. It has to ensure that the involvement of third parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the Grant Agreement.

Section 5: Liability towards each other

5.1 No warranties

In respect of any information or materials (incl. Results and Background) supplied by one Party to another under the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of third parties.

Therefore,

- the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and
- no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a third party resulting from any other Party (or its Affiliated Entities) exercising its Access Rights.

5.2 Limitations of contractual liability

No Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a wilful actor by a breach of confidentiality.

A Party's aggregate liability towards the other Parties collectively shall be limited to once the Party's share of the total costs of the Project as identified in Annex 2 of the Grant Agreement provided such damage was not caused by a wilful actor gross negligence.

The terms of this Consortium Agreement shall not be construed to amend or limit any Party's statutory liability.

5.3 Damage caused to third parties

Each Party shall be solely liable for any loss, damage or injury to third parties resulting from the performance of the said Party's obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background.

5.4 Force Majeure

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124952

No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure.
Each Party will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the competent Consortium Bodies.

Section 6: Governance structure

6.1 General structure

The organisational structure of the Consortium shall comprise the following Consortium Bodies:

The General Assembly (GA) is the ultimate decision-making body of the consortium.

The Executive Board (EB) as the supervisory body for the execution of the Project has two distinct roles. First, the EB will prepare and propose political and strategic orientations of the project to the General Assembly. Second, it will implement the strategy adopted for the Project by the General Assembly. The EB will consult the External Expert Advisory Board (EEAB).

The Coordinator, AMU, is the legal entity acting as the intermediary between the Parties and the Funding Authority. The Coordinator, AMU, shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement.

The Management Support Team (MST) assists the GA and is in charge of the day-to-day project management, and will provide support and assistance to the different project bodies.

The EEAB assists the EB and the GA.

The WP Coordinators (WPC) and the Tasks Leaders are responsible respectively for the performance of their work packages and for their work packages tasks.

6.2 General operational procedures for all Consortium Bodies

6.2.1 Representation in meetings

Any Party which is a member of a Consortium Body (hereinafter referred to as "Member"):
- should be represented at any meeting of such Consortium Body.
- may appoint a substitute or a proxy to attend and vote at any meeting.
- and shall participate in a cooperative manner in the meetings.

6.2.2 Preparation and organisation of meetings

- 6.2.2.1 Convening meetings:

The chairperson of a Consortium Body shall convene meetings of that Consortium Body.

	Ordinary meeting	Extraordinary meeting
General Assembly	At least once a year	At any time upon written request of the EB or 1/3 of the Members of the GA
Executive Board	At least twice a year	At any time upon written request of any Member of the EB
Technical Meeting	At least once a year	N/A

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124953

- 6.2.2.2 Notice of a meeting:

The chairperson of a Consortium Body shall give notice in writing of a meeting to each Member of that Consortium Body as soon as possible and no later than the minimum number of days precedings the meeting as indicated below.

	Ordinary meeting	Extraordinary meeting
General Assembly	45 calendar days	15 calendar days
Executive Board	14 calendar days	7calendar days
Technical Meeting	45 calendar days	N/A

- 6.2.2.3 Sending the agenda:

The chairperson of a Consortium Body shall send each Member of that Consortium Body a written (original) agenda no later than the minimum number of days precedings the meeting as indicated below.

General Assembly	21 calendar days for ordinary meeting, 10 calendar days for extraordinary meeting
Executive Board	7 calendar days for ordinary meeting, 4 calendar days for extraordinary meeting
Technical Meeting	21 calendar days for ordinary meeting

6.2.2.4 Adding agenda items:

Any agenda item requiring a decision by the Members of a Consortium Body must be identified as such on the agenda.
Any Member of a Consortium Body may add an item to the original agenda by written notification to all of the other Members of that Consortium Body up to the minimum number of days precedings the meeting as indicated below.

General Assembly	14 calendar days for ordinary meeting, 7 calendar days for extraordinary meeting
Executive Board	2 calendar days for ordinary and extraordinary meetings
Technical Meeting	2 calendar days for ordinary meeting

6.2.2.5 During a meeting the Members of a Consortium Body present or represented can unanimously agree to add a new item to the original agenda.

6.2.2.6 Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the Consortium Body a written document which is then agreed by the defined majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall include the deadline for responses.

6.2.2.7 Meetings of each Consortium Body may also be held by teleconference or other telecommunication means.

6.2.2.8 Decisions will only be binding once the relevant part of the minutes has been accepted according to Section 6.2.5.

6.2.3 Voting rules and quorum

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124954

6.2.3.1 The GA shall not deliberate and decide validly unless 2/3 of the 26 members are present or represented (quorum). Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast(one vote per member(26), one for the Coordinator, e.g. 18/27 for the plenary sessions; one vote per member(16), one for the Coordinator for sessions restricted to EU members, eg: 13/17).
If the quorum is not reached, the chairperson of the GA shall convene another ordinary meeting within 15 calendar days. If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting which shall be entitled to decide even if less than the quorum of Members are present or represented.

6.2.3.2 The EB shall not deliberate and decide validly unless the 1/3 of the 26 members are present or represented (quorum). Decisions shall be taken by a simple majority is not reached.

6.2.3.3 Defaulting Parties may not vote.

6.2.4 Veto rights

6.2.4.1 A Member which can show that its own work, time for performance, costs, liabilities, intellectual property rights or other legitimate interests would be severely affected by a decision of a Consortium Body may exercise a veto with respect to the corresponding decision or relevant part of the decision.

6.2.4.2 When the decision is foreseen on the original agenda, a Member may veto such a decision during the meeting only.

6.2.4.3 When a decision has been taken on a new item added to the agenda before or during the meeting, a Member may veto such decision during the meeting and within 15 days after the draft minutes of the meeting are sent.

6.2.4.4 In case of exercise of veto, the Members of the related Consortium Body shall make every effort to resolve the matter which occasioned the veto to the general satisfaction of all Members.

6.2.4.5 A Party may not veto decisions relating to its identification as a Defaulting Party. The Defaulting Party may not veto decisions relating to its participation and termination in the consortium or the consequences of them.

6.2.4.6 A Party requesting to leave the consortium may not veto decisions relating thereto.

6.2.5 Minutes of meetings

6.2.5.1 The chairperson of a Consortium Body shall produce written minutes of each meeting which shall be the formal record of all decisions taken. He shall send draft minutes to all Members within 30 calendar days of the meeting.

6.2.5.2 The minutes shall be considered as accepted if, within 15 calendar days from sending, no Member has sent an objection in writing to the chairperson with respect to the accuracy of the draft of the minutes.

6.2.5.3 Accepted minutes shall be sent to all the Members of the Consortium Body, and to the Coordinator, who shall safeguard them. If requested the Coordinator shall provide authenticated duplicates to Parties.

6.3 Specific Operational procedures for the Consortium Bodies

6.3.1 General Assembly

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124955

In addition to the rules described in Section 6.2, the following rules apply:

6.3.1.1Members

6.3.1.1.1 The GA shall consist of one representative of each Member (hereinafter GA Member).

6.3.1.1.2 Each GA Member shall be deemed to be duly authorised to deliberate, negotiate and decide on all matters listed in Section 6.3.1.2 of this Consortium Agreement.

6.3.1.1.3 The Coordinator shall chair all meetings of the GA, unless decided otherwise in a meeting of the General Assembly.

6.3.1.1.4 The Parties agree to abide by all decisions of the GA.

This does not prevent the Parties to submit a dispute for resolution in accordance with the provisions of settlement of disputes in Section 11.8.

6.3.1.2 Decisions

The GA shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein. In addition, all proposals made by the EB shall also be considered and decided upon by the GA.

The following decisions shall be taken by the GA:

Content, finances and intellectual property rights:
- Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the Funding Authority.
- Changes to the Consortium Plan.
- Modifications to Attachment 1 (Background Included).
- Additions to Attachment 3 (List of Third Parties for simplified transfer according to Section 8.2.2).
- Additions to Attachement 4 (Identified Affiliated Entities).
- Additions to Attachment5 (Identified Third Parties with a link to a Party).
- Additions to Attachement 6 (Trans-national access costs).

Evolution of the consortium
- Entry of a new Party to the consortium and approval of the settlement on the conditions of the accession of such a new Party.
- Withdrawal of a Party from the consortium and the approval of the settlement on the conditions of the withdrawal.
- Identification of a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement.
- Declaration of a Party to be a Defaulting Party.
- Remedies to be performed by a Defaulting Party.
- Termination of a Defaulting Party's participation in the consortium and measures relating thereto.
- Proposal to the Funding Authority for a change of the Coordinator.
- Proposal to the Funding Authority for suspension of all or part of the Project.
- Proposal to the Funding Authority for termination of the Project and the Consortium Agreement.

In the case of abolished tasks as a result of a decision of the GA, Members shall rearrange the tasks of the Parties concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled.

Appointments

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124956

On the basis of the Grant Agreement, the appointment if necessary of:

EB Members

6.3.2 Executive Board

In addition to the rules described in Section 6.2, the following rules apply:

6.3.2.1 Members

The EB shall consist of the Coordinator and all the Members (26) appointed by the GA (hereinafter Executive Members).

The Coordinator shall chair all meetings of the EB, unless decided otherwise in a majority of two-thirds.

6.3.2.2 Minutes of meetings

Minutes of EB meetings, once accepted, shall be sent by the Coordinator to the GA Members for information.

6.3.2.3 Tasks

6.3.2.3.1 The EB shall prepare the meetings, propose decisions and prepare the agenda of the GA according to Section 6.3.1.2.

6.3.2.3.2 It shall seek a consensus among the Parties.

6.3.2.3.3 The EB shall be responsible for the proper execution and implementation of the decisions of the General Assembly.

6.3.2.3.4 The EB shall monitor the effective and efficient implementation of the Project.

6.3.2.3.5 In addition, the EB shall collect information at least every 6 months on the progress of the Project, examine that information to assess the compliance of the Project with the Consortium Plan and, if necessary, propose modifications of the Consortium Plan to the General Assembly.

6.3.2.3.6 The EB shall:
- agree on the Members of the MST, upon a proposal by the Coordinator.
- support the Coordinator in preparing meetings with the Funding Authority and in preparing related data and deliverables.
- prepare the content and timing of press releases and joint publications by the Consortium or proposed by the Funding Authority in respect of the procedures of the Grant Agreement Article 29.

6.3.2.3.7 In the case of abolished tasks as a result of a decision of the General Assembly, the EBshall advise the GA on ways to rearrange tasks and budgets of the Parties concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled.

6.4 Coordinator

6.4.1 The Coordinatorshall be the intermediary between the Parties and the Funding Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124957

6.4.2 In particular, the Coordinator shall be responsible for:

- monitoring compliance by the Parties with their obligations.
- collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certifications) and specific requested documents to the Funding Authority.
- transmitting documents and information connected with the Project to any other Parties concerned
- administering the financial contribution of the Funding Authority and fulfilling the financial tasks described in Section 7.3.
- providing, upon request, the Parties with official copies or originals of documents which are in the sole possession of the Coordinator when such copies or originals are necessary for the Parties to present claims.
-

If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertheless submit the other parties' project deliverables and all other documents required by the Grant Agreement to the Funding Authority in time.

- If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertherless submit the other parties' project deliverables and all other documents required by the Grant Agreement to the Funding Authority in time.

6.4.3 If the Coordinator fails in its coordination tasks, the GA may propose to the Funding Authority to change the Coordinator.

6.4.4 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement.

6.4.5 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement.

6.5 Management Support Team

The Management Support Team shall be proposed by the Coordinator.The Management Support Team consists of the Coordinator, a European Project Manager assisted by the European Research Grant Department of AMU, the Business developer and TNA manager, the Webmaster and the Quality manager. It shall assist and facilitate the work of the EB for executing the decisions of the GA as well as the day-to-day management of the Project.

The European Project Manager shall assist and facilitate the work of the Coordinator for executing the decisions of the Management Support Team as well as the day-to-day management of the Project and shall be responsible for:

- keeping the address list of Members and other contact persons updated and available.
- preparing the meetings, drafting the minutes of the meetings and monitoring the implementation of decisions taken at meetings.
- transmitting promptly documents and information connected with the Project.

The Business Developer and TNA manager shall be responsible for:

- organizing an appropriate valuation of the resource generated by the consortium amongst industrial private companies, in conjunction with the Partner's institutions.
- assisting the GA and the EB on any issues related to Resource Dissemination.
- interacting with the industrial sector concerning management of the accessible resource.
- identifying and creating of relationships with pharmaceutical and biotechnology companies or any other private parties that may be interested in EVAg outputs.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124958

- deciding , with the agreement of the GA, on promotion and dissemination within the industrial sector.
- Initiating exploitation plans (deliverables), in collaboration with each partner.

The Webmaster shall be responsible for implementing following the EVA project a secure web facility to centralize all the communication and service tools related to the EVAg consortium activities with the following objectives:

- On line web-based catalogue.
- Promotion of the EVAg organisation and services provided through on-line presentations.
- Information on results available.
- Information on access conditions (research agreement, material transfer agreement, and licence).
- Updated list of the EVAg Publications.

The Quality Manager shall be responsible for:

- creating a working group comprising the quality managers of each Partner.
- defining, agreeing, improving and implementing a set of quality guidelines to be followed by the biological and virological resource centres within EVAg.
- handling Issue and Risk Management.
- working in close contact with WP coordinators, he will be responsible for the anticipation of any changes in the project.
- proposing to the Executive Board mitigation solutions and, upon decision of the GA.
- implementing the best solution for the achievement of project objectives. Each risk will be identified, analysed, its consequences measured and solutions anticipated, where appropriate.

6.6 External Expert Advisory Board (EEAB)

The EEAB shall be made up of a minimum of 11 members appointed by the General Assembly, with a minimum of 4 Scientific community representatives and a minimum of7 stakeholders representatives.

The EEAB shallassist the consortium and will be in charge of:

- Advising on scientific and ethical issues.
- Ensuring the involvement of industry at an early stage of the project to prepare the development phase beyond the project. It will also represent the end users and other stakeholders.
- Addressing recommendations related to the management of actions carried out by the consortium in this very specific field (emerging zoonotic diseases, human viral epidemicity/pandemicity, risk analysis).
- Assisting and Advising the EB and the GA.

Prior to the beginning of its activity, each EEAB member will be requested to complete a non-disclosure agreement (NDA), which terms shall be not less stringent than those stipulated in this Consortium Agreement, no later than 30 calendar days after their nomination or before any confidential information will be exchanged, whichever date is earlier. The EEAB shall be invited to take part in the GA meetings once a year. The EEAB shall also be invited to delegate its President to join the EB meetings and to contribute to opinions on how we can achieve the objectives and milestones for the following year. He/She will also be responsible for submitting yearly activity report on EEAB activities.

6.7 EVAg legal status

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124959

The parties commit to participate to the conceptual and legal design of the future form of the EVAg infrastucture, to establish a business model to prepare a long term sustainable funding for the EVAg consortium, as well as to become member of the EVAg legal entity.

Section 7: Financial provisions

7.1 General Principles

7.1.1 Distribution of Financial Contribution

The financial contribution of the Funding Authority to the Project shall be distributed by the Coordinator according to:

- the Consortium Plan.
- the approval of reports by the Funding Authority, and
- the provisions of payment in Section 7.3.

A Signatory Party shall be funded only for its tasks and for the tasks of its linked Third Party it may represents carried out in accordance with the Consortium Plan.

7.1.2 Justifying Costs

In accordance with its own usual accounting and management principles and practices, each Party shall be solely responsible for justifying its costs with respect to the Project towards the Funding Authority. Neither the Coordinator nor any of the other Parties shall be in any way liable or responsible for such justification of costs towards the Funding Authority.

7.1.3 Funding Principles

Trans-national access costs (TNA) :
TNA will be solely reimbursed on the basis of the eligible costs actually and solely incurred for providing access to the selected user groups and on the basis of Attachment 6Trans-national access costs.

Four scenarios of reimbursement are to be considered:

- Scenario 1: Trans-national access costs are lower than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is equal to the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely incurred for providing access to the selected user groups

- Scenario 2: Trans-national access costs are higher than the estimated cost in Attachment 6 and and the amount of access actually provided under the conditions of the grant agreement is less than the minimum amount foreseen in the grant agreement.The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups on the basis of the average costs defined in attachment 6.
-
- Scenario 3: Trans-national access costs are higher than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is equal to the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups and ceilled at the maximum amount defined in attachment 6.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124960

- The real cost of the provided accesses might be reimbursed after the final payment of the Funding Authority, and only if there is still some available budget within the project maximum EU financial contribution.
-
- Scenario 4: Trans-national access costs are higher than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is higher than the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups and ceilled at the maximum amount defined in attachment 6.
- The real cost of the provided accesses might be reimbursed after the final payement of the Funding Authority, and only if there is still some available budget within the project maximum EU financial contribution.

For other costs than TNA the costs will be reimbursed on the following basis :

- A Party which spends less than its allocated share of the budget as set out in the Consortium Plan or will be funded in accordance with its actual duly justified eligible costs only.
- A Party that spends more than its allocated share of the budget as set out in the Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share.

The estimated budget breakdown indicated in Annex 2 of the Grant Agreement may be adjusted by transfers of amounts between beneficiaries or between budget categories (or both). This does not require an amendment according to Article 55 of the Grant Agreement, if the action is implemented as described in Annex 1 of the Grant Agreement.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1 of the Grant Agreement, unless such additional subcontracts are approved by an amendment or in accordance with Article 13 of the Grant Agreement.

7.1.4 Financial Consequences of the termination of the participation of a Party

A Party leaving the consortium shall refund all payments it has received except the amount of contribution accepted by the Funding Authority or another contributor. Furthermore a Defaulting Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Parties in order to perform its and their tasks.

7.2 Budgeting

The budget set out in the Consortium Plan shall be valued in accordance with the usual accounting and management principles and practices of the respective Parties.

7.3 Payments

7.3.1 Payments to Parties are the exclusive tasks of the Coordinator.

In particular, the Coordinator shall:

- notify the Party concerned promptly of the date and composition of the amount transferred to its bank account, giving the relevant references.
- perform diligently its tasks in the proper administration of any funds and in maintaining financial accounts.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124961

- undertake to keep the Community financial contribution to the Project separated from its normal business accounts, its own assets and property, except if the Coordinator is a Public Body or is not entitled to do so due to statutory legislation.
- With reference to Articles 21.2 and 21.3.2 of the Grant Agreement, no Party shall before the end of the Project receive more than its allocated share of the maximum grant amount from which the amounts retained by the Funding Authority for the Guarantee Fund and for the final payment have been deducted.

7.3.2 Payment schedule

Protisvalor Méditerranée, acting on behalf of the Coordinator as defined in the option of the Article 41.2 of the Grant Agreement, undertakes to transfer the appropriate sums to the respective Parties, in accordance with the Grant Agreement, the Consortium Agreement and the modalities agreed by the GA with minimum delay from the receipt thereof from the European Commission.

The payment schedule, which contains the transfer of pre-financing and interim payments to Parties, will be handled according to the following:

Funding of costs included in the Consortium Plan will be paid to Parties after receipt from the Funding Authority in separate instalments as agreed below:

- 80 %	- On receipt of the pre-financing, and interim payments by the Funding Authority.
- 20 %	- After the submission of the interim and final report to the Funding Authority

Funding for costs accepted by the Funding Authority will be paid to the Party concerned.

The Coordinator, AMU is entitled to withhold any payments due to a Party identified by a responsible Consortium Body to be in breach of its obligations under this Consortium Agreement or the Grant Agreement or to a Beneficiary which has not yet signed this Consortium Agreement.
The Coordinator, AMU is entitled to recover any payments already paid to a Defaulting Party. The Coordinator, AMU is equally entitled to withhold payments to a Party when this is suggested by or agreed with the Funding Authority.

Section 8: Results

8.0 Completion of the Consortium Database

The web-based catalogue is the key interface accessible to any end user entering the wesite to promote the Resource available for distribution. This catalogue is built from the database filled by each partner.
Each partner will commit himself to fill this database with the Background listed in the Attachment 1, that he intend to share with any end-user.According to the Grant Agreement (Article 24) Background is defined as “material, data, know-how or information (...) that is needed to implement the action or exploit the results”. Because of this need, Access Rights have to be granted in principle, but parties must identify and agree amongst them on the Background for the project.

8.1 Ownership of Results

Results are owned by the Party that generates them.

A Third Party Linked to a Beneficiary and a Signatory Party have the same rights regarding the ownership of Result.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124962

8.2 Joint ownership

Unless otherwise agreed:

- each of the joint owners shall be entitled to use their jointly owned Results for non-commercial research activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and
- each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given:

(a) at least 45calendar days advance notice; and
(b) Fair and Reasonable compensation taking into account each owner's relative ownership.

8.3 Transfer of Results

8.3.1 Each Party may transfer ownership of its own Results following the procedures of the Grant Agreement Article 30.

8.3.2 It may identify specific third parties it intends to transfer the ownership of its Resultsto Attachment 3 to this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to object to a transfer to listed third parties according to the Grant Agreement Article 30.1.

8.3.3 The transferring Party shall, however, at the time of the transfer, inform the other Parties of such transfer and shall ensure that the rights of the other Parties will not be affected by such transfer.
Any addition to Attachment 3 after signature of this Agreement requires a decision of the General Assembly.

8.3.4 The Parties recognize that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give the full 45 calendar days prior notice for the transfer as foreseen in the Grant Agreement.

8.3.5 The obligations above apply only for as long as other Parties still have - or still mayrequest - Access Rights to the Results.

8.4 Dissemination

8.4.1 Dissemination of own Results

8.4.1.1 During the Project and for a period of 1 year after the end of the Project, the dissemination of own Results by one or several Parties including but not restricted to publications and presentations, shall be governed by the procedure of Article 29.1 of the Grant Agreement subject to the following provisions.
Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the publication. Any objection to the planned publication shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination within 30 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted.

8.4.1.2 An objection is justified if
(a) the protection of the objecting Party's Results or Background would be adversely affected
(b) the objecting Party's legitimate academic or commercial interests in relation to the Results or Background would be significantly harmed.

The objection has to include a precise request for necessary modifications.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124963

8.4.1.3 If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion.

The objecting Party can request a publication delay of not more than 90 calendar days from the time it raises such an objection. After 90 calendar days the publication is permitted, provided that Confidential Information of the objecting Party has been removed from the Publication as indicated by the objecting Party.

8.4.1.4 Unless Funding Authority requests or agrees otherwise or unless it is impossible, any dissemination of results (in any form, including electronic) must:
(a) display the EU emblem and
(b) include the following text:
'This project has received funding from the European Union's Horizon 2020 research and innovation programmeunder grant agreement N°653316.

8.4.2 Dissemination of another Party's unpublished Results or Background

A Party shall not include in any dissemination activity another Party's Results or Background without obtaining the owning Party's prior written approval, unless they are already published.

8.4.3 Cooperation obligations

The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree which includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement.

8.4.4 Use of names, logos or trademarks

Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Parties or any of their logos or trademarks without their prior written approval.

Nothing contained in the section 8 shall prevent:

- the submission of a thesis to examiners in accordance with the normal regulations and practice of the Public bodies subject where appropriate to such examiners being bound by confidentiality provisions in no less terms than those outlined in Section 10;
- the obligation of a Party to issue a scientific activity report for the State or administrative organisation it belongs to. This communication shall not constitute a public disclosure, but will be an internal communication to the Party.

8.5 Exclusive licenses

Where a Party wishes to grant an exclusive licence to its Results and seeks the written waiver of the other Parties pursuant to Grant Agreement Article 30.2, the other Parties shall respond to the requesting Party within 45 calendar days of the request. Any Party's failure to respond (whether in the negative or the positive) to the request within such 45 calendar days shall be deemed to constitute written approval of the waiver by the non-responding Party.

Section 9: Access Rights

9.1 Background included

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124964

9.1.1 In Attachment 1, the Parties have identified and agreed on the Background for the Project and have also, where relevant, informed each other that Access to specific Background is subject to legal restrictions or limits.

Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background.

9.1.2 Any Party can propose to the GA to modify its Background in Attachment 1.

9.2 General

Any access to the Resource granted to an external end-user will be provided under the conditions mentionned in a Material Transfer Agreement (MTA).

The MTA aims at enforcing the four following prescriptions:

The provider retains the ownership of the Resource provided. This Property may be transfered to a third party according to a specific contract.

The access is granted for research applications only. The Resource will be used for non-commercial research purpose and academic research purposes only. If a commercial application is foreseen by the recipient a commercial agreement will have to be signed between both parties prior to the delivery of the Resource.

The recipient agrees to retain control over this Resource and further agrees not to transfer it to other people not under his direct supervision without advance written approval of the provider.

1. Whenever the recipient decides that the results of the Research should be published, recipient will acknowledge EVAg partner for the supply of the Resource and will make suitable publicity about the support given by the European Community for the Resource provided.

9.2.1 Each Party shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Project do not knowingly infringe third party property rights.

9.2.2 Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise.

9.2.3 Access Rights shall be free of any administrative transfer costs.

9.2.4 Access Rights are granted on a non-exclusive basis.

9.2.5 Results and Background shall be used only for the purposes for which Access Rights to it have been granted.

9.2.6 All requests for Access Rights shall be made in writing.
The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place.

9.2.7 The requesting Party must show that the Access Rights are Needed.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124965

9.3 Access Rights for implementation

Access Rights to Results and Background Needed for the performance of the own work of a Party under the Project shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1.

9.4 Access Rights for Exploitation

9.4.1 Access Rights to Results if Needed forExploitation of a Party's own Results shall be granted on Fair and Reasonable conditions.

Access rights to Resultsfor internal research activities shall be granted on a royalty-free basis.

9.4.2 Access Rights to Background if Needed for Exploitation of a Party's own Results, including for research on behalf of a third party, shall be granted on Fair and Reasonable conditions.

9.4.3 A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section 9.7.2.1.2, after the termination of the requesting Party's participation in the Project.

9.5 Access Rights for Affiliated Entities

Affiliated Entities have Access Rights under the conditions of the Grant Agreement Articles 25.4 and 31.4

Such Access Rights must be requested by the Affiliated Entity from the Party that holds the Background or Results. Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's Affiliated Entities [listed in attachment 4]. Access Rights to Affiliated Entities shall be granted on Fair and Reasonable conditions and upon written bilateral agreement.

Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by the Parties under the Grant Agreement or this Consortium Agreement as if such Affiliated Entities were Parties.

Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate interests of the Party which owns the Background or the Results.

Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights of the Party to which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such Party.

Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former Affiliated Entity shall lapse.
Further arrangements with Affiliated Entities may be negotiated in separate agreements.

9.6 Additional Access Rights

The Parties agree to negotiate in good faith any additional Access Rights to Results as might be asked for by any Party, upon adequate financial conditions to be agreed.

9.7 Access Rights for Parties entering or leaving the consortium

9.7.1 New Parties entering the consortium

As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124966

9.7.2 Parties leaving the consortium

9.7.2.1 Access Rights granted to a leaving Party

9.7.2.1.1 Defaulting Party

Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the GA to terminate its participation in the consortium.

9.7.2.1.2 Non-defaulting Party

A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access Rights to the Results developed until the date of the termination of its participation.
It may request Access Rights within the period of time specified in Section 9.4.3.

9.7.2.2 Access Rights to be granted by any leaving Party

Any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Party for the whole duration of the Project.

Section 10: Non-disclosure of information

10.1 All information in whatever form or mode of communication, which is disclosed by a Party (the "Disclosing Party") to any other Party (the "Recipient") in connection with the Project during its implementation and which has been explicitly marked as "confidential" at the time of disclosure,or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Party, is "Confidential Information".

10.2 The Recipients hereby undertake in addition and without prejudice to any commitment of non-disclosure under the Grant Agreement, for a period of 4 years after the end of the Project:

- not to use Confidential Information otherwise than for the purpose for which it was disclosed;
- not to disclose Confidential Information to any third party without the prior written consent by the Disclosing Party;
- to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and
- to return to the Disclosing Party on demand all Confidential Information which has been supplied to or acquired by the Recipients including all copies thereof and to delete all information stored in a machine readable form. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations.

10.3 The Recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or third parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of the contractual relationship with the employee or third party.

10.4 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124967

- the Confidential Information becomes publicly available by means other than a breach of the Recipient's confidentiality obligations;
- the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential;
- the Confidential Information is communicated to the Recipient without any obligation of confidence by a third party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidence to the Disclosing Party;
- the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement;
- the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party; or
- the Confidential Information was already known to the Recipient prior to disclosure or
- the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.7 hereunder.

10.5 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care.

10.6 Each Party shall promptly advise the other Party in writing of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse.

10.7 If any Party becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure

- notify the Disclosing Party, and
- comply with the Disclosing Party's reasonable instructions to protect the confidentiality of the information.

Section 11: Miscellaneous

11.1 Attachments, inconsistencies and severability

This Consortium Agreement consists of this core text and
Attachment 1 (Background included)
Attachment 2 (Accession document)
Attachment 3 (List of Third Parties for simplified transfer according to Section 8.2.2)
Attachment 4 (Identified Affiliated Entities)
Attachment 5 (Identified Third Parties with a link to a Party)
Attachement 6 (Trans-national access costs)

In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail.

Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated which fulfils the purpose of the original provision.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124968

11.2 No representation, partnership or agency

Except as otherwise provided in Section 6.4.4, no Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Parties.

11.3 Notices and other communication

Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as listed in the most current address list kept by the Coordinator and the European Project Manager.

Formal notices:
If it is required in this Consortium Agreement (Sections 4.2, 9.7.2.1.1, and 11.4) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a Party and shall either be served personally or sent by mail with recorded delivery or e-mail with acknowledgement of receipt with receipt acknowledgement.

Any change of persons or contact details shall be notified immediately by the respective Party to the Coordinator. The address list shall be accessible to all concerned.

11.4 Assignment and amendments

Except as set out in Section 8.2, no rights or obligations of the Parties arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any third party without the other Parties' prior formal approval.

Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.3.1.2 require a separate written agreement to be signed between all Parties.

11.5 Mandatory national law

Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory law under which the Party is operating.

11.6 Language

This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto.

11.7 Applicable law

This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions.

11.8 Settlement of disputes

The parties shall endeavour to settle their disputes amicably.

Any dispute, controversy or claim arising under, out of or relating to this contract and any subsequent amendments of this contract, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination, as well as non-contractual claims, shall be submitted to mediation in accordance with the WIPO Mediation Rules. The place of mediation shall be Brussels unless otherwise agreed upon.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124969

The language to be used in the mediation shall be English unless otherwise agreed upon.

If, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to the mediation within 60 calendar days of the commencement of the mediation, it shall, upon the filing of a Request for Arbitration by either Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules. Alternatively, if, before the expiration of the said period of 60 calendar days, either Party fails to participate or to continue to participate in the mediation, the dispute, controversy or claim shall, upon the filing of a Request for Arbitration by the other Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules. The place of arbitration shall be Brussels unless otherwise agreed upon. The language to be used in the arbitral proceedings shall be English unless otherwise agreed upon.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124970

Section 12: Signatures

AS WITNESS:
The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written.

UNIVERSITE D'AIX-MARSEILLE (AMU)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124971

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124972

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (APHA)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124973

UNIVERSITAETSKLINIKUM BONN (UKB)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124974

DEPARTMENT OF HEALTH (DH PHE)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124975

UNIVERSITAT BASEL (UNIBAS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124976

UNIVERZA V LJUBLJANI (UL)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124977

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124978

ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124979

ROBERT KOCH-INSTITUT (RKI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124980

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124981

ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124982

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124983

INSTITUT PASTEUR (IP)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124984

FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124985

THE PIRBRIGHT INSTITUTE LBG (TPI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124986

THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124987

AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124988

NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124989

FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124990

SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124991

I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124992

NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124993

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124994

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124995

Attachment 1: Background included

According to the Grant Agreement (Article 24) Background is defined as " material, data, know-how or information (…) that is needed to implement the action or exploit the results". Because of this need, Access Rights have to be granted in principle, but parties must identify and agree amongst them on the Background for the project. This is the purpose of this attachment.

UNIVERSITE D'AIX-MARSEILLE (AMU)

As to UNIVERSITE D'AIX-MARSEILLE (AMU), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)

As to BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ANIMAL AND PLANT HEALTH AGENCY (APHA)

As to ANIMAL AND PLANT HEALTH AGENCY (APHA), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

Commented [MP1]: Access rights for other beneficiaries, for implementing their own tasks under the action
The beneficiaries must give each other access — on a royalty-free basis — to background needed to implement their own tasks under the action, unless the beneficiary that holds the background has — before acceding to the Agreement —:
(a) informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel), or

(b) agreed with the other beneficiaries that access would not be on a royalty-free basis.

Commented [MP2]: Access rights for other beneficiaries, for exploiting their own results
The beneficiaries must give each other access — under fair and reasonable conditions — to background needed for exploiting their own results, unless the beneficiary that holds the background has — before acceding to the Agreement — informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel).
'**Fair and reasonable conditions**' means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the results or background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged. Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124996

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERSITAETSKLINIKUM BONN (UKB)

As to UNIVERSITAETSKLINIKUM BONN (UKB), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

DEPARTMENT OF HEALTH (DH PHE)

As to DEPARTMENT OF HEALTH (DH PHE), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERSITAT BASEL (UNIBAS)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124997

As to UNIVERSITAT BASEL (UNIBAS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERZA V LJUBLJANI (UL)

As to UNIVERZA V LJUBLJANI (UL), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)

As to VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124998

ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)

As to ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ROBERT KOCH-INSTITUT (RKI)

As to ROBERT KOCH-INSTITUT (RKI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)

As to ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_124999

This represents the status at the time of signature of this Consortium Agreement.

ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)

As to ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

As to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

INSTITUT PASTEUR (IP)

As to INSTITUT PASTEUR (IP), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125000

This represents the status at the time of signature of this Consortium Agreement.

FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)

As to FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

THE PIRBRIGHT INSTITUTE LBG (TPI)

As to THE PIRBRIGHT INSTITUTE LBG (TPI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)

As to THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125001

This represents the status at the time of signature of this Consortium Agreement.

AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)

As to AGRICULTURAL RESEARCH COUNCIL (ARC-OVI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)

As to NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)

As to FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125002

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)

As to SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)

As to I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125003

As to NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)

As to WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

As to COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125004

Attachment 2: Accession document

ACCESSION

of a new Party to

EVAg Consortium Agreement, version[X, YYYY-MM-DD]

[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE **Grant Agreement**]

hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and obligations of a Party starting [date].

UNIVERSITE D'AIX-MARSEILLE (AMU)

hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date].

This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives.

[Date and Place]

[INSERT NAME OF THE NEW PARTY]
Signature(s)
Name(s)
Title(s)

[Date and Place]

UNIVERSITE D'AIX-MARSEILLE (AMU)
Signature(s)
Name(s)
Title(s)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125005

Attachment 3: List of Third Parties for simplified transfer according to Section 8.2.2

NONE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125006

Attachment 4: Identified Affiliated Entities according to Section 9.5

NONE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125007

Attachment 5: Identified Third Parties with a link to a Party

List of Third Parties to which transfer of Foreground is possible without prior notice to the other Parties.

NONE

Attachment 6: Trans-national access costs

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125008

Participant number	1a	Organisation short name	AMU-EPV	Short name of Infrastructure	EVAg
Installation number	1	Short name of Installation	AMU EPV 1	Unit of access	Virus
				Min. quantity to be provided	100

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus production and characterization and related quality controls; maintenance costs; consumables	68 500,00
	Total A	**68 500,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Engineer	34,5	103 500,00
		Total B	**103 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	43 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**215 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125009

Participant number	1a	Organisation short name	AMU-EPV	Short name of Infrastructure	EVAg
Installation number	2	Short name of Installation	AMU EPV 2	Unit of access	Derived products
				Min. quantity to be provided	115

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Derived production and characterisation and related quality control; maintenance; consumables	21 900,00
	Total A	**21 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Engineer	11,5	34 500,00
	Total B		**34 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	14 100,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**70 500**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125010

Participant number	1a	Organisation short name	AMU-EPV	Short name of Infrastructure	EVAg
Installation number	3	Short name of Installation	AMU EPV 3	Unit of access	Access facility (one week)
				Min. quantity to be provided	4

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables and security equipment	2 700,00
	Total A	**2 700,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Engineer	1	5 300,00
	Total B		**5 300,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	2 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**10 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125011

Participant number	1b	Organisation short name	AMU AFMB	Short name of Infrastructure	EVAg
Installation number	4	Short name of Installation	AMU AFBM 1	Unit of access	Derived products
				Min. quantity to be provided	60

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for the production of expected accesses (molecular biology kits, biochemistry, bacterial growth…)	19 420,00
	Total A	**19 420,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Engineer	4	28 280,00
	Technician	6	19 550,00
	Total B		**47 830,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			16 812,50
D. **Actual Access Cost for the access offered under the project** = A + B + C			**84 062,50**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125012

Participant number	1b	Organisation short name	AMU AFMB	Short name of Infrastructure	EVAg
Installation number	5	Short name of Installation	AMU AFMB 2	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for molecular Biology/biochemistry	3 000,00
	Access to platform (keys, lab cloth, protection)	1 000,00
	Travel for 10 EU researchers	2 500,00
	Accomodation for 10 weeks	6 000,00
	Total A	**12 500,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Engineer or Researcher	2,5	13 282,00
	Total B		**13 282,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	6 445,50
D. **Actual Access Cost for the access offered under the project** = A + B + C	**32 227,50**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125013

Participant number	2	Organisation short name	BNI	Short name of Infrastructure	EVAg
Installation number	6	Short name of Installation	BNI-BSL3/4	Unit of access	Virus (infectious or inactivated virus or virus-infected cells)
				Min. quantity to be provided	85

A. Direct eligible costs of providing access over the last two years[3] excluding personnel costs	Describe the direct eligible costs[2] for providing access to the installation over the reference period (usually the last two closed financial years[3] preceding the current one) . All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Contracts for maintenance and repair for the functioning of the installation	7 881,92
	Costs of energy power supplied for the installation	60 186,11
	Costs of consumables specifically used for the installation	2 869,31
	Costs of consumables specifically used for providing remote scientific services or access	29 640,80
	Total A	**100 578,14**
	of which subcontracting (A')	***7 881,92***

B. Personnel direct eligible costs needed to provide access over the last two years[3]	Category of staff [4]	Person-Months	Personnel Costs (€)
	Staff Scientist (administration, user support, and virus production)	3	16 719,40
	Technician (virus production and user support)	11	55 721,46
	Laboratory Manager (laboratory administration and user support)	11	78 144,51
	Total B		**150 585,37**

C. Indirect eligible costs: 25% x ([A-A']+B)		60 820,40
D. Total access eligible costs over the last two years[3] = A+B+C		311 983,91
E. Total quantity of access provided to all normal users of the installation (i.e. both internal and external) over the last two years[3]		92
F. Unit cost =D/E		**3391,13**
G. Unit cost charged to the project		**3391,13**
H. Quantity of access offered under the project (over the whole duration of the project)		85
I. **Access Cost on the basis of UC for the access offered under the project = G x H**	92%	**288 246**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125014

Participant number	**2**	**Organisation short name**	**BNI**	**Short name of Infrastructure**	**EVAg**
Installation number	**7**	**Short name of Installation**	**BNI-BSL2**	**Unit of access**	**Derived products Plasmid with viral cDNA**
				Min. quantity to be provided	**30**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Costs of consumables specifically used for providing remote scientific services or access		2 000,00
		Total A	**2 000,00**
		of which subcontracting (A')	

	Category of staff [6]	**Person-Months**	**Personnel Costs (€)**
B. Personnel direct eligible costs needed to provide access to the selected user groups	Technician (production and user support)	2	10 000,00
		Total B	**10 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125015

Participant number	2	Organisation short name	BNI	Short name of Infrastructure	EVAg
Installation number	8	Short name of Installation	BNI-BSL3/4	Unit of access	Access facility (8 hours)
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Contracts for maintenance and repair for the functioning of the installation	500,00
	Costs of energy power supplied for the installation	2 000,00
	Costs of consumables specifically used for the installation	500,00
	Costs of consumables specifically used for providing remote scientific services or access	1 000,00
	Total A	**4 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Staff Scientist (administration, user support, and virus production)	0,5	3 000,00
	Technician (virus production and user support)	0,5	2 000,00
	Laboratory Manager (laboratory administration and user support)	0,5	3 500,00
	Engineer (laboratory maintenance and operation)	0,5	3 500,00
	Total B		**12 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125016

Participant number	3	Organisation short name	APHA	Short name of Infrastructure	EVAg
Installation number	9	Short name of Installation	APHA 1	Unit of access	Virus
				Min. quantity to be provided	32

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	7 311,92
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	96 913,80
	Courier charges for viruses	7 850,60
	QC - PCR & Sequencing cost	1 933,00
	QC - Mycoplasma test	1 538,00
	Total A	**115 547,32**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician	5,12	7 899,48
	Total B		**7 899,48**

C. Indirect eligible costs: 25% x ([A-A']+B)		30 861,70
D. **Actual Access Cost for the access offered under the project** = A + B + C		**154 309**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125017

Participant number	3	Organisation short name	APHA	Short name of Infrastructure	EVAg
Installation number	10	Short name of Installation	APHA 2	Unit of access	Derived products
				Min. quantity to be provided	48

Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	10 967,00
Maintenance of CL4 laboratory for EVA CL4 product TNA provision (2% usage) for 4 years	39 765,00
Courier charges for CL4 products	4 799,00
QC - PCR & Sequencing cost	2 908,00
QC - Mycoplasma test	2 320,00
	60 759,00
of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups

Category of staff [5]	Person-Months	Personnel Costs (€)
Technician	7,68	11 850,00
	Total B	**11 850,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	18 152,25
D. **Actual Access Cost for the access offered under the project** = A + B + C	**90 761**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125018

Participant number	4	Organisation short name	UKB	Short name of Infrastructure	EVAg
Installation number	11	Short name of Installation	UKB 1	Unit of access	Virus
				Min. quantity to be provided	10

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables for virus isolation, titration and characterization (Cell Culture media, FCS, antibiotics; plastics; PCR reagents, Next-generation sequencing reagents)	5 988,00
	Total A	**5 988,00**

	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Technician	3	10 012,00
	Total B		**10 012,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125019

Participant number	4	Organisation short name	UKB	Short name of Infrastructure	EVAg
Installation number	12	Short name of Installation	UKB 2	Unit of access	Derived products
				Min. quantity to be provided	125

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables for diagnostic kits (PCR, cloning, in-vitro transcription reagents; DNA sequencing; cell culture reagents; plastics)		60 500,00
	Consumables for genetically modified animal cell lines for enhanced virus isolation (CRISPR Nuclease Vector, Dynabeads CD4 Positive Isolation kit, Transcription activator–like effector nuclease kit, Genomic Cleavage Detection Kit, hTERT Cell Immortalization Reagents, Transfection Reagents, RACE Kits)		65 000,00
	Total A		**125 500,00**
	of which subcontracting (A') for DNA sequencing		***30 000,00***
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	18	60 100,00
	Post-doc	5	26 400,00
	Total B		**86 500,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			45 500,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**257 500**

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125020

Participant number	**4**	**Organisation short name**	**UKB**	**Short name of Infrastructure**	**EVAg**
Installation number	**13**	**Short name of Installation**	**UKB 3**	**Unit of access**	**Access to facility**
				Min. quantity to be provided	**4**
Access provision period (usually the project life-time)			**from:**		**to:**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables for arbovirus isolation training (Cell Culture media, FCS, antibiotics; plastics; PCR reagents, Next-generation sequencing reagents)	5 325,00
	Consumables for Virus detection training (plastics; PCR reagents, cloning reagents, in-vitro transciption reagents, Next-generation sequencing reagents)	9 000,00
	Total A	**14 325,00**

B. Personnel direct eligible costs needed to provide access to the selected user groups	***of which subcontracting (A')***		
	Category of staff [6]	**Person-Months**	**Personnel Costs (€)**
	Technician	2	6 675,00
	Total B		**6 675,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 250,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**26 250**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125021

Participant number	5	Organisation short name	DH PHE 1	Short name of Infrastructure	EVAg
Installation number	14	Short name of Installation	PHE 1	Unit of access	Virus
				Min. quantity to be provided	24

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for virus culture including tissue culture media,	6 000,00
	Plastic ware for virus culture	3 150,00
	General lab consumables for CL2, CL3 & CL4 (gloves, disinfectant, gauntlets, waste containers,	1 000,00
	Total A	**10 150,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Wet lab virology staff band 7	8	28 850,00
	Total B		**28 850,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 750,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**48 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125022

Participant number	5	Organisation short name	DH PHE	Short name of Infrastructure	EVAg
Installation number	15	Short name of Installation	PHE 2	Unit of access	Derived products.
				Min. quantity to be provided	30

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus culture reagents	1 000,00
	Protein expression reagents	3 000,00
	Nucleic acid extraction kits	1 000,00
	PCR probes and primers	6 300,00
	Total A	**11 300,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Molecular virologist	3	12 200,00
	Total B		**12 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 875,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 375**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125023

Participant number	6	Organisation short name	UNIBAS	Short name of Infrastructure	EVAg
Installation number	16	Short name of Installation	UNIBAS 1	Unit of access	Virus (classes 2, 3)
				Min. quantity to be provided	13

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation process	12 350,00
	Quality control of the product	670,00
	Characterization and verification of entities	1 300,00
	Safety- and protective equipment	600,00
	BSL-maintenance	400,00
	Total A	**15 320,00**
	of which subcontracting (A')	***0,00***

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technical personnel	1,5	8 200,00
		Total B	**8 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 880,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 400**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125024

Participant number	**6**	**Organisation short name**	**UNIBAS**	**Short name of Infrastructure**	**EVAg**
Installation number	**17**	**Short name of Installation**	**UNIBAS 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**62**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Entity preparation from specimens	21 960,00
	Characterization, verification of entities	850,00
	Preparation of expression vector, antibody	400,00
	Protective equipment and measures (clinical material)	400,00
	Total A	**23 610,00**
	of which subcontracting (A')	

	Category of staff [6]	**Person-Months**	**Personnel Costs (€)**
B. Personnel direct eligible costs needed to provide access to the selected user groups	Cost for Technical Personnel (production, quality assurance, maintenance of integrity of product)	3	16 366,00
	Total B		**16 366,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 994,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**49 970**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125025

Participant number	6	Organisation short name	UNIBAS	Short name of Infrastructure	EVAg
Installation number	18	Short name of Installation		Unit of access	Access facility
				Min. quantity to be provided	4

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Training and Access to BSL-3 facility	8 600,00
	Total A	**8 600,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technical personnel	1	5 480,00
	Total B		**5 480,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 520,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**17 600**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125026

Participant number	7	Organisation short name	UL	Short name of Infrastructure	EVAg
Installation number	19	Short name of Installation	UL1	Unit of access	Virus
				Min. quantity to be provided	40

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation	9 000,00
	Virus characterization and related quality controls	8 000,00
	Maintenance and utilities	16 200,00
	Protective equipment	1 800,00
	Total A	**35 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Professor	2	11 800,00
	Technician	8	14 200,00
	PhD	7	17 400,00
	PhD student	1	1 600,00
	Total B		**45 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	20 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**100 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125027

Participant number	**7**	**Organisation short name**	**UL**	**Short name of Infrastructure**	**EVAg**
Installation number	**20**	**Short name of Installation**	**UL 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**100**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs

Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
Virus preparation	2 000,00
Preparation of viral derived products	24 000,00
Maintenance and utilities	6 900,00
Protective equipment	800,00
Total A	**33 700,00**
of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups

Category of staff [5]	**Person-Months**	**Personnel Costs (€)**
Professor	1,5	8 800,00
Technician	2,5	4 400,00
PhD	12	29 900,00
PhD student	2	3 200,00
Total B		**46 300,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	20 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**100 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125028

Participant number	7	Organisation short name	UL	Short name of Infrastructure	EVAg
Installation number	21	Short name of Installation	UL 3	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation	5 610,00
	Virus characterization and related quality controls	4 000,00
	Maintenance and utilities	3 400,00
	Protective equipment	1 600,00
	Travel - plane ticket (10 person)	6 030,00
	Travel - hotel (10x 2 nights)	2 000,00
	Total A	**22 640,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Professor	0,57	3 400,00
	Technician	1,72	3 100,00
	PhD	1,72	4 300,00
	Total B		**10 800,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 360,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**41 800**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125029

Participant number	8	**Organisation short name**	**IVSAS**	**Short name of Infrastructure**	**EVAg**
Installation number	22	**Short name of Installation**	**IVSAS 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**30**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Cell culture reagents and plastic-ware for virus isolation and production	7 000,00
	Cell culture reagents and plastic-ware for virus quantification assays	4 000,00
	Molecular biology reagents and plastic-ware for quality control	4 000,00
	Sequencing costs for quality control	3 000,00
	Total A	**20 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	13	13 000,00
	Post-doc	8	9 600,00
	Senior scientist	3	5 400,00
	Total B		**28 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	12 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**60 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125030

Participant number	8	Organisation short name	IVSAS	Short name of Infrastructure	EVAg
Installation number	23	Short name of Installation	IVSAS 2	Unit of access	Derived products
					60

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Molecular biology reagents and plastic ware for derived products production	10 000,00
	qRT-PCR reagents and plastic ware for quantification assays	5 000,00
	Total A	**15 000,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Techincian	9	9 000,00
	Post-doc	5	6 000,00
	Senior scientist	2	3 600,00
	Total B		**18 600,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 400,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**42 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125031

Participant number	9	Organisation short name	INMI	Short name of Infrastructure	EVAg
Installation number	24	Short name of Installation	INMI 1	Unit of access	Virus
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumable (culture medium, sequencing materials)	10 000,00
	Total A	**10 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Researcher	1	5 200,00
	Techician	2	7 200,00
	Total B		**12 400,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 600,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**28 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125032

Participant number	**9**	**Organisation short name**	**INMI**	**Short name of Infrastructure**	**EVAg**
Installation number	**25**	**Short name of Installation**	**INMI 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**40**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumable	10 000,00
	Total A	**10 000,00**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Researcher	5	27 200,00
	Techician	5	18 800,00
	Total B		**46 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	14 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**70 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125033

Participant number	**9**	**Organisation short name**	**INMI**	**Short name of Infrastructure**	**EVAg**
Installation number	**26**	**Short name of Installation**	**INMI 3**	**Unit of access**	**Access facility**
				Min. quantity to be provided	**10**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Travel (6 for Europe:550 € each; 4 outside Europe, 1500 € each); accommodation and subsistence not provided)	9 000,00
	Total A	**9 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Researchers	2	10 500,00
	Techicians	5,5	20 500,00
	Total B		**31 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125034

Participant number	**10**	**Organisation short name**	**RKI**	**Short name of Infrastructure**	**EVAg**
Installation number	**27**	**Short name of Installation**	**RKI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**22**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves etc.	3 820,00
	Total A	**3 820,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	5	21 780,00
	Total B		**21 780,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	6 400,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**32 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125035

Participant number	10	Organisation short name	RKI	Short name of Infrastructure	EVAg
Installation number	28	Short name of Installation	RKI 2	Unit of access	Derived products
				Min. quantity to be provided	130

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves, freezedrying stabilizer, vials etc.	19 600,00
	Total A	**19 600,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Technician	13	58 800,00
	Total B		**58 800,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			19 600,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**98 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125036

Participant number	10	Organisation short name	RKI	Short name of Infrastructure	EVAg
Installation number	29	Short name of Installation	RKI 3	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves, vials, safety equipment etc.	4 000,00
	Total A	**4 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician, scientist	2	12 000,00
	Total B		**12 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125037

Participant number	11	Organisation short name	EMC	Short name of Infrastructure	EVAg
Installation number	30	Short name of Installation	EMC 1	Unit of access	Virus
				Min. quantity to be provided	74

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables lab ware, maintenance	21 200,00
	Total A	**21 200,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	18	74 000,00
	Total B		**74 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	23 800,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**119 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125038

Participant number	**11**	**Organisation short name**	**EMC**	**Short name of Infrastructure**	**EVAg**
Installation number	**31**	**Short name of Installation**	**EMC 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**88**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs		
Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
Consumables		10 200,00
Total A		**10 200,00**
of which subcontracting (A')		

B. Personnel direct eligible costs needed to provide access to the selected user groups		
Category of staff [5]	**Person-Months**	**Personnel Costs (€)**
Technician	6,6	27 200,00
Total B		**27 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 350,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**46 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125039

Participant number	11	Organisation short name	EMC	Short name of Infrastructure	EVAg
Installation number	32	Short name of Installation	EMC 3	Unit of access	Access facility
				Min. quantity to be provided	16

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumabels	6 000,00
	Total A	**6 000,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Technician	2	12 000,00
	Postdoc	1,0	5 800,00
	Total B		**17 800,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 950,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125040

Participant number	**13**	**Organisation short name**	**INSERM**	**Short name of Infrastructure**	**EVAg**
Installation number	**33**	**Short name of Installation**	**Inserm 1**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**90**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Laboratory consumables		4 000,00
	Specific BSL4 consommables (suits, disposal coverall etc..)		3 000,00
	Contract of maintenance of the facility (relative to the time specifically dedicated to the project)		3 000,00
	Total A		**10 000,00**
	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Ingenior	1,5	7 200,00
	Assistant ingenior	1,5	6 300,00
	Total B		**13 500,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			5 875,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**29 375**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125041

Participant number	**13**	**Organisation short name**	**INSERM**	**Short name of Infrastructure**	**EVAg**
Installation number	**34**	**Short name of Installation**	**Inserm 2**	**Unit of access**	**Access facility (half day)**
				Min. quantity to be provided	**60**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Laboratory consumables		2 500,00
	Specific BSL4 consommables (suits, disposal coverall etc..)		2 500,00
	Contract of maintenance of the facility (relative to the time specifically dedicated to the project)		3 750,00
	Total A		**8 750,00**
	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Research ingenior	0,5	3 130,00
	Ingenior	1	4 800,00
	Total B		**7 930,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			4 170,00
D. Actual Access Cost for the access offered under the project = A + B + C			**20 850**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125042

Participant number	**14**	**Organisation short name**	**IP**	**Short name of Infrastructure**	**EVA**
Installation number	**35**	**Short name of Installation**	**IP 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**60**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables	21 250,00
	Total A	**21 250,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Post Doc	7	35 000,00
	Technician	9	39 750,00
		Total B	**74 750,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	24 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**120 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125043

Participant number	**14**	**Organisation short name**	**IP**	**Short name of Infrastructure**	**EVA**
Installation number	**36**	**Short name of Installation**	**IP 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**15**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables	2 580,00
	Total A	**2 580,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Post doc	1,5	7 500,00
	Total B		**7 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	2 520,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**12 600**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125044

Participant number	14	Organisation short name	IP	Short name of Infrastructure	EVA
Installation number	37	Short name of Installation	IP 3	Unit of access	Access
				Min. quantity to be provided	4

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables	2 540,00
	Total A	**2 540,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Post doc	2.5	12 500,00
	Total B		**12 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 760,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**18 800**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125045

Participant number	15	Organisation short name	FLI	Short name of Infrastructure	EVAg
Installation number	38	Short name of Installation	FLI 1	Unit of access	on virus sample
				Min. quantity to be provided	25

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables: media and supplements, cells, plastic material, cell culture material, PCR reagents, NGS, freeze-drying material, packaging material	30 750,00
	Total A	**30 750,00**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups			
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	7 687,50
D. **Actual Access Cost for the access offered under the project** = A + B + C	**38 437**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125046

Participant number	**15**	**Organisation short name**	**FLI**	**Short name of Infrastructure**	**EVAg**
Installation number	**39**	**Short name of Installation**	**FLI 2**	**Unit of access**	**derived products: one sample of a monoclonal antibody or of a suitable cell line**
				Min. quantity to be provided	**40**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	mAbs : consumables: cells, media and supplements, cell culture material, PCR reagents, packaging material	8 000,00
	Cells : consumables: media and supplements, cell culture and plastic material, PCR reagents, antibodies, sequencing reagents, chemicals, packaging material	12 000,00
	Total A	**20 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**25 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125047

Participant number	15	Organisation short name	FLI	Short name of Infrastructure	EVAg
Installation number	40	Short name of Installation	FLI 3	Unit of access	Access facility 1 animal room for 7 days with animals and corresponding labaratory space for sample preparation before and after the trial for 2 days (9 days in total)
				Min. quantity to be provided	30

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	purchasing 75 animals cattles for animal testing	22 500,00
	purchasing 75 animals pigs for animal testing	5 250,00
	animal feed for 7 days cattles	1 038,00
	animal feed for 7 days pigs	321,90
	consumables	3 000,00
	Travel costs for 30 visits (1 scientist per trip: 4x train tickets - 360€; 2xflghts - 400€; 10 nights accomodation - 900€; daily allowance for 10 days - 320€	60 000,00
	Total A	**92 109,90**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Animal care taking (41,25 h per testing cycle) cattles	4,33	12 419,55
	Animal care taking (25,5 h per testing cycle) pigs	2,67	7 678,20
	Total B		**20 097,75**

C. Indirect eligible costs: 25% x ([A-A']+B)	28 051,91
D. **Actual Access Cost for the access offered under the project** = A + B + C	**140 260**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125048

Participant number	**16**	**Organisation short name**	**TPI**	**Short name of Infrastructure**	**EVAg**
Installation number	**41**	**Short name of Installation**	**TPI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**15**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables: media and supplements, cells, plastic material, cell culture material, PCR raegents, NGS, etc.	36 000,00
	Total A	**36 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**45 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125049

Participant number	16	Organisation short name	TPI	Short name of Infrastructure	EVAg
Installation number	42	Short name of Installation	TPI 2	Unit of access	Derived products
				Min. quantity to be provided	145

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables: Biting Midges, Culicoides nubeculosus (gender unsorted), Culicoides sonorensis (gender unsorted), Tick cell line, etc.	26 662,46
	Total A	**26 662,46**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	120 hours of Eric Denison's time for the biting midges work	0,80	3 184,81
	Total B		**3 184,81**

C. Indirect eligible costs: 25% x ([A-A']+B)	7 461,82
D. **Actual Access Cost for the access offered under the project** = A + B + C	**37 309**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125050

Participant number	**16**	**Organisation short name**	**TPI**	**Short name of Infrastructure**	**EVAg**
Installation number	**43**	**Short name of Installation**	**TPI 3**	**Unit of access**	**Access facility (1 week)**
				Min. quantity to be provided	**40**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Total price for testing samples by VNT for 2 FMD vaccine studies, 3 time points	4 154,96
	Shipments	2 389,14
	Consumables eg Rompun, Blood tubes	211,20
	Weekly cost for ISO 10 (1 unit = 1 animal isolation room for 1 week)	239 583,33
	Supply of animals - 34 calves 6 months+	25 221,32
	Total A	**271 559,96**
	of which subcontracting (A')	

	Category of staff [6]	**Person-Months**	**Personnel Costs (€)**
B. Personnel direct eligible costs needed to provide access to the selected user groups	Post Doc (Time to organise the experiment and ship samples, arrange regulatory clearance etc)	1,5	9 900,41
	Total B		**9 900,41**
C. Indirect eligible costs: 25% x ([A-A']+B)			70 365,09
D. **Actual Access Cost for the access offered under the project** = A + B + C			**351 82**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125051

Participant number	17	Organisation short name	UTMB	Short name of Infrastructure	EVAg
Installation number	44	Short name of Installation	UTMB	Unit of access	Virus
				Min. quantity to be provided	25

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	2 400,00
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	32 000,00
	Courier charges for viruses	2 600,00
	QC - PCR & Sequencing cost	2 000,00
	QC - Mycoplasma test	1 000,00
	Total A	**40 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125052

Participant number	**18**	**Organisation short name**	**ARC-OVI**	**Short name of Infrastructure**	**EVAg**
Installation number	**45**	**Short name of Installation**	**ARC-OVI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**20**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Microbiological analysis: Mycoplasma analysis, Endotoxins and other bacterial contaminants. DNA/RNA extractions, RT-PCR, dNTPs (100mM each), Superscript iii Reverse transcriptase (10000U), Molecular grade water (1L), RNase Inhibitor (2 500U), RNase H (5000U), PCR Taq polymerase (250U), PCR tubes, One step-Real time PCR, Iscript one-step RT-PCR kit for probes, Strip tubes, Optical strip caps, Dual labelled probes, Full genome sequencing and sanger sequencing.	7 000,00
	Total A	**7 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Research Scientist	12	25 000,00
	Total B		**25 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**40 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125053

Participant number	**18**	**Organisation short name**	**ARC-OVI**	**Short name of Infrastructure**	**EVAg**
Installation number	**46**	**Short name of Installation**	**ARC-OVI 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**10**

		Eligible Costs (€)
	PCR products for diagnostic tests and infected cell culture	1 200,00
	Total A	**1 200,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Research Scientist	2	4 000,00
	Total B		**4 000,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			1 300,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**6 500,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125054

Participant number	19	Organisation short name	NICD-NHLS	Short name of Infrastructure	EVAg
Installation number	47	Short name of Installation	NICD	Unit of access	Virus (infectious or inactivated virus or virus-infected cells)
				Min. quantity to be provided	15

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Contracts for maintenance and repair for the functioning of the installation	2 600,00
	Costs of energy power supplied for the installation	15 000,00
	Costs of consumables specifically used for the installation	1 000,00
	Costs of consumables specifically used for providing remote scientific services or access	8 000,00
	Total A	**26 600,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Research Scientist	3	6 000,00
	Total B		**6 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 150,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**40 750,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125055

Participant number	20	Organisation short name	IPVE	Short name of Infrastructure	EVAg
Installation number	48	Short name of Installation	IPVE	Unit of access	Derived products
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125056

Participant number	21	Organisation short name	RII	Short name of Infrastructure	EVAg
Installation number	49	Short name of Installation	RII	Unit of access	Derived products
				Min. quantity to be provided	60

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	10 000,00
	Isolation of viruses	2 400,00
	Lyophylization	1 400,00
	Antigenic analysis	5 200,00
	Sequencing	
	Conservation (maintaining the collection)	1 800,00
	Database, networking	4 200,00
	Shipment to the end-user	4 000,00
	Characterization of the biological properties of isolates	7 000,00
	Total A	**36 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Kuzmina M.I. Technician	5	600,00
	Stolyarov K. IT-engineer	8	3 400,00
	Total B		**4 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125057

Participant number	22	Organisation short name	Mechnikov RIVS	Short name of Infrastructure	EVAg
Installation number	50	Short name of Installation	Mechnikov RIVS	Unit of access	Derived products
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125058

Participant number	22	Organisation short name	Mechnikov RIVS	Short name of Infrastructure	EVAg
Installation number	50	Short name of Installation	Mechnikov RIVS	Unit of access	Derived products
				Min. quantity to be provided	25

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125059

Participant number	**23**	**Organisation short name**	**China CDC**	**Short name of Infrastructure**	**EVAg**
Installation number	**52**	**Short name of Installation**	**China CDC 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**50**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Costs of consumables used for RNA/cDNA and diagnosis reagents preparations	30 000,00
	Costs of equipment maintenance and cleaning	5 000,00
	Total A	**35 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Chief	8	4 000,00
	PHD	12	9 000,00
	Technician	6	2 000,00
	Total B		**15 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	12 500,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**62 500**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125060

Participant number	**24**	**Organisation short name**	**WIV**	**Short name of Infrastructure**	**EVAg**
Installation number	**53**	**Short name of Installation**	**WIV 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**22**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	BSL-2 virus strains contain consumables and maintains cost	24 000,00
	BSL-3 virus strains contain consumables and maintains cost	20 000,00
	Total A	**44 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	11 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**55 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125061

Participant number	**24**	**Organisation short name**	**WIV**	**Short name of Infrastructure**	**EVAg**
Installation number	**54**	**Short name of Installation**	**WIV 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**21**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	DNA/RNA materials contain consumables and maintains cost	7 000,00
	recombinant proteins/Antibodies contain consumables and maintains cost	7 700,00
	Total A	**14 700,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 675,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**18 375,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125062

Participant number	**25**	**Organisation short name**	**CSIRO**	**Short name of Infrastructure**	**EVAg**
Installation number	**55**	**Short name of Installation**	**CSIRO**	**Unit of access**	**Virus**
				Min. quantity to be provided	**25**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	2 800,00
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	30 000,00
	Courier charges for viruses	3 000,00
	QC - PCR & Sequencing cost	2 000,00
	QC - Mycoplasma test	1 000,00
	Total A	**38 800,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Scientific staff	2	1 200,00
	Total B		**1 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_125063



653316 — EVAg

Consortium agreement

Version 1, 2015/06/09



Version 1.1 - May 2014

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091765

Table of Content

CONSORTIUM AGREEMENT

Section 1: Definitions 4
Section 2: Purpose 5
Section 3: Entry into force, duration and termination 5
Section 4: Responsibilities of Parties 6
Section 5: Liability towards each other 7
Section 6: Governance structure 8
Section 7: Financial provisions 15
Section 8: Results 17
Section 9: Access Rights 19
Section 10: Non-disclosure of information 22
Section 11: Miscellaneous 23
Section 12: Signatures 26
Attachment 1: Background included 51
Attachment 2: Accession document 60
Attachment 3: List of Third Parties for simplified transfer according to Section 8.2.2 61
Attachment 4: Identified Affiliated Entities according to Section 9.5 62
Attachment 5: Identified Third Parties with a link to a Party 63
Attachment 6: Trans-national access costs 63

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091766

CONSORTIUM AGREEMENT

THIS CONSORTIUM AGREEMENT is based upon
REGULATION (EU) No 1290/2013 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 11 December 2013 laying down the rules for the participation and dissemination in "Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020)" (hereinafter referred to as "the Rules"), and the European Commission Multi-beneficiary General Model Grant Agreement and its Annexes, and is made on 1st of April 2015, hereinafter referred to as the Effective Date

BETWEEN:

1. **UNIVERSITE D'AIX-MARSEILLE (AMU), the COORDINATOR**
   1.a. INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (IRD)
   Linked Third Party of AMU, acting on behalf of the AMU Laboratory EPV (Emergence des Pathologies Virales - UMR D190)
   1.b. CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
   Linked Third Party of AMU, acting on behalf of the AMU Laboratory AFMB (Architecture et Fonction des Macromolécules Biologiques - UMR 7257)
2. BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)
3. ANIMAL AND PLANT HEALTH AGENCY (APHA)
4. UNIVERSITAETSKLINIKUM BONN (UKB)
5. DEPARTMENT OF HEALTH (DH PHE)
6. UNIVERSITAT BASEL (UNIBAS)
7. UNIVERZA V LJUBLJANI (UL)
8. VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)
9. ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)
10. ROBERT KOCH-INSTITUT (RKI)
11. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)
12. ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)
13. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
14. INSTITUT PASTEUR (IP)
15. FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)
16. THE PIRBRIGHT INSTITUTE LBG (TPI)
17. THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)
18. AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)
19. NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)
20. FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)
21. SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)
22. I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)
23. NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)
24. WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)
25. COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

hereinafter, jointly or individually, referred to as "Parties" or "Party"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091767

relating to the Action entitled

"European Virus Archive goes global"

in short

EVAg

hereinafter referred to as "Project"

WHEREAS:
The Parties, having considerable experience in the field concerned, have submitted a proposal for the Project to the Funding Authority as part of the Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020).
The Parties wish to specify or supplement binding commitments among themselves in addition to the provisions of the specific Grant Agreement to be signed by the Parties and the EC (hereinafter "Grant Agreement").
The Parties are aware that this Consortium Agreement is based upon the DESCA model consortium agreement.

NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

Section 1: Definitions

1.1 Definitions

Words beginning with a capital letter shall have the meaning defined either herein or in the Rules or in the Grant Agreement including its Annexes.

1.2 Additional Definitions

"Consortium Plan"

Consortium Plan means the description of the action and the related agreed budget as first defined in the Grant Agreement and which may be updated by the General Assembly.

"Funding Authority"

Funding Authority means the body awarding the grant for the Project.

"Defaulting Party"

Defaulting Party means a Party which the General Assembly has identified to be in breach of this Consortium Agreement and/or the Grant Agreement as specified in Section 4.2 of this Consortium Agreement.

"Needed" means:

For the implementation of the Project:
Access Rights are needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be impossible, significantly delayed, or require significant additional financial or human resources.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091768

For exploitation of own Results:
Access Rights are needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible.

"Resource" means:
Material, data, know-how or information

"Third Party Linked to a Beneficiary" means:
Legal entities, either public or private, represented in the Grant Agreement by a Signatory Party according to the terms of the Article 14 of the Grant Agreement. This Signatory Party and the Third Party Linked to a Beneficiary it represents shall be partners in a "Joint Research Unit".

"Joint Research Unit" means:
Unincorporated entity created by a written contract between a Signatory Party and the legally linked Third Party to a Beneficiary it represents and listed, if any, in the Article 14 of the Grant Agreement and in the Attachment 5.
According to the Article 14 and Article 26.3 of the Grant Agreement, CNRS is a Linked Third Party of UNIVERSITE D'AIX-MARSEILLE (AMU) with rights on results of AMU AFMB (UMR 7257) and IRD is a Linked Third Party of UNIVERSITE D'AIX-MARSEILLE (AMU) with rights on results of AMU EPV (UMR D190).

"Member" means:
The Principal Investigator of each Benecifiarie's team involved in the project.

"Research Infrastructure", (RI) means:
Facilities, resources and services used by the scientific community for conducting research and innovation in their fields.

"Installation" means:
A part or a service of a research infrastructure that could be used independently from the rest. A research infrastructure consists of one or more installations.

"Trans-national Access", (TNA) means:
A "free of charge" provision of access to a research infrastructure to selected researchers or research teams working in a country other than the country where the research infrastructure is located. (Specific provisions for Access to RI are defined in Article 16 of the Grant Agreement).

Section 2: Purpose

The purpose of this Consortium Agreement is to specify with respect to the Project the relationship among the Parties, in particular concerning the organisation of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution.

Section 3: Entry into force, duration and termination

3.1 Entry into force

An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091769

This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this Consortium Agreement.

An entity becomes a Party to the Consortium Agreement upon signature of the accession document (Attachment 2) by the new Party and the Coordinator. Such accession shall have effect from the date identified in the accession document.

3.2 Duration and termination

This Consortium Agreement shall continue in full force and effect until complete fulfilment of all obligations undertaken by the Parties under the Grant Agreement and under this Consortium Agreement.
However, this Consortium Agreement or the participation of one or more Parties to it may be terminated in accordance with the terms of this Consortium Agreement.

If the Grant Agreement is not signed by the Funding Authority or a Party, or is terminated, or if a Party's participation in the Grant Agreement is terminated, this Consortium Agreement shall automatically terminate in respect of the affected Party/ies, subject to the provisions surviving the expiration or termination under Section 3.3 of this Consortium Agreement.

3.3 Survival of rights and obligations

The provisions relating to Access Rights and Confidentiality, for the time period mentioned therein, as well as for Liability, Applicable law and Settlement of disputes shall survive the expiration or termination of this Consortium Agreement.
Termination shall not affect any rights or obligations of a Party leaving the Consortium incurred prior to the date of termination, unless otherwise agreed between the General Assembly and the leaving Party. This includes the obligation to provide all input, deliverables and documents for the period of its participation.

In case of one Party's withdrawal, the other Parties shall use reasonable endeavours to reach a timely agreement on how to reallocate the requesting Party's tasks so that the overall objectives of the Project can still be met after the Party's withdrawal. Following the decisions above the Coordinator shall promptly notify the Funding Authority, for its approval.

Section 4: Responsibilities of Parties

4.1 General principles

Each Party undertakes :

- to take part in the efficient implementation of the Project, and to cooperate, perform and fulfil, promptly and on time, all of its obligations under the Grant Agreement and this Consortium Agreement as may be reasonably required from it and in a manner of good faith as prescribed by Belgian law.
- to notify promptly, in accordance with the governance structure of the Project, any significant information, fact, problem or delay likely to affect the Project.

Each Party shall:

- promptly provide all information reasonably required by a Consortium Body or by the Coordinator to carry out its tasks.
- take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Parties.

4.2 Breach

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091770

In the event that the Executive Board (EB) identifies a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement (e.g. improper implementation of the project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed by the General Assembly, will give formal notice to such Party requiring that such breach will be remedied within 30 calendar days.

If such breach is substantial and is not remedied within that period or is not capable of remedy, the General Assembly may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof which may include termination of its participation.

4.3 Involvement of third parties

A Party that enters into a subcontract or otherwise involves third parties (including but not limited to Affiliated Entities and Third Parties with a link to a Party) in the Project remains responsible for carrying out its relevant part of the Project and for such third party's compliance with the provisions of this Consortium Agreement and of the Grant Agreement. It has to ensure that the involvement of third parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the Grant Agreement.

Section 5: Liability towards each other

5.1 No warranties

In respect of any information or materials (incl. Results and Background) supplied by one Party to another under the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of third parties.

Therefore,

- the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and
- no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a third party resulting from any other Party (or its Affiliated Entities) exercising its Access Rights.

5.2 Limitations of contractual liability

No Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a wilful actor by a breach of confidentiality.

A Party's aggregate liability towards the other Parties collectively shall be limited to once the Party's share of the total costs of the Project as identified in Annex 2 of the Grant Agreement provided such damage was not caused by a wilful actor gross negligence.

The terms of this Consortium Agreement shall not be construed to amend or limit any Party's statutory liability.

5.3 Damage caused to third parties

Each Party shall be solely liable for any loss, damage or injury to third parties resulting from the performance of the said Party's obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background.

5.4 Force Majeure

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091771

No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure.
Each Party will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the competent Consortium Bodies.

Section 6: Governance structure

6.1 General structure

The organisational structure of the Consortium shall comprise the following Consortium Bodies:

The General Assembly (GA) is the ultimate decision-making body of the consortium.

The Executive Board (EB) as the supervisory body for the execution of the Project has two distinct roles. First, the EB will prepare and propose political and strategic orientations of the project to the General Assembly. Second, it will implement the strategy adopted for the Project by the General Assembly. The EB will consult the External Expert Advisory Board (EEAB).

The Coordinator, AMU, is the legal entity acting as the intermediary between the Parties and the Funding Authority. The Coordinator, AMU, shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in the Grant Agreement and this Consortium Agreement.

The Management Support Team (MST) assists the GA and is in charge of the day-to-day project management, and will provide support and assistance to the different project bodies.

The EEAB assists the EB and the GA.

The WP Coordinators (WPC) and the Tasks Leaders are responsible respectively for the performance of their work packages and for their work packages tasks.

6.2 General operational procedures for all Consortium Bodies

6.2.1 Representation in meetings

Any Party which is a member of a Consortium Body (hereinafter referred to as "Member"):
- should be represented at any meeting of such Consortium Body.
- may appoint a substitute or a proxy to attend and vote at any meeting.
- and shall participate in a cooperative manner in the meetings.

6.2.2 Preparation and organisation of meetings

- 6.2.2.1 Convening meetings:

The chairperson of a Consortium Body shall convene meetings of that Consortium Body.

	Ordinary meeting	Extraordinary meeting
General Assembly	At least once a year	At any time upon written request of the EB or 1/3 of the Members of the GA
Executive Board	At least twice a year	At any time upon written request of any Member of the EB
Technical Meeting	At least once a year	N/A

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091772

- 6.2.2.2 Notice of a meeting:

The chairperson of a Consortium Body shall give notice in writing of a meeting to each Member of that Consortium Body as soon as possible and no later than the minimum number of days precedings the meeting as indicated below.

	Ordinary meeting	Extraordinary meeting
General Assembly	45 calendar days	15 calendar days
Executive Board	14 calendar days	7calendar days
Technical Meeting	45 calendar days	N/A

- 6.2.2.3 Sending the agenda:

The chairperson of a Consortium Body shall send each Member of that Consortium Body a written (original) agenda no later than the minimum number of days precedings the meeting as indicated below.

General Assembly	21 calendar days for ordinary meeting, 10 calendar days for extraordinary meeting
Executive Board	7 calendar days for ordinary meeting, 4 calendar days for extraordinary meeting
Technical Meeting	21 calendar days for ordinary meeting

6.2.2.4 Adding agenda items:

Any agenda item requiring a decision by the Members of a Consortium Body must be identified as such on the agenda.
Any Member of a Consortium Body may add an item to the original agenda by written notification to all of the other Members of that Consortium Body up to the minimum number of days precedings the meeting as indicated below.

General Assembly	14 calendar days for ordinary meeting, 7 calendar days for extraordinary meeting
Executive Board	2 calendar days for ordinary and extraordinary meetings
Technical Meeting	2 calendar days for ordinary meeting

6.2.2.5 During a meeting the Members of a Consortium Body present or represented can unanimously agree to add a new item to the original agenda.

6.2.2.6 Any decision may also be taken without a meeting if the Coordinator circulates to all Members of the Consortium Body a written document which is then agreed by the defined majority (see Section 6.2.3) of all Members of the Consortium Body. Such document shall include the deadline for responses.

6.2.2.7 Meetings of each Consortium Body may also be held by teleconference or other telecommunication means.

6.2.2.8 Decisions will only be binding once the relevant part of the minutes has been accepted according to Section 6.2.5.

6.2.3 Voting rules and quorum

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091773

6.2.3.1 The GA shall not deliberate and decide validly unless 2/3 of the 26 members are present or represented (quorum). Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast(one vote per member(26), one for the Coordinator, e.g. 18/27 for the plenary sessions; one vote per member(16), one for the Coordinator for sessions restricted to EU members, eg: 13/17).
If the quorum is not reached, the chairperson of the GA shall convene another ordinary meeting within 15 calendar days. If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting which shall be entitled to decide even if less than the quorum of Members are present or represented.

6.2.3.2 The EB shall not deliberate and decide validly unless the 1/3 of the 26 members are present or represented (quorum). Decisions shall be taken by a simple majority is not reached.

6.2.3.3 Defaulting Parties may not vote.

6.2.4 Veto rights

6.2.4.1 A Member which can show that its own work, time for performance, costs, liabilities, intellectual property rights or other legitimate interests would be severely affected by a decision of a Consortium Body may exercise a veto with respect to the corresponding decision or relevant part of the decision.

6.2.4.2 When the decision is foreseen on the original agenda, a Member may veto such a decision during the meeting only.

6.2.4.3 When a decision has been taken on a new item added to the agenda before or during the meeting, a Member may veto such decision during the meeting and within 15 days after the draft minutes of the meeting are sent.

6.2.4.4 In case of exercise of veto, the Members of the related Consortium Body shall make every effort to resolve the matter which occasioned the veto to the general satisfaction of all Members.

6.2.4.5 A Party may not veto decisions relating to its identification as a Defaulting Party. The Defaulting Party may not veto decisions relating to its participation and termination in the consortium or the consequences of them.

6.2.4.6 A Party requesting to leave the consortium may not veto decisions relating thereto.

6.2.5 Minutes of meetings

6.2.5.1 The chairperson of a Consortium Body shall produce written minutes of each meeting which shall be the formal record of all decisions taken. He shall send draft minutes to all Members within 30 calendar days of the meeting.

6.2.5.2 The minutes shall be considered as accepted if, within 15 calendar days from sending, no Member has sent an objection in writing to the chairperson with respect to the accuracy of the draft of the minutes.

6.2.5.3 Accepted minutes shall be sent to all the Members of the Consortium Body, and to the Coordinator, who shall safeguard them. If requested the Coordinator shall provide authenticated duplicates to Parties.

6.3 Specific Operational procedures for the Consortium Bodies

6.3.1 General Assembly

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091774

In addition to the rules described in Section 6.2, the following rules apply:

6.3.1.1Members

6.3.1.1.1 The GA shall consist of one representative of each Member (hereinafter GA Member).

6.3.1.1.2 Each GA Member shall be deemed to be duly authorised to deliberate, negotiate and decide on all matters listed in Section 6.3.1.2 of this Consortium Agreement.

6.3.1.1.3 The Coordinator shall chair all meetings of the GA, unless decided otherwise in a meeting of the General Assembly.

6.3.1.1.4 The Parties agree to abide by all decisions of the GA.

This does not prevent the Parties to submit a dispute for resolution in accordance with the provisions of settlement of disputes in Section 11.8.

6.3.1.2 Decisions

The GA shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein. In addition, all proposals made by the EB shall also be considered and decided upon by the GA.

The following decisions shall be taken by the GA:

Content, finances and intellectual property rights:
- Proposals for changes to Annexes 1 and 2 of the Grant Agreement to be agreed by the Funding Authority.
- Changes to the Consortium Plan.
- Modifications to Attachment 1 (Background Included).
- Additions to Attachment 3 (List of Third Parties for simplified transfer according to Section 8.2.2).
- Additions to Attachement 4 (Identified Affiliated Entities).
- Additions to Attachment5 (Identified Third Parties with a link to a Party).
- Additions to Attachement 6 (Trans-national access costs).

Evolution of the consortium
- Entry of a new Party to the consortium and approval of the settlement on the conditions of the accession of such a new Party.
- Withdrawal of a Party from the consortium and the approval of the settlement on the conditions of the withdrawal.
- Identification of a breach by a Party of its obligations under this Consortium Agreement or the Grant Agreement.
- Declaration of a Party to be a Defaulting Party.
- Remedies to be performed by a Defaulting Party.
- Termination of a Defaulting Party's participation in the consortium and measures relating thereto.
- Proposal to the Funding Authority for a change of the Coordinator.
- Proposal to the Funding Authority for suspension of all or part of the Project.
- Proposal to the Funding Authority for termination of the Project and the Consortium Agreement.

In the case of abolished tasks as a result of a decision of the GA, Members shall rearrange the tasks of the Parties concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled.

Appointments

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091775

On the basis of the Grant Agreement, the appointment if necessary of:

EB Members

6.3.2 Executive Board

In addition to the rules described in Section 6.2, the following rules apply:

6.3.2.1 Members

The EB shall consist of the Coordinator and all the Members (26) appointed by the GA (hereinafter Executive Members).

The Coordinator shall chair all meetings of the EB, unless decided otherwise in a majority of two-thirds.

6.3.2.2 Minutes of meetings

Minutes of EB meetings, once accepted, shall be sent by the Coordinator to the GA Members for information.

6.3.2.3 Tasks

6.3.2.3.1 The EB shall prepare the meetings, propose decisions and prepare the agenda of the GA according to Section 6.3.1.2.

6.3.2.3.2 It shall seek a consensus among the Parties.

6.3.2.3.3 The EB shall be responsible for the proper execution and implementation of the decisions of the General Assembly.

6.3.2.3.4 The EB shall monitor the effective and efficient implementation of the Project.

6.3.2.3.5 In addition, the EB shall collect information at least every 6 months on the progress of the Project, examine that information to assess the compliance of the Project with the Consortium Plan and, if necessary, propose modifications of the Consortium Plan to the General Assembly.

6.3.2.3.6 The EB shall:
- agree on the Members of the MST, upon a proposal by the Coordinator.
- support the Coordinator in preparing meetings with the Funding Authority and in preparing related data and deliverables.
- prepare the content and timing of press releases and joint publications by the Consortium or proposed by the Funding Authority in respect of the procedures of the Grant Agreement Article 29.

6.3.2.3.7 In the case of abolished tasks as a result of a decision of the General Assembly, the EBshall advise the GA on ways to rearrange tasks and budgets of the Parties concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled.

6.4 Coordinator

6.4.1 The Coordinatorshall be the intermediary between the Parties and the Funding Authority and shall perform all tasks assigned to it as described in the Grant Agreement and in this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091776

6.4.2 In particular, the Coordinator shall be responsible for:

- monitoring compliance by the Parties with their obligations.
- collecting, reviewing to verify consistency and submitting reports, other deliverables (including financial statements and related certifications) and specific requested documents to the Funding Authority.
- transmitting documents and information connected with the Project to any other Parties concerned
- administering the financial contribution of the Funding Authority and fulfilling the financial tasks described in Section 7.3.
- providing, upon request, the Parties with official copies or originals of documents which are in the sole possession of the Coordinator when such copies or originals are necessary for the Parties to present claims.
-

If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertheless submit the other parties' project deliverables and all other documents required by the Grant Agreement to the Funding Authority in time.

- If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertherless submit the other parties' project deliverables and all other documents required by the Grant Agreement to the Funding Authority in time.

6.4.3 If the Coordinator fails in its coordination tasks, the GA may propose to the Funding Authority to change the Coordinator.

6.4.4 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium, unless explicitly stated otherwise in the Grant Agreement or this Consortium Agreement.

6.4.5 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement and in the Grant Agreement.

6.5 Management Support Team

The Management Support Team shall be proposed by the Coordinator.The Management Support Team consists of the Coordinator, a European Project Manager assisted by the European Research Grant Department of AMU, the Business developer and TNA manager, the Webmaster and the Quality manager. It shall assist and facilitate the work of the EB for executing the decisions of the GA as well as the day-to-day management of the Project.

The European Project Manager shall assist and facilitate the work of the Coordinator for executing the decisions of the Management Support Team as well as the day-to-day management of the Project and shall be responsible for:

- keeping the address list of Members and other contact persons updated and available.
- preparing the meetings, drafting the minutes of the meetings and monitoring the implementation of decisions taken at meetings.
- transmitting promptly documents and information connected with the Project.

The Business Developer and TNA manager shall be responsible for:

- organizing an appropriate valuation of the resource generated by the consortium amongst industrial private companies, in conjunction with the Partner's institutions.
- assisting the GA and the EB on any issues related to Resource Dissemination.
- interacting with the industrial sector concerning management of the accessible resource.
- identifying and creating of relationships with pharmaceutical and biotechnology companies or any other private parties that may be interested in EVAg outputs.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091777

- deciding , with the agreement of the GA, on promotion and dissemination within the industrial sector.
- Initiating exploitation plans (deliverables), in collaboration with each partner.

The Webmaster shall be responsible for implementing following the EVA project a secure web facility to centralize all the communication and service tools related to the EVAg consortium activities with the following objectives:

- On line web-based catalogue.
- Promotion of the EVAg organisation and services provided through on-line presentations.
- Information on results available.
- Information on access conditions (research agreement, material transfer agreement, and licence).
- Updated list of the EVAg Publications.

The Quality Manager shall be responsible for:

- creating a working group comprising the quality managers of each Partner.
- defining, agreeing, improving and implementing a set of quality guidelines to be followed by the biological and virological resource centres within EVAg.
- handling Issue and Risk Management.
- working in close contact with WP coordinators, he will be responsible for the anticipation of any changes in the project.
- proposing to the Executive Board mitigation solutions and, upon decision of the GA.
- implementing the best solution for the achievement of project objectives. Each risk will be identified, analysed, its consequences measured and solutions anticipated, where appropriate.

6.6 External Expert Advisory Board (EEAB)

The EEAB shall be made up of a minimum of 11 members appointed by the General Assembly, with a minimum of 4 Scientific community representatives and a minimum of7 stakeholders representatives.

The EEAB shallassist the consortium and will be in charge of:

- Advising on scientific and ethical issues.
- Ensuring the involvement of industry at an early stage of the project to prepare the development phase beyond the project. It will also represent the end users and other stakeholders.
- Addressing recommendations related to the management of actions carried out by the consortium in this very specific field (emerging zoonotic diseases, human viral epidemicity/pandemicity, risk analysis).
- Assisting and Advising the EB and the GA.

Prior to the beginning of its activity, each EEAB member will be requested to complete a non-disclosure agreement (NDA), which terms shall be not less stringent than those stipulated in this Consortium Agreement, no later than 30 calendar days after their nomination or before any confidential information will be exchanged, whichever date is earlier. The EEAB shall be invited to take part in the GA meetings once a year. The EEAB shall also be invited to delegate its President to join the EB meetings and to contribute to opinions on how we can achieve the objectives and milestones for the following year. He/She will also be responsible for submitting yearly activity report on EEAB activities.

6.7 EVAg legal status

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091778

The parties commit to participate to the conceptual and legal design of the future form of the EVAg infrastucture, to establish a business model to prepare a long term sustainable funding for the EVAg consortium, as well as to become member of the EVAg legal entity.

Section 7: Financial provisions

7.1 General Principles

7.1.1 Distribution of Financial Contribution

The financial contribution of the Funding Authority to the Project shall be distributed by the Coordinator according to:

- the Consortium Plan.
- the approval of reports by the Funding Authority, and
- the provisions of payment in Section 7.3.

A Signatory Party shall be funded only for its tasks and for the tasks of its linked Third Party it may represents carried out in accordance with the Consortium Plan.

7.1.2 Justifying Costs

In accordance with its own usual accounting and management principles and practices, each Party shall be solely responsible for justifying its costs with respect to the Project towards the Funding Authority. Neither the Coordinator nor any of the other Parties shall be in any way liable or responsible for such justification of costs towards the Funding Authority.

7.1.3 Funding Principles

Trans-national access costs (TNA) :
TNA will be solely reimbursed on the basis of the eligible costs actually and solely incurred for providing access to the selected user groups and on the basis of Attachment 6Trans-national access costs.

Four scenarios of reimbursement are to be considered:

- Scenario 1: Trans-national access costs are lower than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is equal to the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely incurred for providing access to the selected user groups

- Scenario 2: Trans-national access costs are higher than the estimated cost in Attachment 6 and and the amount of access actually provided under the conditions of the grant agreement is less than the minimum amount foreseen in the grant agreement.The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups on the basis of the average costs defined in attachment 6.
-
- Scenario 3: Trans-national access costs are higher than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is equal to the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups and ceilled at the maximum amount defined in attachment 6.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091779

- The real cost of the provided accesses might be reimbursed after the final payment of the Funding Authority, and only if there is still some available budget within the project maximum EU financial contribution.
-
- Scenario 4: Trans-national access costs are higher than the estimated cost in Attachment 6 and the amount of access actually provided under the conditions of the grant agreement is higher than the minimum amount foreseen in the grant agreement.
- The access provider will be funded in accordance with its eligible costs actually and solely inccured for providing access to the selected user groups and ceilled at the maximum amount defined in attachment 6.
- The real cost of the provided accesses might be reimbursed after the final payement of the Funding Authority, and only if there is still some available budget within the project maximum EU financial contribution.

For other costs than TNA the costs will be reimbursed on the following basis :

- A Party which spends less than its allocated share of the budget as set out in the Consortium Plan or will be funded in accordance with its actual duly justified eligible costs only.
- A Party that spends more than its allocated share of the budget as set out in the Consortium Plan will be funded only in respect of duly justified eligible costs up to an amount not exceeding that share.

The estimated budget breakdown indicated in Annex 2 of the Grant Agreement may be adjusted by transfers of amounts between beneficiaries or between budget categories (or both). This does not require an amendment according to Article 55 of the Grant Agreement, if the action is implemented as described in Annex 1 of the Grant Agreement.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1 of the Grant Agreement, unless such additional subcontracts are approved by an amendment or in accordance with Article 13 of the Grant Agreement.

7.1.4 Financial Consequences of the termination of the participation of a Party

A Party leaving the consortium shall refund all payments it has received except the amount of contribution accepted by the Funding Authority or another contributor. Furthermore a Defaulting Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Parties in order to perform its and their tasks.

7.2 Budgeting

The budget set out in the Consortium Plan shall be valued in accordance with the usual accounting and management principles and practices of the respective Parties.

7.3 Payments

7.3.1 Payments to Parties are the exclusive tasks of the Coordinator.

In particular, the Coordinator shall:

- notify the Party concerned promptly of the date and composition of the amount transferred to its bank account, giving the relevant references.
- perform diligently its tasks in the proper administration of any funds and in maintaining financial accounts.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091780

- undertake to keep the Community financial contribution to the Project separated from its normal business accounts, its own assets and property, except if the Coordinator is a Public Body or is not entitled to do so due to statutory legislation.
- With reference to Articles 21.2 and 21.3.2 of the Grant Agreement, no Party shall before the end of the Project receive more than its allocated share of the maximum grant amount from which the amounts retained by the Funding Authority for the Guarantee Fund and for the final payment have been deducted.

7.3.2 Payment schedule

Protisvalor Méditerranée, acting on behalf of the Coordinator as defined in the option of the Article 41.2 of the Grant Agreement, undertakes to transfer the appropriate sums to the respective Parties, in accordance with the Grant Agreement, the Consortium Agreement and the modalities agreed by the GA with minimum delay from the receipt thereof from the European Commission.

The payment schedule, which contains the transfer of pre-financing and interim payments to Parties, will be handled according to the following:

Funding of costs included in the Consortium Plan will be paid to Parties after receipt from the Funding Authority in separate instalments as agreed below:

- 80 %	- On receipt of the pre-financing, and interim payments by the Funding Authority.
- 20 %	- After the submission of the interim and final report to the Funding Authority

Funding for costs accepted by the Funding Authority will be paid to the Party concerned.

The Coordinator, AMU is entitled to withhold any payments due to a Party identified by a responsible Consortium Body to be in breach of its obligations under this Consortium Agreement or the Grant Agreement or to a Beneficiary which has not yet signed this Consortium Agreement.
The Coordinator, AMU is entitled to recover any payments already paid to a Defaulting Party. The Coordinator, AMU is equally entitled to withhold payments to a Party when this is suggested by or agreed with the Funding Authority.

Section 8: Results

8.0 Completion of the Consortium Database

The web-based catalogue is the key interface accessible to any end user entering the wesite to promote the Resource available for distribution. This catalogue is built from the database filled by each partner.
Each partner will commit himself to fill this database with the Background listed in the Attachment 1, that he intend to share with any end-user.According to the Grant Agreement (Article 24) Background is defined as “material, data, know-how or information (...) that is needed to implement the action or exploit the results”. Because of this need, Access Rights have to be granted in principle, but parties must identify and agree amongst them on the Background for the project.

8.1 Ownership of Results

Results are owned by the Party that generates them.

A Third Party Linked to a Beneficiary and a Signatory Party have the same rights regarding the ownership of Result.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091781

8.2 Joint ownership

Unless otherwise agreed:

- each of the joint owners shall be entitled to use their jointly owned Results for non-commercial research activities on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and
- each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given:

(a) at least 45calendar days advance notice; and
(b) Fair and Reasonable compensation taking into account each owner's relative ownership.

8.3 Transfer of Results

8.3.1 Each Party may transfer ownership of its own Results following the procedures of the Grant Agreement Article 30.

8.3.2 It may identify specific third parties it intends to transfer the ownership of its Resultsto Attachment 3 to this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to object to a transfer to listed third parties according to the Grant Agreement Article 30.1.

8.3.3 The transferring Party shall, however, at the time of the transfer, inform the other Parties of such transfer and shall ensure that the rights of the other Parties will not be affected by such transfer.
Any addition to Attachment 3 after signature of this Agreement requires a decision of the General Assembly.

8.3.4 The Parties recognize that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give the full 45 calendar days prior notice for the transfer as foreseen in the Grant Agreement.

8.3.5 The obligations above apply only for as long as other Parties still have - or still mayrequest - Access Rights to the Results.

8.4 Dissemination

8.4.1 Dissemination of own Results

8.4.1.1 During the Project and for a period of 1 year after the end of the Project, the dissemination of own Results by one or several Parties including but not restricted to publications and presentations, shall be governed by the procedure of Article 29.1 of the Grant Agreement subject to the following provisions.
Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the publication. Any objection to the planned publication shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination within 30 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted.

8.4.1.2 An objection is justified if
(a) the protection of the objecting Party's Results or Background would be adversely affected
(b) the objecting Party's legitimate academic or commercial interests in relation to the Results or Background would be significantly harmed.

The objection has to include a precise request for necessary modifications.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091782

8.4.1.3 If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion.

The objecting Party can request a publication delay of not more than 90 calendar days from the time it raises such an objection. After 90 calendar days the publication is permitted, provided that Confidential Information of the objecting Party has been removed from the Publication as indicated by the objecting Party.

8.4.1.4 Unless Funding Authority requests or agrees otherwise or unless it is impossible, any dissemination of results (in any form, including electronic) must:
(a) display the EU emblem and
(b) include the following text:
'This project has received funding from the European Union's Horizon 2020 research and innovation programmeunder grant agreement N°653316.

8.4.2 Dissemination of another Party's unpublished Results or Background

A Party shall not include in any dissemination activity another Party's Results or Background without obtaining the owning Party's prior written approval, unless they are already published.

8.4.3 Cooperation obligations

The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree which includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement.

8.4.4 Use of names, logos or trademarks

Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Parties or any of their logos or trademarks without their prior written approval.

Nothing contained in the section 8 shall prevent:

- the submission of a thesis to examiners in accordance with the normal regulations and practice of the Public bodies subject where appropriate to such examiners being bound by confidentiality provisions in no less terms than those outlined in Section 10;
- the obligation of a Party to issue a scientific activity report for the State or administrative organisation it belongs to. This communication shall not constitute a public disclosure, but will be an internal communication to the Party.

8.5 Exclusive licenses

Where a Party wishes to grant an exclusive licence to its Results and seeks the written waiver of the other Parties pursuant to Grant Agreement Article 30.2, the other Parties shall respond to the requesting Party within 45 calendar days of the request. Any Party's failure to respond (whether in the negative or the positive) to the request within such 45 calendar days shall be deemed to constitute written approval of the waiver by the non-responding Party.

Section 9: Access Rights

9.1 Background included

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091783

9.1.1 In Attachment 1, the Parties have identified and agreed on the Background for the Project and have also, where relevant, informed each other that Access to specific Background is subject to legal restrictions or limits.

Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background.

9.1.2 Any Party can propose to the GA to modify its Background in Attachment 1.

9.2 General

Any access to the Resource granted to an external end-user will be provided under the conditions mentionned in a Material Transfer Agreement (MTA).

The MTA aims at enforcing the four following prescriptions:

The provider retains the ownership of the Resource provided. This Property may be transfered to a third party according to a specific contract.

The access is granted for research applications only. The Resource will be used for non-commercial research purpose and academic research purposes only. If a commercial application is foreseen by the recipient a commercial agreement will have to be signed between both parties prior to the delivery of the Resource.

The recipient agrees to retain control over this Resource and further agrees not to transfer it to other people not under his direct supervision without advance written approval of the provider.

1. Whenever the recipient decides that the results of the Research should be published, recipient will acknowledge EVAg partner for the supply of the Resource and will make suitable publicity about the support given by the European Community for the Resource provided.

9.2.1 Each Party shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Project do not knowingly infringe third party property rights.

9.2.2 Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise.

9.2.3 Access Rights shall be free of any administrative transfer costs.

9.2.4 Access Rights are granted on a non-exclusive basis.

9.2.5 Results and Background shall be used only for the purposes for which Access Rights to it have been granted.

9.2.6 All requests for Access Rights shall be made in writing.
The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place.

9.2.7 The requesting Party must show that the Access Rights are Needed.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091784

9.3 Access Rights for implementation

Access Rights to Results and Background Needed for the performance of the own work of a Party under the Project shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1.

9.4 Access Rights for Exploitation

9.4.1 Access Rights to Results if Needed forExploitation of a Party's own Results shall be granted on Fair and Reasonable conditions.

Access rights to Resultsfor internal research activities shall be granted on a royalty-free basis.

9.4.2 Access Rights to Background if Needed for Exploitation of a Party's own Results, including for research on behalf of a third party, shall be granted on Fair and Reasonable conditions.

9.4.3 A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section 9.7.2.1.2, after the termination of the requesting Party's participation in the Project.

9.5 Access Rights for Affiliated Entities

Affiliated Entities have Access Rights under the conditions of the Grant Agreement Articles 25.4 and 31.4

Such Access Rights must be requested by the Affiliated Entity from the Party that holds the Background or Results. Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's Affiliated Entities [listed in attachment 4]. Access Rights to Affiliated Entities shall be granted on Fair and Reasonable conditions and upon written bilateral agreement.

Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by the Parties under the Grant Agreement or this Consortium Agreement as if such Affiliated Entities were Parties.

Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate interests of the Party which owns the Background or the Results.

Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights of the Party to which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such Party.

Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former Affiliated Entity shall lapse.
Further arrangements with Affiliated Entities may be negotiated in separate agreements.

9.6 Additional Access Rights

The Parties agree to negotiate in good faith any additional Access Rights to Results as might be asked for by any Party, upon adequate financial conditions to be agreed.

9.7 Access Rights for Parties entering or leaving the consortium

9.7.1 New Parties entering the consortium

As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091785

9.7.2 Parties leaving the consortium

9.7.2.1 Access Rights granted to a leaving Party

9.7.2.1.1 Defaulting Party

Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the GA to terminate its participation in the consortium.

9.7.2.1.2 Non-defaulting Party

A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access Rights to the Results developed until the date of the termination of its participation.
It may request Access Rights within the period of time specified in Section 9.4.3.

9.7.2.2 Access Rights to be granted by any leaving Party

Any Party leaving the Project shall continue to grant Access Rights pursuant to the Grant Agreement and this Consortium Agreement as if it had remained a Party for the whole duration of the Project.

Section 10: Non-disclosure of information

10.1 All information in whatever form or mode of communication, which is disclosed by a Party (the "Disclosing Party") to any other Party (the "Recipient") in connection with the Project during its implementation and which has been explicitly marked as "confidential" at the time of disclosure,or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Party, is "Confidential Information".

10.2 The Recipients hereby undertake in addition and without prejudice to any commitment of non-disclosure under the Grant Agreement, for a period of 4 years after the end of the Project:

- not to use Confidential Information otherwise than for the purpose for which it was disclosed;
- not to disclose Confidential Information to any third party without the prior written consent by the Disclosing Party;
- to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and
- to return to the Disclosing Party on demand all Confidential Information which has been supplied to or acquired by the Recipients including all copies thereof and to delete all information stored in a machine readable form. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations.

10.3 The Recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or third parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of the contractual relationship with the employee or third party.

10.4 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091786

- the Confidential Information becomes publicly available by means other than a breach of the Recipient's confidentiality obligations;
- the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential;
- the Confidential Information is communicated to the Recipient without any obligation of confidence by a third party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidence to the Disclosing Party;
- the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement;
- the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party; or
- the Confidential Information was already known to the Recipient prior to disclosure or
- the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.7 hereunder.

10.5 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care.

10.6 Each Party shall promptly advise the other Party in writing of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse.

10.7 If any Party becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure

- notify the Disclosing Party, and
- comply with the Disclosing Party's reasonable instructions to protect the confidentiality of the information.

Section 11: Miscellaneous

11.1 Attachments, inconsistencies and severability

This Consortium Agreement consists of this core text and
Attachment 1 (Background included)
Attachment 2 (Accession document)
Attachment 3 (List of Third Parties for simplified transfer according to Section 8.2.2)
Attachment 4 (Identified Affiliated Entities)
Attachment 5 (Identified Third Parties with a link to a Party)
Attachement 6 (Trans-national access costs)

In case the terms of this Consortium Agreement are in conflict with the terms of the Grant Agreement, the terms of the latter shall prevail. In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail.

Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated which fulfils the purpose of the original provision.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091787

11.2 No representation, partnership or agency

Except as otherwise provided in Section 6.4.4, no Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Parties.

11.3 Notices and other communication

Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as listed in the most current address list kept by the Coordinator and the European Project Manager.

Formal notices:
If it is required in this Consortium Agreement (Sections 4.2, 9.7.2.1.1, and 11.4) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorised representative of a Party and shall either be served personally or sent by mail with recorded delivery or e-mail with acknowledgement of receipt with receipt acknowledgement.

Any change of persons or contact details shall be notified immediately by the respective Party to the Coordinator. The address list shall be accessible to all concerned.

11.4 Assignment and amendments

Except as set out in Section 8.2, no rights or obligations of the Parties arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any third party without the other Parties' prior formal approval.

Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.3.1.2 require a separate written agreement to be signed between all Parties.

11.5 Mandatory national law

Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory law under which the Party is operating.

11.6 Language

This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto.

11.7 Applicable law

This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions.

11.8 Settlement of disputes

The parties shall endeavour to settle their disputes amicably.

Any dispute, controversy or claim arising under, out of or relating to this contract and any subsequent amendments of this contract, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination, as well as non-contractual claims, shall be submitted to mediation in accordance with the WIPO Mediation Rules. The place of mediation shall be Brussels unless otherwise agreed upon.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091788

The language to be used in the mediation shall be English unless otherwise agreed upon.

If, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to the mediation within 60 calendar days of the commencement of the mediation, it shall, upon the filing of a Request for Arbitration by either Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules. Alternatively, if, before the expiration of the said period of 60 calendar days, either Party fails to participate or to continue to participate in the mediation, the dispute, controversy or claim shall, upon the filing of a Request for Arbitration by the other Party, be referred to and finally determined by arbitration in accordance with the WIPO Expedited Arbitration Rules. The place of arbitration shall be Brussels unless otherwise agreed upon. The language to be used in the arbitral proceedings shall be English unless otherwise agreed upon.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091789

Section 12: Signatures

AS WITNESS:
The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives in separate signature pages the day and year first above written.

UNIVERSITE D'AIX-MARSEILLE (AMU)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091790

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091791

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (APHA)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091792

UNIVERSITAETSKLINIKUM BONN (UKB)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091793

DEPARTMENT OF HEALTH (DH PHE)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091794

UNIVERSITAT BASEL (UNIBAS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091795

UNIVERZA V LJUBLJANI (UL)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091796

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091797

ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091798

ROBERT KOCH-INSTITUT (RKI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091799

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091800

ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091801

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091802

INSTITUT PASTEUR (IP)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091803

FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091804

THE PIRBRIGHT INSTITUTE LBG (TPI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091805

THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091806

AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091807

NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091808

FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091809

SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091810

I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091811

NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)

Name:

Title:

Date:

Signature and stamp:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091812

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091813

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

Name:

Title:

Date:

Signature and stamp:

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091814

Attachment 1: Background included

According to the Grant Agreement (Article 24) Background is defined as " material, data, know-how or information (…) that is needed to implement the action or exploit the results". Because of this need, Access Rights have to be granted in principle, but parties must identify and agree amongst them on the Background for the project. This is the purpose of this attachment.

UNIVERSITE D'AIX-MARSEILLE (AMU)

As to UNIVERSITE D'AIX-MARSEILLE (AMU), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI)

As to BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN (BNI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ANIMAL AND PLANT HEALTH AGENCY (APHA)

As to ANIMAL AND PLANT HEALTH AGENCY (APHA), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

Commented [MP1]: Access rights for other beneficiaries, for implementing their own tasks under the action
The beneficiaries must give each other access — on a royalty-free basis — to background needed to implement their own tasks under the action, unless the beneficiary that holds the background has — before acceding to the Agreement —:
(a) informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel), or

(b) agreed with the other beneficiaries that access would not be on a royalty-free basis.

Commented [MP2]: Access rights for other beneficiaries, for exploiting their own results
The beneficiaries must give each other access — under fair and reasonable conditions — to background needed for exploiting their own results, unless the beneficiary that holds the background has — before acceding to the Agreement — informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel).
'**Fair and reasonable conditions**' means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the results or background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged. Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3.

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091815

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERSITAETSKLINIKUM BONN (UKB)

As to UNIVERSITAETSKLINIKUM BONN (UKB), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

DEPARTMENT OF HEALTH (DH PHE)

As to DEPARTMENT OF HEALTH (DH PHE), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERSITAT BASEL (UNIBAS)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091816

As to UNIVERSITAT BASEL (UNIBAS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

UNIVERZA V LJUBLJANI (UL)

As to UNIVERZA V LJUBLJANI (UL), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS)

As to VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED (IVSAS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091817

ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI)

As to ISTITUTO NAZIONALE MALATTIE INFETTIVE L.SPALLANZANI – IRCCS (INMI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ROBERT KOCH-INSTITUT (RKI)

As to ROBERT KOCH-INSTITUT (RKI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)

As to ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091818

This represents the status at the time of signature of this Consortium Agreement.

ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC)

As to ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM (LUMC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

As to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

INSTITUT PASTEUR (IP)

As to INSTITUT PASTEUR (IP), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091819

This represents the status at the time of signature of this Consortium Agreement.

FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI)

As to FRIEDRICH LOEFFLER INSTITUT – BUNDESFORSCHUNGSINSTITUT FUER TIERGESUNDHEIT (FLI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

THE PIRBRIGHT INSTITUTE LBG (TPI)

As to THE PIRBRIGHT INSTITUTE LBG (TPI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB)

As to THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON (UTMB), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091820

This represents the status at the time of signature of this Consortium Agreement.

AGRICULTURAL RESEARCH COUNCIL (ARC-OVI)

As to AGRICULTURAL RESEARCH COUNCIL (ARC-OVI), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS)

As to NATIONAL HEALTH LABORATORY SERVICES (NICD-NHLS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE)

As to FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES (IPVE), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091821

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII)

As to SCIENTIFIC RESEARCH INSTITUTE OF INFLUENZA OF THE MINISTRY OF HEALTHCARE AND SOCIAL DEVELOPMENT OF THE RUSSIAN FEDERATION (RII), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS)

As to I.I. MECHNIKOV SCIENTIFC RESEARCH INSTITUTE FOR VACCINES AND SERA (MECHNIKOV RIVS), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091822

As to NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (China CDC), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV)

As to WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES (WIV), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO)

As to COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (CSIRO), it is agreed between the parties that, to the best of their knowledge (*please choose)*,

The following background is hereby identified and agreed upon for the Project. In addition a number of products to be added in the data base will be mentinnoed. Specific limitations and/or conditions, shall be as mentioned hereunder:

Describe Background	Specific limitations and/or conditions for implementation (Article 25.2 Grant Agreement)	Specific limitations and/or conditions for exploitation (Article 25.3 Grant Agreement)

This represents the status at the time of signature of this Consortium Agreement.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091823

Attachment 2: Accession document

ACCESSION

of a new Party to

EVAg Consortium Agreement, version[X, YYYY-MM-DD]

[OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE **Grant Agreement**]

hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and obligations of a Party starting [date].

UNIVERSITE D'AIX-MARSEILLE (AMU)

hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date].

This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives.

[Date and Place]

[INSERT NAME OF THE NEW PARTY]
Signature(s)
Name(s)
Title(s)

[Date and Place]

UNIVERSITE D'AIX-MARSEILLE (AMU)
Signature(s)
Name(s)
Title(s)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091824

Attachment 3: List of Third Parties for simplified transfer according to Section 8.2.2

NONE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091825

Attachment 4: Identified Affiliated Entities according to Section 9.5

NONE

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091826

Attachment 5: Identified Third Parties with a link to a Party

List of Third Parties to which transfer of Foreground is possible without prior notice to the other Parties.

NONE

Attachment 6: Trans-national access costs

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091827

Participant number	**1a**	**Organisation short name**	**AMU-EPV**	**Short name of Infrastructure**	**EVAg**
Installation number	**1**	**Short name of Installation**	**AMU EPV 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**100**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Virus production and characterization and related quality controls; maintenance costs; consumables	68 500,00
	Total A	**68 500,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Engineer	34,5	103 500,00
		Total B	**103 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	43 000,00
D. Actual Access Cost for the access offered under the project = A + B + C	**215 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091828

Participant number	1a	Organisation short name	AMU-EPV	Short name of Infrastructure	EVAg
Installation number	2	Short name of Installation	AMU EPV 2	Unit of access	Derived products
				Min. quantity to be provided	115

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Derived production and characterisation and related quality control; maintenance; consumables	21 900,00
	Total A	**21 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Engineer	11,5	34 500,00
	Total B		**34 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	14 100,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**70 500**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091829

Participant number	1a	Organisation short name	AMU-EPV	Short name of Infrastructure	EVAg
Installation number	3	Short name of Installation	AMU EPV 3	Unit of access	Access facility (one week)
				Min. quantity to be provided	4

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables and security equipment	2 700,00
	Total A	**2 700,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Engineer	1	5 300,00
	Total B		**5 300,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	2 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**10 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091830

Participant number	1b	Organisation short name	AMU AFMB	Short name of Infrastructure	EVAg
Installation number	4	Short name of Installation	AMU AFBM 1	Unit of access	Derived products
				Min. quantity to be provided	60

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for the production of expected accesses (molecular biology kits, biochemistry, bacterial growth…)	19 420,00
	Total A	**19 420,00**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Engineer	4	28 280,00
	Technician	6	19 550,00
	Total B		**47 830,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			16 812,50
D. **Actual Access Cost for the access offered under the project** = A + B + C			**84 062,50**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091831

Participant number	1b	Organisation short name	AMU AFMB	Short name of Infrastructure	EVAg
Installation number	5	Short name of Installation	AMU AFMB 2	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for molecular Biology/biochemistry	3 000,00
	Access to platform (keys, lab cloth, protection)	1 000,00
	Travel for 10 EU researchers	2 500,00
	Accomodation for 10 weeks	6 000,00
	Total A	**12 500,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Engineer or Researcher	2,5	13 282,00
	Total B		**13 282,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	6 445,50
D. **Actual Access Cost for the access offered under the project** = A + B + C	**32 227,50**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091832

Participant number	2	Organisation short name	BNI	Short name of Infrastructure	EVAg
Installation number	6	Short name of Installation	BNI-BSL3/4	Unit of access	Virus (infectious or inactivated virus or virus-infected cells)
				Min. quantity to be provided	85

	Describe the direct eligible costs[2] for providing access to the installation over the reference period (usually the last two closed financial years[3] preceding the current one) . All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access over the last two years[3] excluding personnel costs	Contracts for maintenance and repair for the functioning of the installation	7 881,92
	Costs of energy power supplied for the installation	60 186,11
	Costs of consumables specifically used for the installation	2 869,31
	Costs of consumables specifically used for providing remote scientific services or access	29 640,80
	Total A	**100 578,14**
	of which subcontracting (A')	***7 881,92***

	Category of staff [4]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access over the last two years[3]	Staff Scientist (administration, user support, and virus production)	3	16 719,40
	Technician (virus production and user support)	11	55 721,46
	Laboratory Manager (laboratory administration and user support)	11	78 144,51
	Total B		**150 585,37**

C. Indirect eligible costs: 25% x ([A-A']+B)			60 820,40
D. Total access eligible costs over the last two years[3] = A+B+C			311 983,91
E. Total quantity of access provided to all normal users of the installation (i.e. both internal and external) over the last two years[3]			92
F. Unit cost =D/E			**3391,13**
G. Unit cost charged to the project			**3391,13**
H. Quantity of access offered under the project (over the whole duration of the project)			85
I. **Access Cost on the basis of UC for the access offered under the project = G x H**		92%	**288 246**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091833

Participant number	**2**	**Organisation short name**	**BNI**	**Short name of Infrastructure**	**EVAg**
Installation number	**7**	**Short name of Installation**	**BNI-BSL2**	**Unit of access**	**Derived products Plasmid with viral cDNA**
				Min. quantity to be provided	**30**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Costs of consumables specifically used for providing remote scientific services or access		2 000,00
		Total A	**2 000,00**
		of which subcontracting (A')	

	Category of staff [6]	**Person-Months**	**Personnel Costs (€)**
B. Personnel direct eligible costs needed to provide access to the selected user groups	Technician (production and user support)	2	10 000,00
		Total B	**10 000,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			3 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**15 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091834

Participant number	2	Organisation short name	BNI	Short name of Infrastructure	EVAg
Installation number	8	Short name of Installation	BNI-BSL3/4	Unit of access	Access facility (8 hours)
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Contracts for maintenance and repair for the functioning of the installation	500,00
	Costs of energy power supplied for the installation	2 000,00
	Costs of consumables specifically used for the installation	500,00
	Costs of consumables specifically used for providing remote scientific services or access	1 000,00
	Total A	**4 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Staff Scientist (administration, user support, and virus production)	0,5	3 000,00
	Technician (virus production and user support)	0,5	2 000,00
	Laboratory Manager (laboratory administration and user support)	0,5	3 500,00
	Engineer (laboratory maintenance and operation)	0,5	3 500,00
	Total B		**12 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091835

Participant number	**3**	**Organisation short name**	**APHA**	**Short name of Infrastructure**	**EVAg**
Installation number	**9**	**Short name of Installation**	**APHA 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**32**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	7 311,92
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	96 913,80
	Courier charges for viruses	7 850,60
	QC - PCR & Sequencing cost	1 933,00
	QC - Mycoplasma test	1 538,00
	Total A	**115 547,32**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Technician	5,12	7 899,48
	Total B		**7 899,48**

C. Indirect eligible costs: 25% x ([A-A']+B)	30 861,70
D. **Actual Access Cost for the access offered under the project** = A + B + C	**154 309**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091836

Participant number	3	Organisation short name	APHA	Short name of Infrastructure	EVAg
Installation number	10	Short name of Installation	APHA 2	Unit of access	Derived products
				Min. quantity to be provided	48

Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	10 967,00
Maintenance of CL4 laboratory for EVA CL4 product TNA provision (2% usage) for 4 years	39 765,00
Courier charges for CL4 products	4 799,00
QC - PCR & Sequencing cost	2 908,00
QC - Mycoplasma test	2 320,00
	60 759,00
of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups

Category of staff [6]	Person-Months	Personnel Costs (€)
Technician	7,68	11 850,00
	Total B	**11 850,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	18 152,25
D. **Actual Access Cost for the access offered under the project** = A + B + C	**90 761**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091837

Participant number	4	Organisation short name	UKB	Short name of Infrastructure	EVAg
Installation number	11	Short name of Installation	UKB 1	Unit of access	Virus
				Min. quantity to be provided	10

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables for virus isolation, titration and characterization (Cell Culture media, FCS, antibiotics; plastics; PCR reagents, Next-generation sequencing reagents)	5 988,00
	Total A	**5 988,00**

	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Technician	3	10 012,00
	Total B		**10 012,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091838

Participant number	4	Organisation short name	UKB	Short name of Infrastructure	EVAg
Installation number	12	Short name of Installation	UKB 2	Unit of access	Derived products
				Min. quantity to be provided	125

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables for diagnostic kits (PCR, cloning, in-vitro transcription reagents; DNA sequencing; cell culture reagents; plastics)	60 500,00
	Consumables for genetically modified animal cell lines for enhanced virus isolation (CRISPR Nuclease Vector, Dynabeads CD4 Positive Isolation kit, Transcription activator–like effector nuclease kit, Genomic Cleavage Detection Kit, hTERT Cell Immortalization Reagents, Transfection Reagents, RACE Kits)	65 000,00
	Total A	**125 500,00**
	of which subcontracting (A') for DNA sequencing	***30 000,00***

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	18	60 100,00
	Post-doc	5	26 400,00
		Total B	**86 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	45 500,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**257 500**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091839

Participant number	**4**	**Organisation short name**	**UKB**	**Short name of Infrastructure**	**EVAg**
Installation number	**13**	**Short name of Installation**	**UKB 3**	**Unit of access**	**Access to facility**
				Min. quantity to be provided	**4**
Access provision period (usually the project life-time)			**from:**		**to:**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables for arbovirus isolation training (Cell Culture media, FCS, antibiotics; plastics; PCR reagents, Next-generation sequencing reagents)	5 325,00
	Consumables for Virus detection training (plastics; PCR reagents, cloning reagents, in-vitro transciption reagents, Next-generation sequencing reagents)	9 000,00
	Total A	**14 325,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Technician	2	6 675,00
	Total B		**6 675,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 250,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**26 250**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091840

Participant number	**5**	**Organisation short name**	**DH PHE 1**	**Short name of Infrastructure**	**EVAg**
Installation number	**14**	**Short name of Installation**	**PHE 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**24**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables for virus culture including tissue culture media,	6 000,00
	Plastic ware for virus culture	3 150,00
	General lab consumables for CL2, CL3 & CL4 (gloves, disinfectant, gauntlets, waste containers,	1 000,00
	Total A	**10 150,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Wet lab virology staff band 7	8	28 850,00
		Total B	**28 850,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 750,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**48 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091841

Participant number	5	Organisation short name	DH PHE	Short name of Infrastructure	EVAg
Installation number	15	Short name of Installation	PHE 2	Unit of access	Derived products.
				Min. quantity to be provided	30

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus culture reagents	1 000,00
	Protein expression reagents	3 000,00
	Nucleic acid extraction kits	1 000,00
	PCR probes and primers	6 300,00
	Total A	**11 300,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Molecular virologist	3	12 200,00
	Total B		**12 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 875,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 375**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091842

Participant number	6	Organisation short name	UNIBAS	Short name of Infrastructure	EVAg
Installation number	16	Short name of Installation	UNIBAS 1	Unit of access	Virus (classes 2, 3)
				Min. quantity to be provided	13

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation process	12 350,00
	Quality control of the product	670,00
	Characterization and verification of entities	1 300,00
	Safety- and protective equipment	600,00
	BSL-maintenance	400,00
	Total A	**15 320,00**
	of which subcontracting (A')	***0,00***

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technical personnel	1,5	8 200,00
	Total B		**8 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 880,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 400**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091843

Participant number	6	Organisation short name	UNIBAS	Short name of Infrastructure	EVAg
Installation number	17	Short name of Installation	UNIBAS 2	Unit of access	Derived products
				Min. quantity to be provided	62

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Entity preparation from specimens	21 960,00
	Characterization, verification of entities	850,00
	Preparation of expression vector, antibody	400,00
	Protective equipment and measures (clinical material)	400,00
	Total A	**23 610,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Cost for Technical Personnel (production, quality assurance, maintenance of integrity of product)	3	16 366,00
	Total B		**16 366,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 994,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**49 970**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091844

Participant number	6	Organisation short name	UNIBAS	Short name of Infrastructure	EVAg
Installation number	18	Short name of Installation		Unit of access	Access facility
				Min. quantity to be provided	4

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Training and Access to BSL-3 facility	8 600,00
	Total A	**8 600,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technical personnel	1	5 480,00
	Total B		**5 480,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 520,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**17 600**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091845

Participant number	**7**	**Organisation short name**	**UL**	**Short name of Infrastructure**	**EVAg**
Installation number	**19**	**Short name of Installation**	**UL1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**40**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Virus preparation	9 000,00
	Virus characterization and related quality controls	8 000,00
	Maintenance and utilities	16 200,00
	Protective equipment	1 800,00
	Total A	**35 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Professor	2	11 800,00
	Technician	8	14 200,00
	PhD	7	17 400,00
	PhD student	1	1 600,00
	Total B		**45 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	20 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**100 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091846

Participant number	7	Organisation short name	UL	Short name of Infrastructure	EVAg
Installation number	20	Short name of Installation	UL 2	Unit of access	Derived products
				Min. quantity to be provided	100

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation	2 000,00
	Preparation of viral derived products	24 000,00
	Maintenance and utilities	6 900,00
	Protective equipment	800,00
	Total A	**33 700,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Professor	1,5	8 800,00
	Technician	2,5	4 400,00
	PhD	12	29 900,00
	PhD student	2	3 200,00
	Total B		**46 300,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	20 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**100 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091847

Participant number	7	Organisation short name	UL	Short name of Infrastructure	EVAg
Installation number	21	Short name of Installation	UL 3	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Virus preparation	5 610,00
	Virus characterization and related quality controls	4 000,00
	Maintenance and utilities	3 400,00
	Protective equipment	1 600,00
	Travel - plane ticket (10 person)	6 030,00
	Travel - hotel (10x 2 nights)	2 000,00
	Total A	**22 640,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Professor	0,57	3 400,00
	Technician	1,72	3 100,00
	PhD	1,72	4 300,00
	Total B		**10 800,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 360,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**41 800**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091848

Participant number	8	Organisation short name	IVSAS	Short name of Infrastructure	EVAg
Installation number	22	Short name of Installation	IVSAS 1	Unit of access	Virus
				Min. quantity to be provided	30

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Cell culture reagents and plastic-ware for virus isolation and production	7 000,00
	Cell culture reagents and plastic-ware for virus quantification assays	4 000,00
	Molecular biology reagents and plastic-ware for quality control	4 000,00
	Sequencing costs for quality control	3 000,00
	Total A	**20 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician	13	13 000,00
	Post-doc	8	9 600,00
	Senior scientist	3	5 400,00
	Total B		**28 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	12 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**60 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091849

Participant number	8	Organisation short name	IVSAS	Short name of Infrastructure	EVAg
Installation number	23	Short name of Installation	IVSAS 2	Unit of access	Derived products
					60

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Molecular biology reagents and plastic ware for derived products production	10 000,00
	qRT-PCR reagents and plastic ware for quantification assays	5 000,00
	Total A	**15 000,00**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Techincian	9	9 000,00
	Post-doc	5	6 000,00
	Senior scientist	2	3 600,00
	Total B		**18 600,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 400,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**42 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091850

Participant number	9	Organisation short name	INMI	Short name of Infrastructure	EVAg
Installation number	24	Short name of Installation	INMI 1	Unit of access	Virus
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumable (culture medium, sequencing materials)	10 000,00
	Total A	**10 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Researcher	1	5 200,00
	Techician	2	7 200,00
	Total B		**12 400,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 600,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**28 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091851

Participant number	**9**	**Organisation short name**	**INMI**	**Short name of Infrastructure**	**EVAg**
Installation number	**25**	**Short name of Installation**	**INMI 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**40**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumable	10 000,00
	Total A	**10 000,00**
	of which subcontracting (A')	

	Category of staff [5]	**Person-Months**	**Personnel Costs (€)**
B. Personnel direct eligible costs needed to provide access to the selected user groups	Researcher	5	27 200,00
	Techician	5	18 800,00
	Total B		**46 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	14 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**70 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091852

Participant number	9	Organisation short name	INMI	Short name of Infrastructure	EVAg
Installation number	26	Short name of Installation	INMI 3	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Travel (6 for Europe:550 € each; 4 outside Europe, 1500 € each); accommodation and subsistence not provided)	9 000,00
	Total A	**9 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Researchers	2	10 500,00
	Techicians	5,5	20 500,00
	Total B		**31 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)		10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C		**50 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091853

Participant number	**10**	**Organisation short name**	**RKI**	**Short name of Infrastructure**	**EVAg**
Installation number	**27**	**Short name of Installation**	**RKI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**22**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves etc.	3 820,00
	Total A	**3 820,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	5	21 780,00
	Total B		**21 780,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	6 400,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**32 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091854

Participant number	10	Organisation short name	RKI	Short name of Infrastructure	EVAg
Installation number	28	Short name of Installation	RKI 2	Unit of access	Derived products
				Min. quantity to be provided	130

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves, freezedrying stabilizer, vials etc.	19 600,00
	Total A	**19 600,00**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Technician	13	58 800,00
	Total B		**58 800,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			19 600,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**98 000**

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091855

Participant number	10	Organisation short name	RKI	Short name of Infrastructure	EVAg
Installation number	29	Short name of Installation	RKI 3	Unit of access	Access facility
				Min. quantity to be provided	10

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	lab consumables (about 15 %) as cell culture media, cell culture flacs, pipettes, gloves, vials, safety equipment etc.	4 000,00
	Total A	**4 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician, scientist	2	12 000,00
	Total B		**12 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	4 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**20 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091856

Participant number	11	Organisation short name	EMC	Short name of Infrastructure	EVAg
Installation number	30	Short name of Installation	EMC 1	Unit of access	Virus
				Min. quantity to be provided	74

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables lab ware, maintenance	21 200,00
	Total A	**21 200,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	18	74 000,00
	Total B		**74 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	23 800,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**119 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091857

Participant number	11	Organisation short name	EMC	Short name of Infrastructure	EVAg
Installation number	31	Short name of Installation	EMC 2	Unit of access	Derived products
				Min. quantity to be provided	88

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables	10 200,00
	Total A	**10 200,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	6,6	27 200,00
	Total B		**27 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 350,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**46 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091858

Participant number	11	Organisation short name	EMC	Short name of Infrastructure	EVAg
Installation number	32	Short name of Installation	EMC 3	Unit of access	Access facility
				Min. quantity to be provided	16

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumabels	6 000,00
	Total A	**6 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Technician	2	12 000,00
	Postdoc	1,0	5 800,00
	Total B		**17 800,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 950,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**29 750**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091859

Participant number	**13**	**Organisation short name**	**INSERM**	**Short name of Infrastructure**	**EVAg**
Installation number	**33**	**Short name of Installation**	**Inserm 1**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**90**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Laboratory consumables		4 000,00
	Specific BSL4 consommables (suits, disposal coverall etc..)		3 000,00
	Contract of maintenance of the facility (relative to the time specifically dedicated to the project)		3 000,00
	Total A		**10 000,00**
	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Ingenior	1,5	7 200,00
	Assistant ingenior	1,5	6 300,00
	Total B		**13 500,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			5 875,00
D. **Actual Access Cost for the access offered under the project** = A + B + C			**29 375**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091860

Participant number	**13**	**Organisation short name**	**INSERM**	**Short name of Infrastructure**	**EVAg**
Installation number	**34**	**Short name of Installation**	**Inserm 2**	**Unit of access**	**Access facility (half day)**
				Min. quantity to be provided	**60**

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.		**Eligible Costs (€)**
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Laboratory consumables		2 500,00
	Specific BSL4 consommables (suits, disposal coverall etc..)		2 500,00
	Contract of maintenance of the facility (relative to the time specifically dedicated to the project)		3 750,00
	Total A		**8 750,00**
	of which subcontracting (A')		
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Research ingenior	0,5	3 130,00
	Ingenior	1	4 800,00
	Total B		**7 930,00**
C. Indirect eligible costs: 25% x ([A-A']+B)			4 170,00
D. Actual Access Cost for the access offered under the project = A + B + C			**20 850**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091861

Participant number	14	Organisation short name	IP	Short name of Infrastructure	EVA
Installation number	35	Short name of Installation	IP 1	Unit of access	Virus
				Min. quantity to be provided	60

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs

Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
Consumables	21 250,00
Total A	**21 250,00**
of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups

Category of staff [6]	Person-Months	Personnel Costs (€)
Post Doc	7	35 000,00
Technician	9	39 750,00
Total B		**74 750,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	24 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**120 000**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091862

Participant number	**14**	**Organisation short name**	**IP**	**Short name of Infrastructure**	**EVA**
Installation number	**36**	**Short name of Installation**	**IP 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**15**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables	2 580,00
	Total A	**2 580,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Post doc	1,5	7 500,00
	Total B		**7 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	2 520,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**12 600**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091863

Participant number	14	Organisation short name	IP	Short name of Infrastructure	EVA
Installation number	37	Short name of Installation	IP 3	Unit of access	Access
				Min. quantity to be provided	4

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables	2 540,00
	Total A	**2 540,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Post doc	2.5	12 500,00
	Total B		**12 500,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 760,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**18 800**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091864

Participant number	15	Organisation short name	FLI	Short name of Infrastructure	EVAg
Installation number	38	Short name of Installation	FLI 1	Unit of access	on virus sample
				Min. quantity to be provided	25

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables: media and supplements, cells, plastic material, cell culture material, PCR reagents, NGS, freeze-drying material, packaging material	30 750,00
	Total A	**30 750,00**
	of which subcontracting (A')	

	Category of staff [5]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups			
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	7 687,50
D. **Actual Access Cost for the access offered under the project** = A + B + C	**38 437**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091865

Participant number	**15**	**Organisation short name**	**FLI**	**Short name of Infrastructure**	**EVAg**
Installation number	**39**	**Short name of Installation**	**FLI 2**	**Unit of access**	**derived products: one sample of a monoclonal antibody or of a suitable cell line**
				Min. quantity to be provided	**40**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	mAbs : consumables: cells, media and supplements, cell culture material, PCR reagents, packaging material	8 000,00
	Cells : consumables: media and supplements, cell culture and plastic material, PCR reagents, antibodies, sequencing reagents, chemicals, packaging material	12 000,00
	Total A	**20 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	5 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**25 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091866

Participant number	15	Organisation short name	FLI	Short name of Infrastructure	EVAg
Installation number	40	Short name of Installation	FLI 3	Unit of access	Access facility 1 animal room for 7 days with animals and corresponding labaratory space for sample preparation before and after the trial for 2 days (9 days in total)
				Min. quantity to be provided	30

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	purchasing 75 animals cattles for animal testing	22 500,00
	purchasing 75 animals pigs for animal testing	5 250,00
	animal feed for 7 days cattles	1 038,00
	animal feed for 7 days pigs	321,90
	consumables	3 000,00
	Travel costs for 30 visits (1 scientist per trip: 4x train tickets - 360€; 2xflghts - 400€; 10 nights accomodation - 900€; daily allowance for 10 days - 320€	60 000,00
	Total A	**92 109,90**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Animal care taking (41,25 h per testing cycle) cattles	4,33	12 419,55
	Animal care taking (25,5 h per testing cycle) pigs	2,67	7 678,20
	Total B		**20 097,75**

C. Indirect eligible costs: 25% x ([A-A']+B)	28 051,91
D. **Actual Access Cost for the access offered under the project** = A + B + C	**140 260**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091867

Participant number	**16**	**Organisation short name**	**TPI**	**Short name of Infrastructure**	**EVAg**
Installation number	**41**	**Short name of Installation**	**TPI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**15**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables: media and supplements, cells, plastic material, cell culture material, PCR raegents, NGS, etc.	36 000,00
	Total A	**36 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	9 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**45 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091868

Participant number	16	Organisation short name	TPI	Short name of Infrastructure	EVAg
Installation number	42	Short name of Installation	TPI 2	Unit of access	Derived products
				Min. quantity to be provided	145

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Consumables: Biting Midges, Culicoides nubeculosus (gender unsorted), Culicoides sonorensis (gender unsorted), Tick cell line, etc.	26 662,46
	Total A	**26 662,46**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	120 hours of Eric Denison's time for the biting midges work	0,80	3 184,81
	Total B		**3 184,81**

C. Indirect eligible costs: 25% x ([A-A']+B)	7 461,82
D. **Actual Access Cost for the access offered under the project** = A + B + C	**37 309**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091869

Participant number	16	Organisation short name	TPI	Short name of Infrastructure	EVAg
Installation number	43	Short name of Installation	TPI 3	Unit of access	Access facility (1 week)
				Min. quantity to be provided	40

	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Total price for testing samples by VNT for 2 FMD vaccine studies, 3 time points	4 154,96
	Shipments	2 389,14
	Consumables eg Rompun, Blood tubes	211,20
	Weekly cost for ISO 10 (1 unit = 1 animal isolation room for 1 week)	239 583,33
	Supply of animals - 34 calves 6 months+	25 221,32
	Total A	**271 559,96**
	of which subcontracting (A')	

	Category of staff [6]	Person-Months	Personnel Costs (€)
B. Personnel direct eligible costs needed to provide access to the selected user groups	Post Doc (Time to organise the experiment and ship samples, arrange regulatory clearance etc)	1,5	9 900,41
	Total B		**9 900,41**

C. Indirect eligible costs: 25% x ([A-A']+B)	70 365,09
D. **Actual Access Cost for the access offered under the project** = A + B + C	**351 82**

Funded by the Horizon 2020 framework programme of the European Union

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091870

Participant number	17	Organisation short name	UTMB	Short name of Infrastructure	EVAg
Installation number	44	Short name of Installation	UTMB	Unit of access	Virus
				Min. quantity to be provided	25

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	2 400,00
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	32 000,00
	Courier charges for viruses	2 600,00
	QC - PCR & Sequencing cost	2 000,00
	QC - Mycoplasma test	1 000,00
	Total A	**40 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091871

Participant number	**18**	**Organisation short name**	**ARC-OVI**	**Short name of Infrastructure**	**EVAg**
Installation number	**45**	**Short name of Installation**	**ARC-OVI 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**20**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Microbiological analysis: Mycoplasma analysis, Endotoxins and other bacterial contaminants. DNA/RNA extractions, RT-PCR, dNTPs (100mM each), Superscript iii Reverse transcriptase (10000U), Molecular grade water (1L), RNase Inhibitor (2 500U), RNase H (5000U), PCR Taq polymerase (250U), PCR tubes, One step-Real time PCR, Iscript one-step RT-PCR kit for probes, Strip tubes, Optical strip caps, Dual labelled probes, Full genome sequencing and sanger sequencing.	7 000,00
	Total A	**7 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [6]**	**Person-Months**	**Personnel Costs (€)**
	Research Scientist	12	25 000,00
	Total B		**25 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**40 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091872

Participant number	**18**	**Organisation short name**	**ARC-OVI**	**Short name of Infrastructure**	**EVAg**
Installation number	**46**	**Short name of Installation**	**ARC-OVI 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**10**

			Eligible Costs (€)
	PCR products for diagnostic tests and infected cell culture		1 200,00
		Total A	**1 200,00**
		of which subcontracting (A')	
B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Research Scientist	2	4 000,00
		Total B	**4 000,00**
	C. Indirect eligible costs: 25% x ([A-A']+B)		1 300,00
	D. Actual Access Cost for the access offered under the project = A + B + C		**6 500,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091873

Participant number	19	Organisation short name	NICD-NHLS	Short name of Infrastructure	EVAg
Installation number	47	Short name of Installation	NICD	Unit of access	Virus (infectious or inactivated virus or virus-infected cells)
				Min. quantity to be provided	15

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Contracts for maintenance and repair for the functioning of the installation	2 600,00
	Costs of energy power supplied for the installation	15 000,00
	Costs of consumables specifically used for the installation	1 000,00
	Costs of consumables specifically used for providing remote scientific services or access	8 000,00
	Total A	**26 600,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Research Scientist	3	6 000,00
	Total B		**6 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	8 150,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**40 750,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091874

Participant number	20	Organisation short name	IPVE	Short name of Infrastructure	EVAg
Installation number	48	Short name of Installation	IPVE	Unit of access	Derived products
				Min. quantity to be provided	20

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091875

Participant number	21	Organisation short name	RII	Short name of Infrastructure	EVAg
Installation number	49	Short name of Installation	RII	Unit of access	Derived products
				Min. quantity to be provided	60

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	PCR-analysys	10 000,00
	Isolation of viruses	2 400,00
	Lyophylization	1 400,00
	Antigenic analysis	5 200,00
	Sequencing	
	Conservation (maintaining the collection)	1 800,00
	Database, networking	4 200,00
	Shipment to the end-user	4 000,00
	Characterization of the biological properties of isolates	7 000,00
	Total A	**36 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [6]	Person-Months	Personnel Costs (€)
	Kuzmina M.I. Technician	5	600,00
	Stolyarov K. IT-engineer	8	3 400,00
	Total B		**4 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091876

Participant number	**22**	**Organisation short name**	**Mechnikov RIVS**	**Short name of Infrastructure**	**EVAg**
Installation number	**50**	**Short name of Installation**	**Mechnikov RIVS**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**20**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091877

Participant number	**22**	**Organisation short name**	**Mechnikov RIVS**	**Short name of Infrastructure**	**EVAg**
Installation number	**50**	**Short name of Installation**	**Mechnikov RIVS**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**25**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	PCR-analysys	2 500,00
	Isolation of viruses	600,00
	Lyophylization	700,00
	Antigenic analysis	1 300,00
	Sequencing	
	Conservation (maintaining the collection)	900,00
	Database, networking	1 000,00
	Shipment to the end-user	1 100,00
	Characterization of the biological properties of isolates	1 800,00
	Total A	**9 900,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Technician	4	480,00
	IT-engineer	4	1 700,00
	Total B		**2 180,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 020,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**15 100**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091878

Participant number	23	Organisation short name	China CDC	Short name of Infrastructure	EVAg
Installation number	52	Short name of Installation	China CDC 2	Unit of access	Derived products
				Min. quantity to be provided	50

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	Eligible Costs (€)
	Costs of consumables used for RNA/cDNA and diagnosis reagents preparations	30 000,00
	Costs of equipment maintenance and cleaning	5 000,00
	Total A	**35 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	Category of staff [5]	Person-Months	Personnel Costs (€)
	Chief	8	4 000,00
	PHD	12	9 000,00
	Technician	6	2 000,00
	Total B		**15 000,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	12 500,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**62 500**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091879

Participant number	**24**	**Organisation short name**	**WIV**	**Short name of Infrastructure**	**EVAg**
Installation number	**53**	**Short name of Installation**	**WIV 1**	**Unit of access**	**Virus**
				Min. quantity to be provided	**22**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	BSL-2 virus strains contain consumables and maintains cost	24 000,00
	BSL-3 virus strains contain consumables and maintains cost	20 000,00
	Total A	**44 000,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	11 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**55 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091880

Participant number	**24**	**Organisation short name**	**WIV**	**Short name of Infrastructure**	**EVAg**
Installation number	**54**	**Short name of Installation**	**WIV 2**	**Unit of access**	**Derived products**
				Min. quantity to be provided	**21**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	DNA/RNA materials contain consumables and maintains cost	7 000,00
	recombinant proteins/Antibodies contain consumables and maintains cost	7 700,00
	Total A	**14 700,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Total B		**0,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	3 675,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**18 375,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091881

Participant number	**25**	**Organisation short name**	**CSIRO**	**Short name of Infrastructure**	**EVAg**
Installation number	**55**	**Short name of Installation**	**CSIRO**	**Unit of access**	**Virus**
				Min. quantity to be provided	**25**

A. Direct eligible costs of providing access to the selected user groups, excluding personnel costs	Describe the costs actually and solely incurred for providing access to the user groups selected for support under the action. All contributions to capital investments of the installation are not eligible.	**Eligible Costs (€)**
	Consumables (Cells, media, plastics, gloves, antibodies, chemicals)	2 800,00
	Maintenance of laboratory for EVA virus TNA provision (5% usage) for 4 years	30 000,00
	Courier charges for viruses	3 000,00
	QC - PCR & Sequencing cost	2 000,00
	QC - Mycoplasma test	1 000,00
	Total A	**38 800,00**
	of which subcontracting (A')	

B. Personnel direct eligible costs needed to provide access to the selected user groups	**Category of staff [5]**	**Person-Months**	**Personnel Costs (€)**
	Scientific staff	2	1 200,00
	Total B		**1 200,00**

C. Indirect eligible costs: 25% x ([A-A']+B)	10 000,00
D. **Actual Access Cost for the access offered under the project** = A + B + C	**50 000,00**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_091882

From: 吴莹 <wuying@im.ac.cn>
Sent: Wednesday, June 10, 2015 12:40 AM
To: Rusek, Benjamin
Cc: 孙辉;Lei Zhang;高福;LeDuc, James W.;'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004581

welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004582

To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should

FOIA Confidential Treatment Requested by Univ of Texas System

be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004584

Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004585

Best Regards,

Sun Hui

2015-04-10
SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004586

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004587

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004588

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone ([redacted]office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004589

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004590

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004591

in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004592

From: David Franz <davidrfranz@gmail.com>
Sent: Wednesday, June 10, 2015 6:45 AM
Cc: Benjamin Rusek;LeDuc, James W.
Subject: Re: Next steps on the CAS NAS bio workshop?

Seems a good idea. Would we need another person Jim? dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:

> Hi Ben,
>
> We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
> How are things going on from your side?
>
> Best,
>
> Ying Wu

> Rusek, Benjamin 写:
> Greetings Dr. Wu,
>
> I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.
>
> Kind regards,
>
> Benjamin J. Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004632

U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004633

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004634

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004635

<gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004636

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004637

52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004638

Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004639

Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004640

抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone([redacted]office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004641

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好!

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while w are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: ben.rusek

FOIA Confidential Treatment Requested by Univ of Texas System

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in publi health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S National Academy of Sciences. Ben has supported successful NAS work in China for almost ten yea (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S Chinese workshops on nuclear forensics). Ben was the study director for the project that produce the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biologic Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Science since 2005. He has been a member of the Executive Board of International Student/Young Pugwas since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimso Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A in political science from Ohio State University and an M.A. in political science from Purdue Universit where he was the president of Purdue University Student Pugwash.

= =

致

礼!

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004643

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004644

From: Dave Franz <davidrfranz@gmail.com>
Sent: Wednesday, June 10, 2015 10:25 AM
To: LeDuc, James W.
Cc: Benjamin Rusek
Subject: Re: Next steps on the CAS NAS bio workshop?

Agree. Ralph is the only one on this list that I know personally. I am happy to call him or have you call one of the others. I think it's
Especially important since our Chinese colleagues requested this session. Ben, let us know what's possible financially and will try to find someone. Thanks, Dave
Sent from my iPhone

On Jun 10, 2015, at 11:10 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

> If the budget would allow, it would be good to have someone working with MERS virus—either Ralph Baric or Mark Denison are the big players, although we have a person in our lab who has developed a very promising mouse model that has received a lot of attention—Kent Tseng. Kent has some collaborations with China already underway. I don't know the Perlman that Diane mentioned earlier, but I saw his name recently in the press and he might be another good contributor. This is quite timely with the number of cases rapidly expanding in Korea (I heard >100 cases and 9 deaths on NPR this morning!). We need to link this real-world example of an emerging disease with our more policy oriented discussion on biosafety and biosecurity.
>
> Jim
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 6:45 AM
> **Cc:** Benjamin Rusek; LeDuc, James W.
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Seems a good idea. Would we need another person Jim? dave
>
> David R. Franz DVM, Ph.D
>
> Assistant: (b)(6)
> (b)(6)

On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004485

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004486

the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004487

1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004488

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004489

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004490

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004491

have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004492

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax: +86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004493

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone (cell (b)(6) office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

FOIA Confidential Treatment Requested by Univ of Texas System

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004495

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while w are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State

FOIA Confidential Treatment Requested by Univ of Texas System

University. The current focus of his activities relates to the role of international engagement in publi health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S National Academy of Sciences. Ben has supported successful NAS work in China for almost ten yea (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S Chinese workshops on nuclear forensics). Ben was the study director for the project that produce the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biologic Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Science since 2005. He has been a member of the Executive Board of International Student/Young Pugwas since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimso Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A in political science from Ohio State University and an M.A. in political science from Purdue Universit where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004497

From: David Franz <davidrfranz@gmail.com>
Sent: Wednesday, June 10, 2015 11:10 AM
To: LeDuc, James W.
Subject: Re: Next steps on the CAS NAS bio workshop?

Just tried Ben; doesn't answer. Will try again later and then contact MERS person asap. d

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On Jun 10, 2015, at 11:34 AM, LeDuc, James W. wrote:

> If you could make contact, that would be great. I am slammed here and need to be out tomorrow and Friday for a funeral in DC area. I have attached contact information for Mark. All I have for Ralph is his email: rbaric@email.unc.edu This may be out of date. <image001.jpg>
>
> **From:** Dave Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 10:25 AM
> **To:** LeDuc, James W.
> **Cc:** Benjamin Rusek
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Agree. Ralph is the only one on this list that I know personally. I am happy to call him or have you call one of the others. I think it's
> Especially important since our Chinese colleagues requested this session. Ben, let us know what's possible financially and will try to find someone. Thanks, Dave
> Sent from my iPhone
>
> On Jun 10, 2015, at 11:10 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:
>
> > If the budget would allow, it would be good to have someone working with MERS virus—either Ralph Baric or Mark Denison are the big players, although we have a person in our lab who has developed a very promising mouse model that has received a lot of attention—Kent Tseng. Kent has some collaborations with China already underway. I don't know the Perlman that Diane mentioned earlier, but I saw his name

FOIA Confidential Treatment Requested by Univ of Texas System

recently in the press and he might be another good contributor. This is quite timely with the number of cases rapidly expanding in Korea (I heard >100 cases and 9 deaths on NPR this morning!). We need to link this real-world example of an emerging disease with our more policy oriented discussion on biosafety and biosecurity.

Jim

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, June 10, 2015 6:45 AM
Cc: Benjamin Rusek; LeDuc, James W.
Subject: Re: Next steps on the CAS NAS bio workshop?

Seems a good idea. Would we need another person Jim? dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004471

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004472

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)

(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004473

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers' abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004474

with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep

FOIA Confidential Treatment Requested by Univ of Texas System

D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004476

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004477

with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004478

主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004479

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone (cell (b)(6) office +86-10-64888494).

FOIA Confidential Treatment Requested by Univ of Texas System

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004481

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US ex David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health secur including a CAS institute. By this message, I am connecting them with your office, to let you know of their vis case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meet between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese t experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004482

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of years on active duty and retired as Colonel. He served as Commander of the U.S. Army Me Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Me Research and Materiel Command. Prior to joining the Command, he served as Group Veter for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three Un Nations Special Commission biological warfare inspection missions to Iraq and served as te advisor on long-term monitoring. He also served as a member of the first two US-UK teams visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a m of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Tech Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological W released in 1997. Current standing committee appointments include the National Academy Sciences Committee on International Security and Arms Control where he chairs the 'biologi panel', the National Research Council Board on Life Sciences and the Senior Technical Adv Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves Senior Mentor to the Program for Emerging Leaders at the National Defense University. He serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement i health and the life sciences as a component of global biosecurity policy. Domestically he co to encourage thoughtfulness when regulating research in the name of security, thereby mini negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas Sta University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at National Academy of Sciences. Ben has supported successful NAS work in China for almost t (including the Chinese-English English-Chinese glossary of nuclear security terms and t Chinese workshops on nuclear forensics). Ben was the study director for the project that p the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment B Laboratories* and has worked on international biosecurity issues with the NAS Board on Life S since 2005. He has been a member of the Executive Board of International Student/Young P since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben ha in political science from Ohio State University and an M.A. in political science from Purdue Un where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004483



<Mark R Denison.vcf>

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004484

From: Rusek, Benjamin <BRusek@nas.edu>
Sent: Thursday, June 11, 2015 9:56 AM
To: LeDuc, James W.;Dave Franz
Cc: Lowenthal, Micah
Subject: RE: Next steps on the CAS NAS bio workshop?

Hi Dave and Jim,

Sorry I did not get back to you yesterday. We have budgeted for 8 people (7 experts, 1 staff) for the China bio trip so happy to invert a MERS person. Key right now is to get informal commitments so we can get airline fares locked in and hotels booked.

PS I cced Micah as he will be covering for me while I am at Middlebury.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: LeDuc, James W. [mailto:jwleduc@UTMB.EDU]
Sent: Wednesday, June 10, 2015 11:35 AM
To: Dave Franz
Cc: Rusek, Benjamin
Subject: RE: Next steps on the CAS NAS bio workshop?

If you could make contact, that would be great. I am slammed here and need to be out tomorrow and Friday for a funeral in DC area. I have attached contact information for Mark. All I have for Ralph is his



email: rbaric@email.unc.edu This may be out of date.

From: Dave Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, June 10, 2015 10:25 AM
To: LeDuc, James W.
Cc: Benjamin Rusek
Subject: Re: Next steps on the CAS NAS bio workshop?

Agree. Ralph is the only one on this list that I know personally. I am happy to call him or have you call one of the others. I think it's
Especially important since our Chinese colleagues requested this session. Ben, let us know

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004456

what's possible financially and will try to find someone. Thanks, Dave
Sent from my iPhone

On Jun 10, 2015, at 11:10 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

> If the budget would allow, it would be good to have someone working with MERS virus—either Ralph Baric or Mark Denison are the big players, although we have a person in our lab who has developed a very promising mouse model that has received a lot of attention—Kent Tseng. Kent has some collaborations with China already underway. I don't know the Perlman that Diane mentioned earlier, but I saw his name recently in the press and he might be another good contributor. This is quite timely with the number of cases rapidly expanding in Korea (I heard >100 cases and 9 deaths on NPR this morning!). We need to link this real-world example of an emerging disease with our more policy oriented discussion on biosafety and biosecurity.
>
> Jim
>
> ---
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 6:45 AM
> **Cc:** Benjamin Rusek; LeDuc, James W.
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Seems a good idea. Would we need another person Jim? dave
>
> David R. Franz DVM, Ph.D
>
> Assistant: (b)(6)
> (b)(6)
>
> On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:
>
> Hi Ben,
>
> We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
> How are things going on from your side?
>
> Best,
>
> Ying Wu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004457

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004458

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004459

speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004460

收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004461

Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004462

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004463

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004464

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004465

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004466

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好!

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while w are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004467

Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in publi health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S National Academy of Sciences. Ben has supported successful NAS work in China for almost ten yea (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S Chinese workshops on nuclear forensics). Ben was the study director for the project that produce the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biologic Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Science since 2005. He has been a member of the Executive Board of International Student/Young Pugwas since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimso Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A in political science from Ohio State University and an M.A. in political science from Purdue Universit where he was the president of Purdue University Student Pugwash.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004468

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004469

From: Dave Franz <davidrfranz@gmail.com>
Sent: Thursday, June 11, 2015 10:18 AM
To: Rusek, Benjamin
Cc: LeDuc, James W.;Lowenthal, Micah
Subject: Re: Next steps on the CAS NAS bio workshop?

Good. Will contact Ralph B. That failing Jim or I will try some others. What did Diane learn about 28th and Peter yesterday? D

Sent from my iPhone

On Jun 11, 2015, at 10:55 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

> Hi Dave and Jim,
>
> Sorry I did not get back to you yesterday. We have budgeted for 8 people (7 experts, 1 staff) for the China bio trip so happy to invert a MERS person. Key right now is to get informal commitments so we can get airline fares locked in and hotels booked.
>
> PS I cced Micah as he will be covering for me while I am at Middlebury.
>
> Kind regards,
>
> Benjamin J. Rusek
> U.S. National Academy of Sciences
> 1-202-334-3975
>
> **From:** LeDuc, James W. [mailto:jwleduc@UTMB.EDU]
> **Sent:** Wednesday, June 10, 2015 11:35 AM
> **To:** Dave Franz
> **Cc:** Rusek, Benjamin
> **Subject:** RE: Next steps on the CAS NAS bio workshop?
>
> If you could make contact, that would be great. I am slammed here and need to be out tomorrow and Friday for a funeral in DC area. I have attached contact information for Mark. All I have for Ralph is his email: rbaric@email.unc.edu This may be out of date.
>
> **Mark R. Denison**
> Vanderbilt University
>
> (615) 343-9881 Work
> mark.denison@vanderbilt.edu
>
> School of Medicine,D-6217 Medical C...
> D-6217 Medical Center North
> Nashville, TN 37232-2581
> United States of America
>
> **From:** Dave Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 10:25 AM
> **To:** LeDuc, James W.

FOIA Confidential Treatment Requested by Univ of Texas System

Cc: Benjamin Rusek
Subject: Re: Next steps on the CAS NAS bio workshop?

Agree. Ralph is the only one on this list that I know personally. I am happy to call him or have you call one of the others. I think it's
Especially important since our Chinese colleagues requested this session. Ben, let us know what's possible financially and will try to find someone. Thanks, Dave
Sent from my iPhone

On Jun 10, 2015, at 11:10 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

> If the budget would allow, it would be good to have someone working with MERS virus—either Ralph Baric or Mark Denison are the big players, although we have a person in our lab who has developed a very promising mouse model that has received a lot of attention—Kent Tseng. Kent has some collaborations with China already underway. I don't know the Perlman that Diane mentioned earlier, but I saw his name recently in the press and he might be another good contributor. This is quite timely with the number of cases rapidly expanding in Korea (I heard >100 cases and 9 deaths on NPR this morning!). We need to link this real-world example of an emerging disease with our more policy oriented discussion on biosafety and biosecurity.
>
> Jim
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 6:45 AM
> **Cc:** Benjamin Rusek; LeDuc, James W.
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Seems a good idea. Would we need another person Jim? dave
>
> David R. Franz DVM, Ph.D
>
> Assistant: (b)(6)
> (b)(6)
>
> On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:
>
> Hi Ben,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004398

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004399

who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)

(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004400

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004401

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004402

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004403

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004404

收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004405

Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004406

Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004407

发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004408

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US ex
David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health secur
including a CAS institute. By this message, I am connecting them with your office, to let you know of their vis
case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use
are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meet
between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in
year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese t
experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences

FOIA Confidential Treatment Requested by Univ of Texas System

Phone: 001-202-334-3975
(b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of years on active duty and retired as Colonel. He served as Commander of the U.S. Army Me Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Me Research and Materiel Command. Prior to joining the Command, he served as Group Veter for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three Un Nations Special Commission biological warfare inspection missions to Iraq and served as te advisor on long-term monitoring. He also served as a member of the first two US-UK teams visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a m of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Tech Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological W released in 1997. Current standing committee appointments include the National Academy Sciences Committee on International Security and Arms Control where he chairs the 'biologi panel', the National Research Council Board on Life Sciences and the Senior Technical Adv Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves Senior Mentor to the Program for Emerging Leaders at the National Defense University. He serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement i health and the life sciences as a component of global biosecurity policy. Domestically he co to encourage thoughtfulness when regulating research in the name of security, thereby mini negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas Sta University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at National Academy of Sciences. Ben has supported successful NAS work in China for almost t (including the Chinese-English English-Chinese glossary of nuclear security terms and t Chinese workshops on nuclear forensics). Ben was the study director for the project that p the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment B Laboratories* and has worked on international biosecurity issues with the NAS Board on Life S since 2005. He has been a member of the Executive Board of International Student/Young P since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben ha in political science from Ohio State University and an M.A. in political science from Purdue Un where he was the president of Purdue University Student Pugwash.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004410

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004411

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Thursday, June 11, 2015 10:27 AM
To: Dave Franz;Rusek, Benjamin
Cc: LeDuc, James W.
Subject: RE: Next steps on the CAS NAS bio workshop?

I sent a note to Diane to ask her about the call. I will forward the reply when I get it.
Micah

From: Dave Franz [mailto:davidrfranz@gmail.com]
Sent: Thursday, June 11, 2015 11:18 AM
To: Rusek, Benjamin
Cc: LeDuc, James W.; Lowenthal, Micah
Subject: Re: Next steps on the CAS NAS bio workshop?

Good. Will contact Ralph B. That failing Jim or I will try some others. What did Diane learn about 28th and Peter yesterday? D

Sent from my iPhone

On Jun 11, 2015, at 10:55 AM, Rusek, Benjamin <BRusek@nas.edu> wrote:

> Hi Dave and Jim,
>
> Sorry I did not get back to you yesterday. We have budgeted for 8 people (7 experts, 1 staff) for the China bio trip so happy to invert a MERS person. Key right now is to get informal commitments so we can get airline fares locked in and hotels booked.
>
> PS I cced Micah as he will be covering for me while I am at Middlebury.
>
> Kind regards,
>
> Benjamin J. Rusek
> U.S. National Academy of Sciences
> 1-202-334-3975
>
> ---
>
> **From:** LeDuc, James W. [mailto:jwleduc@UTMB.EDU]
> **Sent:** Wednesday, June 10, 2015 11:35 AM
> **To:** Dave Franz
> **Cc:** Rusek, Benjamin
> **Subject:** RE: Next steps on the CAS NAS bio workshop?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004360

If you could make contact, that would be great. I am slammed here and need to be out tomorrow and Friday for a funeral in DC area. I have attached contact information for Mark. All I have for Ralph is his email: rbaric@email.unc.edu This may be out of date.

Mark R. Denison
Vanderbilt University

(615) 343-9881 Work
mark.denison@vanderbilt.edu

School of Medicine,D-6217 Medical C...
D-6217 Medical Center North
Nashville, TN 37232-2581
United States of America

From: Dave Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, June 10, 2015 10:25 AM
To: LeDuc, James W.
Cc: Benjamin Rusek
Subject: Re: Next steps on the CAS NAS bio workshop?

Agree. Ralph is the only one on this list that I know personally. I am happy to call him or have you call one of the others. I think it's
Especially important since our Chinese colleagues requested this session. Ben, let us know what's possible financially and will try to find someone. Thanks, Dave
Sent from my iPhone

On Jun 10, 2015, at 11:10 AM, LeDuc, James W. <jwleduc@UTMB.EDU> wrote:

> If the budget would allow, it would be good to have someone working with MERS virus—either Ralph Baric or Mark Denison are the big players, although we have a person in our lab who has developed a very promising mouse model that has received a lot of attention—Kent Tseng. Kent has some collaborations with China already underway. I don't know the Perlman that Diane mentioned earlier, but I saw his name recently in the press and he might be another good contributor. This is quite timely with the number of cases rapidly expanding in Korea (I heard >100 cases and 9 deaths on NPR this morning!). We need to link this real-world example of an emerging disease with our more policy oriented discussion on biosafety and biosecurity.
>
> Jim
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, June 10, 2015 6:45 AM
> **Cc:** Benjamin Rusek; LeDuc, James W.
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Seems a good idea. Would we need another person Jim? dave
>
> David R. Franz DVM, Ph.D
>
> Assistant: (b)(6)
> (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004361

(b)(6)

On Jun 10, 2015, at 1:40 AM, 吴莹 wrote:

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics

FOIA Confidential Treatment Requested by Univ of Texas System

which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004363

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers' abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004364

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004365

Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004366

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004367

Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004368

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004369

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004370

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004371

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US ex David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health secur including a CAS institute. By this message, I am connecting them with your office, to let you know of their vis case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will us are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meet between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later i

FOIA Confidential Treatment Requested by Univ of Texas System

year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese t
experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of
years on active duty and retired as Colonel. He served as Commander of the U.S. Army Me
Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Me
Research and Materiel Command. Prior to joining the Command, he served as Group Veter
for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three Un
Nations Special Commission biological warfare inspection missions to Iraq and served as te
advisor on long-term monitoring. He also served as a member of the first two US-UK teams
visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a m
of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Tech
Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological W
released in 1997. Current standing committee appointments include the National Academy
Sciences Committee on International Security and Arms Control where he chairs the 'biologi
panel', the National Research Council Board on Life Sciences and the Senior Technical Adv
Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves
Senior Mentor to the Program for Emerging Leaders at the National Defense University. He
serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-
Technologies, LLC. He holds an adjunct appointment as Professor for the Department of
Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State
University. The current focus of his activities relates to the role of international engagement i
health and the life sciences as a component of global biosecurity policy. Domestically he co
to encourage thoughtfulness when regulating research in the name of security, thereby mini
negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas Sta
University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at
National Academy of Sciences. Ben has supported successful NAS work in China for almost t
(including the Chinese-English English-Chinese glossary of nuclear security terms and t
Chinese workshops on nuclear forensics). Ben was the study director for the project that p
the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment E*
Laboratories and has worked on international biosecurity issues with the NAS Board on Life S
since 2005. He has been a member of the Executive Board of International Student/Young P

FOIA Confidential Treatment Requested by Univ of Texas System

since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L.
Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben ha
in political science from Ohio State University and an M.A. in political science from Purdue Un
where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004374

From: Dave Franz <davidrfranz@gmail.com>
Sent: Tuesday, June 16, 2015 5:35 PM
To: Rusek, Benjamin
Cc: ??;孙辉;Lei Zhang;高福;LeDuc, James W.;Lowenthal, Micah
Subject: Re: Next steps on the CAS NAS bio workshop?

Thanks Ben,

Dave Franz here Dr Wu. Just to let you know this is early draft agenda content. We haven't yet finalized the specific talk titles. We will stay in touch with you during Ben's brief absence. With best wishes, dave

Sent from my iPhone

On Jun 16, 2015, at 5:47 PM, Rusek, Benjamin <BRusek@nas.edu> wrote:

> Greetings Dr. Wu,
>
> Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.
>
> David Franz — Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
> James LeDuc — High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
> Peter Palese — Influenza: "Paths to a Better Vaccine?"
> Ruth Berkelman — Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
> Thomas Ksiazek — Ebola: "Sustainable Austere Environment Laboratories"
> Ralph Baric — MERS: "Genetic Systems and Models"
> Diane Griffin — Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"
>
> The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?
>
> Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.
>
> **I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.**
>
> Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004699

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

> Rusek, Benjamin 写:
> Greetings Dr. Wu,
>
> I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.
>
> Kind regards,
>
> Benjamin J. Rusek
> U.S. National Academy of Sciences
> 1-202-334-3975
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, May 13, 2015 11:37 AM
> **To:** ??
> **Cc:** 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
> **Subject:** Re: Next steps on the CAS NAS bio workshop?
>
> Dear Dr Wu,
>
> It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004700

general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004701

U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004702

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004703

J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004704

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (b)(6) ; Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004705

to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004706

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax: +86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (b)(6); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004707

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004708

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004709

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while w are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
(b)(6)
Fax: 001-202-334-1730
Skype (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State

FOIA Confidential Treatment Requested by Univ of Texas System

University. The current focus of his activities relates to the role of international engagement in publi health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S National Academy of Sciences. Ben has supported successful NAS work in China for almost ten yea (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S Chinese workshops on nuclear forensics). Ben was the study director for the project that produce the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biologic Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Science since 2005. He has been a member of the Executive Board of International Student/Young Pugwas since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimso Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A in political science from Ohio State University and an M.A. in political science from Purdue Universit where he was the president of Purdue University Student Pugwash.

= =

致

礼！

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004711

From: Lowenthal, Micah <mlowenth@nas.edu>
Sent: Friday, June 19, 2015 1:34 PM
To: '??'
Cc: 孙辉;Lei Zhang;高福;LeDuc, James W.;'David Franz'
Subject: RE: Next steps on the CAS NAS bio workshop?

Dear Dr. Wu,
At the end of his e-mail to you, Ben Rusek mentioned that he will be on a sabbatical until 17 August. I will serve as the NAS staff contact for this activity over the next two months, until Ben returns. Please feel free to contact me with any questions, concerns, or requests. We can begin by providing you with brief biographical sketches of the participants listed below, if that would be useful to you.
With best regards,
Micah

Micah D. Lowenthal, Ph.D.
Program Director, Policy and Global Affairs Division
The National Academy of Sciences
500 Fifth Street, NW 5th floor
Washington, DC 20001 USA
telephone: +1 (202) 334-3074
fax: +1 (202) 334-1730
e-mail: mlowenthal@nas.edu

From: Rusek, Benjamin
Sent: Tuesday, June 16, 2015 5:48 PM
To: '??'
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'; Lowenthal, Micah
Subject: RE: Next steps on the CAS NAS bio workshop?
Importance: High

Greetings Dr. Wu,

Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.

David Franz	Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
James LeDuc	High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
Peter Palese	Influenza: "Paths to a Better Vaccine?"
Ruth Berkelman	Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
Thomas Ksiazek	Ebola: "Sustainable Austere Environment Laboratories"
Ralph Baric	MERS: "Genetic Systems and Models"
Diane Griffin	Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"

The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004653

Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.

I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

> Rusek, Benjamin 写:
> Greetings Dr. Wu,
>
> I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.
>
> Kind regards,
>
> Benjamin J. Rusek
> U.S. National Academy of Sciences
> 1-202-334-3975
>
> **From:** David Franz [mailto:davidrfranz@gmail.com]
> **Sent:** Wednesday, May 13, 2015 11:37 AM
> **To:** ??
> **Cc:** 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
> **Subject:** Re: Next steps on the CAS NAS bio workshop?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004654

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)

(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004655

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004656

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004657

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004658

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004659

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (b)(6) ; Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004660

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004661

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004662

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

FOIA Confidential Treatment Requested by Univ of Texas System

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004664

Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004665

From: David Franz <davidrfranz@gmail.com>
Sent: Sunday, June 28, 2015 7:06 AM
To: Cheng Cao
Cc: Irene;LeDuc, James W.;Micah Lowenthal
Subject: Fwd: Next steps on the CAS NAS bio workshop?

Dear Cheng,

I hope you and your family are having a good summer. Please see the series of messages below. Ben has been working with the CAS point of contact and Jim and I have been working on the draft program that we discussed as well the invitees list from the US. I hope Dr. Wu or or someone from the China CDC have been in touch with you regarding the meeting organization and content. Ben is now out on a sabbatical leave for much of the summer but will be back before the meeting this fall. Micah Lowenthal, Program Director for our committee has stepped in to help from the NAS side. In a separate email I will forward you a copy of resumes of the US scientists that have agreed to take part in the September meeting. If you have a chance to touch base with Dr. Wu or others please do.

With all best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

Begin forwarded message:

From: "Rusek, Benjamin" <BRusek@nas.edu>
Subject: RE: Next steps on the CAS NAS bio workshop?
Date: June 16, 2015 5:47:58 PM EDT
To: '??' <wuying@im.ac.cn>
Cc: 孙辉 <sunhui@cashq.ac.cn>, Lei Zhang <zhanglei@ibp.ac.cn>, 高福 <gaof@im.ac.cn>, "James W. LeDuc" <jwleduc@UTMB.EDU>, 'David Franz' <davidrfranz@gmail.com>, "Lowenthal, Micah" <mlowenth@nas.edu>

Greetings Dr. Wu,

FOIA Confidential Treatment Requested by Univ of Texas System

Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.

David Franz	Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
James LeDuc	High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
Peter Palese	Influenza: "Paths to a Better Vaccine?"
Ruth Berkelman	Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
Thomas Ksiazek	Ebola: "Sustainable Austere Environment Laboratories"
Ralph Baric	MERS: "Genetic Systems and Models"
Diane Griffin	Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"

The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?

Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.

I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004594

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004595

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福 ; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers' abstracts of their talks and for each speaker please provide a

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004596

description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D

Administrator,

CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

Dear Ben,

Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.

Best Regards,

Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004597

〈wuying@im.ac.cn〉
抄送："Dave Franz (davidrfranz@gmail.com)" 〈davidrfranz@gmail.com〉, "Zhang Lei" 〈zhanglei@ibp.ac.cn〉, 'blning' 〈blning@cashq.ac.cn〉, "'Jinghua Cao'" 〈jh-cao@cashq.ac.cn〉, "张清泉" 〈qqzhang@cashq.ac.cn〉, "高福" 〈gaof@im.ac.cn〉, "jwleduc@UTMB.EDU" 〈jwleduc@UTMB.EDU〉
主题：Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004598

Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004599

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004600

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004601

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004602

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004603

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while w are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calenda year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tan experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System

Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)

David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in publi health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)

Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S National Academy of Sciences. Ben has supported successful NAS work in China for almost ten yea (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S Chinese workshops on nuclear forensics). Ben was the study director for the project that produce the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biologic Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Science since 2005. He has been a member of the Executive Board of International Student/Young Pugwas since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimso Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A in political science from Ohio State University and an M.A. in political science from Purdue Universit where he was the president of Purdue University Student Pugwash.

= =

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004605

致

礼！

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004606

Conference Call Agenda

TOPIC: China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security, September 29-30, 2015 in Beijing

WHEN: July 8, 2015 at 2:30 p.m. EDT, 60-90 minutes (we would like to devote most of the time to discussion of the content of the workshop)

The dial-in information for the call is:
Toll free: 888-537-7715
Access code: 12223052#

1. Welcome and goals for the call (Franz)
2. Introduction of participants: Baric, Franz, Griffin, Ksiazek, Le Duc, Palese, Rusek (see enclosed biographical sketches) (Note: Ruth Berkelman had to cancel)
3. Logistics: A walk through of the plans, visas, etc.—individual travel issues to be worked out separately (Lowenthal and Ahearn)
4. Objectives for the September workshop
5. History of CISAC members' interactions with experts in China (CBSG, CAS, and personal professional connections) and the planning trip in February (Franz, Le Duc)
6. Discussion of content and what we would like to accomplish with each session in the workshop. (Franz)

DRAFT AGENDA OF THE 2015 MEETING IN BEIJING

1. **Talk titles tentative**
2. **Need to discuss order of sessions**

The "Safety-Security-Regulation-Progress" Conundrum:
American Speaker: David Franz, "Finding the Balance Among Safety, Security, Regulation, and Progress: The U.S. Experience"
Chinese Speaker: Qiang Wei

Influenza
Chinese Speaker: Jinhua Liu & Yi Shi
American Speaker: Peter Palese, "Influenza: Paths to a Better Vaccine?"

Ebola
American Speaker: Thomas Ksiazek, "Ebola: Sustainable Austere Environment Laboratories"
Chinese Speaker: Wuchun Cao & Di Liu

Middle East Respiratory Syndrome (MERS)
American Speaker: Ralph Baric, "MERS: Genetic Systems and Models"
Chinese Speaker: Wenjie Tan and Deyin Guo

Gain of Function Research (include discussion of human germline modification?)
Chinese Speaker: Cheng Cao

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004545

American Speaker: (**Need Speaker**), "NAS Gain-of-Function Meeting Report (The scientists' view)"

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Chinese Speaker: Zhiming Yuan
American Speaker: James LeDuc, "High Containment Laboratories: Putting the pieces of laboratory safety and global health security together"

Areas for Enhanced Cooperation
American Speaker: Diane Griffin, "Possible roles for CAS and NAS in Enhancing Cooperation on these topics"
Chinese Speaker: George F Gao

---

7. The National Academies initiative on human gene-editing research (see http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=05182015) and a possible meeting on September 28 (Griffin and Lowenthal)
8. Other issues?
9. Adjourn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004546

Conference Call Agenda

TOPIC: China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security, September 29-30, 2015 in Beijing

WHEN: July 8, 2015 at 2:30 p.m. EDT, 60-90 minutes (we would like to devote most of the time to discussion of the content of the workshop)

The dial-in information for the call is:
Toll free: 888-537-7715
Access code: 12223052#

1. Welcome and goals for the call (Franz)
2. Introduction of participants: Baric, Franz, Griffin, Ksiazek, Le Duc, Palese, Rusek (see enclosed biographical sketches) (Note: Ruth Berkelman had to cancel)
3. Logistics: A walk through of the plans, visas, etc.—individual travel issues to be worked out separately (Lowenthal and Ahearn)
4. Objectives for the September workshop
5. History of CISAC members' interactions with experts in China (CBSG, CAS, and personal professional connections) and the planning trip in February (Franz, Le Duc)
6. Discussion of content and what we would like to accomplish with each session in the workshop. (Franz)

DRAFT AGENDA OF THE 2015 MEETING IN BEIJING

1. **Talk titles tentative**
2. **Need to discuss order of sessions**

The "Safety-Security-Regulation-Progress" Conundrum:
American Speaker: David Franz, "Finding the Balance Among Safety, Security, Regulation, and Progress: The U.S. Experience"
Chinese Speaker: Qiang Wei

Influenza
Chinese Speaker: Jinhua Liu & Yi Shi
American Speaker: Peter Palese, "Influenza: Paths to a Better Vaccine?"

Ebola
American Speaker: Thomas Ksiazek, "Ebola: Sustainable Austere Environment Laboratories"
Chinese Speaker: Wuchun Cao & Di Liu

Middle East Respiratory Syndrome (MERS)
American Speaker: Ralph Baric, "MERS: Genetic Systems and Models"
Chinese Speaker: Wenjie Tan and Deyin Guo

Gain of Function Research (include discussion of human germline modification?)
Chinese Speaker: Cheng Cao

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_045079

American Speaker: (**Need Speaker**), "NAS Gain-of-Function Meeting Report (The scientists' view)"

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Chinese Speaker: Zhiming Yuan
American Speaker: James LeDuc, "High Containment Laboratories: Putting the pieces of laboratory safety and global health security together"

Areas for Enhanced Cooperation
American Speaker: Diane Griffin, "Possible roles for CAS and NAS in Enhancing Cooperation on these topics"
Chinese Speaker: George F Gao

---

7. The National Academies initiative on human gene-editing research (see http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=05182015) and a possible meeting on September 28 (Griffin and Lowenthal)
8. Other issues?
9. Adjourn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_045080

From: LeDuc, James W.
Sent: Thursday, July 9, 2015 1:56 PM
To: Ksiazek, Thomas G.
Subject: FW: Next steps on the CAS NAS bio workshop?
Attachments: NAS speaker bios Sept 2015 mtng_v2.docx

fyi

From: Lowenthal, Micah [mailto:mlowenth@nas.edu]
Sent: Thursday, July 09, 2015 1:09 PM
To: 施一
Cc: 吴莹; masf@im.ac.cn; baiyu@im.ac.cn; 孙辉; Lei Zhang; 高福; LeDuc, James W.; David Franz
Subject: RE: Next steps on the CAS NAS bio workshop?

Dear Sam,

Thanks again for sending the Chinese participant list. As I mentioned in my last e-mail, our group held a conference call yesterday and we discussed the agenda, the participants, and logistics. I have included a brief description of each of these below.

Agenda:
The agenda looks good. We think that it would be useful to revise it with more details, assigning times to the sessions, adding tea breaks, and perhaps including a few sentences for each session, describing the content and objectives for that time. If you agree, we offer to draft this revised version with would then be subject to your revision and approval. It would probably be useful to session chair or moderator for each session. These might alternate between Chinese and American chairs, which brings me to participants.

Participants:
U.S. participants will necessarily be limited to the speakers and Ben Rusek as NAS staff. Because we will be in China, we anticipate that the Chinese group will be larger (perhaps 20 or 25?). In addition to speakers and attendees with no specific role, perhaps other distinguished experts interested in this workshop could participate as session chairs or moderators. For example, Prof. Mifang Liang from the CDC, who was most helpful to Dave and Ben in February, would bring expertise and experience in infectious-disease research in both China and the United States, and perhaps the director of the BSL-4 laboratory in development in Kunming would be interested. It is, of course, your decision whom to include; we just had this idea and decided to share it with you.
I have attached again the brief biographical sketches of the U.S. participants in the meeting. There has been one change: Dr. Ruth Berkelman sent her regrets that she cannot participate in the workshop. We are in the process of finding a replacement for her and we will send that information when we have identified that person.

Logistics:
We are beginning to make our travel arrangements now. We will need invitation letters from CAS for our group to obtain visas. For previous meetings, our hosts have issued a "Invitation Letter of Duly Authorized Unit" for a set of 5 travelers, listing name, sex, date of birth, nationality, and passport number, and we have used that letter to support visa applications for all of the travelers at the Chinese embassy in Washington. Please let me know if you will use this form of invitation or if CAS would like to use some other protocol. We would be glad to provide you with the travelers' information next week.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044945

As noted above, we are in the process of finding a replacement for Dr. Berkelman, so our list today is incomplete. Would you prefer that we send you the names (and dates of birth and passport numbers) we have now or should we wait until we have all of them?

Finally, I will note that we will have a half-day meeting with other CAS experts on Monday, September 28, on human germline editing. My counterpart in arranging that meeting is Mr. Cao Jinghua (Deputy Director of the Bureau of International Cooperation, CAS).

I apologize for this rather long e-mail. I look forward to making progress with you on planning the workshop.
With best regards,
Micah

From: Lowenthal, Micah
Sent: Friday, July 03, 2015 9:08 AM
To: 施一
Cc: Lowenthal, Micah; 吴莹; masf@im.ac.cn; baiyu@im.ac.cn; @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; David Franz
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Sam,
Nice to meet you, too. Thank you for this information.
Our group will hold a conference call next week. I will contact you again after that discussion.
With best regards,
Micah

On Jul 3, 2015, at 2:37 AM, "施一" <shiyi@im.ac.cn> wrote:

Dear Micah,

I am Yi Shi, you can call me Sam. Nice to meet you.

For September 29-30 meeting, George have suggested a list of Chinese experts.

Qiang Wei	Safety, Security, Regulation and Progress
Zhiming Yuan	High Containment Labs
Jinhua Liu, Yi Shi	Influenza
Cheng Cao	Gain of Function
Wuchun Cao, Di Liu	Ebola
Wenjie Tan, Deyin Guo	MERS
George F Gao	Areas for Enhanced Cooperation

Later we'll collect their CVs and talk topics.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044946

Best Wishes.

Sam
Ph.D
CAS Key Laboratory of Pathogenic Microbiology and Immunology(CASPMI)
Institute of Microbiology, Chinese Academy of Sciences (IMCAS)
1#, BeiChenXi Road, Chaoyang District
Beijing
P.R.China
Zip Code:100101
Tel: 86-10-64807569(o)
Fax: 86-10-64807598

Lowenthal, Micah 写:
Dear Ying,
On behalf of my colleagues here, Congratulations! We will gladly work with Dr. Shi and Dr. Ma. We wish you and your family good fortune and great happiness.
Micah

Dear Dr. Shi and Dr. Ma,
It is nice to make your acquaintance by e-mail. The long string of correspondence about this meeting is below. You will see the history of the discussions, including in the May 13 e-mail from Dr. Franz a description of discussions with the Chinese Biological Scientists Group and Dr. Cheng Cao of the Beijing Institute of Biotechnology, and later exchanges concerning the agenda. Attached please find brief biographical sketches of the planned U.S. participants in the September 29-30 meeting.

Also, I have attached a letter from the President of the National Academy of Sciences (NAS), the President of the National Academy of Medicine (NAM), and the Vice President of the NAS to the President of the Chinese Academy of Sciences. The NAS and NAM are conducting a study and a workshop on genome editing technologies and their implications. The letter suggests that we could make good use of the opportunity of having a set of life-science experts from the NAS in Beijing to have a discussion of genome editing issues on September 28. We wanted to you to know about this correspondence and we would be glad to discuss the possible meeting.

Thank you for your attention to these matters. We look forward to working with you.
Micah Lowenthal

From: 吴莹 [wuying@im.ac.cn]
Sent: Sunday, June 28, 2015 2:31 AM
To: Lowenthal, Micah; shiyi@im.ac.cn; masf@im.ac.cn; baiyu@im.ac.cn
Cc: @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Micah,

Sorry to say that (b)(6) and could not get access to network timely.We are contacting the potential Chinese speakers these days and will be fixed soon. My colleagues

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044947

Dr.YiShi(shiyi@im.ac.cn), Dr.Sufang Ma(masf@im.ac.cn) and Ms YuBai(baiyu@im.ac.cn) will follow up this issue in my absence. I also copied this email to them. Hope everything goes smoothly.

Best,
Ying

Lowenthal, Micah 写:

Dear Dr. Wu,

At the end of his e-mail to you, Ben Rusek mentioned that he will be on a sabbatical until 17 August. I will serve as the NAS staff contact for this activity over the next two months, until Ben returns. Please feel free to contact me with any questions, concerns, or requests. We can begin by providing you with brief biographical sketches of the participants listed below, if that would be useful to you.

With best regards,

Micah

Micah D. Lowenthal, Ph.D.
Program Director, Policy and Global Affairs Division
The National Academy of Sciences
500 Fifth Street, NW 5th floor
Washington, DC 20001 USA
telephone: +1 (202) 334-3074
fax: +1 (202) 334-1730
e-mail: mlowenthal@nas.edu

From: Rusek, Benjamin
Sent: Tuesday, June 16, 2015 5:48 PM
To: '??'
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'; Lowenthal, Micah
Subject: RE: Next steps on the CAS NAS bio workshop?
Importance: High

Greetings Dr. Wu,

Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.

David Franz	Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
James LeDuc	High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
Peter Palese	Influenza: "Paths to a Better Vaccine?"
Ruth Berkelman	Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
Thomas Ksiazek	Ebola: "Sustainable Austere Environment Laboratories"
Ralph Baric	MERS: "Genetic Systems and Models"
Diane Griffin	Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"

The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?

Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044948

I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044949

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)

(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044950

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers' abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D
Administrator,
CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044951

Dear Ben,
Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.
Best Regards,
Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044952

Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044953

help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044954

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044955

Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd, Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044956

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044957

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044958

including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
(b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)
David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044959

to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)
Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044960

U.S. National Academy of Sciences Planned Participants in
The China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety, and Global Health Security
29-30 September 2015
Chinese Academy of Sciences Institute of Microbiology, Beijing

Dr. Ralph Baric
University of North Carolina

Ralph Baric is a Research Professor in Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Public Health. The Baric Group uses genetic, immunologic and biochemical approaches to study the molecular mechanisms regulating viral replication, pathogenesis, evolution, virus-host interactions and cross species transmission using coronaviruses and noroviruses as model systems. In recent work, he has used a human antibody-phage library to identify seven human neutralizing antibodies specific for the receptor-binding domain of the MERS-CoV Spike protein. He is a fellow of the American Society for Microbiology and a member of the American Society for Virology and the American Association for the Advancement of Science. Dr. Baric received his Ph.D. in Microbiology from North Carolina State University and was a post-doctoral fellow at the University Of Southern California School Of Medicine in the Department of Microbiology and Neurology.

Dr. David R. Franz
Former Commander, U.S. Army Medical Research Institute for Infectious Diseases

David R. Franz, D.V.M., Ph.D., holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. His current focus and research relates to the role of international engagement in the life sciences as a component of national security policy. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine. Dr. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq. He also served as a member of the first two U.S.-U.K. teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Dr. Franz has co-chaired, chaired or served as a member on over twenty NAS committees.

Dr. Diane E. Griffin
The Johns Hopkins University

FOIA Confidential Treatment Requested by Univ of Texas System

Diane E. Griffin, M.D., Ph.D. is Vice President of the National Academy of Sciences and Professor and Alfred and Jill Sommer Chair of the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins University. Dr. Griffin focuses her work on alphaviruses, acute encephalitis, measles, and malaria. She has identified determinants of virus virulence and mechanisms of noncytolytic clearance of virus from infected neurons. She is also working on the effect of measles virus infection and immune activation in response to infection on the immune system. In Zambia, she and her colleagues are examining the effect of HIV infection on measles and measles virus vaccination. She is a past president of the American Society for Virology, Association of Medical School Microbiology Chairs, and American Society for Microbiology, and a member of the American Academy of Microbiology. She was elected to the National Academy of Sciences and the Institute of Medicine and serves on the councils for both. Dr. Griffin earned a Biology degree from Augustana College, followed by an M.D. and a Ph.D. from Stanford University. She completed her residency in Internal Medicine at Stanford University Hospital.

Dr. James Le Duc
University of Texas Medical Branch

James LeDuc, Ph.D., is the director of the Galveston National Laboratory (GNL) located on the campus of the University of Texas Medical Branch (UTMB) in Galveston, Texas and holds the inaugural Robert E. Shope, M.D. and John S. Dunn Distinguished Chair in Global Health. Dr. LeDuc joined UTMB in late 2006 from the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, where he held various positions including influenza coordinator (2005-2006), director of the Division of Viral and Rickettsial Diseases (2000-2005), and associate director for the Center for Global Health (1996-2000). He was a medical officer in charge of arboviruses and viral hemorrhagic fevers at the World Health Organization in Geneva, Switzerland (1992-1996) and he held leadership positions during a 23-year career as a United States Army officer in the medical research and development command, with assignments in Brazil, Panama, and at various locations in the United States, including the Walter Reed Army Institute of Research and the United States Army Medical Research Institute of Infectious Diseases. He is a member of various professional organizations, has published over 200 scientific articles and book chapters, and is well recognized as an expert in viral diseases, biodefense, and global health. Dr. Le Duc earned his M.S.P.H. and Ph.D. degrees from the University of California at Los Angeles.

Dr. Peter Palese
Icahn School of Medicine at Mount Sinai

Peter Palese, Ph.D. (NAS, IOM), is Professor of Microbiology and Chair of the Department of Microbiology at the Mount Sinai School of Medicine in New York. He has over 270 scientific publications that include research on the replication of RNA-containing viruses with a special emphasis on influenza viruses, which are negative-strand RNA viruses. Specifically, he established the first genetic maps for influenza A, B and C viruses, identified the function of several viral genes, and defined the mechanism of neuraminidase inhibitors (which are now FDA-approved antivirals). Dr. Palese also pioneered the field of reverse genetics for negative

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044962

strand RNA viruses, which allows the introduction of site-specific mutations into the genomes of these viruses. This technique is crucial for the study of the structure/function relationships of viral genes, for investigation of viral pathogenicity and for development and manufacture of novel vaccines. In addition, an improvement of the technique has been effectively used by him and his colleagues to reconstruct and study the pathogenicity of the highly virulent but extinct 1918 pandemic influenza virus. His recent work in collaboration with Garcia-Sastre has revealed that most negative strand RNA viruses possess proteins with interferon antagonist activity, enabling them to counteract the antiviral response of the infected host. Dr. Palese was elected to the National Academy of Sciences in 2000 for his seminal studies on influenza viruses. At present he serves on the editorial board for the Proceedings of the National Academy of Sciences and as an editor for the Journal of Virology. Dr. Palese was president of the Harvey Society in 2004, president of the American Society for Virology in 2005 and he was a recipient of the Robert Koch Prize in 2006 and of the Charles C. Shepard Science Award in 2008.

Dr. Thomas Ksiazek
University of Texas Medical Branch

Thomas Ksiazek is the director of high containment laboratory operations for the Galveston National Laboratory at the University of Texas Medical Branch. In addition to his work for the Galveston National Laboratory, he is a professor in the departments of pathology and microbiology and immunology at the University of Texas Medical Branch. Dr. Ksiazek is also director of the National Biodefense Training Center and a world-renowned virus expert with 40 years of experience on the front lines of some of the worst outbreaks the world has ever seen. Before coming to the medical branch, he was chief of the Special Pathogens Branch at the CDC in Atlanta where he coordinated outbreak and control responses to especially dangerous pathogens such as Ebola, Marburg and SARS. He was one of the discoverers of the SARS virus. Through the years, he has played a significant role in disease discovery and outbreak response efforts in Asia, Africa, South America and the Middle East. He has a bachelor's degree in biological sciences and a DVM from Kansas State University, a master's degree in virology from the University of Wisconsin, Madison, and a Ph.D. in epidemiology/virology from the University of California, Berkeley. He is the author of more than 350 research papers.

Benjamin Rusek
The National Academy of Sciences

Benjamin Rusek, senior program officer for in the Policy and Global Affairs Division of the National Academies of Sciences, Engineering, and Medicine. He has supported successful collaborative work with Chinese counterparts for more than ten years, serving as the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* (2012). He has organized workshops in India, Brazil, and other countries, often focused on the life sciences. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP from 2008-2013. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_044963

From: sunhui@cashq.ac.cn
Sent: Thursday, July 9, 2015 10:03 PM
To: Lowenthal, Micah;施一
Cc: 吴莹;masf@im.ac.cn;baiyu@im.ac.cn;Lei Zhang;高福;LeDuc, James W.;David Franz;宁博伦
Subject: Re: RE: Next steps on the CAS NAS bio workshop?

Dear Micah,

Regarding the half-day meeting on human germline editing on September 28, we are fully aware of the exchange of emails between CAS and NAS Presidents in the past weeks. As you may know, Prof. XU Zhihong, Former President of Beijing University will take the lead for this particular meeting on the Chinese side. Since NAS Vice President will attend the meeting on Sept 28, CAS VP Yaping Zhang may also attend. My colleague Mr. Bolun Ning(blning@cashq.ac.cn) will help Prof. Xu to coordinate this meeting. Please do not hesitate to contact us if you have any questions about the human germline editing meeting. For the CAS-NAS Joint workshop on Sept 29-30, please still coordinate with the staffs at the Instiute of Microbiology.

Best Regards,

Sun Hui

2015-07-10
SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Lowenthal, Micah
发送时间： 2015-07-10 02:08:42
收件人： 施一
抄送： 吴莹; masf@im.ac.cn; baiyu@im.ac.cn; 孙辉; Lei Zhang; 高福; JamesW. LeDuc; David Franz
主题： RE: Next steps on the CAS NAS bio workshop?

Dear Sam,

Thanks again for sending the Chinese participant list. As I mentioned in my last e-mail, our group held a conference call yesterday and we discussed the agenda, the participants, and logistics. I have included a brief description of each of these below.

Agenda:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004441

The agenda looks good. We think that it would be useful to revise it with more details, assigning times to the sessions, adding tea breaks, and perhaps including a few sentences for each session, describing the content and objectives for that time. If you agree, we offer to draft this revised version with would then be subject to your revision and approval. It would probably be useful to session chair or moderator for each session. These might alternate between Chinese and American chairs, which brings me to participants.

Participants:
U.S. participants will necessarily be limited to the speakers and Ben Rusek as NAS staff. Because we will be in China, we anticipate that the Chinese group will be larger (perhaps 20 or 25?). In addition to speakers and attendees with no specific role, perhaps other distinguished experts interested in this workshop could participate as session chairs or moderators. For example, Prof. Mifang Liang from the CDC, who was most helpful to Dave and Ben in February, would bring expertise and experience in infectious-disease research in both China and the United States, and perhaps the director of the BSL-4 laboratory in development in Kunming would be interested. It is, of course, your decision whom to include; we just had this idea and decided to share it with you.
I have attached again the brief biographical sketches of the U.S. participants in the meeting. There has been one change: Dr. Ruth Berkelman sent her regrets that she cannot participate in the workshop. We are in the process of finding a replacement for her and we will send that information when we have identified that person.

Logistics:
We are beginning to make our travel arrangements now. We will need invitation letters from CAS for our group to obtain visas. For previous meetings, our hosts have issued a "Invitation Letter of Duly Authorized Unit" for a set of 5 travelers, listing name, sex, date of birth, nationality, and passport number, and we have used that letter to support visa applications for all of the travelers at the Chinese embassy in Washington. Please let me know if you will use this form of invitation or if CAS would like to use some other protocol. We would be glad to provide you with the travelers' information next week.

As noted above, we are in the process of finding a replacement for Dr. Berkelman, so our list today is incomplete. Would you prefer that we send you the names (and dates of birth and passport numbers) we have now or should we wait until we have all of them?

Finally, I will note that we will have a half-day meeting with other CAS experts on Monday, September 28, on human germline editing. My counterpart in arranging that meeting is Mr. Cao Jinghua (Deputy Director of the Bureau of International Cooperation, CAS).

I apologize for this rather long e-mail. I look forward to making progress with you on planning the workshop.
With best regards,
Micah

From: Lowenthal, Micah
Sent: Friday, July 03, 2015 9:08 AM
To: 施一
Cc: Lowenthal, Micah; 吴莹; masf@im.ac.cn; baiyu@im.ac.cn; @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; David Franz
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Sam,
Nice to meet you, too. Thank you for this information.
Our group will hold a conference call next week. I will contact you again after that discussion.
With best regards,
Micah

On Jul 3, 2015, at 2:37 AM, " 施一" <shiyi@im.ac.cn> wrote:

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004442

Dear Micah,

I am Yi Shi, you can call me Sam. Nice to meet you.

For September 29-30 meeting, George have suggested a list of Chinese experts.

Qiang Wei	Safety, Security, Regulation and Progress
Zhiming Yuan	High Containment Labs
Jinhua Liu, Yi Shi	Influenza
Cheng Cao	Gain of Function
Wuchun Cao, Di Liu	Ebola
Wenjie Tan, Deyin Guo	MERS
George F Gao	Areas for Enhanced Cooperation

Later we'll collect their CVs and talk topics.

Best Wishes.

Sam
Ph.D
CAS Key Laboratory of Pathogenic Microbiology and Immunology(CASPMI)
Institute of Microbiology, Chinese Academy of Sciences (IMCAS)
1#, BeiChenXi Road, Chaoyang District
Beijing
P.R.China
Zip Code:100101
Tel: 86-10-64807569(o)
Fax: 86-10-64807598

> Lowenthal, Micah 写:
> Dear Ying,
> On behalf of my colleagues here, Congratulations! We will gladly work with Dr. Shi and Dr. Ma. We wish you and your family good fortune and great happiness.
> Micah
>
> Dear Dr. Shi and Dr. Ma,
> It is nice to make your acquaintance by e-mail. The long string of correspondence about this meeting is below. You will see the history of the discussions, including in the May 13 e-mail from Dr. Franz a description of discussions with the Chinese Biological Scientists Group and Dr. Cheng Cao of the Beijing Institute of Biotechnology, and later exchanges concerning the agenda. Attached please find brief biographical sketches of the planned U.S. participants in the September 29-30 meeting.
>
> Also, I have attached a letter from the President of the National Academy of Sciences (NAS), the President of the National Academy of Medicine (NAM), and the Vice President of the NAS to the President of the Chinese Academy of Sciences. The NAS and NAM are conducting a study and a workshop on genome editing technologies and their implications. The letter suggests that we could make good use of the opportunity of having a set of life-science experts from the NAS in Beijing to have a discussion of genome editing issues on September 28. We wanted to you to know about this correspondence and we would be glad to discuss the possible meeting.
>
> Thank you for your attention to these matters. We look forward to working with you.
> Micah Lowenthal

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004443

From: 吴莹 [wuying@im.ac.cn]
Sent: Sunday, June 28, 2015 2:31 AM
To: Lowenthal, Micah; shiyi@im.ac.cn; masf@im.ac.cn; baiyu@im.ac.cn
Cc: @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Micah,

Sorry to say that (b)(6) and could not get access to network timely.We are contacting the potential Chinese speakers these days and will be fixed soon. My colleagues Dr.YiShi(shiyi@im.ac.cn), Dr.Sufang Ma(masf@im.ac.cn) and Ms YuBai(baiyu@im.ac.cn) will follow up this issue in my absence. I also copied this email to them. Hope everything goes smoothly.

Best,
Ying

Lowenthal, Micah 写:

Dear Dr. Wu,
At the end of his e-mail to you, Ben Rusek mentioned that he will be on a sabbatical until 17 August. I will serve as the NAS staff contact for this activity over the next two months, until Ben returns. Please feel free to contact me with any questions, concerns, or requests. We can begin by providing you with brief biographical sketches of the participants listed below, if that would be useful to you.
With best regards,
Micah

Micah D. Lowenthal, Ph.D.
Program Director, Policy and Global Affairs Division
The National Academy of Sciences
500 Fifth Street, NW 5th floor
Washington, DC 20001 USA
telephone: +1 (202) 334-3074
fax: +1 (202) 334-1730
e-mail: mlowenthal@nas.edu

From: Rusek, Benjamin
Sent: Tuesday, June 16, 2015 5:48 PM
To: '??'
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'; Lowenthal, Micah
Subject: RE: Next steps on the CAS NAS bio workshop?
Importance: High

Greetings Dr. Wu,

Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.

David Franz	Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
James LeDuc	High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
Peter Palese	Influenza: "Paths to a Better Vaccine?"
Ruth Berkelman	Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
Thomas Ksiazek	Ebola: "Sustainable Austere Environment Laboratories"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004444

Ralph Baric MERS: "Genetic Systems and Models"
Diane Griffin Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"

The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?

Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.

I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004445

Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004446

; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.
According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers'abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D
Administrator,
CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:
Dear Ben,
Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.
Best Regards,
Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004447

<gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004448

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004449

抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004450

收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Dr. Hui,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004451

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (b)(6)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted] office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004452

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好！

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004453

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975
Cell: (b)(6)
Fax: 001-202-334-1730
Skype: (b)(6)

David Franz (Independent Consultant, United States)
David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004454

University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)
Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼！

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004455

From: 施一 <shiyi@im.ac.cn>
Sent: Friday, July 10, 2015 4:33 AM
To: Lowenthal, Micah
Cc: 吴莹;masf@im.ac.cn;baiyu@im.ac.cn;孙辉;Lei Zhang;高福;LeDuc, James W.;David Franz
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Micah,

Glad to receive your letter.

For the Agenda, please give us a draft and we will revise it.

For participants, it is a good suggestion to add some exprerts as session moderators, for example Prof. Mifang Liang.

For the invitation letter, please give us a template and we will prepare it soon.

All the best.

Sam
Ph.D
CAS Key Laboratory of Pathogenic Microbiology and Immunology(CASPMI)
Institute of Microbiology, Chinese Academy of Sciences (IMCAS)
1#, BeiChenXi Road, Chaoyang District
Beijing
P.R.China
Zip Code:100101
Tel: 86-10-64807569(o)
Fax: 86-10-64807598

> Lowenthal, Micah 写:
> Dear Sam,
>
> Thanks again for sending the Chinese participant list. As I mentioned in my last e-mail, our group held a conference call yesterday and we discussed the agenda, the participants, and logistics. I have included a brief description of each of these below.
>
> **Agenda:**

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004515

The agenda looks good. We think that it would be useful to revise it with more details, assigning times to the sessions, adding tea breaks, and perhaps including a few sentences for each session, describing the content and objectives for that time. If you agree, we offer to draft this revised version with would then be subject to your revision and approval. It would probably be useful to session chair or moderator for each session. These might alternate between Chinese and American chairs, which brings me to participants.

Participants:
U.S. participants will necessarily be limited to the speakers and Ben Rusek as NAS staff. Because we will be in China, we anticipate that the Chinese group will be larger (perhaps 20 or 25?). In addition to speakers and attendees with no specific role, perhaps other distinguished experts interested in this workshop could participate as session chairs or moderators. For example, Prof. Mifang Liang from the CDC, who was most helpful to Dave and Ben in February, would bring expertise and experience in infectious-disease research in both China and the United States, and perhaps the director of the BSL-4 laboratory in development in Kunming would be interested. It is, of course, your decision whom to include; we just had this idea and decided to share it with you.
I have attached again the brief biographical sketches of the U.S. participants in the meeting. There has been one change: Dr. Ruth Berkelman sent her regrets that she cannot participate in the workshop. We are in the process of finding a replacement for her and we will send that information when we have identified that person.

Logistics:
We are beginning to make our travel arrangements now. We will need invitation letters from CAS for our group to obtain visas. For previous meetings, our hosts have issued a "Invitation Letter of Duly Authorized Unit" for a set of 5 travelers, listing name, sex, date of birth, nationality, and passport number, and we have used that letter to support visa applications for all of the travelers at the Chinese embassy in Washington. Please let me know if you will use this form of invitation or if CAS would like to use some other protocol. We would be glad to provide you with the travelers' information next week.

As noted above, we are in the process of finding a replacement for Dr. Berkelman, so our list today is incomplete. Would you prefer that we send you the names (and dates of birth and passport numbers) we have now or should we wait until we have all of them?

Finally, I will note that we will have a half-day meeting with other CAS experts on Monday, September 28, on human germline editing. My counterpart in arranging that meeting is Mr. Cao Jinghua (Deputy Director of the Bureau of International Cooperation, CAS).

I apologize for this rather long e-mail. I look forward to making progress with you on planning the workshop.
With best regards,
Micah

From: Lowenthal, Micah
Sent: Friday, July 03, 2015 9:08 AM
To: 施一
Cc: Lowenthal, Micah; 吴莹; masf@im.ac.cn; baiyu@im.ac.cn; @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; David Franz
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Sam,
Nice to meet you, too. Thank you for this information.
Our group will hold a conference call next week. I will contact you again after that discussion.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004516

With best regards,
Micah

On Jul 3, 2015, at 2:37 AM, ″ 施一″ <shiyi@im.ac.cn> wrote:

Dear Micah,

I am Yi Shi, you can call me Sam. Nice to meet you.

For September 29-30 meeting, George have suggested a list of Chinese experts.

Qiang Wei	Safety, Security, Regulation and Progress
Zhiming Yuan	High Containment Labs
Jinhua Liu, Yi Shi	Influenza
Cheng Cao	Gain of Function
Wuchun Cao, Di Liu	Ebola
Wenjie Tan, Deyin Guo	MERS
George F Gao	Areas for Enhanced Cooperation

Later we'll collect their CVs and talk topics.

Best Wishes.

Sam
Ph.D
CAS Key Laboratory of Pathogenic Microbiology and Immunology(CASPMI)
Institute of Microbiology, Chinese Academy of Sciences (IMCAS)
1#, BeiChenXi Road, Chaoyang District
Beijing
P.R.China
Zip Code:100101
Tel: 86-10-64807569(o)
Fax: 86-10-64807598

Lowenthal, Micah 写:
Dear Ying,
On behalf of my colleagues here, Congratulations! We will gladly work with Dr. Shi and Dr. Ma. We wish you and your family good fortune and great happiness.
Micah

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004517

Dear Dr. Shi and Dr. Ma,
It is nice to make your acquaintance by e-mail. The long string of correspondence about this meeting is below. You will see the history of the discussions, including in the May 13 e-mail from Dr. Franz a description of discussions with the Chinese Biological Scientists Group and Dr. Cheng Cao of the Beijing Institute of Biotechnology, and later exchanges concerning the agenda. Attached please find brief biographical sketches of the planned U.S. participants in the September 29-30 meeting.

Also, I have attached a letter from the President of the National Academy of Sciences (NAS), the President of the National Academy of Medicine (NAM), and the Vice President of the NAS to the President of the Chinese Academy of Sciences. The NAS and NAM are conducting a study and a workshop on genome editing technologies and their implications. The letter suggests that we could make good use of the opportunity of having a set of life-science experts from the NAS in Beijing to have a discussion of genome editing issues on September 28. We wanted to you to know about this correspondence and we would be glad to discuss the possible meeting.

Thank you for your attention to these matters. We look forward to working with you.
Micah Lowenthal

From: 吴莹 [wuying@im.ac.cn]
Sent: Sunday, June 28, 2015 2:31 AM
To: Lowenthal, Micah; shiyi@im.ac.cn; masf@im.ac.cn; baiyu@im.ac.cn
Cc: @im.ac.cn; 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Micah,

Sorry to say that (b)(6) and could not get access to network timely.We are contacting the potential Chinese speakers these days and will be fixed soon. My colleagues Dr.YiShi(shiyi@im.ac.cn), Dr.Sufang Ma(masf@im.ac.cn) and Ms YuBai(baiyu@im.ac.cn) will follow up this issue in my absence. I also copied this email to them. Hope everything goes smoothly.

Best,
Ying

Lowenthal, Micah 写:
Dear Dr. Wu,
At the end of his e-mail to you, Ben Rusek mentioned that he will be on a sabbatical until 17 August. I will serve as the NAS staff contact for this activity over the next two months, until Ben returns. Please feel free to contact me with any questions, concerns, or requests. We can begin by providing you with brief biographical sketches of the participants listed below, if that would be useful to you.
With best regards,
Micah

Micah D. Lowenthal, Ph.D.
Program Director, Policy and Global Affairs Division
The National Academy of Sciences
500 Fifth Street, NW 5th floor
Washington, DC 20001 USA
telephone: +1 (202) 334-3074
fax: +1 (202) 334-1730
e-mail: mlowenthal@nas.edu

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004518

From: Rusek, Benjamin
Sent: Tuesday, June 16, 2015 5:48 PM
To: '??'
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'; Lowenthal, Micah
Subject: RE: Next steps on the CAS NAS bio workshop?
Importance: High

Greetings Dr. Wu,

Sorry for the delayed response. The group we have assembled to attend the workshop on September 29-30 at the CAS Institute of Microbiology is below along with a draft of their talk topic.

David Franz	Safety, Security, Regulation and Progress: "Finding the Balance: The US Experience"
James LeDuc	High Containment Labs: "Putting the pieces of laboratory safety and global health security together"
Peter Palese	Influenza: "Paths to a Better Vaccine?"
Ruth Berkelman	Gain of Function: "NAS Gain of Function Meeting Report (The scientists' view)"
Thomas Ksiazek	Ebola: "Sustainable Austere Environment Laboratories"
Ralph Baric	MERS: "Genetic Systems and Models"
Diane Griffin	Areas for Enhanced Cooperation: "Possible roles for CAS and NAS in these areas"

The MERS-CoV suggestion is a good one and we have invited an expert to discuss the topic (and added a seventh session as you suggest). We will send you the experts biographical information as soon as we can. Have you started to reach out to Chinese experts who could speak during the sessions?

Re logistics we are in the process of making travel arrangements and will need to work with CAS to arrange for visa invitation letters in the coming weeks.

I want to let you know that I will be out of the office on a sabbatical from Thursday, June 18 until Monday, August 17. Micah Lowenthal (cced) my NAS colleague in the Policy and Global Affairs Division will be working on the project in my absence. David Franz with James LeDuc (both also cced) are still leading the planning committee on the NAS side and will likely be in contact with you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Wednesday, June 10, 2015 1:40 AM
To: Rusek, Benjamin
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; 'David Franz'
Subject: Re: Next steps on the CAS NAS bio workshop?

Hi Ben,

We are totally agree on the six sessions you suggested. As MERS-CoV is the new coming global threat shall we also add MERS as another session?
How are things going on from your side?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004519

Best,

Ying Wu

Rusek, Benjamin 写:
Greetings Dr. Wu,

I wanted to let you know that Dr. Franz reached out to Dr. Cheng Cao about the meeting and gave him your contact information. Hopefully he will be in touch soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: David Franz [mailto:davidrfranz@gmail.com]
Sent: Wednesday, May 13, 2015 11:37 AM
To: ??
Cc: 孙辉; Lei Zhang; 高福; James W. LeDuc; Rusek, Benjamin
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Dr Wu,

It's good to connect with you. Thanks for your note to Ben. I will be helping to organize the content of the meeting from this end and it appears from your note that you believe the topics which we discussed during our visit to Beijing seem reasonable. This is to let you know that we have general agreement among our (US) committee that these will be relevant and useful points for our meeting discussions. I welcome your thoughts if you wish to make new recommendations, additions or deletions to the short sessions list: *Influenza, Ebola, Gain of Function, Safety-Security-Regulation-Progress, Sustainable High-containment labs and Opportunities for further cooperation.* As soon as we can settle on the topics we can select the US experts who will take part in the meeting and send you their particulars.

I would also mention that Dr. LeDuc and I (through our NAS committee) have been working closely re. biosafety/biosecurity issues with the Chinese Biological Scientists Group, chaired by Wang Hanggyang of the Chinese National Biotechnology Center for some years. I mentioned to Dr. Gao Fu that we have discussed the planned meeting with Dr. Cheng Cao of the Beijing Institute of Biotechnology and would like to have Dr. Cao involved. You may know him as well. Thank you for that consideration.

Please feel free to stay in touch with me if you have suggestions, questions or concerns that I might help address from this end.

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004520

Best wishes, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)

(b)(6)

On May 11, 2015, at 6:07 PM, Rusek, Benjamin wrote:

Greetings Dr. Wu,

Thank you for your reply. We are very grateful that the CAS Institute of Microbiology will be able to host the meeting on Sept 29-30, 2015.
Before we invite the speakers it would be helpful to have some of your experts examine the list of proposed agenda topics that I outline below. Their thoughts and comments on the six proposed agenda topics will help us invite the right U.S. and Chinese speakers.
And thank you for pointing me to the China National Convention Center Grand Hotel, it is close to the InterContinental Hotel where Dr. Franz and I stayed in February. I will need to talk to the members of U.S. group before deciding on the hotel and will get back to you.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: 吴莹 [mailto:wuying@im.ac.cn]
Sent: Sunday, May 10, 2015 4:39 AM
To: Rusek, Benjamin
Cc: 孙辉; Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福 ; jwleduc@UTMB.EDU
Subject: Re: Next steps on the CAS NAS bio workshop?

Dear Ben,
We are happy to host this workshop and the meeting can be held in our Institute of Microbiology, CAS. We could also help to book the hotel. There's one just 5 mins walk to our institute. You can find the info of this hotel through the link below.

http://www.cnccchina.com/en/Hotel/Default.aspx

Yes we can fix the dates of this meeting on September 29th-30th, 2015 and September 28th is the day for registration at the hotel.

FOIA Confidential Treatment Requested by Univ of Texas System

According to your suggested topics of this meeting we need to determine the invited speakers as soon as possible. Please help us to collect all the US speakers' abstracts of their talks and for each speaker please provide a description in one-paragraph including his/her brief CV and research interest.

For the Chinese side we will determine and invite the Chinese speakers and participants soon.

Please feel free to contact me.

Best,

Ying Wu, Ph.D
Administrator,
CAS Key Laboratory of Pathogenic Microbiology
and Immunology, Institute of Microbiology,
Chinese Academy of Sciences
Beijing 100101, PR China
Tel: 86-10-64807688
Fax: 86-10-64807882

孙辉 写:
Dear Ben,
Thank you for sending us the thought about the joint workshop. The proposed scale of the workshop is smalled than what we discussed last time in Beijing, but I think this should be fine with us. Given the scale of the workshop, I think it not so necessary to have a complicated committee to organize the workshop, maybe 2 people from each side will be fine. I am asking George Gao and his assistant Wu Ying to respond to your questions.
Best Regards,
Sun Hui

-----原始邮件-----
发件人: "Rusek, Benjamin" <BRusek@nas.edu>
发送时间: 2015年5月7日 星期四
收件人: "'sunhui@cashq.ac.cn'" <sunhui@cashq.ac.cn>, "吴莹" <wuying@im.ac.cn>
抄送: "Dave Franz (davidrfranz@gmail.com)" <davidrfranz@gmail.com>, "Zhang Lei" <zhanglei@ibp.ac.cn>, 'blning' <blning@cashq.ac.cn>, "'Jinghua Cao'" <jh-cao@cashq.ac.cn>, "张清泉" <qqzhang@cashq.ac.cn>, "高福" <gaof@im.ac.cn>, "jwleduc@UTMB.EDU" <jwleduc@UTMB.EDU>
主题: Next steps on the CAS NAS bio workshop?

Greetings Hui,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004522

I hope you are well. Thank you for working with me to help our VPs come to agreement about holding a China-U.S. Workshop on the Challenges of Emerging Infections, Laboratory Safety and Global Health Security in Beijing later this year. I am a bit unclear on next steps so to try and move the process forward I thought I would get back in touch. The email below includes a few proposals that we think will help move the workshop planning process forward. For your information I have attached the first draft of the invitation letter for U.S. experts that we hope to send out once we get a few of the issues below settled.

Organizing Committee: We have discussed putting together an informal organizing committee to guild the project. Dave Franz, James LeDuc, and Diane Griffin can serve on the U.S. side. Dr. Gao Fu (with Dr. Ying Wu) has agreed to lead the Chinese side but it would be helpful to identify a few others. Mifang Liang and Lei Zhang were most helpful during our visit in February and we believe they could make an excellent contribution to the planning and organization of the meeting and it would be useful to involve Chen Cao from the CBSG, but the decision regarding committee members on the Chinese side will of course be yours. The key function of the organizing committee is to decide on the topics that will make up the agenda and then invite experts from each side to speak to the topics so it is important to set the group soon.

U.S.	China
D Franz	Gao Fu (CDC/CAS)
J Leduc	CBSG rep
D Griffin	CAS rep
Others?	Others?

Possible Session Topics (NAS suggestions) **and Speakers:**

Influenza
Potential Chinese Speaker: Gao Fu (NAS suggestion)
Potential American Speaker: (TBD)

Ebola
Potential American Speaker: Thomas Ksiazek
Potential Chinese Speaker: (TBD)

Gain of Function Research (also might include discussion on Human Germline Genetic Modification)
Potential Chinese Speaker: PI from China's National Avian Influenza Reference Laboratory at the Harbin Veterinary Research Institute (NAS suggestion)
Potential American Speaker: (TBD)
Potential Chinese Speaker: (TBD)
Potential American Speaker: (TBD)

The "Safety-Security-Regulation-Progress" Conundrum:
Potential American Speaker: David Franz
Potential Chinese Speaker: (TBD)

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Potential Chinese Speaker: Director of the Wuhan Institute of Virology (WIV) of the Chinese Academy of Sciences (CAS) (NAS suggestion)
Potential American Speaker: James Leduc

Areas for Enhanced Cooperation
Potential American Speaker: Diane Griffin
Potential Chinese Speaker: (TBD)

Dates: September 29-30, 2015. We agreed on 28-30 September 2015 time frame to avoid the National Day holiday in early October, could we set the dates for 29-30 to allow U.S. participants to arrive on Monday the 28th?

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004523

Venue: We discussed holding the meeting at either the CAS Institute of Microbiology and Immunology or CAS Institute of Biophysics because they are near the Olympic venue and several hotels. What venue do you prefer? NAS is happy to work with either group.

Duration: We thought that a 1.5 or 2 day long meeting would be appropriate depending on the number of experts that agree to speak.

Participants: ~20-25 from China and 6-10 experts from U.S. Travel and accommodation for the U.S. experts will be organized and funded by NAS. NAS can also help with the meeting venue costs if necessary.

Happy to work directly with Dr. Ying Wu to answer these questions as well.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, April 09, 2015 8:46 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉; 高福; 吴莹
Subject: Re: RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Ben,

I have informed Dr. George(Fu) Gao of the CAS-NAS joint workshop and he agreed to be the Chair for the workshop on the Chinese side. His assistant Dr. Ying Wu will help him organize this workshop. Since we will have our National Day holiday between Oct 1-Oct 5, it seems that Sept 28-30 might be better for the workshop. Drs. Gao and Wu will discuss with you about the specific dates, topics, attendees and other details for the workshop.

Please let us know if I could be of any further assitance.

Best Regards,

Sun Hui

2015-04-10

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs
Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax: +86-10-68511095
Email: sunhui@cashq.ac.cn

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004524

http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-04-09 06:25:33
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
主题： RE: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Greetings Hui,

Thank you for this letter. Please send our thanks to Vice President Yaping Zhang.

I apologize for the delay, we just had a coordination meeting at NAS where we discussed the workshop and NAS experts are very excited to move forward. Thank you for letting Dr. George (Fu) Gao know about the letter exchange and the workshop plans and for asking him to help organize the workshop. We are very happy to work with Chinese CDC to plan the workshop as well as the CAS Institute Of Microbiology and/or the CAS Institute of Biophysics to plan/host. I would be grateful if you could designate a contact at either CAS institute so Dr. Franz and could start to discuss the agenda and workshop location. Regarding the workshop dates: Dr. Franz and the other members of the NAS group have let me know that the weeks of **28 Sept 2015 and 5 October 2015** would be a good time for them to travel to Beijing for the workshop. Does this timeframe work for CAS? I think that we would need to allocate about two days during that period for the meeting.

Kind regards,

Ben

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Thursday, March 19, 2015 9:52 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'; 张清泉
Subject: Re: RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

I am pleased to send you the letter replied to Dr. Griffin by Dr. Yaping Zhang. I will let Dr. George(Fu) Gao know about this and ask him to help organize the workshop. Please let us know your thoughts about the time and scale of the workshop. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-20

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004525

Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-15 22:25:10
收件人： 'sunhui@cashq.ac.cn'
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Mr. Sun,

I have attached the signed letter from Dr. Griffin. Thank you for offering to forward it to VP Zhang. We hope to hear back from him soon.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: sunhui@cashq.ac.cn [mailto:sunhui@cashq.ac.cn]
Sent: Tuesday, March 10, 2015 9:02 PM
To: Rusek, Benjamin
Cc: Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
Subject: Re: RE: RE: RE: Visit next week of Ben Rusek and David Franz
Importance: High

Dear Benjamin Rusek,

Thank you for sending me the draft letter addressed to VP Zhang. At your request, I am sending you the updated letter with some minor changes. You may send the final copy of the letter to me by email, and I will help forward it to VP Zhang's office. Let's stay in touch.

Best Regards,

Sun Hui

2015-03-11

SUN Hui (Mr.)
Director
Division of American and Oceanian Affairs

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004526

Bureau of International Cooperation
Chinese Academy of Sciences
52 Sanlihe Rd. Beijing, China 100864
Tel:+86-10-68597506
Fax:+86-10-68511095
Email: sunhui@cashq.ac.cn
http://english.cas.cn/

发件人： Rusek, Benjamin
发送时间： 2015-03-11 00:56:12
收件人： sunhui
抄送： Dave Franz (davidrfranz@gmail.com); Zhang Lei; 'blning'; 'Jinghua Cao'
主题： RE: RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Dr. Hui,

I hope you had a wonderful new year's break. Thank you again for meeting with David Franz and me on February 12. As recommended we have drafted a letter from NAS Vice President Diane E. Griffin to CAS Vice President Academician Zhang Yaping that contains language that we hope will allow the planning for the proposed NAS-CAS workshop to move forward. It is attached for you review. Please feel free to make any necessary changes, and when you are ready, please let us know how Dr. Griffin should send the final signed letter to Academician Zhang.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 9:50 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; Dave Franz (davidrfranz@gmail.com); Zhang Lei
Subject: Re: RE: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

After seeking advice from Jinghua and talking with Ms. Zhang Lei, we would like to change the meeting place tomorrow morning.

Mr. Sun, Director for Office of American & Oceanian Affairs, Ms. Zhang Lei and myself will meet you and your colleague at Meeting Room 706, CAS Headquarters, No. 52 Sanlihe Road, Xicheng District, Beijing 100864 on 9:00 am Thursday. Jinghua will not be able to attend the meeting due to other prior-settled meeting.

Please let me know if you have received this email. Please call me when you arrive at the front door of CAS tomorrow morning on 86-10-68597569 or (b)(6)

Look forward to seeing you tomorrow morning.

Bolun

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004527

发件人：Rusek, Benjamin
发送时间：2015-02-10 16:28:31
收件人：'blning'; 'Jinghua Cao'
抄送：sunhui; Dave Franz (davidrfranz@gmail.com)
主题：RE: RE: Visit next week of Ben Rusek and David Franz

Greetings Bolun,

Thank you for writing. We will met with Zhang Lei at the CAS institute of biophysics on Thursday morning at 9:00 am. Could you, Jinghua and/or Mr Sun join that meeting? Lei can be reached at zhanglei@ibp.ac.cn or by phone [redacted]office +86-10-64888494).

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6)

From: blning [mailto:blning@cashq.ac.cn]
Sent: Tuesday, February 10, 2015 3:21 PM
To: Rusek, Benjamin; 'Jinghua Cao'
Cc: sunhui; David Franz (franz@sri.org)
Subject: Re: RE: Visit next week of Ben Rusek and David Franz

Dear Benjamin,

I am Bolun Ning from Jinghua's office. Welcome to Beijing and to CAS. Our address is No. 52 Sanlihe Road, Xicheng District, Beijing 100864.

It seems that it's not possible to have meeting today. I don't know whether Jinghua would be available tomorrow. Please let me know which CAS institute you are going to visit in Beijing and who is the contact person. Maybe Jinghua or Mr. Sun and myself can join your visit to the CAS institute.

Best,

Bolun

发件人：Rusek, Benjamin
发送时间：2015-02-10 13:57:56
收件人：'Jinghua Cao'
抄送：sunhui; David Franz (franz@sri.org); blning (blning@cashq.ac.cn)
主题：RE: Visit next week of Ben Rusek and David Franz

Greeting Jinghua,

Thank you for agreeing to meet with us. When is a good time for us to visit you? We are free today or could meet late in the day tomorrow after we return from Chinese CDC. Where are you located?

Kind regards,

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004528

Benjamin J. Rusek
U.S. National Academy of Sciences
1-202-334-3975
(b)(6) cell

From: Jinghua Cao [mailto:jh-cao@cashq.ac.cn]
Sent: Monday, February 09, 2015 8:20 AM
To: Boright, John; blning (blning@cashq.ac.cn)
Cc: Rusek, Benjamin; Boright, John; sunhui
Subject: Re: Visit next week of Ben Rusek and David Franz

Boright, John，您好!

Dear John,
My colleagues and I will be pleased to meet with your Ben and David, I will ask Bolun and Sunhui to bring one or two expertsc to the meeting.
(BL, pls find out who else should be at the meeting and invite them)
Best,
Jinghua
======== 2015-02-08 06:25:41 您在来信中写道： ========

Dear Jinghua, and Bolun,

I hope all is well with you. This message is to let you know that next week Ben Rusek of our office, and US expert David Franz will be visiting Beijing. They have arranged visits with counterpart experts on global health security, including a CAS institute. By this message, I am connecting them with your office, to let you know of their visit, and in case it is possible for them to meet with you while they are in Beijing.

Best wishes,

John

From: Rusek, Benjamin
Sent: Friday, February 06, 2015 5:06 PM
To: Boright, John
Subject: FW: 回复：More information on our visit

Hi John,

Thanks for talking to me today. I have attached the one page project description that David Franz and I will use while we are in Beijing next week (Feb 10-13). A major purpose of the trip is to lay the groundwork for a small joint meeting between Chinese and U.S. experts on emerging infections, laboratory safety and global health security later in calendar year 2015. We have set up meetings with CBSG, Chinese CDC, reps from CAS institutes and some Chinese think tank experts. I have included bios for Dave and myself below if you would like to fw this to your CAS contact.

Kind regards,

Benjamin J. Rusek
U.S. National Academy of Sciences
Phone: 001-202-334-3975

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004529

(b)(6)
Fax: 001-202-334-1730
Skype:(b)(6)

David Franz (Independent Consultant, United States)
David R. Franz served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and retired as Colonel. He served as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and as Deputy Commander of the Medical Research and Materiel Command. Prior to joining the Command, he served as Group Veterinarian for the 10th Special Forces Group (Airborne). Dr. Franz was the Chief Inspector on three United Nations Special Commission biological warfare inspection missions to Iraq and served as technical advisor on long-term monitoring. He also served as a member of the first two US-UK teams that visited Russia in support of the Trilateral Joint Statement on Biological Weapons and as a member of the Trilateral Experts' Committee for biological weapons negotiations. Dr. Franz was Technical Editor for the Textbook of Military Medicine on Medical Aspects of Chemical and Biological Warfare released in 1997. Current standing committee appointments include the National Academy of Sciences Committee on International Security and Arms Control where he chairs the 'biological panel', the National Research Council Board on Life Sciences and the Senior Technical Advisory Committee of the National Biodefense Countermeasures Analysis Center (DHS). He serves as a Senior Mentor to the Program for Emerging Leaders at the National Defense University. He also serves on the Boards of the Elizabeth R. Griffin Research Foundation and Integrated Nano-Technologies, LLC. He holds an adjunct appointment as Professor for the Department of Diagnostic Medicine and Pathobiology at the College of Veterinary Medicine, Kansas State University. The current focus of his activities relates to the role of international engagement in public health and the life sciences as a component of global biosecurity policy. Domestically he continues to encourage thoughtfulness when regulating research in the name of security, thereby minimizing negative impact on progress in the life sciences.. Dr. Franz holds a D.V.M. from Kansas State University and a Ph.D. in Physiology from Baylor College of Medicine.

Benjamin Rusek (National Academy of Sciences, United States)
Benjamin Rusek is a Senior Program Officer in the Policy and Global Affairs Division at the U.S. National Academy of Sciences. Ben has supported successful NAS work in China for almost ten years (including the Chinese-English English-Chinese glossary of nuclear security terms and the U.S.-Chinese workshops on nuclear forensics). Ben was the study director for the project that produced the NAS report *Biosecurity Challenges of the Global Expansion of High-Containment Biological Laboratories* and has worked on international biosecurity issues with the NAS Board on Life Sciences since 2005. He has been a member of the Executive Board of International Student/Young Pugwash since 2005 and Chair of ISYP since 2008. He previously held various positions at the Henry L. Stimson Center, the Arms Control Association, and the U.S. National Air and Space Museum. Ben has a B.A. in political science from Ohio State University and an M.A. in political science from Purdue University, where he was the president of Purdue University Student Pugwash.

= =

致

礼!

Jinghua Cao
jh-cao@cashq.ac.cn
2015-02-09

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004530



FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004531

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, July 16, 2015 2:24 PM
To: Lynn W. Enquist
Cc: LeDuc, James W.
Subject: NAS China Bilateral

Hi Lynn,

It's been awhile. I hope this finds you well and enjoying this beautiful Princeton day (I'm actually writing from your fantastic city library which is my office for the week. (b)(6) (b)(6)) First Peggy H starting in 2003 and then Jim LeDuc and I have been working in China off and on and have now organized a small meeting to be held the last two days of September (29-30) this year. It is a follow-on to an Istanbul meeting in July 2011 in which we invited 37 countries and focused on high-containment lab research. Last fall we had a bilateral in Delhi and now this one. We have enough funding to take 7-8 americans and the chinese plan to invite ca. 25-30 of their colleagues. The current agenda pasted below lists committed US and Chinese speakers. You will know all the Americans and probably some of the Chinese. I'm writing to see if you are 1) free and 2) interested in making the trip. There are plans to also hold a small 'human genome/CRISPER' meeting between the NAS and CAS with Diane as head of NAS del, on the 28th. I'm sure you would be welcome to join that as well. You can see we will cover both some hard virology and some policy issues. The actual slot we are trying to fill is the one on GoF. I know you could do that beautifully, but if you have another preference I think we are fairly flexible. We would love to have you if it works in your schedule. I'm also free to visit by phone almost any time or happy to link up for coffee or lunch this week to tell you more and elaborate on the history of these engagements, if you are in town.

Best, dave

The "Safety-Security-Regulation-Progress" Conundrum:
American Speaker: David Franz, "Finding the Balance Among Safety, Security, Regulation, and Progress: The U.S. Experience"
Chinese Speaker: Qiang Wei

Influenza
Chinese Speaker: Jinhua Liu & Yi Shi
American Speaker: Peter Palese, "Influenza: Paths to a Better Vaccine?"

Ebola
American Speaker: Thomas Ksiazek, "Ebola: Sustainable Austere Environment Laboratories"
Chinese Speaker: Wuchun Cao & Di Liu

Middle East Respiratory Syndrome (MERS)
American Speaker: Ralph Baric, "MERS: Genetic Systems and Models"
Chinese Speaker: Wenjie Tan and Deyin Guo

Gain of Function Research (include discussion of human germline modification?)
Chinese Speaker: Cheng Cao
American Speaker: (**Need Speaker**), "NAS Gain-of-Function Meeting Report (The scientists' view)"

FOIA Confidential Treatment Requested by Univ of Texas System

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Chinese Speaker: Zhiming Yuan
American Speaker: James LeDuc, "High Containment Laboratories: Putting the pieces of laboratory safety and global health security together"

Areas for Enhanced Cooperation
American Speaker: Diane Griffin, "Possible roles for CAS and NAS in Enhancing Cooperation on these topics"
Chinese Speaker: George F Gao

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004333

From: Enquist, Lynn W. <lenquist@Princeton.EDU>
Sent: Thursday, July 16, 2015 2:38 PM
To: David Franz
Cc: LeDuc, James W.
Subject: Re: NAS China Bilateral

Dave,
Its great to hear from you. Yes it is a beautiful day here in Princeton!

Unfortunately, I am teaching my virology course this Fall and cannot accept the invitation to travel to China for this NAS China Bilateral meeting.

Thank you for thinking of me and for the invitation.

Lynn

From: David Franz <davidrfranz@gmail.com>
Date: Thursday, July 16, 2015 at 3:23 PM
To: Lynn Enquist <lenquist@exchange.princeton.edu>
Cc: "LeDuc, James W." <jwleduc@utmb.edu>
Subject: NAS China Bilateral

Hi Lynn,

It's been awhile. I hope this finds you well and enjoying this beautiful Princeton day (I'm actually writing from your fantastic city library which is my office for the week. (b)(6) First Peggy H starting in 2003 and then Jim LeDuc and I have been working in China off and on and have now organized a small meeting to be held the last two days of September (29-30) this year. It is a follow-on to an Istanbul meeting in July 2011 in which we invited 37 countries and focused on high-containment lab research. Last fall we had a bilateral in Delhi and now this one. We have enough funding to take 7-8 americans and the chinese plan to invite ca. 25-30 of their colleagues. The current agenda pasted below lists committed US and Chinese speakers. You will know all the Americans and probably some of the Chinese. I'm writing to see if you are 1) free and 2) interested in making the trip. There are plans to also hold a small 'human genome/CRISPER' meeting between the NAS and CAS with Diane as head of NAS del, on the 28th. I'm sure you would be welcome to join that as well. You can see we will cover both some hard virology and some policy issues. The actual slot we are trying to fill is the one on GoF. I know you could do that beautifully, but if you have another preference I think we are fairly flexible. We would love to have you if it works in your schedule. I'm also free to visit by phone almost any time or happy to link up for coffee or lunch this week to tell you more and elaborate on the history of these engagements, if you are in town.

Best, dave

The "Safety-Security-Regulation-Progress" Conundrum:
American Speaker: David Franz, "Finding the Balance Among Safety, Security, Regulation, and Progress: The U.S. Experience"
Chinese Speaker: Qiang Wei

Influenza
Chinese Speaker: Jinhua Liu & Yi Shi
American Speaker: Peter Palese, "Influenza: Paths to a Better Vaccine?"

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004334

Ebola
American Speaker: Thomas Ksiazek, "Ebola: Sustainable Austere Environment Laboratories"
Chinese Speaker: Wuchun Cao & Di Liu

Middle East Respiratory Syndrome (MERS)
American Speaker: Ralph Baric, "MERS: Genetic Systems and Models"
Chinese Speaker: Wenjie Tan and Deyin Guo

Gain of Function Research (include discussion of human germline modification?)
Chinese Speaker: Cheng Cao
American Speaker: (**Need Speaker**), "NAS Gain-of-Function Meeting Report (The scientists' view)"

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Chinese Speaker: Zhiming Yuan
American Speaker: James LeDuc, "High Containment Laboratories: Putting the pieces of laboratory safety and global health security together"

Areas for Enhanced Cooperation
American Speaker: Diane Griffin, "Possible roles for CAS and NAS in Enhancing Cooperation on these topics"
Chinese Speaker: George F Gao

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004335

From: David Franz <davidrfranz@gmail.com>
Sent: Thursday, July 16, 2015 2:51 PM
To: Enquist, Lynn W.
Cc: LeDuc, James W.
Subject: Re: NAS China Bilateral

Thanks for the quick response Lynn. It would have been great to have you, but I totally understand. Have a good summer and hope to see you soon. Best, dave

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

On Jul 16, 2015, at 3:38 PM, Enquist, Lynn W. wrote:

> Dave,
> Its great to hear from you. Yes it is a beautiful day here in Princeton!
>
> Unfortunately, I am teaching my virology course this Fall and cannot accept the invitation to travel to China for this NAS China Bilateral meeting.
>
> Thank you for thinking of me and for the invitation.
>
> Lynn
>
> ---
>
> **From:** David Franz <davidrfranz@gmail.com>
> **Date:** Thursday, July 16, 2015 at 3:23 PM
> **To:** Lynn Enquist <lenquist@exchange.princeton.edu>
> **Cc:** "LeDuc, James W." <jwleduc@utmb.edu>
> **Subject:** NAS China Bilateral
>
> Hi Lynn,
>
> It's been awhile. I hope this finds you well and enjoying this beautiful Princeton day (I'm actually writing from your fantastic city library which is my office for the week. (b)(6)
> (b)(6) First Peggy H starting in 2003 and then Jim LeDuc and I have been working in China off and on and have now organized a small meeting to be held the last two days of September (29-30) this year. It is a follow-on to an Istanbul meeting in July 2011 in which we invited 37 countries and focused on high-

FOIA Confidential Treatment Requested by Univ of Texas System

containment lab research. Last fall we had a bilateral in Delhi and now this one. We have enough funding to take 7-8 americans and the chinese plan to invite ca. 25-30 of their colleagues. The current agenda pasted below lists committed US and Chinese speakers. You will know all the Americans and probably some of the Chinese. I'm writing to see if you are 1) free and 2) interested in making the trip. There are plans to also hold a small 'human genome/CRISPER' meeting between the NAS and CAS with Diane as head of NAS del, on the 28th. I'm sure you would be welcome to join that as well. You can see we will cover both some hard virology and some policy issues. The actual slot we are trying to fill is the one on GoF. I know you could do that beautifully, but if you have another preference I think we are fairly flexible. We would love to have you if it works in your schedule. I'm also free to visit by phone almost any time or happy to link up for coffee or lunch this week to tell you more and elaborate on the history of these engagements, if you are in town.

Best, dave

The "Safety-Security-Regulation-Progress" Conundrum:
American Speaker: David Franz, "Finding the Balance Among Safety, Security, Regulation, and Progress: The U.S. Experience"
Chinese Speaker: Qiang Wei

Influenza
Chinese Speaker: Jinhua Liu & Yi Shi
American Speaker: Peter Palese, "Influenza: Paths to a Better Vaccine?"

Ebola
American Speaker: Thomas Ksiazek, "Ebola: Sustainable Austere Environment Laboratories"
Chinese Speaker: Wuchun Cao & Di Liu

Middle East Respiratory Syndrome (MERS)
American Speaker: Ralph Baric, "MERS: Genetic Systems and Models"
Chinese Speaker: Wenjie Tan and Deyin Guo

Gain of Function Research (include discussion of human germline modification?)
Chinese Speaker: Cheng Cao
American Speaker: (**Need Speaker**), "NAS Gain-of-Function Meeting Report (The scientists' view)"

High-Containment Labs…Safe, Secure, Productive, Sustainable:
Chinese Speaker: Zhiming Yuan
American Speaker: James LeDuc, "High Containment Laboratories: Putting the pieces of laboratory safety and global health security together"

Areas for Enhanced Cooperation
American Speaker: Diane Griffin, "Possible roles for CAS and NAS in Enhancing Cooperation on these topics"
Chinese Speaker: George F Gao

David R. Franz DVM, Ph.D

Assistant: (b)(6)
(b)(6)

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004337

FOIA Confidential Treatment Requested by Univ of Texas System UTSystem_004338